<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002488</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>132</s160></s100><s200><s210>1</s210><s211>1229</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 1Asp Val Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser                85                  90                  95Arg Thr Tyr Val Asn Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly        115                 120                 125Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val    130                 135                 140Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr145                 150                 155                 160Ile Ser Thr Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly                165                 170                 175Leu Glu Trp Ile Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala            180                 185                 190Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn        195                 200                 205Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val    210                 215                 220Tyr Tyr Cys Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn225                 230                 235                 240Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Thr Gly Gly Gly Gly                245                 250                 255Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Lys Gln Ser Gly Pro Gly            260                 265                 270Leu Val Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly        275                 280                 285Phe Ser Leu Thr Asn Tyr Gly Val His Trp Val Arg Gln Ser Pro Gly    290                 295                 300Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly Asn Thr Asp305                 310                 315                 320Tyr Asn Thr Pro Phe Thr Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser                325                 330                 335Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ser Asn Asp Thr            340                 345                 350Ala Ile Tyr Tyr Cys Ala Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe        355                 360                 365Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr    370                 375                 380Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser385                 390                 395                 400Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu                405                 410                 415Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His            420                 425                 430Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser        435                 440                 445Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys    450                 455                 460Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu465                 470                 475                 480Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro                485                 490                 495Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys            500                 505                 510Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val        515                 520                 525Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp    530                 535                 540Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr545                 550                 555                 560Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp                565                 570                 575Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu            580                 585                 590Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg        595                 600                 605Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys    610                 615                 620Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp625                 630                 635                 640Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys                645                 650                 655Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser            660                 665                 670Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser        675                 680                 685Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser    690                 695                 700Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser705                 710                 715                 720Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly                725                 730                 735Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly            740                 745                 750Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp        755                 760                 765Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr Tyr Asp Ala Asn    770                 775                 780Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr785                 790                 795                 800Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr                805                 810                 815Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala Met Asp Leu Trp            820                 825                 830Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly        835                 840                 845Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile    850                 855                 860Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg865                 870                 875                 880Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser His Leu Asn                885                 890                 895Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys            900                 905                 910Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly        915                 920                 925Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp    930                 935                 940Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp Gly Asn Val Asp945                 950                 955                 960Asn Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly                965                 970                 975Ser Gly Gly Gly Gly Ser Gly Arg Ser Leu Val Glu Ser Gly Gly Gly            980                 985                 990Leu Val Gln Pro Gly Gly Ser Leu  Arg Leu Ser Cys Thr  Ala Ser Gly        995                 1000                 1005Phe Thr  Ile Ser Ser Tyr His  Met Gln Trp Val Arg  Gln Ala Pro    1010                 1015                 1020Gly Lys  Gly Leu Glu Tyr Ile  Gly Thr Ile Ser Ser  Gly Gly Asn    1025                 1030                 1035Val Tyr  Tyr Ala Ser Ser Ala  Arg Gly Arg Phe Thr  Ile Ser Arg    1040                 1045                 1050Pro Ser  Ser Lys Asn Thr Val  Asp Leu Gln Met Asn  Ser Leu Arg    1055                 1060                 1065Ala Glu  Asp Thr Ala Val Tyr  Tyr Cys Ala Arg Asp  Ser Gly Tyr    1070                 1075                 1080Ser Asp  Pro Met Trp Gly Gln  Gly Thr Leu Val Thr  Val Ser Ser    1085                 1090                 1095Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser    1100                 1105                 1110Gly Gly  Gly Gly Ser Asp Val  Val Met Thr Gln Ser  Pro Ser Ser    1115                 1120                 1125Val Ser  Ala Ser Val Gly Asp  Arg Val Thr Ile Thr  Cys Gln Ala    1130                 1135                 1140Ser Gln  Asn Ile Arg Thr Tyr  Leu Ser Trp Tyr Gln  Gln Lys Pro    1145                 1150                 1155Gly Lys  Ala Pro Lys Leu Leu  Ile Tyr Ala Ala Ala  Asn Leu Ala    1160                 1165                 1170Ser Gly  Val Pro Ser Arg Phe  Ser Gly Ser Gly Ser  Gly Thr Asp    1175                 1180                 1185Phe Thr  Leu Thr Ile Ser Asp  Leu Glu Pro Gly Asp  Ala Ala Thr    1190                 1195                 1200Tyr Tyr  Cys Gln Ser Thr Tyr  Leu Gly Thr Asp Tyr  Val Gly Gly    1205                 1210                 1215Ala Phe  Gly Gly Gly Thr Lys  Val Glu Ile Lys    1220                 1225</s400><s200><s210>2</s210><s211>3690</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 2gacgtcgtga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc     60atcaattgcc aagccagtga gagcattagc agttggttag cctggtatca gcagaaacca    120gggaaagccc ctaagctcct gatctatgaa gcatccaaac tggcatctgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa tttactctca ccatcagcag cctgcagcct    240gatgattttg caacttatta ctgccaaggc tatttttatt ttattagtcg tacttatgta    300aattctttcg gcggagggac caaggtggag atcaaaggcg gtggcggtag tgggggaggc    360ggttctggcg gcggagggtc cggcggtgga ggatcagagg tgcagctggt ggagtctggg    420ggaggcttgg tccagcctgg ggggtccctg agactctcct gtgcagcctc tggattcacc    480atcagtacca atgcaatgag ctgggtccgc caggctccag ggaaggggct ggagtggatc    540ggagtcatta ctggtcgtga tatcacatac tacgcgagct gggcgaaagg cagattcacc    600atctccagag acaattccaa gaacacgctg tatcttcaaa tgaacagcct gagagccgag    660gacacggctg tgtattactg tgcgagagac ggtggttctt ctgctattac tagtaacaac    720atttggggcc agggaaccct ggtcaccgtg tcgacaggcg gtggagggtc cggcggtggt    780ggatcacagg tgcagctgaa gcagtcagga cctggcctag tgcagccctc acagagcctg    840tccatcacct gcacagtctc tggtttctca ttaactaact atggtgtaca ctgggttcgc    900cagtctccag gaaagggtct ggagtggctg ggagtgatat ggagtggtgg aaacacagac    960tataatacac ctttcacatc cagactgagc atcaacaagg acaattccaa gagccaagtt   1020ttctttaaaa tgaacagtct gcaatctaat gacacagcca tatattactg tgccagagcc   1080ctcacctact atgattacga gtttgcttac tggggccaag ggactctggt cactgtctct   1140agcgctagca ccaagggccc atcggtcttc cccctggcac cctcctccaa gagcacctct   1200gggggcacag cggccctggg ctgcctggtc aaggactact tccccgaacc ggtgacggtg   1260tcgtggaact caggcgccct gaccagcggc gtgcacacct tcccggctgt cctacagtcc   1320tcaggactct actccctcag cagcgtggtg accgtgccct ccagcagctt gggcacccag   1380acctacatct gcaacgtgaa tcacaagccc agcaacacca aggtggacaa gagagttgag   1440cccaaatctt gtgacaaaac tcacacatgc ccaccgtgcc cagcacctga agccgcgggg   1500gcaccgtcag tcttcctctt ccccccaaaa cccaaggaca ccctcatgat ctcccggacc   1560cctgaggtca catgcgtggt ggtggacgtg agccacgaag accctgaggt caagttcaac   1620tggtacgtgg acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagtac   1680aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc   1740aaggagtaca agtgcgcggt ctccaacaaa gccctcccag cccccatcga gaaaaccatc   1800tccaaagcca aagggcagcc ccgagaacca caggtgtaca ccctgccccc atcccgggat   1860gagctgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta tcccagcgac   1920atcgccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cacgcctccc   1980gtgctggact ccgacggctc cttcttcctc tatagcaagc tcaccgtgga caagagcagg   2040tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac   2100acgcagaaga gcctctccct gtctccgggt ggcggtggag ggtccggcgg tggtggatcc   2160gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc   2220tcctgtgcag cctctggatt ctccttcagt agcgggtacg acatgtgctg ggtccgccag   2280gctccaggga aggggctgga gtggatcgca tgcattgctg ctggtagtgc tggtatcact   2340tacgacgcga actgggcgaa aggccggttc accatctcca gagacaattc caagaacacg   2400ctgtatctgc aaatgaacag cctgagagcc gaggacacgg ccgtatatta ctgtgcgaga   2460tcggcgtttt cgttcgacta cgccatggac ctctggggcc agggaaccct ggtcaccgtc   2520tcgagcggtg gaggcggatc tggcggaggt ggttccggcg gtggcggctc cggtggaggc   2580ggctctgaca tccagatgac ccagtctcct tccaccctgt ctgcatctgt aggagacaga   2640gtcaccatca cttgccaggc cagtcagagc attagttccc acttaaactg gtatcagcag   2700aaaccaggga aagcccctaa gctcctgatc tataaggcat ccactctggc atctggggtc   2760ccatcaaggt tcagcggcag tggatctggg acagaattta ctctcaccat cagcagcctg   2820cagcctgatg attttgcaac ttattactgc caacagggtt atagttgggg taatgttgat   2880aatgttttcg gcggagggac caaggtggag atcaaaggcg gtggagggtc cggcggtggt   2940ggctccggac ggtcgctggt ggagtctggg ggaggcttgg tccagcctgg ggggtccctg   3000agactctcct gtactgcctc tggattcacc atcagtagct accacatgca gtgggtccgc   3060caggctccag ggaaggggct ggagtacatc ggaaccatta gtagtggtgg taatgtatac   3120tacgcaagct ccgctagagg cagattcacc atctccagac cctcgtccaa gaacacggtg   3180gatcttcaaa tgaacagcct gagagccgag gacacggctg tgtattactg tgcgagagac   3240tctggttata gtgatcctat gtggggccag ggaaccctgg tcaccgtctc ttcaggcggt   3300ggcggtagtg ggggaggcgg ttctggcggc ggagggtccg gcggtggagg atcagacgtt   3360gtgatgaccc agtctccatc ttccgtgtct gcatctgtag gagacagagt caccatcacc   3420tgtcaggcca gtcagaacat taggacttac ttatcctggt atcagcagaa accagggaaa   3480gcccctaagc tcctgatcta tgctgcagcc aatctggcat ctggggtccc atcaaggttc   3540agcggcagtg gatctgggac agatttcact ctcaccatca gcgacctgga gcctggcgat   3600gctgcaactt actattgtca gtctacctat cttggtactg attatgttgg cggtgctttc   3660ggcggaggga ccaaggtgga gatcaaatga                                    3690</s400><s200><s210>3</s210><s211>473</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 3Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser65                  70                  75                  80Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala            100                 105                 110Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly        115                 120                 125Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala    130                 135                 140Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145                 150                 155                 160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser                165                 170                 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr            180                 185                 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser        195                 200                 205Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser    210                 215                 220Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln225                 230                 235                 240Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr                245                 250                 255Asn Phe Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu            260                 265                 270Met Ile Tyr Asp Val Ser Asp Arg Pro Ser Gly Val Ser Asp Arg Phe        275                 280                 285Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Ile Ile Ser Gly Leu    290                 295                 300Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Gly Ser Ser305                 310                 315                 320Ser Thr His Val Ile Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly                325                 330                 335Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            340                 345                 350Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Lys        355                 360                 365Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe    370                 375                 380Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu385                 390                 395                 400Glu Trp Val Ala Asn Ile Asn Arg Asp Gly Ser Ala Ser Tyr Tyr Val                405                 410                 415Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn            420                 425                 430Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val        435                 440                 445Tyr Tyr Cys Ala Arg Asp Arg Gly Val Gly Tyr Phe Asp Leu Trp Gly    450                 455                 460Arg Gly Thr Leu Val Thr Val Ser Ser465                 470</s400><s200><s210>4</s210><s211>1422</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 4gacatcttgc tgactcagtc tccagtcatc ctgtctgtga gtccaggaga aagagtcagt     60ttctcctgca gggccagtca gagtattggc acaaacatac actggtatca gcaaagaaca    120aatggttctc caaggcttct cataaagtat gcttctgagt ctatctctgg gattccttcc    180aggtttagtg gcagtggatc agggacagat tttactctta gcatcaacag tgtggagtct    240gaagatattg cagattatta ctgtcaacaa aataataact ggccaaccac gttcggtgct    300gggaccaagc tggagctgaa acgtacggtg gctgcaccat ctgtcttcat cttcccgcca    360tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat    420cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag    480gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg    540ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc    600ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gtggcggtgg agggtccggc    660ggtggtggat cccagtctgc cctgactcag cctgcctccg tgtctgggtc tcctggacag    720tcgatcacca tctcctgcac tggaaccagc agtgacgttg gtggttataa ctttgtctcc    780tggtaccaac aacacccagg caaagccccc aaactcatga tctatgatgt cagtgatcgg    840ccctcagggg tgtctgatcg cttctccggc tccaagtctg gcaacacggc ctccctgatc    900atctctggcc tccaggctga cgacgaggct gattattact gcagctcata tgggagcagc    960agcactcatg tgattttcgg cggagggacc aaggtgaccg tcctaggtgg aggcggttca   1020ggcggaggtg gttccggcgg tggcggctcc ggtggaggcg gctctcaggt gcaattgcag   1080gagtcggggg gaggcctggt caagcctgga gggtccctga gactctcctg tgcagcctct   1140ggattcacct ttagtagtta ttggatgagc tgggtccgcc aggctccagg gaaggggctg   1200gagtgggtgg ccaacataaa ccgcgatgga agtgcgagtt actatgtgga ctctgtgaag   1260ggccgattca ccatctccag agacgacgcc aagaactcac tgtatctgca aatgaacagc   1320ctgagagctg aggacacggc tgtgtattac tgtgcgagag atcgtggggt gggctacttc   1380gatctctggg gccgtggcac cctggtcacc gtctcgagct ga                      1422</s400><s200><s210>5</s210><s211>1229</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 5Asp Val Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser                85                  90                  95Arg Thr Tyr Val Asn Ser Phe Gly Cys Gly Thr Lys Val Glu Ile Lys            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly        115                 120                 125Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val    130                 135                 140Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr145                 150                 155                 160Ile Ser Thr Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Cys                165                 170                 175Leu Glu Trp Ile Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala            180                 185                 190Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn        195                 200                 205Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val    210                 215                 220Tyr Tyr Cys Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn225                 230                 235                 240Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Thr Gly Gly Gly Gly                245                 250                 255Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Lys Gln Ser Gly Pro Gly            260                 265                 270Leu Val Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly        275                 280                 285Phe Ser Leu Thr Asn Tyr Gly Val His Trp Val Arg Gln Ser Pro Gly    290                 295                 300Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly Asn Thr Asp305                 310                 315                 320Tyr Asn Thr Pro Phe Thr Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser                325                 330                 335Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ser Asn Asp Thr            340                 345                 350Ala Ile Tyr Tyr Cys Ala Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe        355                 360                 365Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr    370                 375                 380Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser385                 390                 395                 400Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu                405                 410                 415Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His            420                 425                 430Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser        435                 440                 445Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys    450                 455                 460Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu465                 470                 475                 480Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro                485                 490                 495Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys            500                 505                 510Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val        515                 520                 525Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp    530                 535                 540Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr545                 550                 555                 560Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp                565                 570                 575Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu            580                 585                 590Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg        595                 600                 605Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys    610                 615                 620Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp625                 630                 635                 640Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys                645                 650                 655Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser            660                 665                 670Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser        675                 680                 685Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser    690                 695                 700Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser705                 710                 715                 720Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly                725                 730                 735Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly            740                 745                 750Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Cys Leu Glu Trp        755                 760                 765Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr Tyr Asp Ala Asn    770                 775                 780Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr785                 790                 795                 800Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr                805                 810                 815Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala Met Asp Leu Trp            820                 825                 830Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly        835                 840                 845Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile    850                 855                 860Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg865                 870                 875                 880Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser His Leu Asn                885                 890                 895Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys            900                 905                 910Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly        915                 920                 925Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp    930                 935                 940Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp Gly Asn Val Asp945                 950                 955                 960Asn Val Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly                965                 970                 975Ser Gly Gly Gly Gly Ser Gly Arg Ser Leu Val Glu Ser Gly Gly Gly            980                 985                 990Leu Val Gln Pro Gly Gly Ser Leu  Arg Leu Ser Cys Thr  Ala Ser Gly        995                 1000                 1005Phe Thr  Ile Ser Ser Tyr His  Met Gln Trp Val Arg  Gln Ala Pro    1010                 1015                 1020Gly Lys  Cys Leu Glu Tyr Ile  Gly Thr Ile Ser Ser  Gly Gly Asn    1025                 1030                 1035Val Tyr  Tyr Ala Ser Ser Ala  Arg Gly Arg Phe Thr  Ile Ser Arg    1040                 1045                 1050Pro Ser  Ser Lys Asn Thr Val  Asp Leu Gln Met Asn  Ser Leu Arg    1055                 1060                 1065Ala Glu  Asp Thr Ala Val Tyr  Tyr Cys Ala Arg Asp  Ser Gly Tyr    1070                 1075                 1080Ser Asp  Pro Met Trp Gly Gln  Gly Thr Leu Val Thr  Val Ser Ser    1085                 1090                 1095Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser    1100                 1105                 1110Gly Gly  Gly Gly Ser Asp Val  Val Met Thr Gln Ser  Pro Ser Ser    1115                 1120                 1125Val Ser  Ala Ser Val Gly Asp  Arg Val Thr Ile Thr  Cys Gln Ala    1130                 1135                 1140Ser Gln  Asn Ile Arg Thr Tyr  Leu Ser Trp Tyr Gln  Gln Lys Pro    1145                 1150                 1155Gly Lys  Ala Pro Lys Leu Leu  Ile Tyr Ala Ala Ala  Asn Leu Ala    1160                 1165                 1170Ser Gly  Val Pro Ser Arg Phe  Ser Gly Ser Gly Ser  Gly Thr Asp    1175                 1180                 1185Phe Thr  Leu Thr Ile Ser Asp  Leu Glu Pro Gly Asp  Ala Ala Thr    1190                 1195                 1200Tyr Tyr  Cys Gln Ser Thr Tyr  Leu Gly Thr Asp Tyr  Val Gly Gly    1205                 1210                 1215Ala Phe  Gly Cys Gly Thr Lys  Val Glu Ile Lys    1220                 1225</s400><s200><s210>6</s210><s211>3690</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 6gacgtcgtga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc     60atcaattgcc aagccagtga gagcattagc agttggttag cctggtatca gcagaaacca    120gggaaagccc ctaagctcct gatctatgaa gcatccaaac tggcatctgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa tttactctca ccatcagcag cctgcagcct    240gatgattttg caacttatta ctgccaaggc tatttttatt ttattagtcg tacttatgta    300aattctttcg gctgtgggac caaggtggag atcaaaggtg gaggcggttc aggcggaggt    360ggaagtggtg gtggcggctc tggaggcggc ggatctgagg tgcagctggt ggagtctggg    420ggaggcttgg tccagcctgg ggggtccctg agactctcct gtgcagcctc tggattcacc    480atcagtacca atgcaatgag ctgggtccgc caggctccag ggaagtgcct ggagtggatc    540ggagtcatta ctggtcgtga tatcacatac tacgcgagct gggcgaaagg cagattcacc    600atctccagag acaattccaa gaacacgctg tatcttcaaa tgaacagcct gagagccgag    660gacacggctg tgtattactg tgcgagagac ggtggttctt ctgctattac tagtaacaac    720atttggggcc agggaaccct ggtcaccgtg tcgacaggcg gtggagggtc cggcggtggt    780ggatcacagg tgcagctgaa gcagtcagga cctggcctag tgcagccctc acagagcctg    840tccatcacct gcacagtctc tggtttctca ttaactaact atggtgtaca ctgggttcgc    900cagtctccag gaaagggtct ggagtggctg ggagtgatat ggagtggtgg aaacacagac    960tataatacac ctttcacatc cagactgagc atcaacaagg acaattccaa gagccaagtt   1020ttctttaaaa tgaacagtct gcaatctaat gacacagcca tatattactg tgccagagcc   1080ctcacctact atgattacga gtttgcttac tggggccaag ggactctggt cactgtctct   1140agcgctagca ccaagggccc atcggtcttc cccctggcac cctcctccaa gagcacctct   1200gggggcacag cggccctggg ctgcctggtc aaggactact tccccgaacc ggtgacggtg   1260tcgtggaact caggcgccct gaccagcggc gtgcacacct tcccggctgt cctacagtcc   1320tcaggactct actccctcag cagcgtggtg accgtgccct ccagcagctt gggcacccag   1380acctacatct gcaacgtgaa tcacaagccc agcaacacca aggtggacaa gagagttgag   1440cccaaatctt gtgacaaaac tcacacatgc ccaccgtgcc cagcacctga agccgcgggg   1500ggaccgtcag tcttcctctt ccccccaaaa cccaaggaca ccctcatgat ctcccggacc   1560cctgaggtca catgcgtggt ggtggacgtg agccacgaag accctgaggt caagttcaac   1620tggtacgtgg acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagtac   1680gccagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc   1740aaggagtaca agtgcgcggt ctccaacaaa gccctcccag cccccatcga gaaaaccatc   1800tccaaagcca aagggcagcc ccgagaacca caggtgtaca ccctgccccc atcccgggat   1860gagctgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta tcccagcgac   1920atcgccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cacgcctccc   1980gtgctggact ccgacggctc cttcttcctc tatagcaagc tcaccgtgga caagagcagg   2040tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac   2100acgcagaaga gcctctccct gtctccgggt ggcggtggag ggtccggcgg tggtggatcc   2160gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc   2220tcctgtgcag cctctggatt ctccttcagt agcgggtacg acatgtgctg ggtccgccag   2280gctccaggga agtgcctgga gtggatcgca tgcattgctg ctggtagtgc tggtatcact   2340tacgacgcga actgggcgaa aggccggttc accatctcca gagacaattc caagaacacg   2400ctgtatctgc aaatgaacag cctgagagcc gaggacacgg ccgtatatta ctgtgcgaga   2460tcggcgtttt cgttcgacta cgccatggac ctctggggcc agggaaccct ggtcaccgtc   2520tcgagcggtg gaggcggttc aggcggaggt ggaagtggtg gtggcggctc tggaggcggc   2580ggatctgaca tccagatgac ccagtctcct tccaccctgt ctgcatctgt aggagacaga   2640gtcaccatca cttgccaggc cagtcagagc attagttccc acttaaactg gtatcagcag   2700aaaccaggga aagcccctaa gctcctgatc tataaggcat ccactctggc atctggggtc   2760ccatcaaggt tcagcggcag tggatctggg acagaattta ctctcaccat cagcagcctg   2820cagcctgatg attttgcaac ttattactgc caacagggtt atagttgggg taatgttgat   2880aatgttttcg gctgcgggac caaggtggag atcaaaggtg gtggcggctc tggaggagga   2940gggtccggac ggtcgctggt ggagtctggg ggaggcttgg tccagcctgg ggggtccctg   3000agactctcct gtactgcctc tggattcacc atcagtagct accacatgca gtgggtccgg   3060caggcacctg ggaagtgcct ggagtacatc ggaaccatta gtagtggtgg taatgtatac   3120tacgcaagct ccgctagagg cagattcacc atctccagac cctcgtccaa gaacacggtg   3180gatcttcaaa tgaacagcct gagagccgag gacacggctg tgtattactg tgcgagagac   3240tctggttata gtgatcctat gtggggccag ggaaccctgg tcaccgtctc ttcaggcggt   3300ggcggtagtg ggggaggcgg ttctggcggc ggagggtccg gcggtggagg atcagacgtt   3360gtgatgaccc agtctccatc ttccgtgtct gcatctgtag gagacagagt caccatcacc   3420tgtcaggcca gtcagaacat taggacttac ttatcctggt atcagcagaa accagggaaa   3480gcccctaagc tcctgatcta tgctgcagcc aatctggcat ctggggtccc atcaaggttc   3540agcggcagtg gatctgggac agatttcact ctcaccatca gcgacttgga acctggcgat   3600gctgcaactt actattgtca gtctacctat cttggtactg attatgttgg cggtgctttc   3660ggctgtggga ccaaggtgga gatcaaatga                                    3690</s400><s200><s210>7</s210><s211>473</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 7Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser65                  70                  75                  80Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala            100                 105                 110Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly        115                 120                 125Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala    130                 135                 140Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145                 150                 155                 160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser                165                 170                 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr            180                 185                 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser        195                 200                 205Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser    210                 215                 220Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln225                 230                 235                 240Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr                245                 250                 255Asn Phe Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu            260                 265                 270Met Ile Tyr Asp Val Ser Asp Arg Pro Ser Gly Val Ser Asp Arg Phe        275                 280                 285Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Ile Ile Ser Gly Leu    290                 295                 300Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Gly Ser Ser305                 310                 315                 320Ser Thr His Val Ile Phe Gly Cys Gly Thr Lys Val Thr Val Leu Gly                325                 330                 335Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly            340                 345                 350Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Lys        355                 360                 365Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe    370                 375                 380Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Cys Leu385                 390                 395                 400Glu Trp Val Ala Asn Ile Asn Arg Asp Gly Ser Ala Ser Tyr Tyr Val                405                 410                 415Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn            420                 425                 430Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val        435                 440                 445Tyr Tyr Cys Ala Arg Asp Arg Gly Val Gly Tyr Phe Asp Leu Trp Gly    450                 455                 460Arg Gly Thr Leu Val Thr Val Ser Ser465                 470</s400><s200><s210>8</s210><s211>1422</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 8gacatcttgc tgactcagtc tccagtcatc ctgtctgtga gtccaggaga aagagtcagt     60ttctcctgca gggccagtca gagtattggc acaaacatac actggtatca gcaaagaaca    120aatggttctc caaggcttct cataaagtat gcttctgagt ctatctctgg gattccttcc    180aggtttagtg gcagtggatc agggacagat tttactctta gcatcaacag tgtggagtct    240gaagatattg cagattatta ctgtcaacaa aataataact ggccaaccac gttcggtgct    300gggaccaagc tggagctgaa acgtacggtg gctgcaccat ctgtcttcat cttcccgcca    360tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat    420cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag    480gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg    540ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc    600ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gtggcggtgg agggtccggc    660ggtggtggat cccagtctgc cctgactcag cctgcctccg tgtctgggtc tcctggacag    720tcgatcacca tctcctgcac tggaaccagc agtgacgttg gtggttataa ctttgtctcc    780tggtaccaac aacacccagg caaagccccc aaactcatga tctatgatgt cagtgatcgg    840ccctcagggg tgtctgatcg cttctccggc tccaagtctg gcaacacggc ctccctgatc    900atctctggcc tccaggctga cgacgaggct gattattact gcagctcata tgggagcagc    960agcactcatg tgattttcgg ctgcgggacc aaggtgaccg tcctaggtgg aggcggttca   1020ggcggaggtg gttccggcgg tggcggctcc ggtggaggcg gctctcaggt gcaattgcag   1080gagtcggggg gaggcctggt caagcctgga gggtccctga gactctcctg tgcagcctct   1140ggattcacct ttagtagtta ttggatgagc tgggtccgcc aggctccagg gaagtgcctg   1200gagtgggtgg ccaacataaa ccgcgatgga agtgcgagtt actatgtgga ctctgtgaag   1260ggccgattca ccatctccag agacgacgcc aagaactcac tgtatctgca aatgaacagc   1320ctgagagctg aggacacggc tgtgtattac tgtgcgagag atcgtggggt gggctacttc   1380gatctctggg gccgtggcac cctggtcacc gtctcgagct ga                      1422</s400><s200><s210>9</s210><s211>1225</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 9Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Ile            20                  25                  30His Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr        35                  40                  45Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu65                  70                  75                  80Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Thr Ser Asn Pro Pro Thr                85                  90                  95Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val    130                 135                 140Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asn Met145                 150                 155                 160His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile Gly Ala                165                 170                 175Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly            180                 185                 190Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln        195                 200                 205Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg    210                 215                 220Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly Ala Gly225                 230                 235                 240Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly                245                 250                 255Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly            260                 265                 270Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Ser Thr        275                 280                 285Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp    290                 295                 300Ile Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala Ser Trp Ala305                 310                 315                 320Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr                325                 330                 335Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys            340                 345                 350Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn Ile Trp Gly        355                 360                 365Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser    370                 375                 380Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala385                 390                 395                 400Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val                405                 410                 415Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala            420                 425                 430Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val        435                 440                 445Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His    450                 455                 460Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys465                 470                 475                 480Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly                485                 490                 495Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met            500                 505                 510Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His        515                 520                 525Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val    530                 535                 540His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr545                 550                 555                 560Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly                565                 570                 575Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu Pro Ala Pro Ile            580                 585                 590Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val        595                 600                 605Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser    610                 615                 620Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu625                 630                 635                 640Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro                645                 650                 655Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val            660                 665                 670Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met        675                 680                 685His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser    690                 695                 700Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu705                 710                 715                 720Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu                725                 730                 735Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly Tyr Asp Met Cys            740                 745                 750Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala Cys Ile        755                 760                 765Ala Ala Gly Ser Ala Gly Ile Thr Tyr Asp Ala Asn Trp Ala Lys Gly    770                 775                 780Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln785                 790                 795                 800Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg                805                 810                 815Ser Ala Phe Ser Phe Asp Tyr Ala Met Asp Leu Trp Gly Gln Gly Thr            820                 825                 830Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser        835                 840                 845Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln    850                 855                 860Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr865                 870                 875                 880Cys Gln Ala Ser Gln Ser Ile Ser Ser His Leu Asn Trp Tyr Gln Gln                885                 890                 895Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Thr Leu            900                 905                 910Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu        915                 920                 925Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr    930                 935                 940Tyr Cys Gln Gln Gly Tyr Ser Trp Gly Asn Val Asp Asn Val Phe Gly945                 950                 955                 960Gly Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly                965                 970                 975Gly Ser Gly Arg Ser Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro            980                 985                 990Gly Gly Ser Leu Arg Leu Ser Cys  Thr Ala Ser Gly Phe  Thr Ile Ser        995                 1000                 1005Ser Tyr  His Met Gln Trp Val  Arg Gln Ala Pro Gly  Lys Gly Leu    1010                 1015                 1020Glu Tyr  Ile Gly Thr Ile Ser  Ser Gly Gly Asn Val  Tyr Tyr Ala    1025                 1030                 1035Ser Ser  Ala Arg Gly Arg Phe  Thr Ile Ser Arg Pro  Ser Ser Lys    1040                 1045                 1050Asn Thr  Val Asp Leu Gln Met  Asn Ser Leu Arg Ala  Glu Asp Thr    1055                 1060                 1065Ala Val  Tyr Tyr Cys Ala Arg  Asp Ser Gly Tyr Ser  Asp Pro Met    1070                 1075                 1080Trp Gly  Gln Gly Thr Leu Val  Thr Val Ser Ser Gly  Gly Gly Gly    1085                 1090                 1095Ser Gly  Gly Gly Gly Ser Gly  Gly Gly Gly Ser Gly  Gly Gly Gly    1100                 1105                 1110Ser Asp  Val Val Met Thr Gln  Ser Pro Ser Ser Val  Ser Ala Ser    1115                 1120                 1125Val Gly  Asp Arg Val Thr Ile  Thr Cys Gln Ala Ser  Gln Asn Ile    1130                 1135                 1140Arg Thr  Tyr Leu Ser Trp Tyr  Gln Gln Lys Pro Gly  Lys Ala Pro    1145                 1150                 1155Lys Leu  Leu Ile Tyr Ala Ala  Ala Asn Leu Ala Ser  Gly Val Pro    1160                 1165                 1170Ser Arg  Phe Ser Gly Ser Gly  Ser Gly Thr Asp Phe  Thr Leu Thr    1175                 1180                 1185Ile Ser  Asp Leu Glu Pro Gly  Asp Ala Ala Thr Tyr  Tyr Cys Gln    1190                 1195                 1200Ser Thr  Tyr Leu Gly Thr Asp  Tyr Val Gly Gly Ala  Phe Gly Gly    1205                 1210                 1215Gly Thr  Lys Val Glu Ile Lys    1220                 1225</s400><s200><s210>10</s210><s211>3678</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 10cagatcgtgc tgagccagag ccccgccatc ctgagcgcca gccccggcga gaaggtgacc     60atgacctgcc gggccagcag cagcgtgagc tacatccact ggttccagca gaagcccggc    120agcagcccca agccctggat ctacgccacc agcaacctgg ccagcggcgt gcccgtgcgg    180ttcagcggca gcggcagcgg caccagctac agcctgacca tcagccgggt ggaggccgag    240gacgccgcca cctactactg ccagcagtgg accagcaacc cccccacctt cggcggcggc    300accaagctga ccgtgctggg tggtggtggc tctggaggag gcgggagcgg gggtggtggc    360tcaggtggtg gaggttccca ggtgcagctg cagcagcccg gcgccgagct ggtgaagccc    420ggcgccagcg tgaagatgag ctgcaaggcc agcggctaca ccttcaccag ctacaacatg    480cactgggtga agcagacccc cggccggggc ctggagtgga tcggcgccat ctaccccggc    540aacggcgaca ccagctacaa ccagaagttc aagggcaagg ccaccctgac cgccgacaag    600agcagcagca ccgcctacat gcagctgagc agcctgacca gcgaggacag cgccgtgtac    660tactgcgccc ggagcaccta ctacggcggc gactggtact tcaacgtgtg gggcgccggc    720accaccgtga ccgtctcgag tggcggtgga gggtccggcg gtggtggatc agaggtgcag    780ctggtggagt ctgggggagg cttggtccag cctggggggt ccctgagact ctcctgtgca    840gcctctggat tcaccatcag taccaatgca atgagctggg tccgccaggc tccagggaag    900gggctggagt ggatcggagt cattactggt cgtgatatca catactacgc gagctgggcg    960aaaggcagat tcaccatctc cagagacaat tccaagaaca cgctgtatct tcaaatgaac   1020agcctgagag ccgaggacac ggctgtgtat tactgtgcga gagacggtgg ttcttctgct   1080attactagta acaacatttg gggccaggga accctggtca ccgtgtcctc agctagcacc   1140aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg gggcacagcg   1200gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca   1260ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac   1320tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc   1380aacgtgaatc acaagcccag caacaccaag gtggacaaga gagttgagcc caaatcttgt   1440gacaaaactc acacatgccc accgtgccca gcacctgaag ccgcgggggc accgtcagtc   1500ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca   1560tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac   1620ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac   1680cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag   1740tgcgcggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa   1800gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggatga gctgaccaag   1860aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag   1920tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc   1980gacggctcct tcttcctcta tagcaagctc accgtggaca agagcaggtg gcagcagggg   2040aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc   2100ctctccctgt ctccgggtgg cggtggaggg tccggcggtg gtggatccga ggtgcagctg   2160ttggagtctg ggggaggctt ggtacagcct ggggggtccc tgagactctc ctgtgcagcc   2220tctggattct ccttcagtag cgggtacgac atgtgctggg tccgccaggc tccagggaag   2280gggctggagt ggatcgcatg cattgctgct ggtagtgctg gtatcactta cgacgcgaac   2340tgggcgaaag gccggttcac catctccaga gacaattcca agaacacgct gtatctgcaa   2400atgaacagcc tgagagccga ggacacggcc gtatattact gtgcgagatc ggcgttttcg   2460ttcgactacg ccatggacct ctggggccag ggaaccctgg tcaccgtgtc gagcggtgga   2520ggcggatctg gcggaggtgg ttccggcggt ggcggctccg gtggaggcgg ctctgacatc   2580cagatgaccc agtctccttc caccctgtct gcatctgtag gagacagagt caccatcact   2640tgccaggcca gtcagagcat tagttcccac ttaaactggt atcagcagaa accagggaaa   2700gcccctaagc tcctgatcta taaggcatcc actctggcat ctggggtccc atcaaggttc   2760agcggcagtg gatctgggac agaatttact ctcaccatca gcagcctgca gcctgatgat   2820tttgcaactt attactgcca acagggttat agttggggta atgttgataa tgttttcggc   2880ggagggacca aggtggagat caaaggcggt ggagggtccg gcggtggtgg ctccggacgg   2940tcgctggtgg agtctggggg aggcttggtc cagcctgggg ggtccctgag actctcctgt   3000actgcctctg gattcaccat cagtagctac cacatgcagt gggtccgcca ggctccaggg   3060aaggggctgg agtacatcgg aaccattagt agtggtggta atgtatacta cgcaagctcc   3120gctagaggca gattcaccat ctccagaccc tcgtccaaga acacggtgga tcttcaaatg   3180aacagcctga gagccgagga cacggctgtg tattactgtg cgagagactc tggttatagt   3240gatcctatgt ggggccaggg aaccctggtc accgtctctt caggcggtgg cggtagtggg   3300ggaggcggtt ctggcggcgg agggtccggc ggtggaggat cagacgttgt gatgacccag   3360tctccatctt ccgtgtctgc atctgtagga gacagagtca ccatcacctg tcaggccagt   3420cagaacatta ggacttactt atcctggtat cagcagaaac cagggaaagc ccctaagctc   3480ctgatctatg ctgcagccaa tctggcatct ggggtcccat caaggttcag cggcagtgga   3540tctgggacag atttcactct caccatcagc gacctggagc ctggcgatgc tgcaacttac   3600tattgtcagt ctacctatct tggtactgat tatgttggcg gtgctttcgg cggagggacc   3660aaggtggaga tcaaatga                                                 3678</s400><s200><s210>11</s210><s211>475</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 11Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu    130                 135                 140Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met145                 150                 155                 160Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu                165                 170                 175Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys            180                 185                 190Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu        195                 200                 205Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala    210                 215                 220Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Asp Val Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly            260                 265                 270Asp Arg Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp        275                 280                 285Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile    290                 295                 300Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly305                 310                 315                 320Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro                325                 330                 335Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser            340                 345                 350Arg Thr Tyr Val Asn Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys        355                 360                 365Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu    370                 375                 380Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe385                 390                 395                 400Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln                405                 410                 415Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser            420                 425                 430Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu        435                 440                 445Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser    450                 455                 460Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys465                 470                 475</s400><s200><s210>12</s210><s211>1428</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 12gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaagtga cggtactggg tggaggcggt tcaggcggag gtggttccgg cggtggcggc    360tccggtggag gcggctctca ggtcacattg aaggaatctg gccccggcct tgttcagcca    420ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg    480ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg    540tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat    600acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta    660tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact    720ctcgtcacgg tctcgagcgg cggtggaggg tccggcggtg gtggatcaga cgtcgtgatg    780acccagtctc cttccaccct gtctgcatct gtaggagaca gagtcaccat caattgccaa    840gccagtgaga gcattagcag ttggttagcc tggtatcagc agaaaccagg gaaagcccct    900aagctcctga tctatgaagc atccaaactg gcatctgggg tcccatcaag gttcagcggc    960agtggatctg ggacagaatt cactctcacc atcagcagcc tgcagcctga tgattttgca   1020acttattact gccaaggcta tttttatttt attagtcgta cttatgtaaa ttctttcggc   1080ggagggacca aggtggagat caaacgtacg gtggctgcac catctgtctt catcttcccg   1140ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc   1200tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc   1260caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg   1320acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag   1380ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgttga                1428</s400><s200><s210>13</s210><s211>1218</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 13Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Ile            20                  25                  30His Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr        35                  40                  45Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu65                  70                  75                  80Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Thr Ser Asn Pro Pro Thr                85                  90                  95Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val    130                 135                 140Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asn Met145                 150                 155                 160His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile Gly Ala                165                 170                 175Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly            180                 185                 190Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln        195                 200                 205Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg    210                 215                 220Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly Ala Gly225                 230                 235                 240Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly                245                 250                 255Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Arg Leu Val Gln Pro Gly            260                 265                 270Glu Pro Leu Ser Leu Thr Cys Lys Thr Ser Gly Ile Asp Leu Ser Ser        275                 280                 285Asn Ala Ile Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp    290                 295                 300Ile Gly Val Ile Phe Gly Ser Gly Asn Thr Tyr Tyr Ala Ser Trp Ala305                 310                 315                 320Lys Gly Arg Phe Thr Ile Ser Arg Ser Thr Ser Thr Val Tyr Leu Lys                325                 330                 335Met Asn Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg            340                 345                 350Gly Gly Tyr Ser Ser Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val        355                 360                 365Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser    370                 375                 380Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys385                 390                 395                 400Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu                405                 410                 415Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu            420                 425                 430Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr        435                 440                 445Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val    450                 455                 460Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro465                 470                 475                 480Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe                485                 490                 495Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val            500                 505                 510Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe        515                 520                 525Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro    530                 535                 540Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr545                 550                 555                 560Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val                565                 570                 575Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala            580                 585                 590Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg        595                 600                 605Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly    610                 615                 620Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro625                 630                 635                 640Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser                645                 650                 655Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln            660                 665                 670Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His        675                 680                 685Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser    690                 695                 700Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu705                 710                 715                 720Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe                725                 730                 735Ser Phe Ser Ser Gly Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly            740                 745                 750Lys Gly Leu Glu Trp Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile        755                 760                 765Thr Tyr Asp Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp    770                 775                 780Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu785                 790                 795                 800Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr                805                 810                 815Ala Met Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly            820                 825                 830Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly        835                 840                 845Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala    850                 855                 860Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile865                 870                 875                 880Ser Ser His Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys                885                 890                 895Leu Leu Ile Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg            900                 905                 910Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser        915                 920                 925Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser    930                 935                 940Trp Gly Asn Val Asp Asn Val Phe Gly Gly Gly Thr Lys Val Glu Ile945                 950                 955                 960Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Arg Ser Leu Val                965                 970                 975Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser            980                 985                 990Cys Thr Ala Ser Gly Phe Thr Ile  Ser Ser Tyr His Met  Gln Trp Val        995                 1000                 1005Arg Gln  Ala Pro Gly Lys Gly  Leu Glu Tyr Ile Gly  Thr Ile Ser    1010                 1015                 1020Ser Gly  Gly Asn Val Tyr Tyr  Ala Ser Ser Ala Arg  Gly Arg Phe    1025                 1030                 1035Thr Ile  Ser Arg Pro Ser Ser  Lys Asn Thr Val Asp  Leu Gln Met    1040                 1045                 1050Asn Ser  Leu Arg Ala Glu Asp  Thr Ala Val Tyr Tyr  Cys Ala Arg    1055                 1060                 1065Asp Ser  Gly Tyr Ser Asp Pro  Met Trp Gly Gln Gly  Thr Leu Val    1070                 1075                 1080Thr Val  Ser Ser Gly Gly Gly  Gly Ser Gly Gly Gly  Gly Ser Gly    1085                 1090                 1095Gly Gly  Gly Ser Gly Gly Gly  Gly Ser Asp Val Val  Met Thr Gln    1100                 1105                 1110Ser Pro  Ser Ser Val Ser Ala  Ser Val Gly Asp Arg  Val Thr Ile    1115                 1120                 1125Thr Cys  Gln Ala Ser Gln Asn  Ile Arg Thr Tyr Leu  Ser Trp Tyr    1130                 1135                 1140Gln Gln  Lys Pro Gly Lys Ala  Pro Lys Leu Leu Ile  Tyr Ala Ala    1145                 1150                 1155Ala Asn  Leu Ala Ser Gly Val  Pro Ser Arg Phe Ser  Gly Ser Gly    1160                 1165                 1170Ser Gly  Thr Asp Phe Thr Leu  Thr Ile Ser Asp Leu  Glu Pro Gly    1175                 1180                 1185Asp Ala  Ala Thr Tyr Tyr Cys  Gln Ser Thr Tyr Leu  Gly Thr Asp    1190                 1195                 1200Tyr Val  Gly Gly Ala Phe Gly  Gly Gly Thr Lys Val  Glu Ile Lys    1205                 1210                 1215</s400><s200><s210>14</s210><s211>3657</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 14cagatcgtgc tgagccagag ccccgccatc ctgagcgcca gccccggcga gaaggtgacc     60atgacctgcc gggccagcag cagcgtgagc tacatccact ggttccagca gaagcccggc    120agcagcccca agccctggat ctacgccacc agcaacctgg ccagcggcgt gcccgtgcgg    180ttcagcggca gcggcagcgg caccagctac agcctgacca tcagccgggt ggaggccgag    240gacgccgcca cctactactg ccagcagtgg accagcaacc cccccacctt cggcggcggc    300accaagctga ccgtgctggg tggtggtggc tctggaggag gcgggagcgg gggtggtggc    360tcaggtggtg gaggttccca ggtgcagctg cagcagcccg gcgccgagct ggtgaagccc    420ggcgccagcg tgaagatgag ctgcaaggcc agcggctaca ccttcaccag ctacaacatg    480cactgggtga agcagacccc cggccggggc ctggagtgga tcggcgccat ctaccccggc    540aacggcgaca ccagctacaa ccagaagttc aagggcaagg ccaccctgac cgccgacaag    600agcagcagca ccgcctacat gcagctgagc agcctgacca gcgaggacag cgccgtgtac    660tactgcgccc ggagcaccta ctacggcggc gactggtact tcaacgtgtg gggcgccggc    720accaccgtga ccgtctcgag tggcggtgga gggtccggcg gtggtggatc acaagtgcag    780ttgcaagaaa gtggtggtag actggttcag cctggtgaac ccttgtcact gacgtgtaaa    840acaagcggca ttgatctgtc ctctaacgcc atcggatggg tccgacaggc cccaggaaaa    900ggtctggagt ggatcggagt tatcttcggg agcggcaata catactacgc aagctgggca    960aaagggcgat ttacgatatc acggagcacc tctacagttt atttgaaaat gaactccctc   1020cggtccgagg ataccgcgat atattactgt gccagagggg ggtactcctc tgatatctgg   1080gggcagggta cactggttac agtttcatcc gctagcacca agggcccatc ggtcttcccc   1140ctggcaccct cctccaagag cacctctggg ggcacagcgg ccctgggctg cctggtcaag   1200gactacttcc ccgaaccggt gacggtgtcg tggaactcag gcgccctgac cagcggcgtg   1260cacaccttcc cggctgtcct acagtcctca ggactctact ccctcagcag cgtggtgacc   1320gtgccctcca gcagcttggg cacccagacc tacatctgca acgtgaatca caagcccagc   1380aacaccaagg tggacaagag agttgagccc aaatcttgtg acaaaactca cacatgccca   1440ccgtgcccag cacctgaagc cgcgggggca ccgtcagtct tcctcttccc cccaaaaccc   1500aaggacaccc tcatgatctc ccggacccct gaggtcacat gcgtggtggt ggacgtgagc   1560cacgaagacc ctgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc   1620aagacaaagc cgcgggagga gcagtacaac agcacgtacc gtgtggtcag cgtcctcacc   1680gtcctgcacc aggactggct gaatggcaag gagtacaagt gcgcggtctc caacaaagcc   1740ctcccagccc ccatcgagaa aaccatctcc aaagccaaag ggcagccccg agaaccacag   1800gtgtacaccc tgcccccatc ccgggatgag ctgaccaaga accaggtcag cctgacctgc   1860ctggtcaaag gcttctatcc cagcgacatc gccgtggagt gggagagcaa tgggcagccg   1920gagaacaact acaagaccac gcctcccgtg ctggactccg acggctcctt cttcctctat   1980agcaagctca ccgtggacaa gagcaggtgg cagcagggga acgtcttctc atgctccgtg   2040atgcatgagg ctctgcacaa ccactacacg cagaagagcc tctccctgtc tccgggtggc   2100ggtggagggt ccggcggtgg tggatccgag gtgcagctgt tggagtctgg gggaggcttg   2160gtacagcctg gggggtccct gagactctcc tgtgcagcct ctggattctc cttcagtagc   2220gggtacgaca tgtgctgggt ccgccaggct ccagggaagg ggctggagtg gatcgcatgc   2280attgctgctg gtagtgctgg tatcacttac gacgcgaact gggcgaaagg ccggttcacc   2340atctccagag acaattccaa gaacacgctg tatctgcaaa tgaacagcct gagagccgag   2400gacacggccg tatattactg tgcgagatcg gcgttttcgt tcgactacgc catggacctc   2460tggggccagg gaaccctggt caccgtgtcg agcggtggag gcggatctgg cggaggtggt   2520tccggcggtg gcggctccgg tggaggcggc tctgacatcc agatgaccca gtctccttcc   2580accctgtctg catctgtagg agacagagtc accatcactt gccaggccag tcagagcatt   2640agttcccact taaactggta tcagcagaaa ccagggaaag cccctaagct cctgatctat   2700aaggcatcca ctctggcatc tggggtccca tcaaggttca gcggcagtgg atctgggaca   2760gaatttactc tcaccatcag cagcctgcag cctgatgatt ttgcaactta ttactgccaa   2820cagggttata gttggggtaa tgttgataat gttttcggcg gagggaccaa ggtggagatc   2880aaaggcggtg gagggtccgg cggtggtggc tccggacggt cgctggtgga gtctggggga   2940ggcttggtcc agcctggggg gtccctgaga ctctcctgta ctgcctctgg attcaccatc   3000agtagctacc acatgcagtg ggtccgccag gctccaggga aggggctgga gtacatcgga   3060accattagta gtggtggtaa tgtatactac gcaagctccg ctagaggcag attcaccatc   3120tccagaccct cgtccaagaa cacggtggat cttcaaatga acagcctgag agccgaggac   3180acggctgtgt attactgtgc gagagactct ggttatagtg atcctatgtg gggccaggga   3240accctggtca ccgtctcttc aggcggtggc ggtagtgggg gaggcggttc tggcggcgga   3300gggtccggcg gtggaggatc agacgttgtg atgacccagt ctccatcttc cgtgtctgca   3360tctgtaggag acagagtcac catcacctgt caggccagtc agaacattag gacttactta   3420tcctggtatc agcagaaacc agggaaagcc cctaagctcc tgatctatgc tgcagccaat   3480ctggcatctg gggtcccatc aaggttcagc ggcagtggat ctgggacaga tttcactctc   3540accatcagcg acctggagcc tggcgatgct gcaacttact attgtcagtc tacctatctt   3600ggtactgatt atgttggcgg tgctttcggc ggagggacca aggtggagat caaatga      3657</s400><s200><s210>15</s210><s211>478</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 15Asp Pro Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Ser Cys Gln Ser Ser Gln Ser Val Ala Lys Asn            20                  25                  30Asn Asn Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ala Gly Val Pro Ser Arg Phe    50                  55                  60Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val65                  70                  75                  80Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ser Ala Arg Asp Ser Gly                85                  90                  95Asn Ile Gln Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr            100                 105                 110Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu        115                 120                 125Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro    130                 135                 140Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly145                 150                 155                 160Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr                165                 170                 175Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His            180                 185                 190Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val        195                 200                 205Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Gly Gly    210                 215                 220Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Thr Leu Lys Glu Ser Gly225                 230                 235                 240Pro Gly Leu Val Gln Pro Gly Gln Thr Leu Arg Leu Thr Cys Ala Phe                245                 250                 255Ser Gly Phe Ser Leu Ser Thr Ser Gly Met Gly Val Gly Trp Ile Arg            260                 265                 270Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Ala His Ile Trp Trp Asp        275                 280                 285Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys Ser Arg Leu Thr Ile Ser    290                 295                 300Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu Gln Met Asn Ser Leu Asp305                 310                 315                 320Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Met Glu Leu Trp Ser                325                 330                 335Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser            340                 345                 350Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly        355                 360                 365Gly Gly Gly Ser Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser    370                 375                 380Ala Ser Pro Gly Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser385                 390                 395                 400Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys                405                 410                 415Leu Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg            420                 425                 430Phe Ser Gly Ser Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser        435                 440                 445Met Glu Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val    450                 455                 460Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Thr Val Leu465                 470                 475</s400><s200><s210>16</s210><s211>1437</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 16gatccagttc tgacacaaag tccatccagc ctgtctgcct cagtcggcga cagagtgacc     60atcagttgcc agagctcaca gtctgtggct aagaacaaca acttggcgtg gttccaacag    120aaacctggac aggctccgaa attgctgatc tattctgctt ccacgcttgc tgctggtgtt    180ccttcccgct tttcaggtag tggtagcggg acagacttca ctttgactat aagcagcgtg    240cagcctgaag attttgcgac ctactattgt tctgctagag acagtggaaa tattcagtcc    300tttggggggg gaacgaaggt cgaaataaag cgtacggtgg ctgcaccatc tgtcttcatc    360ttcccgccat ctgatgagca gttgaaatct ggaactgcct ctgttgtgtg cctgctgaat    420aacttctatc ccagagaggc caaagtacag tggaaggtgg ataacgccct ccaatcgggt    480aactcccagg agagtgtcac agagcaggac agcaaggaca gcacctacag cctcagcagc    540accctgacgc tgagcaaagc agactacgag aaacacaaag tctacgcctg cgaagtcacc    600catcagggcc tgagctcgcc cgtcacaaag agcttcaaca ggggagagtg tggtggaggc    660ggttcaggcg gaggtggttc cggcggtggc ggctcccagg tcacattgaa ggaatctggc    720cccggccttg ttcagccagg acagaccctt aggctcacct gtgccttcag tggtttttct    780cttagcacta gcggtatggg ggtcggctgg attcggcagc ctcccggcaa aggtcttgag    840tggttggctc acatttggtg ggacgacgac aaacggtata atcctgcctt gaaaagtcgg    900ctgaccatta gtaaggatac ctcaaaaaat caagtgtact tgcaaatgaa tagccttgac    960gccgaggata cggctgtata ttattgcgcg cggatggaac tctggtctta ctactttgat   1020tattgggggc aggggactct cgtcacggtc tcgagtggtg gaggcggttc aggcggaggt   1080ggttccggcg gtggcggctc cggtggaggc ggctctgaaa atgtattgac acagagcccc   1140gcctccctca gtgcctcacc tggggaaagg gtaactatca cttgctctgc atcaagcagc   1200gtctcataca tgcattggta tcaacaaaag cctggacagg cccccaagct ctggatatac   1260gatacgagca agctggcttc cggcgtacct agccgcttca gtggttccgg ctcaggcaac   1320gatcacaccc ttacgatttc cagtatggaa cccgaagatt ttgcaactta ttattgtttc   1380caggggagcg tgtacccatt cactttcggg caggggacaa aagtgacggt actgtga      1437</s400><s200><s210>17</s210><s211>1229</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 17Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Ile Ile Thr Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser                85                  90                  95Arg Thr Tyr Val Asn Ser Phe Gly Cys Gly Thr Lys Leu Thr Val Leu            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly        115                 120                 125Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val    130                 135                 140Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr145                 150                 155                 160Ile Ser Thr Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Cys                165                 170                 175Leu Glu Trp Val Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala            180                 185                 190Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn        195                 200                 205Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val    210                 215                 220Tyr Tyr Cys Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn225                 230                 235                 240Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Thr Gly Gly Gly Gly                245                 250                 255Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu            260                 265                 270Leu Glu Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly        275                 280                 285Tyr Ser Phe Thr Gly Tyr Thr Met Asn Trp Val Lys Gln Ser His Gly    290                 295                 300Lys Ser Leu Glu Trp Ile Gly Leu Ile Thr Pro Tyr Asn Gly Ala Ser305                 310                 315                 320Ser Tyr Asn Gln Lys Phe Arg Gly Lys Ala Thr Leu Thr Val Asp Lys                325                 330                 335Ser Ser Ser Thr Ala Tyr Met Asp Leu Leu Ser Leu Thr Ser Glu Asp            340                 345                 350Ser Ala Val Tyr Phe Cys Ala Arg Gly Gly Tyr Asp Gly Arg Gly Phe        355                 360                 365Asp Tyr Trp Gly Ser Gly Thr Pro Val Thr Val Ser Ser Ala Ser Thr    370                 375                 380Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser385                 390                 395                 400Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu                405                 410                 415Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His            420                 425                 430Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser        435                 440                 445Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys    450                 455                 460Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu465                 470                 475                 480Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro                485                 490                 495Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys            500                 505                 510Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val        515                 520                 525Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp    530                 535                 540Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr545                 550                 555                 560Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp                565                 570                 575Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu            580                 585                 590Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg        595                 600                 605Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys    610                 615                 620Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp625                 630                 635                 640Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys                645                 650                 655Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser            660                 665                 670Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser        675                 680                 685Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser    690                 695                 700Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser705                 710                 715                 720Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly                725                 730                 735Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly            740                 745                 750Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Cys Leu Glu Trp        755                 760                 765Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr Tyr Asp Ala Asn    770                 775                 780Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr785                 790                 795                 800Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr                805                 810                 815Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala Met Asp Leu Trp            820                 825                 830Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly        835                 840                 845Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile    850                 855                 860Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg865                 870                 875                 880Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser His Leu Asn                885                 890                 895Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys            900                 905                 910Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly        915                 920                 925Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp    930                 935                 940Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp Gly Asn Val Asp945                 950                 955                 960Asn Val Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly                965                 970                 975Ser Gly Gly Gly Gly Ser Gly Arg Ser Leu Val Glu Ser Gly Gly Gly            980                 985                 990Leu Val Gln Pro Gly Gly Ser Leu  Arg Leu Ser Cys Thr  Ala Ser Gly        995                 1000                 1005Phe Thr  Ile Ser Ser Tyr His  Met Gln Trp Val Arg  Gln Ala Pro    1010                 1015                 1020Gly Lys  Cys Leu Glu Tyr Ile  Gly Thr Ile Ser Ser  Gly Gly Asn    1025                 1030                 1035Val Tyr  Tyr Ala Ser Ser Ala  Arg Gly Arg Phe Thr  Ile Ser Arg    1040                 1045                 1050Pro Ser  Ser Lys Asn Thr Val  Asp Leu Gln Met Asn  Ser Leu Arg    1055                 1060                 1065Ala Glu  Asp Thr Ala Val Tyr  Tyr Cys Ala Arg Asp  Ser Gly Tyr    1070                 1075                 1080Ser Asp  Pro Met Trp Gly Gln  Gly Thr Leu Val Thr  Val Ser Ser    1085                 1090                 1095Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser    1100                 1105                 1110Gly Gly  Gly Gly Ser Asp Val  Val Met Thr Gln Ser  Pro Ser Ser    1115                 1120                 1125Val Ser  Ala Ser Val Gly Asp  Arg Val Thr Ile Thr  Cys Gln Ala    1130                 1135                 1140Ser Gln  Asn Ile Arg Thr Tyr  Leu Ser Trp Tyr Gln  Gln Lys Pro    1145                 1150                 1155Gly Lys  Ala Pro Lys Leu Leu  Ile Tyr Ala Ala Ala  Asn Leu Ala    1160                 1165                 1170Ser Gly  Val Pro Ser Arg Phe  Ser Gly Ser Gly Ser  Gly Thr Asp    1175                 1180                 1185Phe Thr  Leu Thr Ile Ser Asp  Leu Glu Pro Gly Asp  Ala Ala Thr    1190                 1195                 1200Tyr Tyr  Cys Gln Ser Thr Tyr  Leu Gly Thr Asp Tyr  Val Gly Gly    1205                 1210                 1215Ala Phe  Gly Cys Gly Thr Lys  Val Glu Ile Lys    1220                 1225</s400><s200><s210>18</s210><s211>3690</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 18gagatcgtga tgacccagag ccccagcacc ctgagcgcca gcgtgggcga cagggtgatc     60atcacctgcc aggccagcga gagcatcagc agctggctgg cctggtacca gcagaagccc    120ggcaaggccc ccaagctgct gatctacgag gccagcaagc tggccagcgg cgtgcccagc    180aggttcagcg gcagcggcag cggcgccgag ttcaccctga ccatcagcag cctgcagccc    240gacgacttcg ccacctacta ctgccagggc tacttctact tcatcagcag gacctacgtg    300aacagcttcg gctgcggcac caagctgacc gtgctgggcg gtggcggtag tgggggaggc    360ggttctggcg gcggagggtc cggcggtgga ggatcagagg tgcagctggt ggagagcggc    420ggcggcctgg tgcagcccgg cggcagcctg aggctgagct gcaccgccag cggcttcacc    480atcagcacca acgccatgag ctgggtgagg caggcccccg gcaagtgcct ggagtgggtg    540ggcgtgatca ccggcaggga catcacctac tacgccagct gggccaaggg caggttcacc    600atcagcaggg acaccagcaa gaacaccgtg tacctgcaga tgaacagcct gagggccgag    660gacaccgccg tgtactactg cgccagggac ggcggcagca gcgccatcac cagcaacaac    720atctggggcc agggcaccct ggtgaccgtg tcgacaggcg gtggagggtc cggcggtggt    780ggatcacagg tacaactgca gcagtctggg cctgagctgg agaagcctgg cgcttcagtg    840aagatatcct gcaaggcttc tggttactca ttcactggct acaccatgaa ctgggtgaag    900cagagccatg gaaagagcct tgagtggatt ggacttatta ctccttacaa tggtgcttct    960agctacaacc agaagttcag gggcaaggcc acattaactg tagacaagtc atccagcaca   1020gcctacatgg acctcctcag tctgacatct gaagactctg cagtctattt ctgtgcaagg   1080gggggttacg acgggagggg ttttgactac tggggatccg ggaccccggt caccgtctcc   1140tcagctagca ccaagggccc atcggtcttc cccctggcac cctcctccaa gagcacctct   1200gggggcacag cggccctggg ctgcctggtc aaggactact tccccgaacc ggtgacggtg   1260tcgtggaact caggcgccct gaccagcggc gtgcacacct tcccggctgt cctacagtcc   1320tcaggactct actccctcag cagcgtggtg accgtgccct ccagcagctt gggcacccag   1380acctacatct gcaacgtgaa tcacaagccc agcaacacca aggtggacaa gagagttgag   1440cccaaatctt gtgacaaaac tcacacatgc ccaccgtgcc cagcacctga agccgcgggg   1500ggaccgtcag tcttcctctt ccccccaaaa cccaaggaca ccctcatgat ctcccggacc   1560cctgaggtca catgcgtggt ggtggacgtg agccacgaag accctgaggt caagttcaac   1620tggtacgtgg acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagtac   1680gccagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc   1740aaggagtaca agtgcgcggt ctccaacaaa gccctcccag cccccatcga gaaaaccatc   1800tccaaagcca aagggcagcc ccgagaacca caggtgtaca ccctgccccc atcccgggat   1860gagctgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta tcccagcgac   1920atcgccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cacgcctccc   1980gtgctggact ccgacggctc cttcttcctc tatagcaagc tcaccgtgga caagagcagg   2040tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac   2100acgcagaaga gcctctccct gtctccgggt ggcggtggag ggtccggcgg tggtggatcc   2160gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc   2220tcctgtgcag cctctggatt ctccttcagt agcgggtacg acatgtgctg ggtccgccag   2280gctccaggga agtgcctgga gtggatcgca tgcattgctg ctggtagtgc tggtatcact   2340tacgacgcga actgggcgaa aggccggttc accatctcca gagacaattc caagaacacg   2400ctgtatctgc aaatgaacag cctgagagcc gaggacacgg ccgtatatta ctgtgcgaga   2460tcggcgtttt cgttcgacta cgccatggac ctctggggcc agggaaccct ggtcaccgtc   2520tcgagcggtg gaggcggttc aggcggaggt ggaagtggtg gtggcggctc tggaggcggc   2580ggatctgaca tccagatgac ccagtctcct tccaccctgt ctgcatctgt aggagacaga   2640gtcaccatca cttgccaggc cagtcagagc attagttccc acttaaactg gtatcagcag   2700aaaccaggga aagcccctaa gctcctgatc tataaggcat ccactctggc atctggggtc   2760ccatcaaggt tcagcggcag tggatctggg acagaattta ctctcaccat cagcagcctg   2820cagcctgatg attttgcaac ttattactgc caacagggtt atagttgggg taatgttgat   2880aatgttttcg gctgcgggac caaggtggag atcaaaggtg gtggcggctc tggaggagga   2940gggtccggac ggtcgctggt ggagtctggg ggaggcttgg tccagcctgg ggggtccctg   3000agactctcct gtactgcctc tggattcacc atcagtagct accacatgca gtgggtccgg   3060caggcacctg ggaagtgcct ggagtacatc ggaaccatta gtagtggtgg taatgtatac   3120tacgcaagct ccgctagagg cagattcacc atctccagac cctcgtccaa gaacacggtg   3180gatcttcaaa tgaacagcct gagagccgag gacacggctg tgtattactg tgcgagagac   3240tctggttata gtgatcctat gtggggccag ggaaccctgg tcaccgtctc ttcaggcggt   3300ggcggtagtg ggggaggcgg ttctggcggc ggagggtccg gcggtggagg atcagacgtt   3360gtgatgaccc agtctccatc ttccgtgtct gcatctgtag gagacagagt caccatcacc   3420tgtcaggcca gtcagaacat taggacttac ttatcctggt atcagcagaa accagggaaa   3480gcccctaagc tcctgatcta tgctgcagcc aatctggcat ctggggtccc atcaaggttc   3540agcggcagtg gatctgggac agatttcact ctcaccatca gcgacttgga acctggcgat   3600gctgcaactt actattgtca gtctacctat cttggtactg attatgttgg cggtgctttc   3660ggctgtggga ccaaggtgga gatcaaatga                                    3690</s400><s200><s210>19</s210><s211>521</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 19Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly1               5                   10                  15Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Gly Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu65                  70                  75                  80Asp Asp Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Lys His Pro Leu Thr                85                  90                  95Phe Gly Ser Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro            100                 105                 110Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr        115                 120                 125Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys    130                 135                 140Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu145                 150                 155                 160Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser                165                 170                 175Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala            180                 185                 190Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe        195                 200                 205Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Phe    210                 215                 220Leu Asn Ser Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr Glu Ser225                 230                 235                 240Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn Asn Cys                245                 250                 255Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln Ala Ser            260                 265                 270Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys Glu Asp        275                 280                 285Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly Leu Val    290                 295                 300His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser Ile Leu305                 310                 315                 320Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp Cys Ala                325                 330                 335Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser Thr Pro            340                 345                 350Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Gly Gly Gly Gly Ser Gly        355                 360                 365Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Phe Leu    370                 375                 380Asn Ser Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr Glu Ser Tyr385                 390                 395                 400Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn Asn Cys Tyr                405                 410                 415Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln Ala Ser Cys            420                 425                 430Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys Glu Asp Gln        435                 440                 445Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly Leu Val His    450                 455                 460Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser Ile Leu Ser465                 470                 475                 480Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp Cys Ala Leu                485                 490                 495Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser Thr Pro Asn            500                 505                 510Thr Tyr Ile Cys Met Gln Arg Thr Val        515                 520</s400><s200><s210>20</s210><s211>1566</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 20gacatcgagc tcactcagtc tccagcaatc atgtctgcat ctccagggga gaaggtcacc     60atgacctgca gtgccagctc aagtgtaagt tacatgcact ggtaccagca gaagtcaggc    120acctccccca aaagatggat ttatgacaca tccaaactgg cttctggagt cccaggtcgc    180ttcagtggca gtgggtctgg aaactcttac tctctcacaa tcagcagcgt ggaggctgaa    240gatgatgcaa cttattactg ccagcagtgg agtaagcacc ctctcacgtt cggatccggg    300accaaggtgg aaatcaaacg tacggtggct gcaccatctg tcttcatctt cccgccatct    360gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc    420agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag    480agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg    540agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg    600agctcgcccg tcacaaagag cttcaacagg ggagagtgtg gcggtggagg gtccggcggt    660ggtggatcct ttcttaattc ccttttcaac caagaggttc agatcccctt gactgaaagc    720tattgcggcc cttgtccgaa aaactggata tgttacaaga ataattgtta ccaattcttc    780gacgaaagca agaactggta tgagagtcag gcgtcttgta tgagtcagaa tgccagcctg    840cttaaggttt attcaaaaga agaccaggat ctgcttaagt tggtaaagag ctaccactgg    900atggggctgg tacatatccc aacgaatggg tcatggcagt gggaggacgg ttctattctg    960agtccaaatc tcctgacgat catcgaaatg cagaaagggg actgtgccct gtatgcatca   1020tccttcaagg ggtacatcga gaactgcagt accccaaata cctacatttg tatgcaaaga   1080acggttggag gcggtggctc aggcggaggc ggctcaggag gtggcggttc aggaggcggc   1140ggatctttcc taaactcatt attcaaccaa gaagttcaaa ttcccttgac cgaaagttac   1200tgtggcccat gtcctaaaaa ctggatatgt tacaaaaata actgctacca attttttgat   1260gagagtaaaa actggtatga gagccaggct tcttgtatgt ctcaaaatgc cagccttctg   1320aaagtataca gcaaagagga ccaggattta cttaaactgg tgaagtcata tcattggatg   1380ggactagtac acattccaac aaatggatct tggcagtggg aagatggctc cattctctca   1440cccaacctac taacaataat tgaaatgcag aagggagact gtgcactcta tgcctcgagc   1500tttaaaggct atatagaaaa ctgttcaact ccaaatacgt acatctgcat gcaaaggact   1560gtgtag                                                              1566</s400><s200><s210>21</s210><s211>1230</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 21Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Ile Ile Thr Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser                85                  90                  95Arg Thr Tyr Val Asn Ser Phe Gly Cys Gly Thr Lys Leu Thr Val Leu            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly        115                 120                 125Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val    130                 135                 140Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr145                 150                 155                 160Ile Ser Thr Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Cys                165                 170                 175Leu Glu Trp Val Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala            180                 185                 190Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn        195                 200                 205Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val    210                 215                 220Tyr Tyr Cys Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn225                 230                 235                 240Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Thr Gly Gly Gly Gly                245                 250                 255Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly            260                 265                 270Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly        275                 280                 285Phe Asn Ile Lys Asp Thr Tyr Ile His Trp Val Arg Gln Ala Pro Gly    290                 295                 300Lys Gly Leu Glu Trp Val Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr305                 310                 315                 320Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr                325                 330                 335Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp            340                 345                 350Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala        355                 360                 365Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser    370                 375                 380Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr385                 390                 395                 400Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro                405                 410                 415Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val            420                 425                 430His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser        435                 440                 445Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile    450                 455                 460Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val465                 470                 475                 480Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala                485                 490                 495Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            500                 505                 510Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val        515                 520                 525Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val    530                 535                 540Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln545                 550                 555                 560Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln                565                 570                 575Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala            580                 585                 590Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro        595                 600                 605Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr    610                 615                 620Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser625                 630                 635                 640Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr                645                 650                 655Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr            660                 665                 670Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe        675                 680                 685Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys    690                 695                 700Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly705                 710                 715                 720Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly                725                 730                 735Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser            740                 745                 750Gly Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Cys Leu Glu        755                 760                 765Trp Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr Tyr Asp Ala    770                 775                 780Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn785                 790                 795                 800Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val                805                 810                 815Tyr Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala Met Asp Leu            820                 825                 830Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser        835                 840                 845Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp    850                 855                 860Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp865                 870                 875                 880Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser His Leu                885                 890                 895Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr            900                 905                 910Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser        915                 920                 925Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp    930                 935                 940Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp Gly Asn Val945                 950                 955                 960Asp Asn Val Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Gly Gly Gly                965                 970                 975Gly Ser Gly Gly Gly Gly Ser Gly Arg Ser Leu Val Glu Ser Gly Gly            980                 985                 990Gly Leu Val Gln Pro Gly Gly Ser  Leu Arg Leu Ser Cys  Thr Ala Ser        995                 1000                 1005Gly Phe  Thr Ile Ser Ser Tyr  His Met Gln Trp Val  Arg Gln Ala    1010                 1015                 1020Pro Gly  Lys Cys Leu Glu Tyr  Ile Gly Thr Ile Ser  Ser Gly Gly    1025                 1030                 1035Asn Val  Tyr Tyr Ala Ser Ser  Ala Arg Gly Arg Phe  Thr Ile Ser    1040                 1045                 1050Arg Pro  Ser Ser Lys Asn Thr  Val Asp Leu Gln Met  Asn Ser Leu    1055                 1060                 1065Arg Ala  Glu Asp Thr Ala Val  Tyr Tyr Cys Ala Arg  Asp Ser Gly    1070                 1075                 1080Tyr Ser  Asp Pro Met Trp Gly  Gln Gly Thr Leu Val  Thr Val Ser    1085                 1090                 1095Ser Gly  Gly Gly Gly Ser Gly  Gly Gly Gly Ser Gly  Gly Gly Gly    1100                 1105                 1110Ser Gly  Gly Gly Gly Ser Asp  Val Val Met Thr Gln  Ser Pro Ser    1115                 1120                 1125Ser Val  Ser Ala Ser Val Gly  Asp Arg Val Thr Ile  Thr Cys Gln    1130                 1135                 1140Ala Ser  Gln Asn Ile Arg Thr  Tyr Leu Ser Trp Tyr  Gln Gln Lys    1145                 1150                 1155Pro Gly  Lys Ala Pro Lys Leu  Leu Ile Tyr Ala Ala  Ala Asn Leu    1160                 1165                 1170Ala Ser  Gly Val Pro Ser Arg  Phe Ser Gly Ser Gly  Ser Gly Thr    1175                 1180                 1185Asp Phe  Thr Leu Thr Ile Ser  Asp Leu Glu Pro Gly  Asp Ala Ala    1190                 1195                 1200Thr Tyr  Tyr Cys Gln Ser Thr  Tyr Leu Gly Thr Asp  Tyr Val Gly    1205                 1210                 1215Gly Ala  Phe Gly Cys Gly Thr  Lys Val Glu Ile Lys    1220                 1225                 1230</s400><s200><s210>22</s210><s211>3693</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 22gagatcgtga tgacccagag ccccagcacc ctgagcgcca gcgtgggcga cagggtgatc     60atcacctgcc aggccagcga gagcatcagc agctggctgg cctggtacca gcagaagccc    120ggcaaggccc ccaagctgct gatctacgag gccagcaagc tggccagcgg cgtgcccagc    180aggttcagcg gcagcggcag cggcgccgag ttcaccctga ccatcagcag cctgcagccc    240gacgacttcg ccacctacta ctgccagggc tacttctact tcatcagcag gacctacgtg    300aacagcttcg gctgcggcac caagctgacc gtgctgggcg gtggcggtag tgggggaggc    360ggttctggcg gcggagggtc cggcggtgga ggatcagagg tgcagctggt ggagagcggc    420ggcggcctgg tgcagcccgg cggcagcctg aggctgagct gcaccgccag cggcttcacc    480atcagcacca acgccatgag ctgggtgagg caggcccccg gcaagtgcct ggagtgggtg    540ggcgtgatca ccggcaggga catcacctac tacgccagct gggccaaggg caggttcacc    600atcagcaggg acaccagcaa gaacaccgtg tacctgcaga tgaacagcct gagggccgag    660gacaccgccg tgtactactg cgccagggac ggcggcagca gcgccatcac cagcaacaac    720atctggggcc agggcaccct ggtgaccgtg tcgacaggcg gtggagggtc cggcggtggt    780ggatcagagg ttcagctggt ggagtctggc ggtggcctgg tgcagccagg gggctcactc    840cgtttgtcct gtgcagcttc tggcttcaac attaaagaca cctatataca ctgggtgcgt    900caggccccgg gtaagggcct ggaatgggtt gcaaggattt atcctacgaa tggttatact    960agatatgccg atagcgtcaa gggccgtttc actataagcg cagacacatc caaaaacaca   1020gcctacctgc agatgaacag cctgcgtgct gaggacactg ccgtctatta ttgttctaga   1080tggggagggg acggcttcta tgctatggac tactggggtc aaggaaccct ggtcaccgtc   1140tcctcggcta gcaccaaggg cccatcggtc ttccccctgg caccctcctc caagagcacc   1200tctgggggca cagcggccct gggctgcctg gtcaaggact acttccccga accggtgacg   1260gtgtcgtgga actcaggcgc cctgaccagc ggcgtgcaca ccttcccggc tgtcctacag   1320tcctcaggac tctactccct cagcagcgtg gtgaccgtgc cctccagcag cttgggcacc   1380cagacctaca tctgcaacgt gaatcacaag cccagcaaca ccaaggtgga caagagagtt   1440gagcccaaat cttgtgacaa aactcacaca tgcccaccgt gcccagcacc tgaagccgcg   1500gggggaccgt cagtcttcct cttcccccca aaacccaagg acaccctcat gatctcccgg   1560acccctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc   1620aactggtacg tggacggcgt ggaggtgcat aatgccaaga caaagccgcg ggaggagcag   1680tacgccagca cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat   1740ggcaaggagt acaagtgcgc ggtctccaac aaagccctcc cagcccccat cgagaaaacc   1800atctccaaag ccaaagggca gccccgagaa ccacaggtgt acaccctgcc cccatcccgg   1860gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatcccagc   1920gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct   1980cccgtgctgg actccgacgg ctccttcttc ctctatagca agctcaccgt ggacaagagc   2040aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac   2100tacacgcaga agagcctctc cctgtctccg ggtggcggtg gagggtccgg cggtggtgga   2160tccgaggtgc agctgttgga gtctggggga ggcttggtac agcctggggg gtccctgaga   2220ctctcctgtg cagcctctgg attctccttc agtagcgggt acgacatgtg ctgggtccgc   2280caggctccag ggaagtgcct ggagtggatc gcatgcattg ctgctggtag tgctggtatc   2340acttacgacg cgaactgggc gaaaggccgg ttcaccatct ccagagacaa ttccaagaac   2400acgctgtatc tgcaaatgaa cagcctgaga gccgaggaca cggccgtata ttactgtgcg   2460agatcggcgt tttcgttcga ctacgccatg gacctctggg gccagggaac cctggtcacc   2520gtctcgagcg gtggaggcgg ttcaggcgga ggtggaagtg gtggtggcgg ctctggaggc   2580ggcggatctg acatccagat gacccagtct ccttccaccc tgtctgcatc tgtaggagac   2640agagtcacca tcacttgcca ggccagtcag agcattagtt cccacttaaa ctggtatcag   2700cagaaaccag ggaaagcccc taagctcctg atctataagg catccactct ggcatctggg   2760gtcccatcaa ggttcagcgg cagtggatct gggacagaat ttactctcac catcagcagc   2820ctgcagcctg atgattttgc aacttattac tgccaacagg gttatagttg gggtaatgtt   2880gataatgttt tcggctgcgg gaccaaggtg gagatcaaag gtggtggcgg ctctggagga   2940ggagggtccg gacggtcgct ggtggagtct gggggaggct tggtccagcc tggggggtcc   3000ctgagactct cctgtactgc ctctggattc accatcagta gctaccacat gcagtgggtc   3060cggcaggcac ctgggaagtg cctggagtac atcggaacca ttagtagtgg tggtaatgta   3120tactacgcaa gctccgctag aggcagattc accatctcca gaccctcgtc caagaacacg   3180gtggatcttc aaatgaacag cctgagagcc gaggacacgg ctgtgtatta ctgtgcgaga   3240gactctggtt atagtgatcc tatgtggggc cagggaaccc tggtcaccgt ctcttcaggc   3300ggtggcggta gtgggggagg cggttctggc ggcggagggt ccggcggtgg aggatcagac   3360gttgtgatga cccagtctcc atcttccgtg tctgcatctg taggagacag agtcaccatc   3420acctgtcagg ccagtcagaa cattaggact tacttatcct ggtatcagca gaaaccaggg   3480aaagccccta agctcctgat ctatgctgca gccaatctgg catctggggt cccatcaagg   3540ttcagcggca gtggatctgg gacagatttc actctcacca tcagcgactt ggaacctggc   3600gatgctgcaa cttactattg tcagtctacc tatcttggta ctgattatgt tggcggtgct   3660ttcggctgtg ggaccaaggt ggagatcaaa tga                                3693</s400><s200><s210>23</s210><s211>522</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 23Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala            20                  25                  30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala            100                 105                 110Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly        115                 120                 125Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala    130                 135                 140Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145                 150                 155                 160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser                165                 170                 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr            180                 185                 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser        195                 200                 205Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser    210                 215                 220Phe Leu Asn Ser Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr Glu225                 230                 235                 240Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn Asn                245                 250                 255Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln Ala            260                 265                 270Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys Glu        275                 280                 285Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly Leu    290                 295                 300Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser Ile305                 310                 315                 320Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp Cys                325                 330                 335Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser Thr            340                 345                 350Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Gly Gly Gly Gly Ser        355                 360                 365Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Phe    370                 375                 380Leu Asn Ser Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr Glu Ser385                 390                 395                 400Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn Asn Cys                405                 410                 415Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln Ala Ser            420                 425                 430Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys Glu Asp        435                 440                 445Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly Leu Val    450                 455                 460His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser Ile Leu465                 470                 475                 480Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp Cys Ala                485                 490                 495Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser Thr Pro            500                 505                 510Asn Thr Tyr Ile Cys Met Gln Arg Thr Val        515                 520</s400><s200><s210>24</s210><s211>1569</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 24gatatccaga tgacccagtc cccgagctcc ctgtccgcct ctgtgggcga tagggtcacc     60atcacctgcc gtgccagtca ggatgtgaat actgctgtag cctggtatca acagaaacca    120ggaaaagctc cgaaactact gatttactcg gcatccttcc tctactctgg agtcccttct    180cgcttctctg gctccagatc tgggacggat ttcactctga ccatcagcag tctgcagccg    240gaagacttcg caacttatta ctgtcagcaa cattatacta ctcctcccac gttcggacag    300ggtaccaagg tggagatcaa acgtacggtg gctgcaccat ctgtcttcat cttcccgcca    360tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat    420cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag    480gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg    540ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc    600ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gtggcggtgg agggtccggc    660ggtggtggat cctttcttaa ttcccttttc aaccaagagg ttcagatccc cttgactgaa    720agctattgcg gcccttgtcc gaaaaactgg atatgttaca agaataattg ttaccaattc    780ttcgacgaaa gcaagaactg gtatgagagt caggcgtctt gtatgagtca gaatgccagc    840ctgcttaagg tttattcaaa agaagaccag gatctgctta agttggtaaa gagctaccac    900tggatggggc tggtacatat cccaacgaat gggtcatggc agtgggagga cggttctatt    960ctgagtccaa atctcctgac gatcatcgaa atgcagaaag gggactgtgc cctgtatgca   1020tcatccttca aggggtacat cgagaactgc agtaccccaa atacctacat ttgtatgcaa   1080agaacggttg gaggcggtgg ctcaggcgga ggcggctcag gaggtggcgg ttcaggaggc   1140ggcggatctt tcctaaactc attattcaac caagaagttc aaattccctt gaccgaaagt   1200tactgtggcc catgtcctaa aaactggata tgttacaaaa ataactgcta ccaatttttt   1260gatgagagta aaaactggta tgagagccag gcttcttgta tgtctcaaaa tgccagcctt   1320ctgaaagtat acagcaaaga ggaccaggat ttacttaaac tggtgaagtc atatcattgg   1380atgggactag tacacattcc aacaaatgga tcttggcagt gggaagatgg ctccattctc   1440tcacccaacc tactaacaat aattgaaatg cagaagggag actgtgcact ctatgcctcg   1500agctttaaag gctatataga aaactgttca actccaaata cgtacatctg catgcaaagg   1560actgtgtag                                                           1569</s400><s200><s210>25</s210><s211>1217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 25Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Ile Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu        115                 120                 125Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    130                 135                 140Leu Arg Leu Ser Cys Ser Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly145                 150                 155                 160Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly                165                 170                 175Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser            180                 185                 190Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val Tyr Leu Gln        195                 200                 205Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg    210                 215                 220Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Gln Val Gln Leu Gln Glu Ser Gly Gly Arg Leu Val Gln Pro Gly Glu            260                 265                 270Pro Leu Ser Leu Thr Cys Lys Thr Ser Gly Ile Asp Leu Ser Ser Asn        275                 280                 285Ala Ile Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile    290                 295                 300Gly Val Ile Phe Gly Ser Gly Asn Thr Tyr Tyr Ala Ser Trp Ala Lys305                 310                 315                 320Gly Arg Phe Thr Ile Ser Arg Ser Thr Ser Thr Val Tyr Leu Lys Met                325                 330                 335Asn Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly            340                 345                 350Gly Tyr Ser Ser Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser        355                 360                 365Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser    370                 375                 380Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp385                 390                 395                 400Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr                405                 410                 415Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr            420                 425                 430Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln        435                 440                 445Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp    450                 455                 460Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro465                 470                 475                 480Cys Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe Pro                485                 490                 495Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr            500                 505                 510Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn        515                 520                 525Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg    530                 535                 540Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val545                 550                 555                 560Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser                565                 570                 575Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys            580                 585                 590Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp        595                 600                 605Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe    610                 615                 620Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu625                 630                 635                 640Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe                645                 650                 655Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly            660                 665                 670Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr        675                 680                 685Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly    690                 695                 700Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val705                 710                 715                 720Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser                725                 730                 735Phe Ser Ser Gly Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys            740                 745                 750Gly Leu Glu Trp Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr        755                 760                 765Tyr Asp Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn    770                 775                 780Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp785                 790                 795                 800Thr Ala Val Tyr Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala                805                 810                 815Met Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly            820                 825                 830Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        835                 840                 845Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser    850                 855                 860Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser865                 870                 875                 880Ser His Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu                885                 890                 895Leu Ile Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe            900                 905                 910Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu        915                 920                 925Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp    930                 935                 940Gly Asn Val Asp Asn Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys945                 950                 955                 960Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Arg Ser Leu Val Glu                965                 970                 975Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys            980                 985                 990Thr Ala Ser Gly Phe Thr Ile Ser  Ser Tyr His Met Gln  Trp Val Arg        995                 1000                 1005Gln Ala  Pro Gly Lys Gly Leu  Glu Tyr Ile Gly Thr  Ile Ser Ser    1010                 1015                 1020Gly Gly  Asn Val Tyr Tyr Ala  Ser Ser Ala Arg Gly  Arg Phe Thr    1025                 1030                 1035Ile Ser  Arg Pro Ser Ser Lys  Asn Thr Val Asp Leu  Gln Met Asn    1040                 1045                 1050Ser Leu  Arg Ala Glu Asp Thr  Ala Val Tyr Tyr Cys  Ala Arg Asp    1055                 1060                 1065Ser Gly  Tyr Ser Asp Pro Met  Trp Gly Gln Gly Thr  Leu Val Thr    1070                 1075                 1080Val Ser  Ser Gly Gly Gly Gly  Ser Gly Gly Gly Gly  Ser Gly Gly    1085                 1090                 1095Gly Gly  Ser Gly Gly Gly Gly  Ser Asp Val Val Met  Thr Gln Ser    1100                 1105                 1110Pro Ser  Ser Val Ser Ala Ser  Val Gly Asp Arg Val  Thr Ile Thr    1115                 1120                 1125Cys Gln  Ala Ser Gln Asn Ile  Arg Thr Tyr Leu Ser  Trp Tyr Gln    1130                 1135                 1140Gln Lys  Pro Gly Lys Ala Pro  Lys Leu Leu Ile Tyr  Ala Ala Ala    1145                 1150                 1155Asn Leu  Ala Ser Gly Val Pro  Ser Arg Phe Ser Gly  Ser Gly Ser    1160                 1165                 1170Gly Thr  Asp Phe Thr Leu Thr  Ile Ser Asp Leu Glu  Pro Gly Asp    1175                 1180                 1185Ala Ala  Thr Tyr Tyr Cys Gln  Ser Thr Tyr Leu Gly  Thr Asp Tyr    1190                 1195                 1200Val Gly  Gly Ala Phe Gly Gly  Gly Thr Lys Val Glu  Ile Lys    1205                 1210                 1215</s400><s200><s210>26</s210><s211>3654</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 26gaaatcgtta tgacacagtc cccatccact cttagcgctt ctgtagggga tcgagtgatt     60atcacatgcc gggcctccca atccatagga accaacatac actggtatca acaaaaacca    120ggcaaagcgc caaaactgct tatctactac gcctccgaga gtatttctgg aatcccgagt    180cgcttctcag gttctggaag cggcgctgag tttaccctca caatttcttc actccaaccg    240gatgacttcg ctacatatta ctgccaacaa aacaataatt ggccgacgac ctttggccag    300ggcacgaaac ttacggtact tggcggtggc ggtagtgggg gaggcggttc tggcggcgga    360gggtccggcg gtggaggatc agaagtacag cttgtcgagt ccggtggggg gcttgttcag    420ccagggggtt ccttgaggct ttcctgctcc gtctctgggt ttagcttgac gaattacggc    480gttcactggg ttagacaagc accggggaag gggctggaat gggtcggtgt gatatggtcc    540gggggtaata cggattacaa tacacctttc acgtcacgct ttacgattag cagggacacg    600tcaaaaaata cagtctactt gcagatgaac tctcttaggg cggaagatac tgcagtttat    660tactgcgcaa gggctctgac atactacgat tatgaatttg catattgggg ccaggggact    720ttggtcacgg tctcgagcgg cggtggaggg tccggcggtg gtggatcaca agtgcagttg    780caagaaagtg gtggtagact ggttcagcct ggtgaaccct tgtcactgac gtgtaaaaca    840agcggcattg atctgtcctc taacgccatc ggatgggtcc gacaggcccc aggaaaaggt    900ctggagtgga tcggagttat cttcgggagc ggcaatacat actacgcaag ctgggcaaaa    960gggcgattta cgatatcacg gagcacctct acagtttatt tgaaaatgaa ctccctccgg   1020tccgaggata ccgcgatata ttactgtgcc agaggggggt actcctctga tatctggggg   1080cagggtacac tggttacagt ttcatccgct agcaccaagg gcccatcggt cttccccctg   1140gcaccctcct ccaagagcac ctctgggggc acagcggccc tgggctgcct ggtcaaggac   1200tacttccccg aaccggtgac ggtgtcgtgg aactcaggcg ccctgaccag cggcgtgcac   1260accttcccgg ctgtcctaca gtcctcagga ctctactccc tcagcagcgt ggtgaccgtg   1320ccctccagca gcttgggcac ccagacctac atctgcaacg tgaatcacaa gcccagcaac   1380accaaggtgg acaagagagt tgagcccaaa tcttgtgaca aaactcacac atgcccaccg   1440tgcccagcac ctgaagccgc gggggcaccg tcagtcttcc tcttcccccc aaaacccaag   1500gacaccctca tgatctcccg gacccctgag gtcacatgcg tggtggtgga cgtgagccac   1560gaagaccctg aggtcaagtt caactggtac gtggacggcg tggaggtgca taatgccaag   1620acaaagccgc gggaggagca gtacaacagc acgtaccgtg tggtcagcgt cctcaccgtc   1680ctgcaccagg actggctgaa tggcaaggag tacaagtgcg cggtctccaa caaagccctc   1740ccagccccca tcgagaaaac catctccaaa gccaaagggc agccccgaga accacaggtg   1800tacaccctgc ccccatcccg ggatgagctg accaagaacc aggtcagcct gacctgcctg   1860gtcaaaggct tctatcccag cgacatcgcc gtggagtggg agagcaatgg gcagccggag   1920aacaactaca agaccacgcc tcccgtgctg gactccgacg gctccttctt cctctatagc   1980aagctcaccg tggacaagag caggtggcag caggggaacg tcttctcatg ctccgtgatg   2040catgaggctc tgcacaacca ctacacgcag aagagcctct ccctgtctcc gggtggcggt   2100ggagggtccg gcggtggtgg atccgaggtg cagctgttgg agtctggggg aggcttggta   2160cagcctgggg ggtccctgag actctcctgt gcagcctctg gattctcctt cagtagcggg   2220tacgacatgt gctgggtccg ccaggctcca gggaaggggc tggagtggat cgcatgcatt   2280gctgctggta gtgctggtat cacttacgac gcgaactggg cgaaaggccg gttcaccatc   2340tccagagaca attccaagaa cacgctgtat ctgcaaatga acagcctgag agccgaggac   2400acggccgtat attactgtgc gagatcggcg ttttcgttcg actacgccat ggacctctgg   2460ggccagggaa ccctggtcac cgtgtcgagc ggtggaggcg gatctggcgg aggtggttcc   2520ggcggtggcg gctccggtgg aggcggctct gacatccaga tgacccagtc tccttccacc   2580ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc aggccagtca gagcattagt   2640tcccacttaa actggtatca gcagaaacca gggaaagccc ctaagctcct gatctataag   2700gcatccactc tggcatctgg ggtcccatca aggttcagcg gcagtggatc tgggacagaa   2760tttactctca ccatcagcag cctgcagcct gatgattttg caacttatta ctgccaacag   2820ggttatagtt ggggtaatgt tgataatgtt ttcggcggag ggaccaaggt ggagatcaaa   2880ggcggtggag ggtccggcgg tggtggctcc ggacggtcgc tggtggagtc tgggggaggc   2940ttggtccagc ctggggggtc cctgagactc tcctgtactg cctctggatt caccatcagt   3000agctaccaca tgcagtgggt ccgccaggct ccagggaagg ggctggagta catcggaacc   3060attagtagtg gtggtaatgt atactacgca agctccgcta gaggcagatt caccatctcc   3120agaccctcgt ccaagaacac ggtggatctt caaatgaaca gcctgagagc cgaggacacg   3180gctgtgtatt actgtgcgag agactctggt tatagtgatc ctatgtgggg ccagggaacc   3240ctggtcaccg tctcttcagg cggtggcggt agtgggggag gcggttctgg cggcggaggg   3300tccggcggtg gaggatcaga cgttgtgatg acccagtctc catcttccgt gtctgcatct   3360gtaggagaca gagtcaccat cacctgtcag gccagtcaga acattaggac ttacttatcc   3420tggtatcagc agaaaccagg gaaagcccct aagctcctga tctatgctgc agccaatctg   3480gcatctgggg tcccatcaag gttcagcggc agtggatctg ggacagattt cactctcacc   3540atcagcgacc tggagcctgg cgatgctgca acttactatt gtcagtctac ctatcttggt   3600actgattatg ttggcggtgc tttcggcgga gggaccaagg tggagatcaa atga         3654</s400><s200><s210>27</s210><s211>473</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 27Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu    130                 135                 140Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met145                 150                 155                 160Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu                165                 170                 175Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys            180                 185                 190Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu        195                 200                 205Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala    210                 215                 220Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Asp Pro Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly            260                 265                 270Asp Arg Val Thr Ile Ser Cys Gln Ser Ser Gln Ser Val Ala Lys Asn        275                 280                 285Asn Asn Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu    290                 295                 300Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ala Gly Val Pro Ser Arg Phe305                 310                 315                 320Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val                325                 330                 335Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ser Ala Arg Asp Ser Gly            340                 345                 350Asn Ile Gln Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr        355                 360                 365Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu    370                 375                 380Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro385                 390                 395                 400Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly                405                 410                 415Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr            420                 425                 430Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His        435                 440                 445Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val    450                 455                 460Thr Lys Ser Phe Asn Arg Gly Glu Cys465                 470</s400><s200><s210>28</s210><s211>1422</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 28gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaagtga cggtactggg tggaggcggt tcaggcggag gtggttccgg cggtggcggc    360tccggtggag gcggctctca ggtcacattg aaggaatctg gccccggcct tgttcagcca    420ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg    480ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg    540tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat    600acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta    660tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact    720ctcgtcacgg tctcgagtgg cggtggaggg tccggcggtg gtggatccga tccagttctg    780acacaaagtc catccagcct gtctgcctca gtcggcgaca gagtgaccat cagttgccag    840agctcacagt ctgtggctaa gaacaacaac ttggcgtggt tccaacagaa acctggacag    900gctccgaaat tgctgatcta ttctgcttcc acgcttgctg ctggtgttcc ttcccgcttt    960tcaggtagtg gtagcgggac agacttcact ttgactataa gcagcgtgca gcctgaagat   1020tttgcgacct actattgttc tgctagagac agtggaaata ttcagtcctt tgggggggga   1080acgaaggtcg aaataaagcg tacggtggct gcaccatctg tcttcatctt cccgccatct   1140gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc   1200agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag   1260agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg   1320agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg   1380agctcgcccg tcacaaagag cttcaacagg ggagagtgtt ga                      1422</s400><s200><s210>29</s210><s211>1533</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 29Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Ile Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu        115                 120                 125Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    130                 135                 140Leu Arg Leu Ser Cys Ser Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly145                 150                 155                 160Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly                165                 170                 175Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser            180                 185                 190Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val Tyr Leu Gln        195                 200                 205Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg    210                 215                 220Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Gln Val Gln Leu Gln Glu Ser Gly Gly Arg Leu Val Gln Pro Gly Glu            260                 265                 270Pro Leu Ser Leu Thr Cys Lys Thr Ser Gly Ile Asp Leu Ser Ser Asn        275                 280                 285Ala Ile Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile    290                 295                 300Gly Val Ile Phe Gly Ser Gly Asn Thr Tyr Tyr Ala Ser Trp Ala Lys305                 310                 315                 320Gly Arg Phe Thr Ile Ser Arg Ser Thr Ser Thr Val Tyr Leu Lys Met                325                 330                 335Asn Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly            340                 345                 350Gly Tyr Ser Ser Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser        355                 360                 365Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser    370                 375                 380Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp385                 390                 395                 400Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr                405                 410                 415Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr            420                 425                 430Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln        435                 440                 445Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp    450                 455                 460Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro465                 470                 475                 480Cys Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe Pro                485                 490                 495Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr            500                 505                 510Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn        515                 520                 525Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg    530                 535                 540Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val545                 550                 555                 560Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser                565                 570                 575Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys            580                 585                 590Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp        595                 600                 605Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe    610                 615                 620Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu625                 630                 635                 640Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe                645                 650                 655Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly            660                 665                 670Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr        675                 680                 685Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly    690                 695                 700Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val705                 710                 715                 720Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser                725                 730                 735Phe Ser Ser Gly Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys            740                 745                 750Gly Leu Glu Trp Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr        755                 760                 765Tyr Asp Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn    770                 775                 780Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp785                 790                 795                 800Thr Ala Val Tyr Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala                805                 810                 815Met Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly            820                 825                 830Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        835                 840                 845Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser    850                 855                 860Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser865                 870                 875                 880Ser His Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu                885                 890                 895Leu Ile Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe            900                 905                 910Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu        915                 920                 925Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp    930                 935                 940Gly Asn Val Asp Asn Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys945                 950                 955                 960Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Arg Glu Gly Pro Glu                965                 970                 975Leu Ser Pro Asp Asp Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met            980                 985                 990Phe Ala Gln Leu Val Ala Gln Asn  Val Leu Leu Ile Asp  Gly Pro Leu        995                 1000                 1005Ser Trp  Tyr Ser Asp Pro Gly  Leu Ala Gly Val Ser  Leu Thr Gly    1010                 1015                 1020Gly Leu  Ser Tyr Lys Glu Asp  Thr Lys Glu Leu Val  Val Ala Lys    1025                 1030                 1035Ala Gly  Val Tyr Tyr Val Phe  Phe Gln Leu Glu Leu  Arg Arg Val    1040                 1045                 1050Val Ala  Gly Glu Gly Ser Gly  Ser Val Ser Leu Ala  Leu His Leu    1055                 1060                 1065Gln Pro  Leu Arg Ser Ala Ala  Gly Ala Ala Ala Leu  Ala Leu Thr    1070                 1075                 1080Val Asp  Leu Pro Pro Ala Ser  Ser Glu Ala Arg Asn  Ser Ala Phe    1085                 1090                 1095Gly Phe  Gln Gly Arg Leu Leu  His Leu Ser Ala Gly  Gln Arg Leu    1100                 1105                 1110Gly Val  His Leu His Thr Glu  Ala Arg Ala Arg His  Ala Trp Gln    1115                 1120                 1125Leu Thr  Gln Gly Ala Thr Val  Leu Gly Leu Phe Arg  Val Thr Pro    1130                 1135                 1140Glu Ile  Pro Ala Gly Leu Gly  Ser Thr Gly Ser Gly  Ser Lys Pro    1145                 1150                 1155Gly Ser  Gly Glu Gly Ser Thr  Lys Gly Arg Glu Gly  Pro Glu Leu    1160                 1165                 1170Ser Pro  Asp Asp Pro Ala Gly  Leu Leu Asp Leu Arg  Gln Gly Met    1175                 1180                 1185Phe Ala  Gln Leu Val Ala Gln  Asn Val Leu Leu Ile  Asp Gly Pro    1190                 1195                 1200Leu Ser  Trp Tyr Ser Asp Pro  Gly Leu Ala Gly Val  Ser Leu Thr    1205                 1210                 1215Gly Gly  Leu Ser Tyr Lys Glu  Asp Thr Lys Glu Leu  Val Val Ala    1220                 1225                 1230Lys Ala  Gly Val Tyr Tyr Val  Phe Phe Gln Leu Glu  Leu Arg Arg    1235                 1240                 1245Val Val  Ala Gly Glu Gly Ser  Gly Ser Val Ser Leu  Ala Leu His    1250                 1255                 1260Leu Gln  Pro Leu Arg Ser Ala  Ala Gly Ala Ala Ala  Leu Ala Leu    1265                 1270                 1275Thr Val  Asp Leu Pro Pro Ala  Ser Ser Glu Ala Arg  Asn Ser Ala    1280                 1285                 1290Phe Gly  Phe Gln Gly Arg Leu  Leu His Leu Ser Ala  Gly Gln Arg    1295                 1300                 1305Leu Gly  Val His Leu His Thr  Glu Ala Arg Ala Arg  His Ala Trp    1310                 1315                 1320Gln Leu  Thr Gln Gly Ala Thr  Val Leu Gly Leu Phe  Arg Val Thr    1325                 1330                 1335Pro Glu  Ile Pro Ala Gly Leu  Gly Gly Gly Gly Ser  Gly Gly Gly    1340                 1345                 1350Gly Ser  Arg Glu Gly Pro Glu  Leu Ser Pro Asp Asp  Pro Ala Gly    1355                 1360                 1365Leu Leu  Asp Leu Arg Gln Gly  Met Phe Ala Gln Leu  Val Ala Gln    1370                 1375                 1380Asn Val  Leu Leu Ile Asp Gly  Pro Leu Ser Trp Tyr  Ser Asp Pro    1385                 1390                 1395Gly Leu  Ala Gly Val Ser Leu  Thr Gly Gly Leu Ser  Tyr Lys Glu    1400                 1405                 1410Asp Thr  Lys Glu Leu Val Val  Ala Lys Ala Gly Val  Tyr Tyr Val    1415                 1420                 1425Phe Phe  Gln Leu Glu Leu Arg  Arg Val Val Ala Gly  Glu Gly Ser    1430                 1435                 1440Gly Ser  Val Ser Leu Ala Leu  His Leu Gln Pro Leu  Arg Ser Ala    1445                 1450                 1455Ala Gly  Ala Ala Ala Leu Ala  Leu Thr Val Asp Leu  Pro Pro Ala    1460                 1465                 1470Ser Ser  Glu Ala Arg Asn Ser  Ala Phe Gly Phe Gln  Gly Arg Leu    1475                 1480                 1485Leu His  Leu Ser Ala Gly Gln  Arg Leu Gly Val His  Leu His Thr    1490                 1495                 1500Glu Ala  Arg Ala Arg His Ala  Trp Gln Leu Thr Gln  Gly Ala Thr    1505                 1510                 1515Val Leu  Gly Leu Phe Arg Val  Thr Pro Glu Ile Pro  Ala Gly Leu    1520                 1525                 1530</s400><s200><s210>30</s210><s211>4602</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 30gaaatcgtta tgacacagtc cccatccact cttagcgctt ctgtagggga tcgagtgatt     60atcacatgcc gggcctccca atccatagga accaacatac actggtatca acaaaaacca    120ggcaaagcgc caaaactgct tatctactac gcctccgaga gtatttctgg aatcccgagt    180cgcttctcag gttctggaag cggcgctgag tttaccctca caatttcttc actccaaccg    240gatgacttcg ctacatatta ctgccaacaa aacaataatt ggccgacgac ctttggccag    300ggcacgaaac ttacggtact tggcggtggc ggtagtgggg gaggcggttc tggcggcgga    360gggtccggcg gtggaggatc agaagtacag cttgtcgagt ccggtggggg gcttgttcag    420ccagggggtt ccttgaggct ttcctgctcc gtctctgggt ttagcttgac gaattacggc    480gttcactggg ttagacaagc accggggaag gggctggaat gggtcggtgt gatatggtcc    540gggggtaata cggattacaa tacacctttc acgtcacgct ttacgattag cagggacacg    600tcaaaaaata cagtctactt gcagatgaac tctcttaggg cggaagatac tgcagtttat    660tactgcgcaa gggctctgac atactacgat tatgaatttg catattgggg ccaggggact    720ttggtcacgg tctcgagcgg cggtggaggg tccggcggtg gtggatcaca agtgcagttg    780caagaaagtg gtggtagact ggttcagcct ggtgaaccct tgtcactgac gtgtaaaaca    840agcggcattg atctgtcctc taacgccatc ggatgggtcc gacaggcccc aggaaaaggt    900ctggagtgga tcggagttat cttcgggagc ggcaatacat actacgcaag ctgggcaaaa    960gggcgattta cgatatcacg gagcacctct acagtttatt tgaaaatgaa ctccctccgg   1020tccgaggata ccgcgatata ttactgtgcc agaggggggt actcctctga tatctggggg   1080cagggtacac tggttacagt ttcatccgct agcaccaagg gcccatcggt cttccccctg   1140gcaccctcct ccaagagcac ctctgggggc acagcggccc tgggctgcct ggtcaaggac   1200tacttccccg aaccggtgac ggtgtcgtgg aactcaggcg ccctgaccag cggcgtgcac   1260accttcccgg ctgtcctaca gtcctcagga ctctactccc tcagcagcgt ggtgaccgtg   1320ccctccagca gcttgggcac ccagacctac atctgcaacg tgaatcacaa gcccagcaac   1380accaaggtgg acaagagagt tgagcccaaa tcttgtgaca aaactcacac atgcccaccg   1440tgcccagcac ctgaagccgc gggggcaccg tcagtcttcc tcttcccccc aaaacccaag   1500gacaccctca tgatctcccg gacccctgag gtcacatgcg tggtggtgga cgtgagccac   1560gaagaccctg aggtcaagtt caactggtac gtggacggcg tggaggtgca taatgccaag   1620acaaagccgc gggaggagca gtacaacagc acgtaccgtg tggtcagcgt cctcaccgtc   1680ctgcaccagg actggctgaa tggcaaggag tacaagtgcg cggtctccaa caaagccctc   1740ccagccccca tcgagaaaac catctccaaa gccaaagggc agccccgaga accacaggtg   1800tacaccctgc ccccatcccg ggatgagctg accaagaacc aggtcagcct gacctgcctg   1860gtcaaaggct tctatcccag cgacatcgcc gtggagtggg agagcaatgg gcagccggag   1920aacaactaca agaccacgcc tcccgtgctg gactccgacg gctccttctt cctctatagc   1980aagctcaccg tggacaagag caggtggcag caggggaacg tcttctcatg ctccgtgatg   2040catgaggctc tgcacaacca ctacacgcag aagagcctct ccctgtctcc gggtggcggt   2100ggagggtccg gcggtggtgg atccgaggtg cagctgttgg agtctggggg aggcttggta   2160cagcctgggg ggtccctgag actctcctgt gcagcctctg gattctcctt cagtagcggg   2220tacgacatgt gctgggtccg ccaggctcca gggaaggggc tggagtggat cgcatgcatt   2280gctgctggta gtgctggtat cacttacgac gcgaactggg cgaaaggccg gttcaccatc   2340tccagagaca attccaagaa cacgctgtat ctgcaaatga acagcctgag agccgaggac   2400acggccgtat attactgtgc gagatcggcg ttttcgttcg actacgccat ggacctctgg   2460ggccagggaa ccctggtcac cgtgtcgagc ggtggaggcg gatctggcgg aggtggttcc   2520ggcggtggcg gctccggtgg aggcggctct gacatccaga tgacccagtc tccttccacc   2580ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc aggccagtca gagcattagt   2640tcccacttaa actggtatca gcagaaacca gggaaagccc ctaagctcct gatctataag   2700gcatccactc tggcatctgg ggtcccatca aggttcagcg gcagtggatc tgggacagaa   2760tttactctca ccatcagcag cctgcagcct gatgattttg caacttatta ctgccaacag   2820ggttatagtt ggggtaatgt tgataatgtt ttcggcggag ggaccaaggt ggagatcaaa   2880ggcggtggag ggtccggcgg tggtggctcc ggacgagagg gccccgagct gtctcctgat   2940gacccagcag gcctcttgga cttgcggcag ggtatgttcg ctcaacttgt ggctcagaat   3000gttctgctca ttgatggacc actctcttgg tatagtgacc ccggtctggc cggggtgagt   3060ctgaccggcg ggctctctta taaagaggat actaaggaac tggtcgtagc aaaagcgggc   3120gtttattacg ttttttttca gctggagctc aggcgcgtgg tggccggcga gggcagtggc   3180tctgtgtccc tggccctgca cttacagccc ttgagaagcg ctgcaggtgc tgccgcactg   3240gctttaactg ttgacctccc tccggcctct tctgaagcta gaaacagcgc tttcggcttc   3300caagggcgcc tgctgcacct gagcgcaggc cagcgcttag gtgtgcacct tcatacagag   3360gccagggccc gacacgcttg gcagctcaca cagggtgcca cggttctcgg acttttccgc   3420gttactcccg agatccccgc tggcctcgga agtactggtt ctgggtctaa acccggttcc   3480ggcgaaggta gtactaaagg acgagaaggg ccagagttaa gtccagatga ccctgctggg   3540cttttggacc tgcggcaggg catgttcgct caactggtgg ctcagaacgt gctgctgatc   3600gatggccccc tgagttggta cagcgatccc gggctggcag gcgtgtcact tacagggggc   3660ctctcttaca aggaagacac caaggagtta gtggtcgcta aggctggcgt gtattacgtg   3720ttcttccaac tggagctgag aagggttgtg gcaggagagg gtagcggcag cgtgtcttta   3780gcccttcact tgcagcccct gaggtctgct gcaggtgcag ccgctctcgc gctcaccgtg   3840gatctccccc cagcctcatc tgaagctagg aacagtgcat ttggctttca gggacgcttg   3900ctgcacctct ccgctggaca gaggctgggc gtgcaccttc acacagaggc ccgtgccagg   3960catgcatggc agctcactca gggggcaaca gtgctgggtc tcttccgcgt gactcctgaa   4020ataccagctg gacttggcgg tggaggcagc ggcggaggag gatctcgtga ggggccagaa   4080ctgtcccccg atgacccagc cggactgctc gatctcagac agggcatgtt cgctcagctt   4140gtagcccaaa atgtcctcct gattgacggc cctttgagct ggtatagtga tcccggcttg   4200gccggggtat ctctgaccgg aggcctctcc tacaaggaag acaccaaaga gctggtggtg   4260gcaaaagcgg gggtgtatta tgtgttcttt cagctcgagc tgcggagagt tgtggccggg   4320gaagggtctg ggagcgtatc tcttgcactt cacctgcagc ccctgcgcag cgccgctgga   4380gccgccgccc ttgctcttac tgtggatctg cctcctgctt cctcagaagc acgcaacagc   4440gccttcggct ttcaaggacg tctcctgcac ttgtccgcag gacagaggtt gggcgtccat   4500ttacacactg aggcacgggc acggcacgct tggcagctta cccagggagc caccgtgctg   4560ggactcttta gagtgacacc cgagatcccc gctggcttgt ga                      4602</s400><s200><s210>31</s210><s211>473</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 31Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu    130                 135                 140Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met145                 150                 155                 160Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu                165                 170                 175Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys            180                 185                 190Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu        195                 200                 205Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala    210                 215                 220Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Asp Pro Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly            260                 265                 270Asp Arg Val Thr Ile Ser Cys Gln Ser Ser Gln Ser Val Ala Lys Asn        275                 280                 285Asn Asn Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu    290                 295                 300Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ala Gly Val Pro Ser Arg Phe305                 310                 315                 320Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val                325                 330                 335Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ser Ala Arg Asp Ser Gly            340                 345                 350Asn Ile Gln Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr        355                 360                 365Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu    370                 375                 380Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro385                 390                 395                 400Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly                405                 410                 415Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr            420                 425                 430Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His        435                 440                 445Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val    450                 455                 460Thr Lys Ser Phe Asn Arg Gly Glu Cys465                 470</s400><s200><s210>32</s210><s211>1422</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 32gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaagtga cggtactggg tggaggcggt tcaggcggag gtggttccgg cggtggcggc    360tccggtggag gcggctctca ggtcacattg aaggaatctg gccccggcct tgttcagcca    420ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg    480ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg    540tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat    600acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta    660tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact    720ctcgtcacgg tctcgagtgg cggtggaggg tccggcggtg gtggatccga tccagttctg    780acacaaagtc catccagcct gtctgcctca gtcggcgaca gagtgaccat cagttgccag    840agctcacagt ctgtggctaa gaacaacaac ttggcgtggt tccaacagaa acctggacag    900gctccgaaat tgctgatcta ttctgcttcc acgcttgctg ctggtgttcc ttcccgcttt    960tcaggtagtg gtagcgggac agacttcact ttgactataa gcagcgtgca gcctgaagat   1020tttgcgacct actattgttc tgctagagac agtggaaata ttcagtcctt tgggggggga   1080acgaaggtcg aaataaagcg tacggtggct gcaccatctg tcttcatctt cccgccatct   1140gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc   1200agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag   1260agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg   1320agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg   1380agctcgcccg tcacaaagag cttcaacagg ggagagtgtt ga                      1422</s400><s200><s210>33</s210><s211>1224</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 33Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Asp Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Val Gln Ser65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Pro Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln        115                 120                 125Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr    130                 135                 140Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly145                 150                 155                 160Val His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Gly                165                 170                 175Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser            180                 185                 190Arg Phe Thr Ile Thr Lys Asp Asn Ser Lys Asn Gln Val Tyr Phe Lys        195                 200                 205Leu Arg Ser Val Arg Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Arg    210                 215                 220Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly            260                 265                 270Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Ser Thr Asn        275                 280                 285Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile    290                 295                 300Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala Ser Trp Ala Lys305                 310                 315                 320Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu                325                 330                 335Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala            340                 345                 350Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn Ile Trp Gly Gln        355                 360                 365Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val    370                 375                 380Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala385                 390                 395                 400Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser                405                 410                 415Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val            420                 425                 430Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro        435                 440                 445Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys    450                 455                 460Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp465                 470                 475                 480Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala                485                 490                 495Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile            500                 505                 510Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu        515                 520                 525Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His    530                 535                 540Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg545                 550                 555                 560Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys                565                 570                 575Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu            580                 585                 590Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr        595                 600                 605Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu    610                 615                 620Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp625                 630                 635                 640Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val                645                 650                 655Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp            660                 665                 670Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His        675                 680                 685Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro    690                 695                 700Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Leu705                 710                 715                 720Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser                725                 730                 735Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly Tyr Asp Met Cys Trp            740                 745                 750Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala Cys Ile Ala        755                 760                 765Ala Gly Ser Ala Gly Ile Thr Tyr Asp Ala Asn Trp Ala Lys Gly Arg    770                 775                 780Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met785                 790                 795                 800Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser                805                 810                 815Ala Phe Ser Phe Asp Tyr Ala Met Asp Leu Trp Gly Gln Gly Thr Leu            820                 825                 830Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly        835                 840                 845Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser    850                 855                 860Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys865                 870                 875                 880Gln Ala Ser Gln Ser Ile Ser Ser His Leu Asn Trp Tyr Gln Gln Lys                885                 890                 895Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Thr Leu Ala            900                 905                 910Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe        915                 920                 925Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr    930                 935                 940Cys Gln Gln Gly Tyr Ser Trp Gly Asn Val Asp Asn Val Phe Gly Gly945                 950                 955                 960Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly                965                 970                 975Ser Gly Arg Ser Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly            980                 985                 990Gly Ser Leu Arg Leu Ser Cys Thr  Ala Ser Gly Phe Thr  Ile Ser Ser        995                 1000                 1005Tyr His  Met Gln Trp Val Arg  Gln Ala Pro Gly Lys  Gly Leu Glu    1010                 1015                 1020Tyr Ile  Gly Thr Ile Ser Ser  Gly Gly Asn Val Tyr  Tyr Ala Ser    1025                 1030                 1035Ser Ala  Arg Gly Arg Phe Thr  Ile Ser Arg Pro Ser  Ser Lys Asn    1040                 1045                 1050Thr Val  Asp Leu Gln Met Asn  Ser Leu Arg Ala Glu  Asp Thr Ala    1055                 1060                 1065Val Tyr  Tyr Cys Ala Arg Asp  Ser Gly Tyr Ser Asp  Pro Met Trp    1070                 1075                 1080Gly Gln  Gly Thr Leu Val Thr  Val Ser Ser Gly Gly  Gly Gly Ser    1085                 1090                 1095Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser    1100                 1105                 1110Asp Val  Val Met Thr Gln Ser  Pro Ser Ser Val Ser  Ala Ser Val    1115                 1120                 1125Gly Asp  Arg Val Thr Ile Thr  Cys Gln Ala Ser Gln  Asn Ile Arg    1130                 1135                 1140Thr Tyr  Leu Ser Trp Tyr Gln  Gln Lys Pro Gly Lys  Ala Pro Lys    1145                 1150                 1155Leu Leu  Ile Tyr Ala Ala Ala  Asn Leu Ala Ser Gly  Val Pro Ser    1160                 1165                 1170Arg Phe  Ser Gly Ser Gly Ser  Gly Thr Asp Phe Thr  Leu Thr Ile    1175                 1180                 1185Ser Asp  Leu Glu Pro Gly Asp  Ala Ala Thr Tyr Tyr  Cys Gln Ser    1190                 1195                 1200Thr Tyr  Leu Gly Thr Asp Tyr  Val Gly Gly Ala Phe  Gly Gly Gly    1205                 1210                 1215Thr Lys  Val Glu Ile Lys    1220</s400><s200><s210>34</s210><s211>3675</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 34gaaatcgtcc ttacacaatc tcctagcaca ctgagtgtga gccccggcga acgcgcgact     60ttctcttgca gggcaagtca atccataggg actaatatac attggtatca acaaaagcca    120ggtaaaccac ccaggctttt gattaagtat gcaagtgagt ctatttccgg tatccctgac    180cgcttctctg gatcaggcag tggcacagag ttcacactca ccatatctag tgtgcaatca    240gaggacttcg ccgtgtatta ctgccaacag aataataact ggccgactac cttcggaccc    300ggtacaaagc tgaccgtttt aggcggtggc ggtagtgggg gaggcggttc tggcggcgga    360gggtccggcg gtggaggatc acaagtacag ttgcagcaat ccggtcccgg tctcgtcaaa    420ccgagtgaga cgcttagtat aacgtgtact gtttcaggct ttagccttac gaactatgga    480gttcactgga ttcggcaggc acccggcaaa ggtttggaat ggctgggtgt tatttggtca    540ggtggaaata cagactataa cacccccttt acaagtcggt tcacaattac gaaagataat    600tccaaaaatc aagtttattt caagttgaga tccgtccgcg cggacgacac tgcgatctac    660tattgtgcga gggcactgac ctactacgat tacgaatttg cgtattgggg gcaagggact    720cttgtaacag tctcgagcgg cggtggaggg tccggcggtg gtggatcaga ggtgcagctg    780gtggagtctg ggggaggctt ggtccagcct ggggggtccc tgagactctc ctgtgcagcc    840tctggattca ccatcagtac caatgcaatg agctgggtcc gccaggctcc agggaagggg    900ctggagtgga tcggagtcat tactggtcgt gatatcacat actacgcgag ctgggcgaaa    960ggcagattca ccatctccag agacaattcc aagaacacgc tgtatcttca aatgaacagc   1020ctgagagccg aggacacggc tgtgtattac tgtgcgagag acggtggttc ttctgctatt   1080actagtaaca acatttgggg ccagggaacc ctggtcaccg tgtcctcagc tagcaccaag   1140ggcccatcgg tcttccccct ggcaccctcc tccaagagca cctctggggg cacagcggcc   1200ctgggctgcc tggtcaagga ctacttcccc gaaccggtga cggtgtcgtg gaactcaggc   1260gccctgacca gcggcgtgca caccttcccg gctgtcctac agtcctcagg actctactcc   1320ctcagcagcg tggtgaccgt gccctccagc agcttgggca cccagaccta catctgcaac   1380gtgaatcaca agcccagcaa caccaaggtg gacaagagag ttgagcccaa atcttgtgac   1440aaaactcaca catgcccacc gtgcccagca cctgaagccg cgggggcacc gtcagtcttc   1500ctcttccccc caaaacccaa ggacaccctc atgatctccc ggacccctga ggtcacatgc   1560gtggtggtgg acgtgagcca cgaagaccct gaggtcaagt tcaactggta cgtggacggc   1620gtggaggtgc ataatgccaa gacaaagccg cgggaggagc agtacaacag cacgtaccgt   1680gtggtcagcg tcctcaccgt cctgcaccag gactggctga atggcaagga gtacaagtgc   1740gcggtctcca acaaagccct cccagccccc atcgagaaaa ccatctccaa agccaaaggg   1800cagccccgag aaccacaggt gtacaccctg cccccatccc gggatgagct gaccaagaac   1860caggtcagcc tgacctgcct ggtcaaaggc ttctatccca gcgacatcgc cgtggagtgg   1920gagagcaatg ggcagccgga gaacaactac aagaccacgc ctcccgtgct ggactccgac   1980ggctccttct tcctctatag caagctcacc gtggacaaga gcaggtggca gcaggggaac   2040gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacgca gaagagcctc   2100tccctgtctc cgggtggcgg tggagggtcc ggcggtggtg gatccgaggt gcagctgttg   2160gagtctgggg gaggcttggt acagcctggg gggtccctga gactctcctg tgcagcctct   2220ggattctcct tcagtagcgg gtacgacatg tgctgggtcc gccaggctcc agggaagggg   2280ctggagtgga tcgcatgcat tgctgctggt agtgctggta tcacttacga cgcgaactgg   2340gcgaaaggcc ggttcaccat ctccagagac aattccaaga acacgctgta tctgcaaatg   2400aacagcctga gagccgagga cacggccgta tattactgtg cgagatcggc gttttcgttc   2460gactacgcca tggacctctg gggccaggga accctggtca ccgtgtcgag cggtggaggc   2520ggatctggcg gaggtggttc cggcggtggc ggctccggtg gaggcggctc tgacatccag   2580atgacccagt ctccttccac cctgtctgca tctgtaggag acagagtcac catcacttgc   2640caggccagtc agagcattag ttcccactta aactggtatc agcagaaacc agggaaagcc   2700cctaagctcc tgatctataa ggcatccact ctggcatctg gggtcccatc aaggttcagc   2760ggcagtggat ctgggacaga atttactctc accatcagca gcctgcagcc tgatgatttt   2820gcaacttatt actgccaaca gggttatagt tggggtaatg ttgataatgt tttcggcgga   2880gggaccaagg tggagatcaa aggcggtgga gggtccggcg gtggtggctc cggacggtcg   2940ctggtggagt ctgggggagg cttggtccag cctggggggt ccctgagact ctcctgtact   3000gcctctggat tcaccatcag tagctaccac atgcagtggg tccgccaggc tccagggaag   3060gggctggagt acatcggaac cattagtagt ggtggtaatg tatactacgc aagctccgct   3120agaggcagat tcaccatctc cagaccctcg tccaagaaca cggtggatct tcaaatgaac   3180agcctgagag ccgaggacac ggctgtgtat tactgtgcga gagactctgg ttatagtgat   3240cctatgtggg gccagggaac cctggtcacc gtctcttcag gcggtggcgg tagtggggga   3300ggcggttctg gcggcggagg gtccggcggt ggaggatcag acgttgtgat gacccagtct   3360ccatcttccg tgtctgcatc tgtaggagac agagtcacca tcacctgtca ggccagtcag   3420aacattagga cttacttatc ctggtatcag cagaaaccag ggaaagcccc taagctcctg   3480atctatgctg cagccaatct ggcatctggg gtcccatcaa ggttcagcgg cagtggatct   3540gggacagatt tcactctcac catcagcgac ctggagcctg gcgatgctgc aacttactat   3600tgtcagtcta cctatcttgg tactgattat gttggcggtg ctttcggcgg agggaccaag   3660gtggagatca aatga                                                    3675</s400><s200><s210>35</s210><s211>475</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 35Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu    130                 135                 140Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met145                 150                 155                 160Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu                165                 170                 175Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys            180                 185                 190Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu        195                 200                 205Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala    210                 215                 220Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Asp Val Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly            260                 265                 270Asp Arg Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp        275                 280                 285Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile    290                 295                 300Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly305                 310                 315                 320Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro                325                 330                 335Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser            340                 345                 350Arg Thr Tyr Val Asn Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys        355                 360                 365Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu    370                 375                 380Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe385                 390                 395                 400Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln                405                 410                 415Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser            420                 425                 430Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu        435                 440                 445Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser    450                 455                 460Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys465                 470                 475</s400><s200><s210>36</s210><s211>1428</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 36gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaagtga cggtactggg tggaggcggt tcaggcggag gtggttccgg cggtggcggc    360tccggtggag gcggctctca ggtcacattg aaggaatctg gccccggcct tgttcagcca    420ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg    480ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg    540tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat    600acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta    660tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact    720ctcgtcacgg tctcgagcgg cggtggaggg tccggcggtg gtggatcaga cgtcgtgatg    780acccagtctc cttccaccct gtctgcatct gtaggagaca gagtcaccat caattgccaa    840gccagtgaga gcattagcag ttggttagcc tggtatcagc agaaaccagg gaaagcccct    900aagctcctga tctatgaagc atccaaactg gcatctgggg tcccatcaag gttcagcggc    960agtggatctg ggacagaatt cactctcacc atcagcagcc tgcagcctga tgattttgca   1020acttattact gccaaggcta tttttatttt attagtcgta cttatgtaaa ttctttcggc   1080ggagggacca aggtggagat caaacgtacg gtggctgcac catctgtctt catcttcccg   1140ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc   1200tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc   1260caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg   1320acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag   1380ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgttga                1428</s400><s200><s210>37</s210><s211>1540</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 37Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Asp Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Val Gln Ser65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Pro Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln        115                 120                 125Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr    130                 135                 140Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly145                 150                 155                 160Val His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Gly                165                 170                 175Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser            180                 185                 190Arg Phe Thr Ile Thr Lys Asp Asn Ser Lys Asn Gln Val Tyr Phe Lys        195                 200                 205Leu Arg Ser Val Arg Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Arg    210                 215                 220Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly            260                 265                 270Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Ser Thr Asn        275                 280                 285Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile    290                 295                 300Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala Ser Trp Ala Lys305                 310                 315                 320Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu                325                 330                 335Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala            340                 345                 350Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn Ile Trp Gly Gln        355                 360                 365Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val    370                 375                 380Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala385                 390                 395                 400Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser                405                 410                 415Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val            420                 425                 430Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro        435                 440                 445Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys    450                 455                 460Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp465                 470                 475                 480Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala                485                 490                 495Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile            500                 505                 510Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu        515                 520                 525Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His    530                 535                 540Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg545                 550                 555                 560Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys                565                 570                 575Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu            580                 585                 590Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr        595                 600                 605Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu    610                 615                 620Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp625                 630                 635                 640Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val                645                 650                 655Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp            660                 665                 670Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His        675                 680                 685Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro    690                 695                 700Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Leu705                 710                 715                 720Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser                725                 730                 735Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly Tyr Asp Met Cys Trp            740                 745                 750Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala Cys Ile Ala        755                 760                 765Ala Gly Ser Ala Gly Ile Thr Tyr Asp Ala Asn Trp Ala Lys Gly Arg    770                 775                 780Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met785                 790                 795                 800Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser                805                 810                 815Ala Phe Ser Phe Asp Tyr Ala Met Asp Leu Trp Gly Gln Gly Thr Leu            820                 825                 830Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly        835                 840                 845Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser    850                 855                 860Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys865                 870                 875                 880Gln Ala Ser Gln Ser Ile Ser Ser His Leu Asn Trp Tyr Gln Gln Lys                885                 890                 895Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Thr Leu Ala            900                 905                 910Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe        915                 920                 925Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr    930                 935                 940Cys Gln Gln Gly Tyr Ser Trp Gly Asn Val Asp Asn Val Phe Gly Gly945                 950                 955                 960Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly                965                 970                 975Ser Gly Arg Glu Gly Pro Glu Leu Ser Pro Asp Asp Pro Ala Gly Leu            980                 985                 990Leu Asp Leu Arg Gln Gly Met Phe  Ala Gln Leu Val Ala  Gln Asn Val        995                 1000                 1005Leu Leu  Ile Asp Gly Pro Leu  Ser Trp Tyr Ser Asp  Pro Gly Leu    1010                 1015                 1020Ala Gly  Val Ser Leu Thr Gly  Gly Leu Ser Tyr Lys  Glu Asp Thr    1025                 1030                 1035Lys Glu  Leu Val Val Ala Lys  Ala Gly Val Tyr Tyr  Val Phe Phe    1040                 1045                 1050Gln Leu  Glu Leu Arg Arg Val  Val Ala Gly Glu Gly  Ser Gly Ser    1055                 1060                 1065Val Ser  Leu Ala Leu His Leu  Gln Pro Leu Arg Ser  Ala Ala Gly    1070                 1075                 1080Ala Ala  Ala Leu Ala Leu Thr  Val Asp Leu Pro Pro  Ala Ser Ser    1085                 1090                 1095Glu Ala  Arg Asn Ser Ala Phe  Gly Phe Gln Gly Arg  Leu Leu His    1100                 1105                 1110Leu Ser  Ala Gly Gln Arg Leu  Gly Val His Leu His  Thr Glu Ala    1115                 1120                 1125Arg Ala  Arg His Ala Trp Gln  Leu Thr Gln Gly Ala  Thr Val Leu    1130                 1135                 1140Gly Leu  Phe Arg Val Thr Pro  Glu Ile Pro Ala Gly  Leu Gly Ser    1145                 1150                 1155Thr Gly  Ser Gly Ser Lys Pro  Gly Ser Gly Glu Gly  Ser Thr Lys    1160                 1165                 1170Gly Arg  Glu Gly Pro Glu Leu  Ser Pro Asp Asp Pro  Ala Gly Leu    1175                 1180                 1185Leu Asp  Leu Arg Gln Gly Met  Phe Ala Gln Leu Val  Ala Gln Asn    1190                 1195                 1200Val Leu  Leu Ile Asp Gly Pro  Leu Ser Trp Tyr Ser  Asp Pro Gly    1205                 1210                 1215Leu Ala  Gly Val Ser Leu Thr  Gly Gly Leu Ser Tyr  Lys Glu Asp    1220                 1225                 1230Thr Lys  Glu Leu Val Val Ala  Lys Ala Gly Val Tyr  Tyr Val Phe    1235                 1240                 1245Phe Gln  Leu Glu Leu Arg Arg  Val Val Ala Gly Glu  Gly Ser Gly    1250                 1255                 1260Ser Val  Ser Leu Ala Leu His  Leu Gln Pro Leu Arg  Ser Ala Ala    1265                 1270                 1275Gly Ala  Ala Ala Leu Ala Leu  Thr Val Asp Leu Pro  Pro Ala Ser    1280                 1285                 1290Ser Glu  Ala Arg Asn Ser Ala  Phe Gly Phe Gln Gly  Arg Leu Leu    1295                 1300                 1305His Leu  Ser Ala Gly Gln Arg  Leu Gly Val His Leu  His Thr Glu    1310                 1315                 1320Ala Arg  Ala Arg His Ala Trp  Gln Leu Thr Gln Gly  Ala Thr Val    1325                 1330                 1335Leu Gly  Leu Phe Arg Val Thr  Pro Glu Ile Pro Ala  Gly Leu Gly    1340                 1345                 1350Gly Gly  Gly Ser Gly Gly Gly  Gly Ser Arg Glu Gly  Pro Glu Leu    1355                 1360                 1365Ser Pro  Asp Asp Pro Ala Gly  Leu Leu Asp Leu Arg  Gln Gly Met    1370                 1375                 1380Phe Ala  Gln Leu Val Ala Gln  Asn Val Leu Leu Ile  Asp Gly Pro    1385                 1390                 1395Leu Ser  Trp Tyr Ser Asp Pro  Gly Leu Ala Gly Val  Ser Leu Thr    1400                 1405                 1410Gly Gly  Leu Ser Tyr Lys Glu  Asp Thr Lys Glu Leu  Val Val Ala    1415                 1420                 1425Lys Ala  Gly Val Tyr Tyr Val  Phe Phe Gln Leu Glu  Leu Arg Arg    1430                 1435                 1440Val Val  Ala Gly Glu Gly Ser  Gly Ser Val Ser Leu  Ala Leu His    1445                 1450                 1455Leu Gln  Pro Leu Arg Ser Ala  Ala Gly Ala Ala Ala  Leu Ala Leu    1460                 1465                 1470Thr Val  Asp Leu Pro Pro Ala  Ser Ser Glu Ala Arg  Asn Ser Ala    1475                 1480                 1485Phe Gly  Phe Gln Gly Arg Leu  Leu His Leu Ser Ala  Gly Gln Arg    1490                 1495                 1500Leu Gly  Val His Leu His Thr  Glu Ala Arg Ala Arg  His Ala Trp    1505                 1510                 1515Gln Leu  Thr Gln Gly Ala Thr  Val Leu Gly Leu Phe  Arg Val Thr    1520                 1525                 1530Pro Glu  Ile Pro Ala Gly Leu    1535                 1540</s400><s200><s210>38</s210><s211>4623</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 38Gly Ala Ala Ala Thr Cys Gly Thr Cys Cys Thr Thr Ala Cys Ala Cys1               5                   10                  15Ala Ala Thr Cys Thr Cys Cys Thr Ala Gly Cys Ala Cys Ala Cys Thr            20                  25                  30Gly Ala Gly Thr Gly Thr Gly Ala Gly Cys Cys Cys Cys Gly Gly Cys        35                  40                  45Gly Ala Ala Cys Gly Cys Gly Cys Gly Ala Cys Thr Thr Thr Cys Thr    50                  55                  60Cys Thr Thr Gly Cys Ala Gly Gly Gly Cys Ala Ala Gly Thr Cys Ala65                  70                  75                  80Ala Thr Cys Cys Ala Thr Ala Gly Gly Gly Ala Cys Thr Ala Ala Thr                85                  90                  95Ala Thr Ala Cys Ala Thr Thr Gly Gly Thr Ala Thr Cys Ala Ala Cys            100                 105                 110Ala Ala Ala Ala Gly Cys Cys Ala Gly Gly Thr Ala Ala Ala Cys Cys        115                 120                 125Ala Cys Cys Cys Ala Gly Gly Cys Thr Thr Thr Thr Gly Ala Thr Thr    130                 135                 140Ala Ala Gly Thr Ala Thr Gly Cys Ala Ala Gly Thr Gly Ala Gly Thr145                 150                 155                 160Cys Thr Ala Thr Thr Thr Cys Cys Gly Gly Thr Ala Thr Cys Cys Cys                165                 170                 175Thr Gly Ala Cys Cys Gly Cys Thr Thr Cys Thr Cys Thr Gly Gly Ala            180                 185                 190Thr Cys Ala Gly Gly Cys Ala Gly Thr Gly Gly Cys Ala Cys Ala Gly        195                 200                 205Ala Gly Thr Thr Cys Ala Cys Ala Cys Thr Cys Ala Cys Cys Ala Thr    210                 215                 220Ala Thr Cys Thr Ala Gly Thr Gly Thr Gly Cys Ala Ala Thr Cys Ala225                 230                 235                 240Gly Ala Gly Gly Ala Cys Thr Thr Cys Gly Cys Cys Gly Thr Gly Thr                245                 250                 255Ala Thr Thr Ala Cys Thr Gly Cys Cys Ala Ala Cys Ala Gly Ala Ala            260                 265                 270Thr Ala Ala Thr Ala Ala Cys Thr Gly Gly Cys Cys Gly Ala Cys Thr        275                 280                 285Ala Cys Cys Thr Thr Cys Gly Gly Ala Cys Cys Cys Gly Gly Thr Ala    290                 295                 300Cys Ala Ala Ala Gly Cys Thr Gly Ala Cys Cys Gly Thr Thr Thr Thr305                 310                 315                 320Ala Gly Gly Cys Gly Gly Thr Gly Gly Cys Gly Gly Thr Ala Gly Thr                325                 330                 335Gly Gly Gly Gly Gly Ala Gly Gly Cys Gly Gly Thr Thr Cys Thr Gly            340                 345                 350Gly Cys Gly Gly Cys Gly Gly Ala Gly Gly Gly Thr Cys Cys Gly Gly        355                 360                 365Cys Gly Gly Thr Gly Gly Ala Gly Gly Ala Thr Cys Ala Cys Ala Ala    370                 375                 380Gly Thr Ala Cys Ala Gly Thr Thr Gly Cys Ala Gly Cys Ala Ala Thr385                 390                 395                 400Cys Cys Gly Gly Thr Cys Cys Cys Gly Gly Thr Cys Thr Cys Gly Thr                405                 410                 415Cys Ala Ala Ala Cys Cys Gly Ala Gly Thr Gly Ala Gly Ala Cys Gly            420                 425                 430Cys Thr Thr Ala Gly Thr Ala Thr Ala Ala Cys Gly Thr Gly Thr Ala        435                 440                 445Cys Thr Gly Thr Thr Thr Cys Ala Gly Gly Cys Thr Thr Thr Ala Gly    450                 455                 460Cys Cys Thr Thr Ala Cys Gly Ala Ala Cys Thr Ala Thr Gly Gly Ala465                 470                 475                 480Gly Thr Thr Cys Ala Cys Thr Gly Gly Ala Thr Thr Cys Gly Gly Cys                485                 490                 495Ala Gly Gly Cys Ala Cys Cys Cys Gly Gly Cys Ala Ala Ala Gly Gly            500                 505                 510Thr Thr Thr Gly Gly Ala Ala Thr Gly Gly Cys Thr Gly Gly Gly Thr        515                 520                 525Gly Thr Thr Ala Thr Thr Thr Gly Gly Thr Cys Ala Gly Gly Thr Gly    530                 535                 540Gly Ala Ala Ala Thr Ala Cys Ala Gly Ala Cys Thr Ala Thr Ala Ala545                 550                 555                 560Cys Ala Cys Cys Cys Cys Cys Thr Thr Thr Ala Cys Ala Ala Gly Thr                565                 570                 575Cys Gly Gly Thr Thr Cys Ala Cys Ala Ala Thr Thr Ala Cys Gly Ala            580                 585                 590Ala Ala Gly Ala Thr Ala Ala Thr Thr Cys Cys Ala Ala Ala Ala Ala        595                 600                 605Thr Cys Ala Ala Gly Thr Thr Thr Ala Thr Thr Thr Cys Ala Ala Gly    610                 615                 620Thr Thr Gly Ala Gly Ala Thr Cys Cys Gly Thr Cys Cys Gly Cys Gly625                 630                 635                 640Cys Gly Gly Ala Cys Gly Ala Cys Ala Cys Thr Gly Cys Gly Ala Thr                645                 650                 655Cys Thr Ala Cys Thr Ala Thr Thr Gly Thr Gly Cys Gly Ala Gly Gly            660                 665                 670Gly Cys Ala Cys Thr Gly Ala Cys Cys Thr Ala Cys Thr Ala Cys Gly        675                 680                 685Ala Thr Thr Ala Cys Gly Ala Ala Thr Thr Thr Gly Cys Gly Thr Ala    690                 695                 700Thr Thr Gly Gly Gly Gly Gly Cys Ala Ala Gly Gly Gly Ala Cys Thr705                 710                 715                 720Cys Thr Thr Gly Thr Ala Ala Cys Ala Gly Thr Cys Thr Cys Gly Ala                725                 730                 735Gly Cys Gly Gly Cys Gly Gly Thr Gly Gly Ala Gly Gly Gly Thr Cys            740                 745                 750Cys Gly Gly Cys Gly Gly Thr Gly Gly Thr Gly Gly Ala Thr Cys Ala        755                 760                 765Gly Ala Gly Gly Thr Gly Cys Ala Gly Cys Thr Gly Gly Thr Gly Gly    770                 775                 780Ala Gly Thr Cys Thr Gly Gly Gly Gly Gly Ala Gly Gly Cys Thr Thr785                 790                 795                 800Gly Gly Thr Cys Cys Ala Gly Cys Cys Thr Gly Gly Gly Gly Gly Gly                805                 810                 815Thr Cys Cys Cys Thr Gly Ala Gly Ala Cys Thr Cys Thr Cys Cys Thr            820                 825                 830Gly Thr Gly Cys Ala Gly Cys Cys Thr Cys Thr Gly Gly Ala Thr Thr        835                 840                 845Cys Ala Cys Cys Ala Thr Cys Ala Gly Thr Ala Cys Cys Ala Ala Thr    850                 855                 860Gly Cys Ala Ala Thr Gly Ala Gly Cys Thr Gly Gly Gly Thr Cys Cys865                 870                 875                 880Gly Cys Cys Ala Gly Gly Cys Thr Cys Cys Ala Gly Gly Gly Ala Ala                885                 890                 895Gly Gly Gly Gly Cys Thr Gly Gly Ala Gly Thr Gly Gly Ala Thr Cys            900                 905                 910Gly Gly Ala Gly Thr Cys Ala Thr Thr Ala Cys Thr Gly Gly Thr Cys        915                 920                 925Gly Thr Gly Ala Thr Ala Thr Cys Ala Cys Ala Thr Ala Cys Thr Ala    930                 935                 940Cys Gly Cys Gly Ala Gly Cys Thr Gly Gly Gly Cys Gly Ala Ala Ala945                 950                 955                 960Gly Gly Cys Ala Gly Ala Thr Thr Cys Ala Cys Cys Ala Thr Cys Thr                965                 970                 975Cys Cys Ala Gly Ala Gly Ala Cys Ala Ala Thr Thr Cys Cys Ala Ala            980                 985                 990Gly Ala Ala Cys Ala Cys Gly Cys  Thr Gly Thr Ala Thr  Cys Thr Thr        995                 1000                 1005Cys Ala  Ala Ala Thr Gly Ala  Ala Cys Ala Gly Cys  Cys Thr Gly    1010                 1015                 1020Ala Gly  Ala Gly Cys Cys Gly  Ala Gly Gly Ala Cys  Ala Cys Gly    1025                 1030                 1035Gly Cys  Thr Gly Thr Gly Thr  Ala Thr Thr Ala Cys  Thr Gly Thr    1040                 1045                 1050Gly Cys  Gly Ala Gly Ala Gly  Ala Cys Gly Gly Thr  Gly Gly Thr    1055                 1060                 1065Thr Cys  Thr Thr Cys Thr Gly  Cys Thr Ala Thr Thr  Ala Cys Thr    1070                 1075                 1080Ala Gly  Thr Ala Ala Cys Ala  Ala Cys Ala Thr Thr  Thr Gly Gly    1085                 1090                 1095Gly Gly  Cys Cys Ala Gly Gly  Gly Ala Ala Cys Cys  Cys Thr Gly    1100                 1105                 1110Gly Thr  Cys Ala Cys Cys Gly  Thr Gly Thr Cys Cys  Thr Cys Ala    1115                 1120                 1125Gly Cys  Thr Ala Gly Cys Ala  Cys Cys Ala Ala Gly  Gly Gly Cys    1130                 1135                 1140Cys Cys  Ala Thr Cys Gly Gly  Thr Cys Thr Thr Cys  Cys Cys Cys    1145                 1150                 1155Cys Thr  Gly Gly Cys Ala Cys  Cys Cys Thr Cys Cys  Thr Cys Cys    1160                 1165                 1170Ala Ala  Gly Ala Gly Cys Ala  Cys Cys Thr Cys Thr  Gly Gly Gly    1175                 1180                 1185Gly Gly  Cys Ala Cys Ala Gly  Cys Gly Gly Cys Cys  Cys Thr Gly    1190                 1195                 1200Gly Gly  Cys Thr Gly Cys Cys  Thr Gly Gly Thr Cys  Ala Ala Gly    1205                 1210                 1215Gly Ala  Cys Thr Ala Cys Thr  Thr Cys Cys Cys Cys  Gly Ala Ala    1220                 1225                 1230Cys Cys  Gly Gly Thr Gly Ala  Cys Gly Gly Thr Gly  Thr Cys Gly    1235                 1240                 1245Thr Gly  Gly Ala Ala Cys Thr  Cys Ala Gly Gly Cys  Gly Cys Cys    1250                 1255                 1260Cys Thr  Gly Ala Cys Cys Ala  Gly Cys Gly Gly Cys  Gly Thr Gly    1265                 1270                 1275Cys Ala  Cys Ala Cys Cys Thr  Thr Cys Cys Cys Gly  Gly Cys Thr    1280                 1285                 1290Gly Thr  Cys Cys Thr Ala Cys  Ala Gly Thr Cys Cys  Thr Cys Ala    1295                 1300                 1305Gly Gly  Ala Cys Thr Cys Thr  Ala Cys Thr Cys Cys  Cys Thr Cys    1310                 1315                 1320Ala Gly  Cys Ala Gly Cys Gly  Thr Gly Gly Thr Gly  Ala Cys Cys    1325                 1330                 1335Gly Thr  Gly Cys Cys Cys Thr  Cys Cys Ala Gly Cys  Ala Gly Cys    1340                 1345                 1350Thr Thr  Gly Gly Gly Cys Ala  Cys Cys Cys Ala Gly  Ala Cys Cys    1355                 1360                 1365Thr Ala  Cys Ala Thr Cys Thr  Gly Cys Ala Ala Cys  Gly Thr Gly    1370                 1375                 1380Ala Ala  Thr Cys Ala Cys Ala  Ala Gly Cys Cys Cys  Ala Gly Cys    1385                 1390                 1395Ala Ala  Cys Ala Cys Cys Ala  Ala Gly Gly Thr Gly  Gly Ala Cys    1400                 1405                 1410Ala Ala  Gly Ala Gly Ala Gly  Thr Thr Gly Ala Gly  Cys Cys Cys    1415                 1420                 1425Ala Ala  Ala Thr Cys Thr Thr  Gly Thr Gly Ala Cys  Ala Ala Ala    1430                 1435                 1440Ala Cys  Thr Cys Ala Cys Ala  Cys Ala Thr Gly Cys  Cys Cys Ala    1445                 1450                 1455Cys Cys  Gly Thr Gly Cys Cys  Cys Ala Gly Cys Ala  Cys Cys Thr    1460                 1465                 1470Gly Ala  Ala Gly Cys Cys Gly  Cys Gly Gly Gly Gly  Gly Cys Ala    1475                 1480                 1485Cys Cys  Gly Thr Cys Ala Gly  Thr Cys Thr Thr Cys  Cys Thr Cys    1490                 1495                 1500Thr Thr  Cys Cys Cys Cys Cys  Cys Ala Ala Ala Ala  Cys Cys Cys    1505                 1510                 1515Ala Ala  Gly Gly Ala Cys Ala  Cys Cys Cys Thr Cys  Ala Thr Gly    1520                 1525                 1530Ala Thr  Cys Thr Cys Cys Cys  Gly Gly Ala Cys Cys  Cys Cys Thr    1535                 1540                 1545Gly Ala  Gly Gly Thr Cys Ala  Cys Ala Thr Gly Cys  Gly Thr Gly    1550                 1555                 1560Gly Thr  Gly Gly Thr Gly Gly  Ala Cys Gly Thr Gly  Ala Gly Cys    1565                 1570                 1575Cys Ala  Cys Gly Ala Ala Gly  Ala Cys Cys Cys Thr  Gly Ala Gly    1580                 1585                 1590Gly Thr  Cys Ala Ala Gly Thr  Thr Cys Ala Ala Cys  Thr Gly Gly    1595                 1600                 1605Thr Ala  Cys Gly Thr Gly Gly  Ala Cys Gly Gly Cys  Gly Thr Gly    1610                 1615                 1620Gly Ala  Gly Gly Thr Gly Cys  Ala Thr Ala Ala Thr  Gly Cys Cys    1625                 1630                 1635Ala Ala  Gly Ala Cys Ala Ala  Ala Gly Cys Cys Gly  Cys Gly Gly    1640                 1645                 1650Gly Ala  Gly Gly Ala Gly Cys  Ala Gly Thr Ala Cys  Ala Ala Cys    1655                 1660                 1665Ala Gly  Cys Ala Cys Gly Thr  Ala Cys Cys Gly Thr  Gly Thr Gly    1670                 1675                 1680Gly Thr  Cys Ala Gly Cys Gly  Thr Cys Cys Thr Cys  Ala Cys Cys    1685                 1690                 1695Gly Thr  Cys Cys Thr Gly Cys  Ala Cys Cys Ala Gly  Gly Ala Cys    1700                 1705                 1710Thr Gly  Gly Cys Thr Gly Ala  Ala Thr Gly Gly Cys  Ala Ala Gly    1715                 1720                 1725Gly Ala  Gly Thr Ala Cys Ala  Ala Gly Thr Gly Cys  Gly Cys Gly    1730                 1735                 1740Gly Thr  Cys Thr Cys Cys Ala  Ala Cys Ala Ala Ala  Gly Cys Cys    1745                 1750                 1755Cys Thr  Cys Cys Cys Ala Gly  Cys Cys Cys Cys Cys  Ala Thr Cys    1760                 1765                 1770Gly Ala  Gly Ala Ala Ala Ala  Cys Cys Ala Thr Cys  Thr Cys Cys    1775                 1780                 1785Ala Ala  Ala Gly Cys Cys Ala  Ala Ala Gly Gly Gly  Cys Ala Gly    1790                 1795                 1800Cys Cys  Cys Cys Gly Ala Gly  Ala Ala Cys Cys Ala  Cys Ala Gly    1805                 1810                 1815Gly Thr  Gly Thr Ala Cys Ala  Cys Cys Cys Thr Gly  Cys Cys Cys    1820                 1825                 1830Cys Cys  Ala Thr Cys Cys Cys  Gly Gly Gly Ala Thr  Gly Ala Gly    1835                 1840                 1845Cys Thr  Gly Ala Cys Cys Ala  Ala Gly Ala Ala Cys  Cys Ala Gly    1850                 1855                 1860Gly Thr  Cys Ala Gly Cys Cys  Thr Gly Ala Cys Cys  Thr Gly Cys    1865                 1870                 1875Cys Thr  Gly Gly Thr Cys Ala  Ala Ala Gly Gly Cys  Thr Thr Cys    1880                 1885                 1890Thr Ala  Thr Cys Cys Cys Ala  Gly Cys Gly Ala Cys  Ala Thr Cys    1895                 1900                 1905Gly Cys  Cys Gly Thr Gly Gly  Ala Gly Thr Gly Gly  Gly Ala Gly    1910                 1915                 1920Ala Gly  Cys Ala Ala Thr Gly  Gly Gly Cys Ala Gly  Cys Cys Gly    1925                 1930                 1935Gly Ala  Gly Ala Ala Cys Ala  Ala Cys Thr Ala Cys  Ala Ala Gly    1940                 1945                 1950Ala Cys  Cys Ala Cys Gly Cys  Cys Thr Cys Cys Cys  Gly Thr Gly    1955                 1960                 1965Cys Thr  Gly Gly Ala Cys Thr  Cys Cys Gly Ala Cys  Gly Gly Cys    1970                 1975                 1980Thr Cys  Cys Thr Thr Cys Thr  Thr Cys Cys Thr Cys  Thr Ala Thr    1985                 1990                 1995Ala Gly  Cys Ala Ala Gly Cys  Thr Cys Ala Cys Cys  Gly Thr Gly    2000                 2005                 2010Gly Ala  Cys Ala Ala Gly Ala  Gly Cys Ala Gly Gly  Thr Gly Gly    2015                 2020                 2025Cys Ala  Gly Cys Ala Gly Gly  Gly Gly Ala Ala Cys  Gly Thr Cys    2030                 2035                 2040Thr Thr  Cys Thr Cys Ala Thr  Gly Cys Thr Cys Cys  Gly Thr Gly    2045                 2050                 2055Ala Thr  Gly Cys Ala Thr Gly  Ala Gly Gly Cys Thr  Cys Thr Gly    2060                 2065                 2070Cys Ala  Cys Ala Ala Cys Cys  Ala Cys Thr Ala Cys  Ala Cys Gly    2075                 2080                 2085Cys Ala  Gly Ala Ala Gly Ala  Gly Cys Cys Thr Cys  Thr Cys Cys    2090                 2095                 2100Cys Thr  Gly Thr Cys Thr Cys  Cys Gly Gly Gly Thr  Gly Gly Cys    2105                 2110                 2115Gly Gly  Thr Gly Gly Ala Gly  Gly Gly Thr Cys Cys  Gly Gly Cys    2120                 2125                 2130Gly Gly  Thr Gly Gly Thr Gly  Gly Ala Thr Cys Cys  Gly Ala Gly    2135                 2140                 2145Gly Thr  Gly Cys Ala Gly Cys  Thr Gly Thr Thr Gly  Gly Ala Gly    2150                 2155                 2160Thr Cys  Thr Gly Gly Gly Gly  Gly Ala Gly Gly Cys  Thr Thr Gly    2165                 2170                 2175Gly Thr  Ala Cys Ala Gly Cys  Cys Thr Gly Gly Gly  Gly Gly Gly    2180                 2185                 2190Thr Cys  Cys Cys Thr Gly Ala  Gly Ala Cys Thr Cys  Thr Cys Cys    2195                 2200                 2205Thr Gly  Thr Gly Cys Ala Gly  Cys Cys Thr Cys Thr  Gly Gly Ala    2210                 2215                 2220Thr Thr  Cys Thr Cys Cys Thr  Thr Cys Ala Gly Thr  Ala Gly Cys    2225                 2230                 2235Gly Gly  Gly Thr Ala Cys Gly  Ala Cys Ala Thr Gly  Thr Gly Cys    2240                 2245                 2250Thr Gly  Gly Gly Thr Cys Cys  Gly Cys Cys Ala Gly  Gly Cys Thr    2255                 2260                 2265Cys Cys  Ala Gly Gly Gly Ala  Ala Gly Gly Gly Gly  Cys Thr Gly    2270                 2275                 2280Gly Ala  Gly Thr Gly Gly Ala  Thr Cys Gly Cys Ala  Thr Gly Cys    2285                 2290                 2295Ala Thr  Thr Gly Cys Thr Gly  Cys Thr Gly Gly Thr  Ala Gly Thr    2300                 2305                 2310Gly Cys  Thr Gly Gly Thr Ala  Thr Cys Ala Cys Thr  Thr Ala Cys    2315                 2320                 2325Gly Ala  Cys Gly Cys Gly Ala  Ala Cys Thr Gly Gly  Gly Cys Gly    2330                 2335                 2340Ala Ala  Ala Gly Gly Cys Cys  Gly Gly Thr Thr Cys  Ala Cys Cys    2345                 2350                 2355Ala Thr  Cys Thr Cys Cys Ala  Gly Ala Gly Ala Cys  Ala Ala Thr    2360                 2365                 2370Thr Cys  Cys Ala Ala Gly Ala  Ala Cys Ala Cys Gly  Cys Thr Gly    2375                 2380                 2385Thr Ala  Thr Cys Thr Gly Cys  Ala Ala Ala Thr Gly  Ala Ala Cys    2390                 2395                 2400Ala Gly  Cys Cys Thr Gly Ala  Gly Ala Gly Cys Cys  Gly Ala Gly    2405                 2410                 2415Gly Ala  Cys Ala Cys Gly Gly  Cys Cys Gly Thr Ala  Thr Ala Thr    2420                 2425                 2430Thr Ala  Cys Thr Gly Thr Gly  Cys Gly Ala Gly Ala  Thr Cys Gly    2435                 2440                 2445Gly Cys  Gly Thr Thr Thr Thr  Cys Gly Thr Thr Cys  Gly Ala Cys    2450                 2455                 2460Thr Ala  Cys Gly Cys Cys Ala  Thr Gly Gly Ala Cys  Cys Thr Cys    2465                 2470                 2475Thr Gly  Gly Gly Gly Cys Cys  Ala Gly Gly Gly Ala  Ala Cys Cys    2480                 2485                 2490Cys Thr  Gly Gly Thr Cys Ala  Cys Cys Gly Thr Gly  Thr Cys Gly    2495                 2500                 2505Ala Gly  Cys Gly Gly Thr Gly  Gly Ala Gly Gly Cys  Gly Gly Ala    2510                 2515                 2520Thr Cys  Thr Gly Gly Cys Gly  Gly Ala Gly Gly Thr  Gly Gly Thr    2525                 2530                 2535Thr Cys  Cys Gly Gly Cys Gly  Gly Thr Gly Gly Cys  Gly Gly Cys    2540                 2545                 2550Thr Cys  Cys Gly Gly Thr Gly  Gly Ala Gly Gly Cys  Gly Gly Cys    2555                 2560                 2565Thr Cys  Thr Gly Ala Cys Ala  Thr Cys Cys Ala Gly  Ala Thr Gly    2570                 2575                 2580Ala Cys  Cys Cys Ala Gly Thr  Cys Thr Cys Cys Thr  Thr Cys Cys    2585                 2590                 2595Ala Cys  Cys Cys Thr Gly Thr  Cys Thr Gly Cys Ala  Thr Cys Thr    2600                 2605                 2610Gly Thr  Ala Gly Gly Ala Gly  Ala Cys Ala Gly Ala  Gly Thr Cys    2615                 2620                 2625Ala Cys  Cys Ala Thr Cys Ala  Cys Thr Thr Gly Cys  Cys Ala Gly    2630                 2635                 2640Gly Cys  Cys Ala Gly Thr Cys  Ala Gly Ala Gly Cys  Ala Thr Thr    2645                 2650                 2655Ala Gly  Thr Thr Cys Cys Cys  Ala Cys Thr Thr Ala  Ala Ala Cys    2660                 2665                 2670Thr Gly  Gly Thr Ala Thr Cys  Ala Gly Cys Ala Gly  Ala Ala Ala    2675                 2680                 2685Cys Cys  Ala Gly Gly Gly Ala  Ala Ala Gly Cys Cys  Cys Cys Thr    2690                 2695                 2700Ala Ala  Gly Cys Thr Cys Cys  Thr Gly Ala Thr Cys  Thr Ala Thr    2705                 2710                 2715Ala Ala  Gly Gly Cys Ala Thr  Cys Cys Ala Cys Thr  Cys Thr Gly    2720                 2725                 2730Gly Cys  Ala Thr Cys Thr Gly  Gly Gly Gly Thr Cys  Cys Cys Ala    2735                 2740                 2745Thr Cys  Ala Ala Gly Gly Thr  Thr Cys Ala Gly Cys  Gly Gly Cys    2750                 2755                 2760Ala Gly  Thr Gly Gly Ala Thr  Cys Thr Gly Gly Gly  Ala Cys Ala    2765                 2770                 2775Gly Ala  Ala Thr Thr Thr Ala  Cys Thr Cys Thr Cys  Ala Cys Cys    2780                 2785                 2790Ala Thr  Cys Ala Gly Cys Ala  Gly Cys Cys Thr Gly  Cys Ala Gly    2795                 2800                 2805Cys Cys  Thr Gly Ala Thr Gly  Ala Thr Thr Thr Thr  Gly Cys Ala    2810                 2815                 2820Ala Cys  Thr Thr Ala Thr Thr  Ala Cys Thr Gly Cys  Cys Ala Ala    2825                 2830                 2835Cys Ala  Gly Gly Gly Thr Thr  Ala Thr Ala Gly Thr  Thr Gly Gly    2840                 2845                 2850Gly Gly  Thr Ala Ala Thr Gly  Thr Thr Gly Ala Thr  Ala Ala Thr    2855                 2860                 2865Gly Thr  Thr Thr Thr Cys Gly  Gly Cys Gly Gly Ala  Gly Gly Gly    2870                 2875                 2880Ala Cys  Cys Ala Ala Gly Gly  Thr Gly Gly Ala Gly  Ala Thr Cys    2885                 2890                 2895Ala Ala  Ala Gly Gly Cys Gly  Gly Thr Gly Gly Ala  Gly Gly Gly    2900                 2905                 2910Thr Cys  Cys Gly Gly Cys Gly  Gly Thr Gly Gly Thr  Gly Gly Cys    2915                 2920                 2925Thr Cys  Cys Gly Gly Ala Cys  Gly Ala Gly Ala Gly  Gly Gly Cys    2930                 2935                 2940Cys Cys  Cys Gly Ala Gly Cys  Thr Gly Thr Cys Thr  Cys Cys Thr    2945                 2950                 2955Gly Ala  Thr Gly Ala Cys Cys  Cys Ala Gly Cys Ala  Gly Gly Cys    2960                 2965                 2970Cys Thr  Cys Thr Thr Gly Gly  Ala Cys Thr Thr Gly  Cys Gly Gly    2975                 2980                 2985Cys Ala  Gly Gly Gly Thr Ala  Thr Gly Thr Thr Cys  Gly Cys Thr    2990                 2995                 3000Cys Ala  Ala Cys Thr Thr Gly  Thr Gly Gly Cys Thr  Cys Ala Gly    3005                 3010                 3015Ala Ala  Thr Gly Thr Thr Cys  Thr Gly Cys Thr Cys  Ala Thr Thr    3020                 3025                 3030Gly Ala  Thr Gly Gly Ala Cys  Cys Ala Cys Thr Cys  Thr Cys Thr    3035                 3040                 3045Thr Gly  Gly Thr Ala Thr Ala  Gly Thr Gly Ala Cys  Cys Cys Cys    3050                 3055                 3060Gly Gly  Thr Cys Thr Gly Gly  Cys Cys Gly Gly Gly  Gly Thr Gly    3065                 3070                 3075Ala Gly  Thr Cys Thr Gly Ala  Cys Cys Gly Gly Cys  Gly Gly Gly    3080                 3085                 3090Cys Thr  Cys Thr Cys Thr Thr  Ala Thr Ala Ala Ala  Gly Ala Gly    3095                 3100                 3105Gly Ala  Thr Ala Cys Thr Ala  Ala Gly Gly Ala Ala  Cys Thr Gly    3110                 3115                 3120Gly Thr  Cys Gly Thr Ala Gly  Cys Ala Ala Ala Ala  Gly Cys Gly    3125                 3130                 3135Gly Gly  Cys Gly Thr Thr Thr  Ala Thr Thr Ala Cys  Gly Thr Thr    3140                 3145                 3150Thr Thr  Thr Thr Thr Thr Cys  Ala Gly Cys Thr Gly  Gly Ala Gly    3155                 3160                 3165Cys Thr  Cys Ala Gly Gly Cys  Gly Cys Gly Thr Gly  Gly Thr Gly    3170                 3175                 3180Gly Cys  Cys Gly Gly Cys Gly  Ala Gly Gly Gly Cys  Ala Gly Thr    3185                 3190                 3195Gly Gly  Cys Thr Cys Thr Gly  Thr Gly Thr Cys Cys  Cys Thr Gly    3200                 3205                 3210Gly Cys  Cys Cys Thr Gly Cys  Ala Cys Thr Thr Ala  Cys Ala Gly    3215                 3220                 3225Cys Cys  Cys Thr Thr Gly Ala  Gly Ala Ala Gly Cys  Gly Cys Thr    3230                 3235                 3240Gly Cys  Ala Gly Gly Thr Gly  Cys Thr Gly Cys Cys  Gly Cys Ala    3245                 3250                 3255Cys Thr  Gly Gly Cys Thr Thr  Thr Ala Ala Cys Thr  Gly Thr Thr    3260                 3265                 3270Gly Ala  Cys Cys Thr Cys Cys  Cys Thr Cys Cys Gly  Gly Cys Cys    3275                 3280                 3285Thr Cys  Thr Thr Cys Thr Gly  Ala Ala Gly Cys Thr  Ala Gly Ala    3290                 3295                 3300Ala Ala  Cys Ala Gly Cys Gly  Cys Thr Thr Thr Cys  Gly Gly Cys    3305                 3310                 3315Thr Thr  Cys Cys Ala Ala Gly  Gly Gly Cys Gly Cys  Cys Thr Gly    3320                 3325                 3330Cys Thr  Gly Cys Ala Cys Cys  Thr Gly Ala Gly Cys  Gly Cys Ala    3335                 3340                 3345Gly Gly  Cys Cys Ala Gly Cys  Gly Cys Thr Thr Ala  Gly Gly Thr    3350                 3355                 3360Gly Thr  Gly Cys Ala Cys Cys  Thr Thr Cys Ala Thr  Ala Cys Ala    3365                 3370                 3375Gly Ala  Gly Gly Cys Cys Ala  Gly Gly Gly Cys Cys  Cys Gly Ala    3380                 3385                 3390Cys Ala  Cys Gly Cys Thr Thr  Gly Gly Cys Ala Gly  Cys Thr Cys    3395                 3400                 3405Ala Cys  Ala Cys Ala Gly Gly  Gly Thr Gly Cys Cys  Ala Cys Gly    3410                 3415                 3420Gly Thr  Thr Cys Thr Cys Gly  Gly Ala Cys Thr Thr  Thr Thr Cys    3425                 3430                 3435Cys Gly  Cys Gly Thr Thr Ala  Cys Thr Cys Cys Cys  Gly Ala Gly    3440                 3445                 3450Ala Thr  Cys Cys Cys Cys Gly  Cys Thr Gly Gly Cys  Cys Thr Cys    3455                 3460                 3465Gly Gly  Ala Ala Gly Thr Ala  Cys Thr Gly Gly Thr  Thr Cys Thr    3470                 3475                 3480Gly Gly  Gly Thr Cys Thr Ala  Ala Ala Cys Cys Cys  Gly Gly Thr    3485                 3490                 3495Thr Cys  Cys Gly Gly Cys Gly  Ala Ala Gly Gly Thr  Ala Gly Thr    3500                 3505                 3510Ala Cys  Thr Ala Ala Ala Gly  Gly Ala Cys Gly Ala  Gly Ala Ala    3515                 3520                 3525Gly Gly  Gly Cys Cys Ala Gly  Ala Gly Thr Thr Ala  Ala Gly Thr    3530                 3535                 3540Cys Cys  Ala Gly Ala Thr Gly  Ala Cys Cys Cys Thr  Gly Cys Thr    3545                 3550                 3555Gly Gly  Gly Cys Thr Thr Thr  Thr Gly Gly Ala Cys  Cys Thr Gly    3560                 3565                 3570Cys Gly  Gly Cys Ala Gly Gly  Gly Cys Ala Thr Gly  Thr Thr Cys    3575                 3580                 3585Gly Cys  Thr Cys Ala Ala Cys  Thr Gly Gly Thr Gly  Gly Cys Thr    3590                 3595                 3600Cys Ala  Gly Ala Ala Cys Gly  Thr Gly Cys Thr Gly  Cys Thr Gly    3605                 3610                 3615Ala Thr  Cys Gly Ala Thr Gly  Gly Cys Cys Cys Cys  Cys Thr Gly    3620                 3625                 3630Ala Gly  Thr Thr Gly Gly Thr  Ala Cys Ala Gly Cys  Gly Ala Thr    3635                 3640                 3645Cys Cys  Cys Gly Gly Gly Cys  Thr Gly Gly Cys Ala  Gly Gly Cys    3650                 3655                 3660Gly Thr  Gly Thr Cys Ala Cys  Thr Thr Ala Cys Ala  Gly Gly Gly    3665                 3670                 3675Gly Gly  Cys Cys Thr Cys Thr  Cys Thr Thr Ala Cys  Ala Ala Gly    3680                 3685                 3690Gly Ala  Ala Gly Ala Cys Ala  Cys Cys Ala Ala Gly  Gly Ala Gly    3695                 3700                 3705Thr Thr  Ala Gly Thr Gly Gly  Thr Cys Gly Cys Thr  Ala Ala Gly    3710                 3715                 3720Gly Cys  Thr Gly Gly Cys Gly  Thr Gly Thr Ala Thr  Thr Ala Cys    3725                 3730                 3735Gly Thr  Gly Thr Thr Cys Thr  Thr Cys Cys Ala Ala  Cys Thr Gly    3740                 3745                 3750Gly Ala  Gly Cys Thr Gly Ala  Gly Ala Ala Gly Gly  Gly Thr Thr    3755                 3760                 3765Gly Thr  Gly Gly Cys Ala Gly  Gly Ala Gly Ala Gly  Gly Gly Thr    3770                 3775                 3780Ala Gly  Cys Gly Gly Cys Ala  Gly Cys Gly Thr Gly  Thr Cys Thr    3785                 3790                 3795Thr Thr  Ala Gly Cys Cys Cys  Thr Thr Cys Ala Cys  Thr Thr Gly    3800                 3805                 3810Cys Ala  Gly Cys Cys Cys Cys  Thr Gly Ala Gly Gly  Thr Cys Thr    3815                 3820                 3825Gly Cys  Thr Gly Cys Ala Gly  Gly Thr Gly Cys Ala  Gly Cys Cys    3830                 3835                 3840Gly Cys  Thr Cys Thr Cys Gly  Cys Gly Cys Thr Cys  Ala Cys Cys    3845                 3850                 3855Gly Thr  Gly Gly Ala Thr Cys  Thr Cys Cys Cys Cys  Cys Cys Ala    3860                 3865                 3870Gly Cys  Cys Thr Cys Ala Thr  Cys Thr Gly Ala Ala  Gly Cys Thr    3875                 3880                 3885Ala Gly  Gly Ala Ala Cys Ala  Gly Thr Gly Cys Ala  Thr Thr Thr    3890                 3895                 3900Gly Gly  Cys Thr Thr Thr Cys  Ala Gly Gly Gly Ala  Cys Gly Cys    3905                 3910                 3915Thr Thr  Gly Cys Thr Gly Cys  Ala Cys Cys Thr Cys  Thr Cys Cys    3920                 3925                 3930Gly Cys  Thr Gly Gly Ala Cys  Ala Gly Ala Gly Gly  Cys Thr Gly    3935                 3940                 3945Gly Gly  Cys Gly Thr Gly Cys  Ala Cys Cys Thr Thr  Cys Ala Cys    3950                 3955                 3960Ala Cys  Ala Gly Ala Gly Gly  Cys Cys Cys Gly Thr  Gly Cys Cys    3965                 3970                 3975Ala Gly  Gly Cys Ala Thr Gly  Cys Ala Thr Gly Gly  Cys Ala Gly    3980                 3985                 3990Cys Thr  Cys Ala Cys Thr Cys  Ala Gly Gly Gly Gly  Gly Cys Ala    3995                 4000                 4005Ala Cys  Ala Gly Thr Gly Cys  Thr Gly Gly Gly Thr  Cys Thr Cys    4010                 4015                 4020Thr Thr  Cys Cys Gly Cys Gly  Thr Gly Ala Cys Thr  Cys Cys Thr    4025                 4030                 4035Gly Ala  Ala Ala Thr Ala Cys  Cys Ala Gly Cys Thr  Gly Gly Ala    4040                 4045                 4050Cys Thr  Thr Gly Gly Cys Gly  Gly Thr Gly Gly Ala  Gly Gly Cys    4055                 4060                 4065Ala Gly  Cys Gly Gly Cys Gly  Gly Ala Gly Gly Ala  Gly Gly Ala    4070                 4075                 4080Thr Cys  Thr Cys Gly Thr Gly  Ala Gly Gly Gly Gly  Cys Cys Ala    4085                 4090                 4095Gly Ala  Ala Cys Thr Gly Thr  Cys Cys Cys Cys Cys  Gly Ala Thr    4100                 4105                 4110Gly Ala  Cys Cys Cys Ala Gly  Cys Cys Gly Gly Ala  Cys Thr Gly    4115                 4120                 4125Cys Thr  Cys Gly Ala Thr Cys  Thr Cys Ala Gly Ala  Cys Ala Gly    4130                 4135                 4140Gly Gly  Cys Ala Thr Gly Thr  Thr Cys Gly Cys Thr  Cys Ala Gly    4145                 4150                 4155Cys Thr  Thr Gly Thr Ala Gly  Cys Cys Cys Ala Ala  Ala Ala Thr    4160                 4165                 4170Gly Thr  Cys Cys Thr Cys Cys  Thr Gly Ala Thr Thr  Gly Ala Cys    4175                 4180                 4185Gly Gly  Cys Cys Cys Thr Thr  Thr Gly Ala Gly Cys  Thr Gly Gly    4190                 4195                 4200Thr Ala  Thr Ala Gly Thr Gly  Ala Thr Cys Cys Cys  Gly Gly Cys    4205                 4210                 4215Thr Thr  Gly Gly Cys Cys Gly  Gly Gly Gly Thr Ala  Thr Cys Thr    4220                 4225                 4230Cys Thr  Gly Ala Cys Cys Gly  Gly Ala Gly Gly Cys  Cys Thr Cys    4235                 4240                 4245Thr Cys  Cys Thr Ala Cys Ala  Ala Gly Gly Ala Ala  Gly Ala Cys    4250                 4255                 4260Ala Cys  Cys Ala Ala Ala Gly  Ala Gly Cys Thr Gly  Gly Thr Gly    4265                 4270                 4275Gly Thr  Gly Gly Cys Ala Ala  Ala Ala Gly Cys Gly  Gly Gly Gly    4280                 4285                 4290Gly Thr  Gly Thr Ala Thr Thr  Ala Thr Gly Thr Gly  Thr Thr Cys    4295                 4300                 4305Thr Thr  Thr Cys Ala Gly Cys  Thr Cys Gly Ala Gly  Cys Thr Gly    4310                 4315                 4320Cys Gly  Gly Ala Gly Ala Gly  Thr Thr Gly Thr Gly  Gly Cys Cys    4325                 4330                 4335Gly Gly  Gly Gly Ala Ala Gly  Gly Gly Thr Cys Thr  Gly Gly Gly    4340                 4345                 4350Ala Gly  Cys Gly Thr Ala Thr  Cys Thr Cys Thr Thr  Gly Cys Ala    4355                 4360                 4365Cys Thr  Thr Cys Ala Cys Cys  Thr Gly Cys Ala Gly  Cys Cys Cys    4370                 4375                 4380Cys Thr  Gly Cys Gly Cys Ala  Gly Cys Gly Cys Cys  Gly Cys Thr    4385                 4390                 4395Gly Gly  Ala Gly Cys Cys Gly  Cys Cys Gly Cys Cys  Cys Thr Thr    4400                 4405                 4410Gly Cys  Thr Cys Thr Thr Ala  Cys Thr Gly Thr Gly  Gly Ala Thr    4415                 4420                 4425Cys Thr  Gly Cys Cys Thr Cys  Cys Thr Gly Cys Thr  Thr Cys Cys    4430                 4435                 4440Thr Cys  Ala Gly Ala Ala Gly  Cys Ala Cys Gly Cys  Ala Ala Cys    4445                 4450                 4455Ala Gly  Cys Gly Cys Cys Thr  Thr Cys Gly Gly Cys  Thr Thr Thr    4460                 4465                 4470Cys Ala  Ala Gly Gly Ala Cys  Gly Thr Cys Thr Cys  Cys Thr Gly    4475                 4480                 4485Cys Ala  Cys Thr Thr Gly Thr  Cys Cys Gly Cys Ala  Gly Gly Ala    4490                 4495                 4500Cys Ala  Gly Ala Gly Gly Thr  Thr Gly Gly Gly Cys  Gly Thr Cys    4505                 4510                 4515Cys Ala  Thr Thr Thr Ala Cys  Ala Cys Ala Cys Thr  Gly Ala Gly    4520                 4525                 4530Gly Cys  Ala Cys Gly Gly Gly  Cys Ala Cys Gly Gly  Cys Ala Cys    4535                 4540                 4545Gly Cys  Thr Thr Gly Gly Cys  Ala Gly Cys Thr Thr  Ala Cys Cys    4550                 4555                 4560Cys Ala  Gly Gly Gly Ala Gly  Cys Cys Ala Cys Cys  Gly Thr Gly    4565                 4570                 4575Cys Thr  Gly Gly Gly Ala Cys  Thr Cys Thr Thr Thr  Ala Gly Ala    4580                 4585                 4590Gly Thr  Gly Ala Cys Ala Cys  Cys Cys Gly Ala Gly  Ala Thr Cys    4595                 4600                 4605Cys Cys  Cys Gly Cys Thr Gly  Gly Cys Thr Thr Gly  Thr Gly Ala    4610                 4615                 4620</s400><s200><s210>39</s210><s211>475</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 39Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu    130                 135                 140Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met145                 150                 155                 160Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu                165                 170                 175Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys            180                 185                 190Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu        195                 200                 205Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala    210                 215                 220Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Asp Val Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly            260                 265                 270Asp Arg Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp        275                 280                 285Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile    290                 295                 300Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly305                 310                 315                 320Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro                325                 330                 335Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser            340                 345                 350Arg Thr Tyr Val Asn Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys        355                 360                 365Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu    370                 375                 380Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe385                 390                 395                 400Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln                405                 410                 415Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser            420                 425                 430Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu        435                 440                 445Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser    450                 455                 460Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys465                 470                 475</s400><s200><s210>40</s210><s211>1428</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 40gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaagtga cggtactggg tggaggcggt tcaggcggag gtggttccgg cggtggcggc    360tccggtggag gcggctctca ggtcacattg aaggaatctg gccccggcct tgttcagcca    420ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg    480ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg    540tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat    600acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta    660tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact    720ctcgtcacgg tctcgagcgg cggtggaggg tccggcggtg gtggatcaga cgtcgtgatg    780acccagtctc cttccaccct gtctgcatct gtaggagaca gagtcaccat caattgccaa    840gccagtgaga gcattagcag ttggttagcc tggtatcagc agaaaccagg gaaagcccct    900aagctcctga tctatgaagc atccaaactg gcatctgggg tcccatcaag gttcagcggc    960agtggatctg ggacagaatt cactctcacc atcagcagcc tgcagcctga tgattttgca   1020acttattact gccaaggcta tttttatttt attagtcgta cttatgtaaa ttctttcggc   1080ggagggacca aggtggagat caaacgtacg gtggctgcac catctgtctt catcttcccg   1140ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc   1200tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc   1260caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg   1320acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag   1380ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgttga                1428</s400><s200><s210>41</s210><s211>1165</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 41Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro1               5                   10                  15Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser            20                  25                  30Arg Thr Tyr Val Asn Ser Phe Gly Gln Gly Thr Lys Leu Thr Val Leu        35                  40                  45Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly    50                  55                  60Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val65                  70                  75                  80Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr                85                  90                  95Ile Ser Thr Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly            100                 105                 110Leu Glu Trp Val Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala        115                 120                 125Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn    130                 135                 140Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val145                 150                 155                 160Tyr Tyr Cys Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn                165                 170                 175Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly            180                 185                 190Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Gly        195                 200                 205Leu Val Lys Pro Ser Glu Thr Leu Ser Ile Thr Cys Thr Val Ser Gly    210                 215                 220Phe Ser Leu Thr Asn Tyr Gly Val His Trp Ile Arg Gln Ala Pro Gly225                 230                 235                 240Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly Asn Thr Asp                245                 250                 255Tyr Asn Thr Pro Phe Thr Ser Arg Phe Thr Ile Thr Lys Asp Asn Ser            260                 265                 270Lys Asn Gln Val Tyr Phe Lys Leu Arg Ser Val Arg Ala Asp Asp Thr        275                 280                 285Ala Ile Tyr Tyr Cys Ala Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe    290                 295                 300Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr305                 310                 315                 320Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser                325                 330                 335Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu            340                 345                 350Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His        355                 360                 365Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser    370                 375                 380Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys385                 390                 395                 400Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu                405                 410                 415Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro            420                 425                 430Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys        435                 440                 445Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val    450                 455                 460Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp465                 470                 475                 480Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr                485                 490                 495Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp            500                 505                 510Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu        515                 520                 525Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg    530                 535                 540Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys545                 550                 555                 560Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp                565                 570                 575Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys            580                 585                 590Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser        595                 600                 605Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser    610                 615                 620Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser625                 630                 635                 640Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                645                 650                 655Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly            660                 665                 670Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly        675                 680                 685Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp    690                 695                 700Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr Tyr Asp Ala Asn705                 710                 715                 720Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr                725                 730                 735Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr            740                 745                 750Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala Met Asp Leu Trp        755                 760                 765Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly    770                 775                 780Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile785                 790                 795                 800Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg                805                 810                 815Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser His Leu Asn            820                 825                 830Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys        835                 840                 845Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly    850                 855                 860Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp865                 870                 875                 880Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp Gly Asn Val Asp                885                 890                 895Asn Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly            900                 905                 910Ser Gly Gly Gly Gly Ser Gly Arg Ser Leu Val Glu Ser Gly Gly Gly        915                 920                 925Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly    930                 935                 940Phe Thr Ile Ser Ser Tyr His Met Gln Trp Val Arg Gln Ala Pro Gly945                 950                 955                 960Lys Gly Leu Glu Tyr Ile Gly Thr Ile Ser Ser Gly Gly Asn Val Tyr                965                 970                 975Tyr Ala Ser Ser Ala Arg Gly Arg Phe Thr Ile Ser Arg Pro Ser Ser            980                 985                 990Lys Asn Thr Val Asp Leu Gln Met  Asn Ser Leu Arg Ala  Glu Asp Thr        995                 1000                 1005Ala Val  Tyr Tyr Cys Ala Arg  Asp Ser Gly Tyr Ser  Asp Pro Met    1010                 1015                 1020Trp Gly  Gln Gly Thr Leu Val  Thr Val Ser Ser Gly  Gly Gly Gly    1025                 1030                 1035Ser Gly  Gly Gly Gly Ser Gly  Gly Gly Gly Ser Gly  Gly Gly Gly    1040                 1045                 1050Ser Asp  Val Val Met Thr Gln  Ser Pro Ser Ser Val  Ser Ala Ser    1055                 1060                 1065Val Gly  Asp Arg Val Thr Ile  Thr Cys Gln Ala Ser  Gln Asn Ile    1070                 1075                 1080Arg Thr  Tyr Leu Ser Trp Tyr  Gln Gln Lys Pro Gly  Lys Ala Pro    1085                 1090                 1095Lys Leu  Leu Ile Tyr Ala Ala  Ala Asn Leu Ala Ser  Gly Val Pro    1100                 1105                 1110Ser Arg  Phe Ser Gly Ser Gly  Ser Gly Thr Asp Phe  Thr Leu Thr    1115                 1120                 1125Ile Ser  Asp Leu Glu Pro Gly  Asp Ala Ala Thr Tyr  Tyr Cys Gln    1130                 1135                 1140Ser Thr  Tyr Leu Gly Thr Asp  Tyr Val Gly Gly Ala  Phe Gly Gly    1145                 1150                 1155Gly Thr  Lys Val Glu Ile Lys    1160                 1165</s400><s200><s210>42</s210><s211>3687</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 42gaaatcgtta tgacgcagag tccctccacg ctctccgcta gtgtcgggga tcgcgtcatt     60atcacatgcc aggcctccga gtcaatcagc agctggcttg catggtatca acagaagccg    120ggaaaagctc ctaaattgct gatctatgaa gcgtcaaaat tggcgtctgg tgtcccatct    180aggttctccg gctctgggtc tggtgcggaa tttactttga caatctccag tcttcaacca    240gacgatttcg ctacctacta ctgccaaggg tatttctatt ttataagccg gacatatgta    300aactccttcg gccaaggaac aaagttgact gttcttggtg gcggaggcag tggtggcggg    360ggcagcggag gtggtggttc agggggtggt gggagcgaag tccaattggt agaaagtggc    420ggtggtctgg tgcaacctgg tggatctctt cgcctctcat gcgccgctag tggctttact    480atttcaacta atgcgatgag ctgggttcgc caggcccccg gcaaaggact tgagtgggtc    540ggcgtcatca ccggcaggga cattacatac tatgcgagtt gggcaaaggg caggttcacg    600attagccgcg atacttcaaa gaataccgtt taccttcaaa tgaatagctt gagggcggaa    660gacacagctg tgtattactg cgcgagggat ggaggtagtt ccgccataac ttccaacaac    720atatggggac aaggcacgct ggttactgtc tcgagtggcg gtggagggtc cggcggtggt    780ggatcacaag tacagttgca gcaatccggt cccggtctcg tcaaaccgag tgagacgctt    840agtataacgt gtactgtttc aggctttagc cttacgaact atggagttca ctggattcgg    900caggcacccg gcaaaggttt ggaatggctg ggtgttattt ggtcaggtgg aaatacagac    960tataacaccc cctttacaag tcggttcaca attacgaaag ataattccaa aaatcaagtt   1020tatttcaagt tgagatccgt ccgcgcggac gacactgcga tctactattg tgcgagggca   1080ctgacctact acgattacga atttgcgtat tgggggcaag ggactcttgt aacagtctcc   1140agtgctagca ccaagggccc atcggtcttc cccctggcac cctcctccaa gagcacctct   1200gggggcacag cggccctggg ctgcctggtc aaggactact tccccgaacc ggtgacggtg   1260tcgtggaact caggcgccct gaccagcggc gtgcacacct tcccggctgt cctacagtcc   1320tcaggactct actccctcag cagcgtggtg accgtgccct ccagcagctt gggcacccag   1380acctacatct gcaacgtgaa tcacaagccc agcaacacca aggtggacaa gagagttgag   1440cccaaatctt gtgacaaaac tcacacatgc ccaccgtgcc cagcacctga agccgcgggg   1500gcaccgtcag tcttcctctt ccccccaaaa cccaaggaca ccctcatgat ctcccggacc   1560cctgaggtca catgcgtggt ggtggacgtg agccacgaag accctgaggt caagttcaac   1620tggtacgtgg acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagtac   1680aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc   1740aaggagtaca agtgcgcggt ctccaacaaa gccctcccag cccccatcga gaaaaccatc   1800tccaaagcca aagggcagcc ccgagaacca caggtgtaca ccctgccccc atcccgggat   1860gagctgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta tcccagcgac   1920atcgccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cacgcctccc   1980gtgctggact ccgacggctc cttcttcctc tatagcaagc tcaccgtgga caagagcagg   2040tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac   2100acgcagaaga gcctctccct gtctccgggt ggcggtggag ggtccggcgg tggtggatcc   2160gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc   2220tcctgtgcag cctctggatt ctccttcagt agcgggtacg acatgtgctg ggtccgccag   2280gctccaggga aggggctgga gtggatcgca tgcattgctg ctggtagtgc tggtatcact   2340tacgacgcga actgggcgaa aggccggttc accatctcca gagacaattc caagaacacg   2400ctgtatctgc aaatgaacag cctgagagcc gaggacacgg ccgtatatta ctgtgcgaga   2460tcggcgtttt cgttcgacta cgccatggac ctctggggcc agggaaccct ggtcaccgtg   2520tcgagcggtg gaggcggatc tggcggaggt ggttccggcg gtggcggctc cggtggaggc   2580ggctctgaca tccagatgac ccagtctcct tccaccctgt ctgcatctgt aggagacaga   2640gtcaccatca cttgccaggc cagtcagagc attagttccc acttaaactg gtatcagcag   2700aaaccaggga aagcccctaa gctcctgatc tataaggcat ccactctggc atctggggtc   2760ccatcaaggt tcagcggcag tggatctggg acagaattta ctctcaccat cagcagcctg   2820cagcctgatg attttgcaac ttattactgc caacagggtt atagttgggg taatgttgat   2880aatgttttcg gcggagggac caaggtggag atcaaaggcg gtggagggtc cggcggtggt   2940ggctccggac ggtcgctggt ggagtctggg ggaggcttgg tccagcctgg ggggtccctg   3000agactctcct gtactgcctc tggattcacc atcagtagct accacatgca gtgggtccgc   3060caggctccag ggaaggggct ggagtacatc ggaaccatta gtagtggtgg taatgtatac   3120tacgcaagct ccgctagagg cagattcacc atctccagac cctcgtccaa gaacacggtg   3180gatcttcaaa tgaacagcct gagagccgag gacacggctg tgtattactg tgcgagagac   3240tctggttata gtgatcctat gtggggccag ggaaccctgg tcaccgtctc ttcaggcggt   3300ggcggtagtg ggggaggcgg ttctggcggc ggagggtccg gcggtggagg atcagacgtt   3360gtgatgaccc agtctccatc ttccgtgtct gcatctgtag gagacagagt caccatcacc   3420tgtcaggcca gtcagaacat taggacttac ttatcctggt atcagcagaa accagggaaa   3480gcccctaagc tcctgatcta tgctgcagcc aatctggcat ctggggtccc atcaaggttc   3540agcggcagtg gatctgggac agatttcact ctcaccatca gcgacctgga gcctggcgat   3600gctgcaactt actattgtca gtctacctat cttggtactg attatgttgg cggtgctttc   3660ggcggaggga ccaaggtgga gatcaaa                                       3687</s400><s200><s210>43</s210><s211>470</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 43Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu    130                 135                 140Ser Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met145                 150                 155                 160Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu                165                 170                 175Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys            180                 185                 190Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu        195                 200                 205Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala    210                 215                 220Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Val Ser Pro Gly            260                 265                 270Glu Arg Ala Thr Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn        275                 280                 285Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Arg Leu Leu Ile    290                 295                 300Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Asp Arg Phe Ser Gly305                 310                 315                 320Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Val Gln Ser                325                 330                 335Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr            340                 345                 350Thr Phe Gly Pro Gly Thr Lys Leu Thr Val Leu Arg Thr Val Ala Ala        355                 360                 365Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly    370                 375                 380Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala385                 390                 395                 400Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln                405                 410                 415Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser            420                 425                 430Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr        435                 440                 445Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser    450                 455                 460Phe Asn Arg Gly Glu Cys465                 470</s400><s200><s210>44</s210><s211>1413</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 44gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaagtga ccgtcctagg cggtggcggt agtgggggag gcggttctgg cggcggaggg    360tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca    420ggacagaccc ttagcctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg    480ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg    540tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat    600acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta    660tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact    720ctcgtcacgg tctcgagtgg cggtggaggg tccggcggtg gtggatcaga aatcgtcctt    780acacaatctc ctagcacact gagtgtgagc cccggcgaac gcgcgacttt ctcttgcagg    840gcaagtcaat ccatagggac taatatacat tggtatcaac aaaagccagg taaaccaccc    900aggcttttga ttaagtatgc aagtgagtct atttccggta tccctgaccg cttctctgga    960tcaggcagtg gcacagagtt cacactcacc atatctagtg tgcaatcaga ggacttcgcc   1020gtgtattact gccaacagaa taataactgg ccgactacct tcggacccgg tacaaagctg   1080accgttttac gtacggtggc tgcaccatct gtcttcatct tcccgccatc tgatgagcag   1140ttgaaatctg gaactgcctc tgttgtgtgc ctgctgaata acttctatcc cagagaggcc   1200aaagtacagt ggaaggtgga taacgccctc caatcgggta actcccagga gagtgtcaca   1260gagcaggaca gcaaggacag cacctacagc ctcagcagca ccctgacgct gagcaaagca   1320gactacgaga aacacaaagt ctacgcctgc gaagtcaccc atcagggcct gagctcgccc   1380gtcacaaaga gcttcaacag gggagagtgt tag                                1413</s400><s200><s210>45</s210><s211>1217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 45Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Asp Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Val Gln Ser65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Pro Gly Thr Lys Leu Glu Leu Lys Gly Gly Gly Gly Ser            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln        115                 120                 125Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr    130                 135                 140Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly145                 150                 155                 160Val His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Gly                165                 170                 175Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser            180                 185                 190Arg Phe Thr Ile Thr Lys Asp Asn Ser Lys Asn Gln Val Tyr Phe Lys        195                 200                 205Leu Arg Ser Val Arg Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Arg    210                 215                 220Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Gln Val Gln Leu Gln Glu Ser Gly Gly Arg Leu Val Gln Pro Gly Glu            260                 265                 270Pro Leu Ser Leu Thr Cys Lys Thr Ser Gly Ile Asp Leu Ser Ser Asn        275                 280                 285Ala Ile Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile    290                 295                 300Gly Val Ile Phe Gly Ser Gly Asn Thr Tyr Tyr Ala Ser Trp Ala Lys305                 310                 315                 320Gly Arg Phe Thr Ile Ser Arg Ser Thr Ser Thr Val Tyr Leu Lys Met                325                 330                 335Asn Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly            340                 345                 350Gly Tyr Ser Ser Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser        355                 360                 365Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser    370                 375                 380Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp385                 390                 395                 400Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr                405                 410                 415Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr            420                 425                 430Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln        435                 440                 445Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp    450                 455                 460Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro465                 470                 475                 480Cys Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe Pro                485                 490                 495Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr            500                 505                 510Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn        515                 520                 525Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg    530                 535                 540Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val545                 550                 555                 560Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser                565                 570                 575Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys            580                 585                 590Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp        595                 600                 605Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe    610                 615                 620Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu625                 630                 635                 640Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe                645                 650                 655Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly            660                 665                 670Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr        675                 680                 685Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly    690                 695                 700Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val705                 710                 715                 720Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser                725                 730                 735Phe Ser Ser Gly Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys            740                 745                 750Gly Leu Glu Trp Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr        755                 760                 765Tyr Asp Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn    770                 775                 780Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp785                 790                 795                 800Thr Ala Val Tyr Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala                805                 810                 815Met Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly            820                 825                 830Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        835                 840                 845Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser    850                 855                 860Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser865                 870                 875                 880Ser His Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu                885                 890                 895Leu Ile Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe            900                 905                 910Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu        915                 920                 925Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp    930                 935                 940Gly Asn Val Asp Asn Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys945                 950                 955                 960Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Arg Ser Leu Val Glu                965                 970                 975Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys            980                 985                 990Thr Ala Ser Gly Phe Thr Ile Ser  Ser Tyr His Met Gln  Trp Val Arg        995                 1000                 1005Gln Ala  Pro Gly Lys Gly Leu  Glu Tyr Ile Gly Thr  Ile Ser Ser    1010                 1015                 1020Gly Gly  Asn Val Tyr Tyr Ala  Ser Ser Ala Arg Gly  Arg Phe Thr    1025                 1030                 1035Ile Ser  Arg Pro Ser Ser Lys  Asn Thr Val Asp Leu  Gln Met Asn    1040                 1045                 1050Ser Leu  Arg Ala Glu Asp Thr  Ala Val Tyr Tyr Cys  Ala Arg Asp    1055                 1060                 1065Ser Gly  Tyr Ser Asp Pro Met  Trp Gly Gln Gly Thr  Leu Val Thr    1070                 1075                 1080Val Ser  Ser Gly Gly Gly Gly  Ser Gly Gly Gly Gly  Ser Gly Gly    1085                 1090                 1095Gly Gly  Ser Gly Gly Gly Gly  Ser Asp Val Val Met  Thr Gln Ser    1100                 1105                 1110Pro Ser  Ser Val Ser Ala Ser  Val Gly Asp Arg Val  Thr Ile Thr    1115                 1120                 1125Cys Gln  Ala Ser Gln Asn Ile  Arg Thr Tyr Leu Ser  Trp Tyr Gln    1130                 1135                 1140Gln Lys  Pro Gly Lys Ala Pro  Lys Leu Leu Ile Tyr  Ala Ala Ala    1145                 1150                 1155Asn Leu  Ala Ser Gly Val Pro  Ser Arg Phe Ser Gly  Ser Gly Ser    1160                 1165                 1170Gly Thr  Asp Phe Thr Leu Thr  Ile Ser Asp Leu Glu  Pro Gly Asp    1175                 1180                 1185Ala Ala  Thr Tyr Tyr Cys Gln  Ser Thr Tyr Leu Gly  Thr Asp Tyr    1190                 1195                 1200Val Gly  Gly Ala Phe Gly Gly  Gly Thr Lys Val Glu  Ile Lys    1205                 1210                 1215</s400><s200><s210>46</s210><s211>3654</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 46gaaatcgtcc ttacacaatc tcctagcaca ctgagtgtga gccccggcga acgcgcgact     60ttctcttgca gggcaagtca atccataggg actaatatac attggtatca acaaaagcca    120ggtaaaccac ccaggctttt gattaagtat gcaagtgagt ctatttccgg tatccctgac    180cgcttctctg gatcaggcag tggcacagag ttcacactca ccatatctag tgtgcaatca    240gaggacttcg ccgtgtatta ctgccaacag aataataact ggccgactac cttcggaccc    300ggtacaaagt tggaactgaa aggcggtggc ggtagtgggg gaggcggttc tggcggcgga    360gggtccggcg gtggaggatc acaagtacag ttgcagcaat ccggtcccgg tctcgtcaaa    420ccgagtgaga cgcttagtat aacgtgtact gtttcaggct ttagccttac gaactatgga    480gttcactgga ttcggcaggc acccggcaaa ggtttggaat ggctgggtgt tatttggtca    540ggtggaaata cagactataa cacccccttt acaagtcggt tcacaattac gaaagataat    600tccaaaaatc aagtttattt caagttgaga tccgtccgcg cggacgacac tgcgatctac    660tattgtgcga gggcactgac ctactacgat tacgaatttg cgtattgggg gcaagggact    720cttgtaacag tctcgagcgg cggtggaggg tccggcggtg gtggatcaca agtgcagttg    780caagaaagtg gtggtagact ggttcagcct ggtgaaccct tgtcactgac gtgtaaaaca    840agcggcattg atctgtcctc taacgccatc ggatgggtcc gacaggcccc aggaaaaggt    900ctggagtgga tcggagttat cttcgggagc ggcaatacat actacgcaag ctgggcaaaa    960gggcgattta cgatatcacg gagcacctct acagtttatt tgaaaatgaa ctccctccgg   1020tccgaggata ccgcgatata ttactgtgcc agaggggggt actcctctga tatctggggg   1080cagggtacac tggttacagt ttcatccgct agcaccaagg gcccatcggt cttccccctg   1140gcaccctcct ccaagagcac ctctgggggc acagcggccc tgggctgcct ggtcaaggac   1200tacttccccg aaccggtgac ggtgtcgtgg aactcaggcg ccctgaccag cggcgtgcac   1260accttcccgg ctgtcctaca gtcctcagga ctctactccc tcagcagcgt ggtgaccgtg   1320ccctccagca gcttgggcac ccagacctac atctgcaacg tgaatcacaa gcccagcaac   1380accaaggtgg acaagagagt tgagcccaaa tcttgtgaca aaactcacac atgcccaccg   1440tgcccagcac ctgaagccgc gggggcaccg tcagtcttcc tcttcccccc aaaacccaag   1500gacaccctca tgatctcccg gacccctgag gtcacatgcg tggtggtgga cgtgagccac   1560gaagaccctg aggtcaagtt caactggtac gtggacggcg tggaggtgca taatgccaag   1620acaaagccgc gggaggagca gtacaacagc acgtaccgtg tggtcagcgt cctcaccgtc   1680ctgcaccagg actggctgaa tggcaaggag tacaagtgcg cggtctccaa caaagccctc   1740ccagccccca tcgagaaaac catctccaaa gccaaagggc agccccgaga accacaggtg   1800tacaccctgc ccccatcccg ggatgagctg accaagaacc aggtcagcct gacctgcctg   1860gtcaaaggct tctatcccag cgacatcgcc gtggagtggg agagcaatgg gcagccggag   1920aacaactaca agaccacgcc tcccgtgctg gactccgacg gctccttctt cctctatagc   1980aagctcaccg tggacaagag caggtggcag caggggaacg tcttctcatg ctccgtgatg   2040catgaggctc tgcacaacca ctacacgcag aagagcctct ccctgtctcc gggtggcggt   2100ggagggtccg gcggtggtgg atccgaggtg cagctgttgg agtctggggg aggcttggta   2160cagcctgggg ggtccctgag actctcctgt gcagcctctg gattctcctt cagtagcggg   2220tacgacatgt gctgggtccg ccaggctcca gggaaggggc tggagtggat cgcatgcatt   2280gctgctggta gtgctggtat cacttacgac gcgaactggg cgaaaggccg gttcaccatc   2340tccagagaca attccaagaa cacgctgtat ctgcaaatga acagcctgag agccgaggac   2400acggccgtat attactgtgc gagatcggcg ttttcgttcg actacgccat ggacctctgg   2460ggccagggaa ccctggtcac cgtgtcgagc ggtggaggcg gatctggcgg aggtggttcc   2520ggcggtggcg gctccggtgg aggcggctct gacatccaga tgacccagtc tccttccacc   2580ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc aggccagtca gagcattagt   2640tcccacttaa actggtatca gcagaaacca gggaaagccc ctaagctcct gatctataag   2700gcatccactc tggcatctgg ggtcccatca aggttcagcg gcagtggatc tgggacagaa   2760tttactctca ccatcagcag cctgcagcct gatgattttg caacttatta ctgccaacag   2820ggttatagtt ggggtaatgt tgataatgtt ttcggcggag ggaccaaggt ggagatcaaa   2880ggcggtggag ggtccggcgg tggtggctcc ggacggtcgc tggtggagtc tgggggaggc   2940ttggtccagc ctggggggtc cctgagactc tcctgtactg cctctggatt caccatcagt   3000agctaccaca tgcagtgggt ccgccaggct ccagggaagg ggctggagta catcggaacc   3060attagtagtg gtggtaatgt atactacgca agctccgcta gaggcagatt caccatctcc   3120agaccctcgt ccaagaacac ggtggatctt caaatgaaca gcctgagagc cgaggacacg   3180gctgtgtatt actgtgcgag agactctggt tatagtgatc ctatgtgggg ccagggaacc   3240ctggtcaccg tctcttcagg cggtggcggt agtgggggag gcggttctgg cggcggaggg   3300tccggcggtg gaggatcaga cgttgtgatg acccagtctc catcttccgt gtctgcatct   3360gtaggagaca gagtcaccat cacctgtcag gccagtcaga acattaggac ttacttatcc   3420tggtatcagc agaaaccagg gaaagcccct aagctcctga tctatgctgc agccaatctg   3480gcatctgggg tcccatcaag gttcagcggc agtggatctg ggacagattt cactctcacc   3540atcagcgacc tggagcctgg cgatgctgca acttactatt gtcagtctac ctatcttggt   3600actgattatg ttggcggtgc tttcggcgga gggaccaagg tggagatcaa atga         3654</s400><s200><s210>47</s210><s211>473</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 47Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu    130                 135                 140Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met145                 150                 155                 160Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu                165                 170                 175Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys            180                 185                 190Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu        195                 200                 205Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala    210                 215                 220Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Asp Pro Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly            260                 265                 270Asp Arg Val Thr Ile Ser Cys Gln Ser Ser Gln Ser Val Ala Lys Asn        275                 280                 285Asn Asn Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu    290                 295                 300Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ala Gly Val Pro Ser Arg Phe305                 310                 315                 320Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val                325                 330                 335Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ser Ala Arg Asp Ser Gly            340                 345                 350Asn Ile Gln Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr        355                 360                 365Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu    370                 375                 380Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro385                 390                 395                 400Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly                405                 410                 415Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr            420                 425                 430Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His        435                 440                 445Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val    450                 455                 460Thr Lys Ser Phe Asn Arg Gly Glu Cys465                 470</s400><s200><s210>48</s210><s211>1422</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 48gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaagtga cggtactggg tggaggcggt tcaggcggag gtggttccgg cggtggcggc    360tccggtggag gcggctctca ggtcacattg aaggaatctg gccccggcct tgttcagcca    420ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg    480ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg    540tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat    600acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta    660tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact    720ctcgtcacgg tctcgagtgg cggtggaggg tccggcggtg gtggatccga tccagttctg    780acacaaagtc catccagcct gtctgcctca gtcggcgaca gagtgaccat cagttgccag    840agctcacagt ctgtggctaa gaacaacaac ttggcgtggt tccaacagaa acctggacag    900gctccgaaat tgctgatcta ttctgcttcc acgcttgctg ctggtgttcc ttcccgcttt    960tcaggtagtg gtagcgggac agacttcact ttgactataa gcagcgtgca gcctgaagat   1020tttgcgacct actattgttc tgctagagac agtggaaata ttcagtcctt tgggggggga   1080acgaaggtcg aaataaagcg tacggtggct gcaccatctg tcttcatctt cccgccatct   1140gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc   1200agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag   1260agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg   1320agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg   1380agctcgcccg tcacaaagag cttcaacagg ggagagtgtt ga                      1422</s400><s200><s210>49</s210><s211>1533</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 49Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Asp Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Val Gln Ser65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Pro Gly Thr Lys Leu Glu Leu Lys Gly Gly Gly Gly Ser            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln        115                 120                 125Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr    130                 135                 140Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly145                 150                 155                 160Val His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Gly                165                 170                 175Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser            180                 185                 190Arg Phe Thr Ile Thr Lys Asp Asn Ser Lys Asn Gln Val Tyr Phe Lys        195                 200                 205Leu Arg Ser Val Arg Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Arg    210                 215                 220Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Gln Val Gln Leu Gln Glu Ser Gly Gly Arg Leu Val Gln Pro Gly Glu            260                 265                 270Pro Leu Ser Leu Thr Cys Lys Thr Ser Gly Ile Asp Leu Ser Ser Asn        275                 280                 285Ala Ile Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile    290                 295                 300Gly Val Ile Phe Gly Ser Gly Asn Thr Tyr Tyr Ala Ser Trp Ala Lys305                 310                 315                 320Gly Arg Phe Thr Ile Ser Arg Ser Thr Ser Thr Val Tyr Leu Lys Met                325                 330                 335Asn Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly            340                 345                 350Gly Tyr Ser Ser Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser        355                 360                 365Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser    370                 375                 380Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp385                 390                 395                 400Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr                405                 410                 415Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr            420                 425                 430Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln        435                 440                 445Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp    450                 455                 460Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro465                 470                 475                 480Cys Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe Pro                485                 490                 495Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr            500                 505                 510Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn        515                 520                 525Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg    530                 535                 540Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val545                 550                 555                 560Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser                565                 570                 575Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys            580                 585                 590Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp        595                 600                 605Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe    610                 615                 620Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu625                 630                 635                 640Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe                645                 650                 655Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly            660                 665                 670Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr        675                 680                 685Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly    690                 695                 700Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val705                 710                 715                 720Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser                725                 730                 735Phe Ser Ser Gly Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys            740                 745                 750Gly Leu Glu Trp Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr        755                 760                 765Tyr Asp Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn    770                 775                 780Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp785                 790                 795                 800Thr Ala Val Tyr Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala                805                 810                 815Met Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly            820                 825                 830Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly        835                 840                 845Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser    850                 855                 860Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser865                 870                 875                 880Ser His Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu                885                 890                 895Leu Ile Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe            900                 905                 910Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu        915                 920                 925Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp    930                 935                 940Gly Asn Val Asp Asn Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys945                 950                 955                 960Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Arg Glu Gly Pro Glu                965                 970                 975Leu Ser Pro Asp Asp Pro Ala Gly Leu Leu Asp Leu Arg Gln Gly Met            980                 985                 990Phe Ala Gln Leu Val Ala Gln Asn  Val Leu Leu Ile Asp  Gly Pro Leu        995                 1000                 1005Ser Trp  Tyr Ser Asp Pro Gly  Leu Ala Gly Val Ser  Leu Thr Gly    1010                 1015                 1020Gly Leu  Ser Tyr Lys Glu Asp  Thr Lys Glu Leu Val  Val Ala Lys    1025                 1030                 1035Ala Gly  Val Tyr Tyr Val Phe  Phe Gln Leu Glu Leu  Arg Arg Val    1040                 1045                 1050Val Ala  Gly Glu Gly Ser Gly  Ser Val Ser Leu Ala  Leu His Leu    1055                 1060                 1065Gln Pro  Leu Arg Ser Ala Ala  Gly Ala Ala Ala Leu  Ala Leu Thr    1070                 1075                 1080Val Asp  Leu Pro Pro Ala Ser  Ser Glu Ala Arg Asn  Ser Ala Phe    1085                 1090                 1095Gly Phe  Gln Gly Arg Leu Leu  His Leu Ser Ala Gly  Gln Arg Leu    1100                 1105                 1110Gly Val  His Leu His Thr Glu  Ala Arg Ala Arg His  Ala Trp Gln    1115                 1120                 1125Leu Thr  Gln Gly Ala Thr Val  Leu Gly Leu Phe Arg  Val Thr Pro    1130                 1135                 1140Glu Ile  Pro Ala Gly Leu Gly  Ser Thr Gly Ser Gly  Ser Lys Pro    1145                 1150                 1155Gly Ser  Gly Glu Gly Ser Thr  Lys Gly Arg Glu Gly  Pro Glu Leu    1160                 1165                 1170Ser Pro  Asp Asp Pro Ala Gly  Leu Leu Asp Leu Arg  Gln Gly Met    1175                 1180                 1185Phe Ala  Gln Leu Val Ala Gln  Asn Val Leu Leu Ile  Asp Gly Pro    1190                 1195                 1200Leu Ser  Trp Tyr Ser Asp Pro  Gly Leu Ala Gly Val  Ser Leu Thr    1205                 1210                 1215Gly Gly  Leu Ser Tyr Lys Glu  Asp Thr Lys Glu Leu  Val Val Ala    1220                 1225                 1230Lys Ala  Gly Val Tyr Tyr Val  Phe Phe Gln Leu Glu  Leu Arg Arg    1235                 1240                 1245Val Val  Ala Gly Glu Gly Ser  Gly Ser Val Ser Leu  Ala Leu His    1250                 1255                 1260Leu Gln  Pro Leu Arg Ser Ala  Ala Gly Ala Ala Ala  Leu Ala Leu    1265                 1270                 1275Thr Val  Asp Leu Pro Pro Ala  Ser Ser Glu Ala Arg  Asn Ser Ala    1280                 1285                 1290Phe Gly  Phe Gln Gly Arg Leu  Leu His Leu Ser Ala  Gly Gln Arg    1295                 1300                 1305Leu Gly  Val His Leu His Thr  Glu Ala Arg Ala Arg  His Ala Trp    1310                 1315                 1320Gln Leu  Thr Gln Gly Ala Thr  Val Leu Gly Leu Phe  Arg Val Thr    1325                 1330                 1335Pro Glu  Ile Pro Ala Gly Leu  Gly Gly Gly Gly Ser  Gly Gly Gly    1340                 1345                 1350Gly Ser  Arg Glu Gly Pro Glu  Leu Ser Pro Asp Asp  Pro Ala Gly    1355                 1360                 1365Leu Leu  Asp Leu Arg Gln Gly  Met Phe Ala Gln Leu  Val Ala Gln    1370                 1375                 1380Asn Val  Leu Leu Ile Asp Gly  Pro Leu Ser Trp Tyr  Ser Asp Pro    1385                 1390                 1395Gly Leu  Ala Gly Val Ser Leu  Thr Gly Gly Leu Ser  Tyr Lys Glu    1400                 1405                 1410Asp Thr  Lys Glu Leu Val Val  Ala Lys Ala Gly Val  Tyr Tyr Val    1415                 1420                 1425Phe Phe  Gln Leu Glu Leu Arg  Arg Val Val Ala Gly  Glu Gly Ser    1430                 1435                 1440Gly Ser  Val Ser Leu Ala Leu  His Leu Gln Pro Leu  Arg Ser Ala    1445                 1450                 1455Ala Gly  Ala Ala Ala Leu Ala  Leu Thr Val Asp Leu  Pro Pro Ala    1460                 1465                 1470Ser Ser  Glu Ala Arg Asn Ser  Ala Phe Gly Phe Gln  Gly Arg Leu    1475                 1480                 1485Leu His  Leu Ser Ala Gly Gln  Arg Leu Gly Val His  Leu His Thr    1490                 1495                 1500Glu Ala  Arg Ala Arg His Ala  Trp Gln Leu Thr Gln  Gly Ala Thr    1505                 1510                 1515Val Leu  Gly Leu Phe Arg Val  Thr Pro Glu Ile Pro  Ala Gly Leu    1520                 1525                 1530</s400><s200><s210>50</s210><s211>4602</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 50gaaatcgtcc ttacacaatc tcctagcaca ctgagtgtga gccccggcga acgcgcgact     60ttctcttgca gggcaagtca atccataggg actaatatac attggtatca acaaaagcca    120ggtaaaccac ccaggctttt gattaagtat gcaagtgagt ctatttccgg tatccctgac    180cgcttctctg gatcaggcag tggcacagag ttcacactca ccatatctag tgtgcaatca    240gaggacttcg ccgtgtatta ctgccaacag aataataact ggccgactac cttcggaccc    300ggtacaaagt tggaactgaa aggcggtggc ggtagtgggg gaggcggttc tggcggcgga    360gggtccggcg gtggaggatc acaagtacag ttgcagcaat ccggtcccgg tctcgtcaaa    420ccgagtgaga cgcttagtat aacgtgtact gtttcaggct ttagccttac gaactatgga    480gttcactgga ttcggcaggc acccggcaaa ggtttggaat ggctgggtgt tatttggtca    540ggtggaaata cagactataa cacccccttt acaagtcggt tcacaattac gaaagataat    600tccaaaaatc aagtttattt caagttgaga tccgtccgcg cggacgacac tgcgatctac    660tattgtgcga gggcactgac ctactacgat tacgaatttg cgtattgggg gcaagggact    720cttgtaacag tctcgagcgg cggtggaggg tccggcggtg gtggatcaca agtgcagttg    780caagaaagtg gtggtagact ggttcagcct ggtgaaccct tgtcactgac gtgtaaaaca    840agcggcattg atctgtcctc taacgccatc ggatgggtcc gacaggcccc aggaaaaggt    900ctggagtgga tcggagttat cttcgggagc ggcaatacat actacgcaag ctgggcaaaa    960gggcgattta cgatatcacg gagcacctct acagtttatt tgaaaatgaa ctccctccgg   1020tccgaggata ccgcgatata ttactgtgcc agaggggggt actcctctga tatctggggg   1080cagggtacac tggttacagt ttcatccgct agcaccaagg gcccatcggt cttccccctg   1140gcaccctcct ccaagagcac ctctgggggc acagcggccc tgggctgcct ggtcaaggac   1200tacttccccg aaccggtgac ggtgtcgtgg aactcaggcg ccctgaccag cggcgtgcac   1260accttcccgg ctgtcctaca gtcctcagga ctctactccc tcagcagcgt ggtgaccgtg   1320ccctccagca gcttgggcac ccagacctac atctgcaacg tgaatcacaa gcccagcaac   1380accaaggtgg acaagagagt tgagcccaaa tcttgtgaca aaactcacac atgcccaccg   1440tgcccagcac ctgaagccgc gggggcaccg tcagtcttcc tcttcccccc aaaacccaag   1500gacaccctca tgatctcccg gacccctgag gtcacatgcg tggtggtgga cgtgagccac   1560gaagaccctg aggtcaagtt caactggtac gtggacggcg tggaggtgca taatgccaag   1620acaaagccgc gggaggagca gtacaacagc acgtaccgtg tggtcagcgt cctcaccgtc   1680ctgcaccagg actggctgaa tggcaaggag tacaagtgcg cggtctccaa caaagccctc   1740ccagccccca tcgagaaaac catctccaaa gccaaagggc agccccgaga accacaggtg   1800tacaccctgc ccccatcccg ggatgagctg accaagaacc aggtcagcct gacctgcctg   1860gtcaaaggct tctatcccag cgacatcgcc gtggagtggg agagcaatgg gcagccggag   1920aacaactaca agaccacgcc tcccgtgctg gactccgacg gctccttctt cctctatagc   1980aagctcaccg tggacaagag caggtggcag caggggaacg tcttctcatg ctccgtgatg   2040catgaggctc tgcacaacca ctacacgcag aagagcctct ccctgtctcc gggtggcggt   2100ggagggtccg gcggtggtgg atccgaggtg cagctgttgg agtctggggg aggcttggta   2160cagcctgggg ggtccctgag actctcctgt gcagcctctg gattctcctt cagtagcggg   2220tacgacatgt gctgggtccg ccaggctcca gggaaggggc tggagtggat cgcatgcatt   2280gctgctggta gtgctggtat cacttacgac gcgaactggg cgaaaggccg gttcaccatc   2340tccagagaca attccaagaa cacgctgtat ctgcaaatga acagcctgag agccgaggac   2400acggccgtat attactgtgc gagatcggcg ttttcgttcg actacgccat ggacctctgg   2460ggccagggaa ccctggtcac cgtgtcgagc ggtggaggcg gatctggcgg aggtggttcc   2520ggcggtggcg gctccggtgg aggcggctct gacatccaga tgacccagtc tccttccacc   2580ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc aggccagtca gagcattagt   2640tcccacttaa actggtatca gcagaaacca gggaaagccc ctaagctcct gatctataag   2700gcatccactc tggcatctgg ggtcccatca aggttcagcg gcagtggatc tgggacagaa   2760tttactctca ccatcagcag cctgcagcct gatgattttg caacttatta ctgccaacag   2820ggttatagtt ggggtaatgt tgataatgtt ttcggcggag ggaccaaggt ggagatcaaa   2880ggcggtggag ggtccggcgg tggtggctcc ggacgagagg gccccgagct gtctcctgat   2940gacccagcag gcctcttgga cttgcggcag ggtatgttcg ctcaacttgt ggctcagaat   3000gttctgctca ttgatggacc actctcttgg tatagtgacc ccggtctggc cggggtgagt   3060ctgaccggcg ggctctctta taaagaggat actaaggaac tggtcgtagc aaaagcgggc   3120gtttattacg ttttttttca gctggagctc aggcgcgtgg tggccggcga gggcagtggc   3180tctgtgtccc tggccctgca cttacagccc ttgagaagcg ctgcaggtgc tgccgcactg   3240gctttaactg ttgacctccc tccggcctct tctgaagcta gaaacagcgc tttcggcttc   3300caagggcgcc tgctgcacct gagcgcaggc cagcgcttag gtgtgcacct tcatacagag   3360gccagggccc gacacgcttg gcagctcaca cagggtgcca cggttctcgg acttttccgc   3420gttactcccg agatccccgc tggcctcgga agtactggtt ctgggtctaa acccggttcc   3480ggcgaaggta gtactaaagg acgagaaggg ccagagttaa gtccagatga ccctgctggg   3540cttttggacc tgcggcaggg catgttcgct caactggtgg ctcagaacgt gctgctgatc   3600gatggccccc tgagttggta cagcgatccc gggctggcag gcgtgtcact tacagggggc   3660ctctcttaca aggaagacac caaggagtta gtggtcgcta aggctggcgt gtattacgtg   3720ttcttccaac tggagctgag aagggttgtg gcaggagagg gtagcggcag cgtgtcttta   3780gcccttcact tgcagcccct gaggtctgct gcaggtgcag ccgctctcgc gctcaccgtg   3840gatctccccc cagcctcatc tgaagctagg aacagtgcat ttggctttca gggacgcttg   3900ctgcacctct ccgctggaca gaggctgggc gtgcaccttc acacagaggc ccgtgccagg   3960catgcatggc agctcactca gggggcaaca gtgctgggtc tcttccgcgt gactcctgaa   4020ataccagctg gacttggcgg tggaggcagc ggcggaggag gatctcgtga ggggccagaa   4080ctgtcccccg atgacccagc cggactgctc gatctcagac agggcatgtt cgctcagctt   4140gtagcccaaa atgtcctcct gattgacggc cctttgagct ggtatagtga tcccggcttg   4200gccggggtat ctctgaccgg aggcctctcc tacaaggaag acaccaaaga gctggtggtg   4260gcaaaagcgg gggtgtatta tgtgttcttt cagctcgagc tgcggagagt tgtggccggg   4320gaagggtctg ggagcgtatc tcttgcactt cacctgcagc ccctgcgcag cgccgctgga   4380gccgccgccc ttgctcttac tgtggatctg cctcctgctt cctcagaagc acgcaacagc   4440gccttcggct ttcaaggacg tctcctgcac ttgtccgcag gacagaggtt gggcgtccat   4500ttacacactg aggcacgggc acggcacgct tggcagctta cccagggagc caccgtgctg   4560ggactcttta gagtgacacc cgagatcccc gctggcttgt ga                      4602</s400><s200><s210>51</s210><s211>473</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 51Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu    130                 135                 140Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met145                 150                 155                 160Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu                165                 170                 175Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys            180                 185                 190Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu        195                 200                 205Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala    210                 215                 220Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Asp Pro Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly            260                 265                 270Asp Arg Val Thr Ile Ser Cys Gln Ser Ser Gln Ser Val Ala Lys Asn        275                 280                 285Asn Asn Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu    290                 295                 300Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ala Gly Val Pro Ser Arg Phe305                 310                 315                 320Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val                325                 330                 335Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ser Ala Arg Asp Ser Gly            340                 345                 350Asn Ile Gln Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr        355                 360                 365Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu    370                 375                 380Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro385                 390                 395                 400Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly                405                 410                 415Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr            420                 425                 430Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His        435                 440                 445Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val    450                 455                 460Thr Lys Ser Phe Asn Arg Gly Glu Cys465                 470</s400><s200><s210>52</s210><s211>1422</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 52gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaagtga cggtactggg tggaggcggt tcaggcggag gtggttccgg cggtggcggc    360tccggtggag gcggctctca ggtcacattg aaggaatctg gccccggcct tgttcagcca    420ggacagaccc ttaggctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg    480ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg    540tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat    600acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta    660tattattgcg cgcggatgga actctggtct tactactttg attattgggg gcaggggact    720ctcgtcacgg tctcgagtgg cggtggaggg tccggcggtg gtggatccga tccagttctg    780acacaaagtc catccagcct gtctgcctca gtcggcgaca gagtgaccat cagttgccag    840agctcacagt ctgtggctaa gaacaacaac ttggcgtggt tccaacagaa acctggacag    900gctccgaaat tgctgatcta ttctgcttcc acgcttgctg ctggtgttcc ttcccgcttt    960tcaggtagtg gtagcgggac agacttcact ttgactataa gcagcgtgca gcctgaagat   1020tttgcgacct actattgttc tgctagagac agtggaaata ttcagtcctt tgggggggga   1080acgaaggtcg aaataaagcg tacggtggct gcaccatctg tcttcatctt cccgccatct   1140gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc   1200agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag   1260agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg   1320agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg   1380agctcgcccg tcacaaagag cttcaacagg ggagagtgtt ga                      1422</s400><s200><s210>53</s210><s211>1234</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 53Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Asp Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Val Gln Ser65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Pro Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln        115                 120                 125Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr    130                 135                 140Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly145                 150                 155                 160Val His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Gly                165                 170                 175Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser            180                 185                 190Arg Phe Thr Ile Thr Lys Asp Asn Ser Lys Asn Gln Val Tyr Phe Lys        195                 200                 205Leu Arg Ser Val Arg Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Arg    210                 215                 220Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu            260                 265                 270Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys        275                 280                 285Ala Ala Ser Gly Phe Thr Ile Ser Thr Asn Ala Met Ser Trp Val Arg    290                 295                 300Glu Ala Pro Gly Lys Cys Leu Glu Trp Ile Gly Val Ile Thr Gly Arg305                 310                 315                 320Asp Ile Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser                325                 330                 335Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg            340                 345                 350Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Gly Ser Ser        355                 360                 365Ala Ile Thr Ser Asn Asn Ile Trp Gly Gln Gly Thr Leu Val Thr Val    370                 375                 380Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser385                 390                 395                 400Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys                405                 410                 415Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu            420                 425                 430Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu        435                 440                 445Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr    450                 455                 460Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val465                 470                 475                 480Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro                485                 490                 495Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe            500                 505                 510Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val        515                 520                 525Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe    530                 535                 540Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro545                 550                 555                 560Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr                565                 570                 575Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val            580                 585                 590Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala        595                 600                 605Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg    610                 615                 620Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly625                 630                 635                 640Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro                645                 650                 655Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser            660                 665                 670Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln        675                 680                 685Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His    690                 695                 700Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser705                 710                 715                 720Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu                725                 730                 735Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe            740                 745                 750Ser Phe Ser Ser Gly Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly        755                 760                 765Lys Gly Leu Glu Trp Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile    770                 775                 780Thr Tyr Asp Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp785                 790                 795                 800Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu                805                 810                 815Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr            820                 825                 830Ala Met Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly        835                 840                 845Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly    850                 855                 860Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala865                 870                 875                 880Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile                885                 890                 895Ser Ser His Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys            900                 905                 910Leu Leu Ile Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg        915                 920                 925Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser    930                 935                 940Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser945                 950                 955                 960Trp Gly Asn Val Asp Asn Val Phe Gly Gly Gly Thr Lys Val Glu Ile                965                 970                 975Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Arg Ser Leu Val            980                 985                 990Glu Ser Gly Gly Gly Leu Val Gln  Pro Gly Gly Ser Leu  Arg Leu Ser        995                 1000                 1005Cys Thr  Ala Ser Gly Phe Thr  Ile Ser Ser Tyr His  Met Gln Trp    1010                 1015                 1020Val Arg  Gln Ala Pro Gly Lys  Gly Leu Glu Tyr Ile  Gly Thr Ile    1025                 1030                 1035Ser Ser  Gly Gly Asn Val Tyr  Tyr Ala Ser Ser Ala  Arg Gly Arg    1040                 1045                 1050Phe Thr  Ile Ser Arg Pro Ser  Ser Lys Asn Thr Val  Asp Leu Gln    1055                 1060                 1065Met Asn  Ser Leu Arg Ala Glu  Asp Thr Ala Val Tyr  Tyr Cys Ala    1070                 1075                 1080Arg Asp  Ser Gly Tyr Ser Asp  Pro Met Trp Gly Gln  Gly Thr Leu    1085                 1090                 1095Val Thr  Val Ser Ser Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser    1100                 1105                 1110Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser Asp Val  Val Met Thr    1115                 1120                 1125Gln Ser  Pro Ser Ser Val Ser  Ala Ser Val Gly Asp  Arg Val Thr    1130                 1135                 1140Ile Thr  Cys Gln Ala Ser Gln  Asn Ile Arg Thr Tyr  Leu Ser Trp    1145                 1150                 1155Tyr Gln  Gln Lys Pro Gly Lys  Ala Pro Lys Leu Leu  Ile Tyr Ala    1160                 1165                 1170Ala Ala  Asn Leu Ala Ser Gly  Val Pro Ser Arg Phe  Ser Gly Ser    1175                 1180                 1185Gly Ser  Gly Thr Asp Phe Thr  Leu Thr Ile Ser Asp  Leu Glu Pro    1190                 1195                 1200Gly Asp  Ala Ala Thr Tyr Tyr  Cys Gln Ser Thr Tyr  Leu Gly Thr    1205                 1210                 1215Asp Tyr  Val Gly Gly Ala Phe  Gly Gly Gly Thr Lys  Val Glu Ile    1220                 1225                 1230Lys</s400><s200><s210>54</s210><s211>3705</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 54gaaatcgtcc ttacacaatc tcctagcaca ctgagtgtga gccccggcga acgcgcgact     60ttctcttgca gggcaagtca atccataggg actaatatac attggtatca acaaaagcca    120ggtaaaccac ccaggctttt gattaagtat gcaagtgagt ctatttccgg tatccctgac    180cgcttctctg gatcaggcag tggcacagag ttcacactca ccatatctag tgtgcaatca    240gaggacttcg ccgtgtatta ctgccaacag aataataact ggccgactac cttcggaccc    300ggtacaaagc tgaccgtttt aggcggtggc ggtagtgggg gaggcggttc tggcggcgga    360gggtccggcg gtggaggatc acaagtacag ttgcagcaat ccggtcccgg tctcgtcaaa    420ccgagtgaga cgcttagtat aacgtgtact gtttcaggct ttagccttac gaactatgga    480gttcactgga ttcggcaggc acccggcaaa ggtttggaat ggctgggtgt tatttggtca    540ggtggaaata cagactataa cacccccttt acaagtcggt tcacaattac gaaagataat    600tccaaaaatc aagtttattt caagttgaga tccgtccgcg cggacgacac tgcgatctac    660tattgtgcga gggcactgac ctactacgat tacgaatttg cgtattgggg gcaagggact    720cttgtaacag tctcgagcgg tggaggcgga tctggcggag gtggttccgg cggtggcggc    780tccggtggag gcggctctga ggtgcagctg gtggagtctg ggggaggctt ggtccagcct    840ggggggtccc tgagactctc ctgtgcagcc tctggattca ccatcagtac caatgcaatg    900agctgggtcc gcgaggctcc agggaagtgt ctggagtgga tcggagtcat tactggtcgt    960gatatcacat actacgcgag ctgggcgaaa ggcagattca ccatctccag agacaattcc   1020aagaacacgc tgtatcttca aatgaacagc ctgagagccg aggacacggc tgtgtattac   1080tgtgcgagag acggtggttc ttctgctatt actagtaaca acatttgggg ccagggaacc   1140ctggtcaccg tgtcctcagc tagcaccaag ggcccatcgg tcttccccct ggcaccctcc   1200tccaagagca cctctggggg cacagcggcc ctgggctgcc tggtcaagga ctacttcccc   1260gaaccggtga cggtgtcgtg gaactcaggc gccctgacca gcggcgtgca caccttcccg   1320gctgtcctac agtcctcagg actctactcc ctcagcagcg tggtgaccgt gccctccagc   1380agcttgggca cccagaccta catctgcaac gtgaatcaca agcccagcaa caccaaggtg   1440gacaagagag ttgagcccaa atcttgtgac aaaactcaca catgcccacc gtgcccagca   1500cctgaagccg cgggggcacc gtcagtcttc ctcttccccc caaaacccaa ggacaccctc   1560atgatctccc ggacccctga ggtcacatgc gtggtggtgg acgtgagcca cgaagaccct   1620gaggtcaagt tcaactggta cgtggacggc gtggaggtgc ataatgccaa gacaaagccg   1680cgggaggagc agtacaacag cacgtaccgt gtggtcagcg tcctcaccgt cctgcaccag   1740gactggctga atggcaagga gtacaagtgc gcggtctcca acaaagccct cccagccccc   1800atcgagaaaa ccatctccaa agccaaaggg cagccccgag aaccacaggt gtacaccctg   1860cccccatccc gggatgagct gaccaagaac caggtcagcc tgacctgcct ggtcaaaggc   1920ttctatccca gcgacatcgc cgtggagtgg gagagcaatg ggcagccgga gaacaactac   1980aagaccacgc ctcccgtgct ggactccgac ggctccttct tcctctatag caagctcacc   2040gtggacaaga gcaggtggca gcaggggaac gtcttctcat gctccgtgat gcatgaggct   2100ctgcacaacc actacacgca gaagagcctc tccctgtctc cgggtggcgg tggagggtcc   2160ggcggtggtg gatccgaggt gcagctgttg gagtctgggg gaggcttggt acagcctggg   2220gggtccctga gactctcctg tgcagcctct ggattctcct tcagtagcgg gtacgacatg   2280tgctgggtcc gccaggctcc agggaagggg ctggagtgga tcgcatgcat tgctgctggt   2340agtgctggta tcacttacga cgcgaactgg gcgaaaggcc ggttcaccat ctccagagac   2400aattccaaga acacgctgta tctgcaaatg aacagcctga gagccgagga cacggccgta   2460tattactgtg cgagatcggc gttttcgttc gactacgcca tggacctctg gggccaggga   2520accctggtca ccgtgtcgag cggtggaggc ggatctggcg gaggtggttc cggcggtggc   2580ggctccggtg gaggcggctc tgacatccag atgacccagt ctccttccac cctgtctgca   2640tctgtaggag acagagtcac catcacttgc caggccagtc agagcattag ttcccactta   2700aactggtatc agcagaaacc agggaaagcc cctaagctcc tgatctataa ggcatccact   2760ctggcatctg gggtcccatc aaggttcagc ggcagtggat ctgggacaga atttactctc   2820accatcagca gcctgcagcc tgatgatttt gcaacttatt actgccaaca gggttatagt   2880tggggtaatg ttgataatgt tttcggcgga gggaccaagg tggagatcaa aggcggtgga   2940gggtccggcg gtggtggctc cggacggtcg ctggtggagt ctgggggagg cttggtccag   3000cctggggggt ccctgagact ctcctgtact gcctctggat tcaccatcag tagctaccac   3060atgcagtggg tccgccaggc tccagggaag gggctggagt acatcggaac cattagtagt   3120ggtggtaatg tatactacgc aagctccgct agaggcagat tcaccatctc cagaccctcg   3180tccaagaaca cggtggatct tcaaatgaac agcctgagag ccgaggacac ggctgtgtat   3240tactgtgcga gagactctgg ttatagtgat cctatgtggg gccagggaac cctggtcacc   3300gtctcttcag gcggtggcgg tagtggggga ggcggttctg gcggcggagg gtccggcggt   3360ggaggatcag acgttgtgat gacccagtct ccatcttccg tgtctgcatc tgtaggagac   3420agagtcacca tcacctgtca ggccagtcag aacattagga cttacttatc ctggtatcag   3480cagaaaccag ggaaagcccc taagctcctg atctatgctg cagccaatct ggcatctggg   3540gtcccatcaa ggttcagcgg cagtggatct gggacagatt tcactctcac catcagcgac   3600ctggagcctg gcgatgctgc aacttactat tgtcagtcta cctatcttgg tactgattat   3660gttggcggtg ctttcggcgg agggaccaag gtggagatca aatga                   3705</s400><s200><s210>55</s210><s211>739</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 55Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu    130                 135                 140Ser Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met145                 150                 155                 160Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu                165                 170                 175Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys            180                 185                 190Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu        195                 200                 205Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala    210                 215                 220Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Asp Val Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly            260                 265                 270Asp Arg Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp        275                 280                 285Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile    290                 295                 300Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly305                 310                 315                 320Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro                325                 330                 335Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser            340                 345                 350Arg Thr Tyr Val Asn Ser Phe Gly Cys Gly Thr Lys Val Glu Ile Lys        355                 360                 365Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu    370                 375                 380Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe385                 390                 395                 400Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln                405                 410                 415Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser            420                 425                 430Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu        435                 440                 445Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser    450                 455                 460Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser465                 470                 475                 480Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln                485                 490                 495Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys            500                 505                 510Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Phe Val Ser Trp Tyr        515                 520                 525Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser    530                 535                 540Asp Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly545                 550                 555                 560Asn Thr Ala Ser Leu Ile Ile Ser Gly Leu Gln Ala Asp Asp Glu Ala                565                 570                 575Asp Tyr Tyr Cys Ser Ser Tyr Gly Ser Ser Ser Thr His Val Ile Phe            580                 585                 590Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly Gly        595                 600                 605Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln    610                 615                 620Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Ser625                 630                 635                 640Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser                645                 650                 655Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile            660                 665                 670Asn Arg Asp Gly Ser Ala Ser Tyr Tyr Val Asp Ser Val Lys Gly Arg        675                 680                 685Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Ser Leu Tyr Leu Gln Met    690                 695                 700Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp705                 710                 715                 720Arg Gly Val Gly Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr                725                 730                 735Val Ser Ser</s400><s200><s210>56</s210><s211>2220</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 56gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaagtga ccgtcctagg cggtggcggt agtgggggag gcggttctgg cggcggaggg    360tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca    420ggacagaccc ttagcctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg    480ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg    540tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat    600acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta    660tattattgcg ctcggatgga actctggtct tactactttg attattgggg gcaggggact    720ctcgtcacgg tctcgagtgg cggtggaggg tccggcggtg gtggatcaga cgtcgtgatg    780acccagtctc cttccaccct gtctgcatct gtaggagaca gagtcaccat caattgccaa    840gccagtgaga gcattagcag ttggttagcc tggtatcagc agaaaccagg gaaagcccct    900aagctcctga tctatgaagc atccaaactg gcatctgggg tcccatcaag gttcagcggc    960agtggatctg ggacagaatt tactctcacc atcagcagcc tgcagcctga tgattttgca   1020acttattact gccaaggcta tttttatttt attagtcgta cttatgtaaa ttctttcggc   1080tgtgggacca aggtggagat caaacgtacg gtggctgcac catctgtctt catcttcccg   1140ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc   1200tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc   1260caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg   1320acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag   1380ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgtggcgg tggcggtagc   1440ggtggcggcg gaagtggtgg cggaggatcc cagtctgccc tgactcagcc tgcctccgtg   1500tctgggtctc ctggacagtc gatcaccatc tcctgcactg gaaccagcag tgacgttggt   1560ggttataact ttgtctcctg gtaccaacaa cacccaggca aagcccccaa actcatgatc   1620tatgatgtca gtgatcggcc ctcaggggtg tctgatcgct tctccggctc caagtctggc   1680aacacggcct ccctgatcat ctctggcctc caggctgacg acgaggctga ttattactgc   1740agctcatatg ggagcagcag cactcatgtg attttcggcg gagggaccaa ggtgaccgtc   1800ctaggtggag gcggttcagg cggaggtggt tccggcggtg gcggctccgg tggaggcggc   1860tctcaggtgc aattgcagga gtcgggggga ggcctggtca agcctggagg gtccctgagt   1920ctctcctgtg cagcctctgg attcaccttt agtagttatt ggatgagctg ggtccgccag   1980gctccaggga aggggctgga gtgggtggcc aacataaacc gcgatggaag tgcgagttac   2040tatgtggact ctgtgaaggg ccgattcacc atctccagag acgacgccaa gaactcactg   2100tatctgcaaa tgaacagcct gagagctgag gacacggctg tgtattactg tgcgagagat   2160cgtggggtgg gctacttcga tctctggggc cgtggcaccc tggtcaccgt ctctagctga   2220</s400><s200><s210>57</s210><s211>1234</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 57Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Asp Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Val Gln Ser65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Pro Gly Thr Lys Leu Thr Val Leu Gly Gly Gly Gly Ser            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln        115                 120                 125Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr    130                 135                 140Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly145                 150                 155                 160Val His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Gly                165                 170                 175Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser            180                 185                 190Arg Phe Thr Ile Thr Lys Asp Asn Ser Lys Asn Gln Val Tyr Phe Lys        195                 200                 205Leu Arg Ser Val Arg Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Arg    210                 215                 220Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu            260                 265                 270Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys        275                 280                 285Ala Ala Ser Gly Phe Thr Ile Ser Thr Asn Ala Met Ser Trp Val Arg    290                 295                 300Glu Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Val Ile Thr Gly Arg305                 310                 315                 320Asp Ile Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser                325                 330                 335Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg            340                 345                 350Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Gly Ser Ser        355                 360                 365Ala Ile Thr Ser Asn Asn Ile Trp Gly Gln Gly Thr Leu Val Thr Val    370                 375                 380Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser385                 390                 395                 400Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys                405                 410                 415Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu            420                 425                 430Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu        435                 440                 445Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr    450                 455                 460Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val465                 470                 475                 480Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro                485                 490                 495Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe            500                 505                 510Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val        515                 520                 525Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe    530                 535                 540Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro545                 550                 555                 560Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr                565                 570                 575Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val            580                 585                 590Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala        595                 600                 605Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg    610                 615                 620Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly625                 630                 635                 640Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro                645                 650                 655Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser            660                 665                 670Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln        675                 680                 685Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His    690                 695                 700Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser705                 710                 715                 720Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu                725                 730                 735Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe            740                 745                 750Ser Phe Ser Ser Gly Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly        755                 760                 765Lys Gly Leu Glu Trp Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile    770                 775                 780Thr Tyr Asp Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp785                 790                 795                 800Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu                805                 810                 815Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr            820                 825                 830Ala Met Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly        835                 840                 845Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly    850                 855                 860Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala865                 870                 875                 880Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile                885                 890                 895Ser Ser His Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys            900                 905                 910Leu Leu Ile Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg        915                 920                 925Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser    930                 935                 940Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser945                 950                 955                 960Trp Gly Asn Val Asp Asn Val Phe Gly Gly Gly Thr Lys Val Glu Ile                965                 970                 975Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Arg Ser Leu Val            980                 985                 990Glu Ser Gly Gly Gly Leu Val Gln  Pro Gly Gly Ser Leu  Arg Leu Ser        995                 1000                 1005Cys Thr  Ala Ser Gly Phe Thr  Ile Ser Ser Tyr His  Met Gln Trp    1010                 1015                 1020Val Arg  Gln Ala Pro Gly Lys  Gly Leu Glu Tyr Ile  Gly Thr Ile    1025                 1030                 1035Ser Ser  Gly Gly Asn Val Tyr  Tyr Ala Ser Ser Ala  Arg Gly Arg    1040                 1045                 1050Phe Thr  Ile Ser Arg Pro Ser  Ser Lys Asn Thr Val  Asp Leu Gln    1055                 1060                 1065Met Asn  Ser Leu Arg Ala Glu  Asp Thr Ala Val Tyr  Tyr Cys Ala    1070                 1075                 1080Arg Asp  Ser Gly Tyr Ser Asp  Pro Met Trp Gly Gln  Gly Thr Leu    1085                 1090                 1095Val Thr  Val Ser Ser Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser    1100                 1105                 1110Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser Asp Val  Val Met Thr    1115                 1120                 1125Gln Ser  Pro Ser Ser Val Ser  Ala Ser Val Gly Asp  Arg Val Thr    1130                 1135                 1140Ile Thr  Cys Gln Ala Ser Gln  Asn Ile Arg Thr Tyr  Leu Ser Trp    1145                 1150                 1155Tyr Gln  Gln Lys Pro Gly Lys  Ala Pro Lys Leu Leu  Ile Tyr Ala    1160                 1165                 1170Ala Ala  Asn Leu Ala Ser Gly  Val Pro Ser Arg Phe  Ser Gly Ser    1175                 1180                 1185Gly Ser  Gly Thr Asp Phe Thr  Leu Thr Ile Ser Asp  Leu Glu Pro    1190                 1195                 1200Gly Asp  Ala Ala Thr Tyr Tyr  Cys Gln Ser Thr Tyr  Leu Gly Thr    1205                 1210                 1215Asp Tyr  Val Gly Gly Ala Phe  Gly Gly Gly Thr Lys  Val Glu Ile    1220                 1225                 1230Lys</s400><s200><s210>58</s210><s211>3705</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 58gaaatcgtcc ttacacaatc tcctagcaca ctgagtgtga gccccggcga acgcgcgact     60ttctcttgca gggcaagtca atccataggg actaatatac attggtatca acaaaagcca    120ggtaaaccac ccaggctttt gattaagtat gcaagtgagt ctatttccgg tatccctgac    180cgcttctctg gatcaggcag tggcacagag ttcacactca ccatatctag tgtgcaatca    240gaggacttcg ccgtgtatta ctgccaacag aataataact ggccgactac cttcggaccc    300ggtacaaagc tgaccgtttt aggcggtggc ggtagtgggg gaggcggttc tggcggcgga    360gggtccggcg gtggaggatc acaagtacag ttgcagcaat ccggtcccgg tctcgtcaaa    420ccgagtgaga cgcttagtat aacgtgtact gtttcaggct ttagccttac gaactatgga    480gttcactgga ttcggcaggc acccggcaaa ggtttggaat ggctgggtgt tatttggtca    540ggtggaaata cagactataa cacccccttt acaagtcggt tcacaattac gaaagataat    600tccaaaaatc aagtttattt caagttgaga tccgtccgcg cggacgacac tgcgatctac    660tattgtgcga gggcactgac ctactacgat tacgaatttg cgtattgggg gcaagggact    720cttgtaacag tctcgagcgg tggaggcgga tctggcggag gtggttccgg cggtggcggc    780tccggtggag gcggctctga ggtgcagctg gtggagtctg ggggaggctt ggtccagcct    840ggggggtccc tgagactctc ctgtgcagcc tctggattca ccatcagtac caatgcaatg    900agctgggtcc gcgaggctcc agggaagggc ctggagtgga tcggagtcat tactggtcgt    960gatatcacat actacgcgag ctgggcgaaa ggcagattca ccatctccag agacaattcc   1020aagaacacgc tgtatcttca aatgaacagc ctgagagccg aggacacggc tgtgtattac   1080tgtgcgagag acggtggttc ttctgctatt actagtaaca acatttgggg ccagggaacc   1140ctggtcaccg tgtcctcagc tagcaccaag ggcccatcgg tcttccccct ggcaccctcc   1200tccaagagca cctctggggg cacagcggcc ctgggctgcc tggtcaagga ctacttcccc   1260gaaccggtga cggtgtcgtg gaactcaggc gccctgacca gcggcgtgca caccttcccg   1320gctgtcctac agtcctcagg actctactcc ctcagcagcg tggtgaccgt gccctccagc   1380agcttgggca cccagaccta catctgcaac gtgaatcaca agcccagcaa caccaaggtg   1440gacaagagag ttgagcccaa atcttgtgac aaaactcaca catgcccacc gtgcccagca   1500cctgaagccg cgggggcacc gtcagtcttc ctcttccccc caaaacccaa ggacaccctc   1560atgatctccc ggacccctga ggtcacatgc gtggtggtgg acgtgagcca cgaagaccct   1620gaggtcaagt tcaactggta cgtggacggc gtggaggtgc ataatgccaa gacaaagccg   1680cgggaggagc agtacaacag cacgtaccgt gtggtcagcg tcctcaccgt cctgcaccag   1740gactggctga atggcaagga gtacaagtgc gcggtctcca acaaagccct cccagccccc   1800atcgagaaaa ccatctccaa agccaaaggg cagccccgag aaccacaggt gtacaccctg   1860cccccatccc gggatgagct gaccaagaac caggtcagcc tgacctgcct ggtcaaaggc   1920ttctatccca gcgacatcgc cgtggagtgg gagagcaatg ggcagccgga gaacaactac   1980aagaccacgc ctcccgtgct ggactccgac ggctccttct tcctctatag caagctcacc   2040gtggacaaga gcaggtggca gcaggggaac gtcttctcat gctccgtgat gcatgaggct   2100ctgcacaacc actacacgca gaagagcctc tccctgtctc cgggtggcgg tggagggtcc   2160ggcggtggtg gatccgaggt gcagctgttg gagtctgggg gaggcttggt acagcctggg   2220gggtccctga gactctcctg tgcagcctct ggattctcct tcagtagcgg gtacgacatg   2280tgctgggtcc gccaggctcc agggaagggg ctggagtgga tcgcatgcat tgctgctggt   2340agtgctggta tcacttacga cgcgaactgg gcgaaaggcc ggttcaccat ctccagagac   2400aattccaaga acacgctgta tctgcaaatg aacagcctga gagccgagga cacggccgta   2460tattactgtg cgagatcggc gttttcgttc gactacgcca tggacctctg gggccaggga   2520accctggtca ccgtgtcgag cggtggaggc ggatctggcg gaggtggttc cggcggtggc   2580ggctccggtg gaggcggctc tgacatccag atgacccagt ctccttccac cctgtctgca   2640tctgtaggag acagagtcac catcacttgc caggccagtc agagcattag ttcccactta   2700aactggtatc agcagaaacc agggaaagcc cctaagctcc tgatctataa ggcatccact   2760ctggcatctg gggtcccatc aaggttcagc ggcagtggat ctgggacaga atttactctc   2820accatcagca gcctgcagcc tgatgatttt gcaacttatt actgccaaca gggttatagt   2880tggggtaatg ttgataatgt tttcggcgga gggaccaagg tggagatcaa aggcggtgga   2940gggtccggcg gtggtggctc cggacggtcg ctggtggagt ctgggggagg cttggtccag   3000cctggggggt ccctgagact ctcctgtact gcctctggat tcaccatcag tagctaccac   3060atgcagtggg tccgccaggc tccagggaag gggctggagt acatcggaac cattagtagt   3120ggtggtaatg tatactacgc aagctccgct agaggcagat tcaccatctc cagaccctcg   3180tccaagaaca cggtggatct tcaaatgaac agcctgagag ccgaggacac ggctgtgtat   3240tactgtgcga gagactctgg ttatagtgat cctatgtggg gccagggaac cctggtcacc   3300gtctcttcag gcggtggcgg tagtggggga ggcggttctg gcggcggagg gtccggcggt   3360ggaggatcag acgttgtgat gacccagtct ccatcttccg tgtctgcatc tgtaggagac   3420agagtcacca tcacctgtca ggccagtcag aacattagga cttacttatc ctggtatcag   3480cagaaaccag ggaaagcccc taagctcctg atctatgctg cagccaatct ggcatctggg   3540gtcccatcaa ggttcagcgg cagtggatct gggacagatt tcactctcac catcagcgac   3600ctggagcctg gcgatgctgc aacttactat tgtcagtcta cctatcttgg tactgattat   3660gttggcggtg ctttcggcgg agggaccaag gtggagatca aatga                   3705</s400><s200><s210>59</s210><s211>739</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 59Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu    130                 135                 140Ser Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met145                 150                 155                 160Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu                165                 170                 175Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys            180                 185                 190Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu        195                 200                 205Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala    210                 215                 220Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Asp Val Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly            260                 265                 270Asp Arg Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp        275                 280                 285Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile    290                 295                 300Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly305                 310                 315                 320Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro                325                 330                 335Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser            340                 345                 350Arg Thr Tyr Val Asn Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys        355                 360                 365Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu    370                 375                 380Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe385                 390                 395                 400Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln                405                 410                 415Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser            420                 425                 430Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu        435                 440                 445Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser    450                 455                 460Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser465                 470                 475                 480Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln                485                 490                 495Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys            500                 505                 510Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Phe Val Ser Trp Tyr        515                 520                 525Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser    530                 535                 540Asp Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly545                 550                 555                 560Asn Thr Ala Ser Leu Ile Ile Ser Gly Leu Gln Ala Asp Asp Glu Ala                565                 570                 575Asp Tyr Tyr Cys Ser Ser Tyr Gly Ser Ser Ser Thr His Val Ile Phe            580                 585                 590Gly Gly Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly Gly        595                 600                 605Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln    610                 615                 620Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Ser625                 630                 635                 640Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser                645                 650                 655Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile            660                 665                 670Asn Arg Asp Gly Ser Ala Ser Tyr Tyr Val Asp Ser Val Lys Gly Arg        675                 680                 685Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Ser Leu Tyr Leu Gln Met    690                 695                 700Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp705                 710                 715                 720Arg Gly Val Gly Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr                725                 730                 735Val Ser Ser</s400><s200><s210>60</s210><s211>2220</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 60gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaagtga ccgtcctagg cggtggcggt agtgggggag gcggttctgg cggcggaggg    360tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca    420ggacagaccc ttagcctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg    480ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg    540tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat    600acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta    660tattattgcg ctcggatgga actctggtct tactactttg attattgggg gcaggggact    720ctcgtcacgg tctcgagtgg cggtggaggg tccggcggtg gtggatcaga cgtcgtgatg    780acccagtctc cttccaccct gtctgcatct gtaggagaca gagtcaccat caattgccaa    840gccagtgaga gcattagcag ttggttagcc tggtatcagc agaaaccagg gaaagcccct    900aagctcctga tctatgaagc atccaaactg gcatctgggg tcccatcaag gttcagcggc    960agtggatctg ggacagaatt tactctcacc atcagcagcc tgcagcctga tgattttgca   1020acttattact gccaaggcta tttttatttt attagtcgta cttatgtaaa ttctttcggc   1080ggcgggacca aggtggagat caaacgtacg gtggctgcac catctgtctt catcttcccg   1140ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc   1200tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc   1260caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg   1320acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag   1380ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgtggcgg tggcggtagc   1440ggtggcggcg gaagtggtgg cggaggatcc cagtctgccc tgactcagcc tgcctccgtg   1500tctgggtctc ctggacagtc gatcaccatc tcctgcactg gaaccagcag tgacgttggt   1560ggttataact ttgtctcctg gtaccaacaa cacccaggca aagcccccaa actcatgatc   1620tatgatgtca gtgatcggcc ctcaggggtg tctgatcgct tctccggctc caagtctggc   1680aacacggcct ccctgatcat ctctggcctc caggctgacg acgaggctga ttattactgc   1740agctcatatg ggagcagcag cactcatgtg attttcggcg gagggaccaa ggtgaccgtc   1800ctaggtggag gcggttcagg cggaggtggt tccggcggtg gcggctccgg tggaggcggc   1860tctcaggtgc aattgcagga gtcgggggga ggcctggtca agcctggagg gtccctgagt   1920ctctcctgtg cagcctctgg attcaccttt agtagttatt ggatgagctg ggtccgccag   1980gctccaggga aggggctgga gtgggtggcc aacataaacc gcgatggaag tgcgagttac   2040tatgtggact ctgtgaaggg ccgattcacc atctccagag acgacgccaa gaactcactg   2100tatctgcaaa tgaacagcct gagagctgag gacacggctg tgtattactg tgcgagagat   2160cgtggggtgg gctacttcga tctctggggc cgtggcaccc tggtcaccgt ctctagctga   2220</s400><s200><s210>61</s210><s211>1229</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 61Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Ile Ile Thr Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser                85                  90                  95Arg Thr Tyr Val Asn Ser Phe Gly Gln Gly Thr Lys Leu Thr Val Leu            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly        115                 120                 125Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val    130                 135                 140Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr145                 150                 155                 160Ile Ser Thr Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly                165                 170                 175Leu Glu Trp Val Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala            180                 185                 190Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn        195                 200                 205Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val    210                 215                 220Tyr Tyr Cys Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn225                 230                 235                 240Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly                245                 250                 255Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Gly            260                 265                 270Leu Val Lys Pro Ser Glu Thr Leu Ser Ile Thr Cys Thr Val Ser Gly        275                 280                 285Phe Ser Leu Thr Asn Tyr Gly Val His Trp Ile Arg Gln Ala Pro Gly    290                 295                 300Lys Cys Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly Asn Thr Asp305                 310                 315                 320Tyr Asn Thr Pro Phe Thr Ser Arg Phe Thr Ile Thr Lys Asp Asn Ser                325                 330                 335Lys Asn Gln Val Tyr Phe Lys Leu Arg Ser Val Arg Ala Asp Asp Thr            340                 345                 350Ala Ile Tyr Tyr Cys Ala Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe        355                 360                 365Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr    370                 375                 380Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser385                 390                 395                 400Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu                405                 410                 415Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His            420                 425                 430Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser        435                 440                 445Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys    450                 455                 460Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu465                 470                 475                 480Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro                485                 490                 495Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys            500                 505                 510Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val        515                 520                 525Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp    530                 535                 540Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr545                 550                 555                 560Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp                565                 570                 575Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu            580                 585                 590Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg        595                 600                 605Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys    610                 615                 620Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp625                 630                 635                 640Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys                645                 650                 655Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser            660                 665                 670Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser        675                 680                 685Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser    690                 695                 700Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser705                 710                 715                 720Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly                725                 730                 735Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly            740                 745                 750Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp        755                 760                 765Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr Tyr Asp Ala Asn    770                 775                 780Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr785                 790                 795                 800Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr                805                 810                 815Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala Met Asp Leu Trp            820                 825                 830Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly        835                 840                 845Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile    850                 855                 860Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg865                 870                 875                 880Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser His Leu Asn                885                 890                 895Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys            900                 905                 910Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly        915                 920                 925Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp    930                 935                 940Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp Gly Asn Val Asp945                 950                 955                 960Asn Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly                965                 970                 975Ser Gly Gly Gly Gly Ser Gly Arg Ser Leu Val Glu Ser Gly Gly Gly            980                 985                 990Leu Val Gln Pro Gly Gly Ser Leu  Arg Leu Ser Cys Thr  Ala Ser Gly        995                 1000                 1005Phe Thr  Ile Ser Ser Tyr His  Met Gln Trp Val Arg  Gln Ala Pro    1010                 1015                 1020Gly Lys  Gly Leu Glu Tyr Ile  Gly Thr Ile Ser Ser  Gly Gly Asn    1025                 1030                 1035Val Tyr  Tyr Ala Ser Ser Ala  Arg Gly Arg Phe Thr  Ile Ser Arg    1040                 1045                 1050Pro Ser  Ser Lys Asn Thr Val  Asp Leu Gln Met Asn  Ser Leu Arg    1055                 1060                 1065Ala Glu  Asp Thr Ala Val Tyr  Tyr Cys Ala Arg Asp  Ser Gly Tyr    1070                 1075                 1080Ser Asp  Pro Met Trp Gly Gln  Gly Thr Leu Val Thr  Val Ser Ser    1085                 1090                 1095Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser    1100                 1105                 1110Gly Gly  Gly Gly Ser Asp Val  Val Met Thr Gln Ser  Pro Ser Ser    1115                 1120                 1125Val Ser  Ala Ser Val Gly Asp  Arg Val Thr Ile Thr  Cys Gln Ala    1130                 1135                 1140Ser Gln  Asn Ile Arg Thr Tyr  Leu Ser Trp Tyr Gln  Gln Lys Pro    1145                 1150                 1155Gly Lys  Ala Pro Lys Leu Leu  Ile Tyr Ala Ala Ala  Asn Leu Ala    1160                 1165                 1170Ser Gly  Val Pro Ser Arg Phe  Ser Gly Ser Gly Ser  Gly Thr Asp    1175                 1180                 1185Phe Thr  Leu Thr Ile Ser Asp  Leu Glu Pro Gly Asp  Ala Ala Thr    1190                 1195                 1200Tyr Tyr  Cys Gln Ser Thr Tyr  Leu Gly Thr Asp Tyr  Val Gly Gly    1205                 1210                 1215Ala Phe  Gly Gly Gly Thr Lys  Val Glu Ile Lys    1220                 1225</s400><s200><s210>62</s210><s211>3690</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 62gaaatcgtta tgacgcagag tccctccacg ctctccgcta gtgtcgggga tcgcgtcatt     60atcacatgcc aggcctccga gtcaatcagc agctggcttg catggtatca acagaagccg    120ggaaaagctc ctaaattgct gatctatgaa gcgtcaaaat tggcgtctgg tgtcccatct    180aggttctccg gctctgggtc tggtgcggaa tttactttga caatctccag tcttcaacca    240gacgatttcg ctacctacta ctgccaaggg tatttctatt ttataagccg gacatatgta    300aactccttcg gccaaggaac aaagttgact gttcttggtg gcggaggcag tggtggcggg    360ggcagcggag gtggtggttc agggggtggt gggagcgaag tccaattggt agaaagtggc    420ggtggtctgg tgcaacctgg tggatctctt cgcctctcat gcgccgctag tggctttact    480atttcaacta atgcgatgag ctgggttcgc caggcccccg gcaaaggact tgagtgggtc    540ggcgtcatca ccggcaggga cattacatac tatgcgagtt gggcaaaggg caggttcacg    600attagccgcg atacttcaaa gaataccgtt taccttcaaa tgaatagctt gagggcggaa    660gacacagctg tgtattactg cgcgagggat ggaggtagtt ccgccataac ttccaacaac    720atatggggac aaggcacgct ggttactgtc tcgagtggcg gtggagggtc cggcggtggt    780ggatcacaag tacagttgca gcaatccggt cccggtctcg tcaaaccgag tgagacgctt    840agtataacgt gtactgtttc aggctttagc cttacgaact atggagttca ctggattcgg    900caggcacccg gcaaatgttt ggaatggctg ggtgttattt ggtcaggtgg aaatacagac    960tataacaccc cctttacaag tcggttcaca attacgaaag ataattccaa aaatcaagtt   1020tatttcaagt tgagatccgt ccgcgcggac gacactgcga tctactattg tgcgagggca   1080ctgacctact acgattacga atttgcgtat tgggggcaag ggactcttgt aacagtctcc   1140agtgctagca ccaagggccc atcggtcttc cccctggcac cctcctccaa gagcacctct   1200gggggcacag cggccctggg ctgcctggtc aaggactact tccccgaacc ggtgacggtg   1260tcgtggaact caggcgccct gaccagcggc gtgcacacct tcccggctgt cctacagtcc   1320tcaggactct actccctcag cagcgtggtg accgtgccct ccagcagctt gggcacccag   1380acctacatct gcaacgtgaa tcacaagccc agcaacacca aggtggacaa gagagttgag   1440cccaaatctt gtgacaaaac tcacacatgc ccaccgtgcc cagcacctga agccgcgggg   1500gcaccgtcag tcttcctctt ccccccaaaa cccaaggaca ccctcatgat ctcccggacc   1560cctgaggtca catgcgtggt ggtggacgtg agccacgaag accctgaggt caagttcaac   1620tggtacgtgg acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagtac   1680aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc   1740aaggagtaca agtgcgcggt ctccaacaaa gccctcccag cccccatcga gaaaaccatc   1800tccaaagcca aagggcagcc ccgagaacca caggtgtaca ccctgccccc atcccgggat   1860gagctgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta tcccagcgac   1920atcgccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cacgcctccc   1980gtgctggact ccgacggctc cttcttcctc tatagcaagc tcaccgtgga caagagcagg   2040tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac   2100acgcagaaga gcctctccct gtctccgggt ggcggtggag ggtccggcgg tggtggatcc   2160gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc   2220tcctgtgcag cctctggatt ctccttcagt agcgggtacg acatgtgctg ggtccgccag   2280gctccaggga aggggctgga gtggatcgca tgcattgctg ctggtagtgc tggtatcact   2340tacgacgcga actgggcgaa aggccggttc accatctcca gagacaattc caagaacacg   2400ctgtatctgc aaatgaacag cctgagagcc gaggacacgg ccgtatatta ctgtgcgaga   2460tcggcgtttt cgttcgacta cgccatggac ctctggggcc agggaaccct ggtcaccgtg   2520tcgagcggtg gaggcggatc tggcggaggt ggttccggcg gtggcggctc cggtggaggc   2580ggctctgaca tccagatgac ccagtctcct tccaccctgt ctgcatctgt aggagacaga   2640gtcaccatca cttgccaggc cagtcagagc attagttccc acttaaactg gtatcagcag   2700aaaccaggga aagcccctaa gctcctgatc tataaggcat ccactctggc atctggggtc   2760ccatcaaggt tcagcggcag tggatctggg acagaattta ctctcaccat cagcagcctg   2820cagcctgatg attttgcaac ttattactgc caacagggtt atagttgggg taatgttgat   2880aatgttttcg gcggagggac caaggtggag atcaaaggcg gtggagggtc cggcggtggt   2940ggctccggac ggtcgctggt ggagtctggg ggaggcttgg tccagcctgg ggggtccctg   3000agactctcct gtactgcctc tggattcacc atcagtagct accacatgca gtgggtccgc   3060caggctccag ggaaggggct ggagtacatc ggaaccatta gtagtggtgg taatgtatac   3120tacgcaagct ccgctagagg cagattcacc atctccagac cctcgtccaa gaacacggtg   3180gatcttcaaa tgaacagcct gagagccgag gacacggctg tgtattactg tgcgagagac   3240tctggttata gtgatcctat gtggggccag ggaaccctgg tcaccgtctc ttcaggcggt   3300ggcggtagtg ggggaggcgg ttctggcggc ggagggtccg gcggtggagg atcagacgtt   3360gtgatgaccc agtctccatc ttccgtgtct gcatctgtag gagacagagt caccatcacc   3420tgtcaggcca gtcagaacat taggacttac ttatcctggt atcagcagaa accagggaaa   3480gcccctaagc tcctgatcta tgctgcagcc aatctggcat ctggggtccc atcaaggttc   3540agcggcagtg gatctgggac agatttcact ctcaccatca gcgacctgga gcctggcgat   3600gctgcaactt actattgtca gtctacctat cttggtactg attatgttgg cggtgctttc   3660ggcggaggga ccaaggtgga gatcaaatga                                    3690</s400><s200><s210>63</s210><s211>734</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 63Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu    130                 135                 140Ser Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met145                 150                 155                 160Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu                165                 170                 175Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys            180                 185                 190Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu        195                 200                 205Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala    210                 215                 220Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Val Ser Pro Gly            260                 265                 270Glu Arg Ala Thr Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn        275                 280                 285Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Arg Leu Leu Ile    290                 295                 300Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Asp Arg Phe Ser Gly305                 310                 315                 320Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Val Gln Ser                325                 330                 335Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr            340                 345                 350Thr Phe Gly Cys Gly Thr Lys Leu Thr Val Leu Arg Thr Val Ala Ala        355                 360                 365Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly    370                 375                 380Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala385                 390                 395                 400Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln                405                 410                 415Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser            420                 425                 430Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr        435                 440                 445Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser    450                 455                 460Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser465                 470                 475                 480Gly Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser                485                 490                 495Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser            500                 505                 510Asp Val Gly Gly Tyr Asn Phe Val Ser Trp Tyr Gln Gln His Pro Gly        515                 520                 525Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asp Arg Pro Ser Gly    530                 535                 540Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu545                 550                 555                 560Ile Ile Ser Gly Leu Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys Ser                565                 570                 575Ser Tyr Gly Ser Ser Ser Thr His Val Ile Phe Gly Gly Gly Thr Lys            580                 585                 590Val Thr Val Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly        595                 600                 605Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly    610                 615                 620Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Ser Leu Ser Cys Ala Ala625                 630                 635                 640Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala                645                 650                 655Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Asn Arg Asp Gly Ser            660                 665                 670Ala Ser Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg        675                 680                 685Asp Asp Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala    690                 695                 700Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Val Gly Tyr705                 710                 715                 720Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser                725                 730</s400><s200><s210>64</s210><s211>2205</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 64Gly Ala Ala Ala Ala Thr Gly Thr Ala Thr Thr Gly Ala Cys Ala Cys1               5                   10                  15Ala Gly Ala Gly Cys Cys Cys Cys Gly Cys Cys Thr Cys Cys Cys Thr            20                  25                  30Cys Ala Gly Thr Gly Cys Cys Thr Cys Ala Cys Cys Thr Gly Gly Gly        35                  40                  45Gly Ala Ala Ala Gly Gly Gly Thr Ala Ala Cys Thr Ala Thr Cys Ala    50                  55                  60Cys Thr Thr Gly Cys Thr Cys Thr Gly Cys Ala Thr Cys Ala Ala Gly65                  70                  75                  80Cys Ala Gly Cys Gly Thr Cys Thr Cys Ala Thr Ala Cys Ala Thr Gly                85                  90                  95Cys Ala Thr Thr Gly Gly Thr Ala Thr Cys Ala Ala Cys Ala Ala Ala            100                 105                 110Ala Gly Cys Cys Thr Gly Gly Ala Cys Ala Gly Gly Cys Cys Cys Cys        115                 120                 125Cys Ala Ala Gly Cys Thr Cys Thr Gly Gly Ala Thr Ala Thr Ala Cys    130                 135                 140Gly Ala Thr Ala Cys Gly Ala Gly Cys Ala Ala Gly Cys Thr Gly Gly145                 150                 155                 160Cys Thr Thr Cys Cys Gly Gly Cys Gly Thr Ala Cys Cys Thr Ala Gly                165                 170                 175Cys Cys Gly Cys Thr Thr Cys Ala Gly Thr Gly Gly Thr Thr Cys Cys            180                 185                 190Gly Gly Cys Thr Cys Ala Gly Gly Cys Ala Ala Cys Gly Ala Thr Cys        195                 200                 205Ala Cys Ala Cys Cys Cys Thr Thr Ala Cys Gly Ala Thr Thr Thr Cys    210                 215                 220Cys Ala Gly Thr Ala Thr Gly Gly Ala Ala Cys Cys Cys Gly Ala Ala225                 230                 235                 240Gly Ala Thr Thr Thr Thr Gly Cys Ala Ala Cys Thr Thr Ala Thr Thr                245                 250                 255Ala Thr Thr Gly Thr Thr Thr Cys Cys Ala Gly Gly Gly Gly Ala Gly            260                 265                 270Cys Gly Thr Gly Thr Ala Cys Cys Cys Ala Thr Thr Cys Ala Cys Thr        275                 280                 285Thr Thr Cys Gly Gly Gly Cys Ala Gly Gly Gly Gly Ala Cys Ala Ala    290                 295                 300Ala Ala Gly Thr Gly Ala Cys Cys Gly Thr Cys Cys Thr Ala Gly Gly305                 310                 315                 320Cys Gly Gly Thr Gly Gly Cys Gly Gly Thr Ala Gly Thr Gly Gly Gly                325                 330                 335Gly Gly Ala Gly Gly Cys Gly Gly Thr Thr Cys Thr Gly Gly Cys Gly            340                 345                 350Gly Cys Gly Gly Ala Gly Gly Gly Thr Cys Cys Gly Gly Cys Gly Gly        355                 360                 365Thr Gly Gly Ala Gly Gly Ala Thr Cys Ala Cys Ala Gly Gly Thr Cys    370                 375                 380Ala Cys Ala Thr Thr Gly Ala Ala Gly Gly Ala Ala Thr Cys Thr Gly385                 390                 395                 400Gly Cys Cys Cys Cys Gly Gly Cys Cys Thr Thr Gly Thr Thr Cys Ala                405                 410                 415Gly Cys Cys Ala Gly Gly Ala Cys Ala Gly Ala Cys Cys Cys Thr Thr            420                 425                 430Ala Gly Cys Cys Thr Cys Ala Cys Cys Thr Gly Thr Gly Cys Cys Thr        435                 440                 445Thr Cys Ala Gly Thr Gly Gly Thr Thr Thr Thr Thr Cys Thr Cys Thr    450                 455                 460Thr Ala Gly Cys Ala Cys Thr Ala Gly Cys Gly Gly Thr Ala Thr Gly465                 470                 475                 480Gly Gly Gly Gly Thr Cys Gly Gly Cys Thr Gly Gly Ala Thr Thr Cys                485                 490                 495Gly Gly Cys Ala Gly Cys Cys Thr Cys Cys Cys Gly Gly Cys Ala Ala            500                 505                 510Ala Gly Gly Thr Cys Thr Thr Gly Ala Gly Thr Gly Gly Thr Thr Gly        515                 520                 525Gly Cys Thr Cys Ala Cys Ala Thr Thr Thr Gly Gly Thr Gly Gly Gly    530                 535                 540Ala Cys Gly Ala Cys Gly Ala Cys Ala Ala Ala Cys Gly Gly Thr Ala545                 550                 555                 560Thr Ala Ala Thr Cys Cys Thr Gly Cys Cys Thr Thr Gly Ala Ala Ala                565                 570                 575Ala Gly Thr Cys Gly Gly Cys Thr Gly Ala Cys Cys Ala Thr Thr Ala            580                 585                 590Gly Thr Ala Ala Gly Gly Ala Thr Ala Cys Cys Thr Cys Ala Ala Ala        595                 600                 605Ala Ala Ala Thr Cys Ala Ala Gly Thr Gly Thr Ala Cys Thr Thr Gly    610                 615                 620Cys Ala Ala Ala Thr Gly Ala Ala Thr Ala Gly Cys Cys Thr Thr Gly625                 630                 635                 640Ala Cys Gly Cys Cys Gly Ala Gly Gly Ala Thr Ala Cys Gly Gly Cys                645                 650                 655Thr Gly Thr Ala Thr Ala Thr Thr Ala Thr Thr Gly Cys Gly Cys Thr            660                 665                 670Cys Gly Gly Ala Thr Gly Gly Ala Ala Cys Thr Cys Thr Gly Gly Thr        675                 680                 685Cys Thr Thr Ala Cys Thr Ala Cys Thr Thr Thr Gly Ala Thr Thr Ala    690                 695                 700Thr Thr Gly Gly Gly Gly Gly Cys Ala Gly Gly Gly Gly Ala Cys Thr705                 710                 715                 720Cys Thr Cys Gly Thr Cys Ala Cys Gly Gly Thr Cys Thr Cys Gly Ala                725                 730                 735Gly Thr Gly Gly Cys Gly Gly Thr Gly Gly Ala Gly Gly Gly Thr Cys            740                 745                 750Cys Gly Gly Cys Gly Gly Thr Gly Gly Thr Gly Gly Ala Thr Cys Ala        755                 760                 765Gly Ala Ala Ala Thr Cys Gly Thr Cys Cys Thr Thr Ala Cys Ala Cys    770                 775                 780Ala Ala Thr Cys Thr Cys Cys Thr Ala Gly Cys Ala Cys Ala Cys Thr785                 790                 795                 800Gly Ala Gly Thr Gly Thr Gly Ala Gly Cys Cys Cys Cys Gly Gly Cys                805                 810                 815Gly Ala Ala Cys Gly Cys Gly Cys Gly Ala Cys Thr Thr Thr Cys Thr            820                 825                 830Cys Thr Thr Gly Cys Ala Gly Gly Gly Cys Ala Ala Gly Thr Cys Ala        835                 840                 845Ala Thr Cys Cys Ala Thr Ala Gly Gly Gly Ala Cys Thr Ala Ala Thr    850                 855                 860Ala Thr Ala Cys Ala Thr Thr Gly Gly Thr Ala Thr Cys Ala Ala Cys865                 870                 875                 880Ala Ala Ala Ala Gly Cys Cys Ala Gly Gly Thr Ala Ala Ala Cys Cys                885                 890                 895Ala Cys Cys Cys Ala Gly Gly Cys Thr Thr Thr Thr Gly Ala Thr Thr            900                 905                 910Ala Ala Gly Thr Ala Thr Gly Cys Ala Ala Gly Thr Gly Ala Gly Thr        915                 920                 925Cys Thr Ala Thr Thr Thr Cys Cys Gly Gly Thr Ala Thr Cys Cys Cys    930                 935                 940Thr Gly Ala Cys Cys Gly Cys Thr Thr Cys Thr Cys Thr Gly Gly Ala945                 950                 955                 960Thr Cys Ala Gly Gly Cys Ala Gly Thr Gly Gly Cys Ala Cys Ala Gly                965                 970                 975Ala Gly Thr Thr Cys Ala Cys Ala Cys Thr Cys Ala Cys Cys Ala Thr            980                 985                 990Ala Thr Cys Thr Ala Gly Thr Gly  Thr Gly Cys Ala Ala  Thr Cys Ala        995                 1000                 1005Gly Ala  Gly Gly Ala Cys Thr  Thr Cys Gly Cys Cys  Gly Thr Gly    1010                 1015                 1020Thr Ala  Thr Thr Ala Cys Thr  Gly Cys Cys Ala Ala  Cys Ala Gly    1025                 1030                 1035Ala Ala  Thr Ala Ala Thr Ala  Ala Cys Thr Gly Gly  Cys Cys Gly    1040                 1045                 1050Ala Cys  Thr Ala Cys Cys Thr  Thr Cys Gly Gly Ala  Thr Gly Cys    1055                 1060                 1065Gly Gly  Thr Ala Cys Ala Ala  Ala Gly Cys Thr Gly  Ala Cys Cys    1070                 1075                 1080Gly Thr  Thr Thr Thr Ala Cys  Gly Thr Ala Cys Gly  Gly Thr Gly    1085                 1090                 1095Gly Cys  Thr Gly Cys Ala Cys  Cys Ala Thr Cys Thr  Gly Thr Cys    1100                 1105                 1110Thr Thr  Cys Ala Thr Cys Thr  Thr Cys Cys Cys Gly  Cys Cys Ala    1115                 1120                 1125Thr Cys  Thr Gly Ala Thr Gly  Ala Gly Cys Ala Gly  Thr Thr Gly    1130                 1135                 1140Ala Ala  Ala Thr Cys Thr Gly  Gly Ala Ala Cys Thr  Gly Cys Cys    1145                 1150                 1155Thr Cys  Thr Gly Thr Thr Gly  Thr Gly Thr Gly Cys  Cys Thr Gly    1160                 1165                 1170Cys Thr  Gly Ala Ala Thr Ala  Ala Cys Thr Thr Cys  Thr Ala Thr    1175                 1180                 1185Cys Cys  Cys Ala Gly Ala Gly  Ala Gly Gly Cys Cys  Ala Ala Ala    1190                 1195                 1200Gly Thr  Ala Cys Ala Gly Thr  Gly Gly Ala Ala Gly  Gly Thr Gly    1205                 1210                 1215Gly Ala  Thr Ala Ala Cys Gly  Cys Cys Cys Thr Cys  Cys Ala Ala    1220                 1225                 1230Thr Cys  Gly Gly Gly Thr Ala  Ala Cys Thr Cys Cys  Cys Ala Gly    1235                 1240                 1245Gly Ala  Gly Ala Gly Thr Gly  Thr Cys Ala Cys Ala  Gly Ala Gly    1250                 1255                 1260Cys Ala  Gly Gly Ala Cys Ala  Gly Cys Ala Ala Gly  Gly Ala Cys    1265                 1270                 1275Ala Gly  Cys Ala Cys Cys Thr  Ala Cys Ala Gly Cys  Cys Thr Cys    1280                 1285                 1290Ala Gly  Cys Ala Gly Cys Ala  Cys Cys Cys Thr Gly  Ala Cys Gly    1295                 1300                 1305Cys Thr  Gly Ala Gly Cys Ala  Ala Ala Gly Cys Ala  Gly Ala Cys    1310                 1315                 1320Thr Ala  Cys Gly Ala Gly Ala  Ala Ala Cys Ala Cys  Ala Ala Ala    1325                 1330                 1335Gly Thr  Cys Thr Ala Cys Gly  Cys Cys Thr Gly Cys  Gly Ala Ala    1340                 1345                 1350Gly Thr  Cys Ala Cys Cys Cys  Ala Thr Cys Ala Gly  Gly Gly Cys    1355                 1360                 1365Cys Thr  Gly Ala Gly Cys Thr  Cys Gly Cys Cys Cys  Gly Thr Cys    1370                 1375                 1380Ala Cys  Ala Ala Ala Gly Ala  Gly Cys Thr Thr Cys  Ala Ala Cys    1385                 1390                 1395Ala Gly  Gly Gly Gly Ala Gly  Ala Gly Thr Gly Thr  Gly Gly Cys    1400                 1405                 1410Gly Gly  Thr Gly Gly Cys Gly  Gly Thr Ala Gly Cys  Gly Gly Thr    1415                 1420                 1425Gly Gly  Cys Gly Gly Cys Gly  Gly Ala Ala Gly Thr  Gly Gly Thr    1430                 1435                 1440Gly Gly  Cys Gly Gly Ala Gly  Gly Ala Thr Cys Cys  Cys Ala Gly    1445                 1450                 1455Thr Cys  Thr Gly Cys Cys Cys  Thr Gly Ala Cys Thr  Cys Ala Gly    1460                 1465                 1470Cys Cys  Thr Gly Cys Cys Thr  Cys Cys Gly Thr Gly  Thr Cys Thr    1475                 1480                 1485Gly Gly  Gly Thr Cys Thr Cys  Cys Thr Gly Gly Ala  Cys Ala Gly    1490                 1495                 1500Thr Cys  Gly Ala Thr Cys Ala  Cys Cys Ala Thr Cys  Thr Cys Cys    1505                 1510                 1515Thr Gly  Cys Ala Cys Thr Gly  Gly Ala Ala Cys Cys  Ala Gly Cys    1520                 1525                 1530Ala Gly  Thr Gly Ala Cys Gly  Thr Thr Gly Gly Thr  Gly Gly Thr    1535                 1540                 1545Thr Ala  Thr Ala Ala Cys Thr  Thr Thr Gly Thr Cys  Thr Cys Cys    1550                 1555                 1560Thr Gly  Gly Thr Ala Cys Cys  Ala Ala Cys Ala Ala  Cys Ala Cys    1565                 1570                 1575Cys Cys  Ala Gly Gly Cys Ala  Ala Ala Gly Cys Cys  Cys Cys Cys    1580                 1585                 1590Ala Ala  Ala Cys Thr Cys Ala  Thr Gly Ala Thr Cys  Thr Ala Thr    1595                 1600                 1605Gly Ala  Thr Gly Thr Cys Ala  Gly Thr Gly Ala Thr  Cys Gly Gly    1610                 1615                 1620Cys Cys  Cys Thr Cys Ala Gly  Gly Gly Gly Thr Gly  Thr Cys Thr    1625                 1630                 1635Gly Ala  Thr Cys Gly Cys Thr  Thr Cys Thr Cys Cys  Gly Gly Cys    1640                 1645                 1650Thr Cys  Cys Ala Ala Gly Thr  Cys Thr Gly Gly Cys  Ala Ala Cys    1655                 1660                 1665Ala Cys  Gly Gly Cys Cys Thr  Cys Cys Cys Thr Gly  Ala Thr Cys    1670                 1675                 1680Ala Thr  Cys Thr Cys Thr Gly  Gly Cys Cys Thr Cys  Cys Ala Gly    1685                 1690                 1695Gly Cys  Thr Gly Ala Cys Gly  Ala Cys Gly Ala Gly  Gly Cys Thr    1700                 1705                 1710Gly Ala  Thr Thr Ala Thr Thr  Ala Cys Thr Gly Cys  Ala Gly Cys    1715                 1720                 1725Thr Cys  Ala Thr Ala Thr Gly  Gly Gly Ala Gly Cys  Ala Gly Cys    1730                 1735                 1740Ala Gly  Cys Ala Cys Thr Cys  Ala Thr Gly Thr Gly  Ala Thr Thr    1745                 1750                 1755Thr Thr  Cys Gly Gly Cys Gly  Gly Ala Gly Gly Gly  Ala Cys Cys    1760                 1765                 1770Ala Ala  Gly Gly Thr Gly Ala  Cys Cys Gly Thr Cys  Cys Thr Ala    1775                 1780                 1785Gly Gly  Thr Gly Gly Ala Gly  Gly Cys Gly Gly Thr  Thr Cys Ala    1790                 1795                 1800Gly Gly  Cys Gly Gly Ala Gly  Gly Thr Gly Gly Thr  Thr Cys Cys    1805                 1810                 1815Gly Gly  Cys Gly Gly Thr Gly  Gly Cys Gly Gly Cys  Thr Cys Cys    1820                 1825                 1830Gly Gly  Thr Gly Gly Ala Gly  Gly Cys Gly Gly Cys  Thr Cys Thr    1835                 1840                 1845Cys Ala  Gly Gly Thr Gly Cys  Ala Ala Thr Thr Gly  Cys Ala Gly    1850                 1855                 1860Gly Ala  Gly Thr Cys Gly Gly  Gly Gly Gly Gly Ala  Gly Gly Cys    1865                 1870                 1875Cys Thr  Gly Gly Thr Cys Ala  Ala Gly Cys Cys Thr  Gly Gly Ala    1880                 1885                 1890Gly Gly  Gly Thr Cys Cys Cys  Thr Gly Ala Gly Thr  Cys Thr Cys    1895                 1900                 1905Thr Cys  Cys Thr Gly Thr Gly  Cys Ala Gly Cys Cys  Thr Cys Thr    1910                 1915                 1920Gly Gly  Ala Thr Thr Cys Ala  Cys Cys Thr Thr Thr  Ala Gly Thr    1925                 1930                 1935Ala Gly  Thr Thr Ala Thr Thr  Gly Gly Ala Thr Gly  Ala Gly Cys    1940                 1945                 1950Thr Gly  Gly Gly Thr Cys Cys  Gly Cys Cys Ala Gly  Gly Cys Thr    1955                 1960                 1965Cys Cys  Ala Gly Gly Gly Ala  Ala Gly Gly Gly Gly  Cys Thr Gly    1970                 1975                 1980Gly Ala  Gly Thr Gly Gly Gly  Thr Gly Gly Cys Cys  Ala Ala Cys    1985                 1990                 1995Ala Thr  Ala Ala Ala Cys Cys  Gly Cys Gly Ala Thr  Gly Gly Ala    2000                 2005                 2010Ala Gly  Thr Gly Cys Gly Ala  Gly Thr Thr Ala Cys  Thr Ala Thr    2015                 2020                 2025Gly Thr  Gly Gly Ala Cys Thr  Cys Thr Gly Thr Gly  Ala Ala Gly    2030                 2035                 2040Gly Gly  Cys Cys Gly Ala Thr  Thr Cys Ala Cys Cys  Ala Thr Cys    2045                 2050                 2055Thr Cys  Cys Ala Gly Ala Gly  Ala Cys Gly Ala Cys  Gly Cys Cys    2060                 2065                 2070Ala Ala  Gly Ala Ala Cys Thr  Cys Ala Cys Thr Gly  Thr Ala Thr    2075                 2080                 2085Cys Thr  Gly Cys Ala Ala Ala  Thr Gly Ala Ala Cys  Ala Gly Cys    2090                 2095                 2100Cys Thr  Gly Ala Gly Ala Gly  Cys Thr Gly Ala Gly  Gly Ala Cys    2105                 2110                 2115Ala Cys  Gly Gly Cys Thr Gly  Thr Gly Thr Ala Thr  Thr Ala Cys    2120                 2125                 2130Thr Gly  Thr Gly Cys Gly Ala  Gly Ala Gly Ala Thr  Cys Gly Thr    2135                 2140                 2145Gly Gly  Gly Gly Thr Gly Gly  Gly Cys Thr Ala Cys  Thr Thr Cys    2150                 2155                 2160Gly Ala  Thr Cys Thr Cys Thr  Gly Gly Gly Gly Cys  Cys Gly Thr    2165                 2170                 2175Gly Gly  Cys Ala Cys Cys Cys  Thr Gly Gly Thr Cys  Ala Cys Cys    2180                 2185                 2190Gly Thr  Cys Thr Cys Thr Ala  Gly Cys Thr Gly Ala    2195                 2200                 2205</s400><s200><s210>65</s210><s211>1229</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 65Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Ile Ile Thr Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser                85                  90                  95Arg Thr Tyr Val Asn Ser Phe Gly Gln Gly Thr Lys Leu Thr Val Leu            100                 105                 110Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly        115                 120                 125Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val    130                 135                 140Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr145                 150                 155                 160Ile Ser Thr Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly                165                 170                 175Leu Glu Trp Val Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala            180                 185                 190Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn        195                 200                 205Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val    210                 215                 220Tyr Tyr Cys Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn225                 230                 235                 240Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly                245                 250                 255Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Lys Gln Ser Gly Pro Gly            260                 265                 270Leu Val Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly        275                 280                 285Phe Ser Leu Thr Asn Tyr Gly Val His Trp Val Arg Gln Ser Pro Gly    290                 295                 300Lys Cys Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly Asn Thr Asp305                 310                 315                 320Tyr Asn Thr Pro Phe Thr Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser                325                 330                 335Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ser Asn Asp Thr            340                 345                 350Ala Ile Tyr Tyr Cys Ala Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe        355                 360                 365Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr    370                 375                 380Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser385                 390                 395                 400Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu                405                 410                 415Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His            420                 425                 430Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser        435                 440                 445Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys    450                 455                 460Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu465                 470                 475                 480Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro                485                 490                 495Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys            500                 505                 510Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val        515                 520                 525Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp    530                 535                 540Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr545                 550                 555                 560Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp                565                 570                 575Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu            580                 585                 590Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg        595                 600                 605Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys    610                 615                 620Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp625                 630                 635                 640Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys                645                 650                 655Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser            660                 665                 670Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser        675                 680                 685Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser    690                 695                 700Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser705                 710                 715                 720Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly                725                 730                 735Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly            740                 745                 750Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp        755                 760                 765Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr Tyr Asp Ala Asn    770                 775                 780Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr785                 790                 795                 800Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr                805                 810                 815Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala Met Asp Leu Trp            820                 825                 830Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly        835                 840                 845Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile    850                 855                 860Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg865                 870                 875                 880Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser His Leu Asn                885                 890                 895Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys            900                 905                 910Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly        915                 920                 925Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp    930                 935                 940Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp Gly Asn Val Asp945                 950                 955                 960Asn Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly                965                 970                 975Ser Gly Gly Gly Gly Ser Gly Arg Ser Leu Val Glu Ser Gly Gly Gly            980                 985                 990Leu Val Gln Pro Gly Gly Ser Leu  Arg Leu Ser Cys Thr  Ala Ser Gly        995                 1000                 1005Phe Thr  Ile Ser Ser Tyr His  Met Gln Trp Val Arg  Gln Ala Pro    1010                 1015                 1020Gly Lys  Gly Leu Glu Tyr Ile  Gly Thr Ile Ser Ser  Gly Gly Asn    1025                 1030                 1035Val Tyr  Tyr Ala Ser Ser Ala  Arg Gly Arg Phe Thr  Ile Ser Arg    1040                 1045                 1050Pro Ser  Ser Lys Asn Thr Val  Asp Leu Gln Met Asn  Ser Leu Arg    1055                 1060                 1065Ala Glu  Asp Thr Ala Val Tyr  Tyr Cys Ala Arg Asp  Ser Gly Tyr    1070                 1075                 1080Ser Asp  Pro Met Trp Gly Gln  Gly Thr Leu Val Thr  Val Ser Ser    1085                 1090                 1095Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser Gly Gly  Gly Gly Ser    1100                 1105                 1110Gly Gly  Gly Gly Ser Asp Val  Val Met Thr Gln Ser  Pro Ser Ser    1115                 1120                 1125Val Ser  Ala Ser Val Gly Asp  Arg Val Thr Ile Thr  Cys Gln Ala    1130                 1135                 1140Ser Gln  Asn Ile Arg Thr Tyr  Leu Ser Trp Tyr Gln  Gln Lys Pro    1145                 1150                 1155Gly Lys  Ala Pro Lys Leu Leu  Ile Tyr Ala Ala Ala  Asn Leu Ala    1160                 1165                 1170Ser Gly  Val Pro Ser Arg Phe  Ser Gly Ser Gly Ser  Gly Thr Asp    1175                 1180                 1185Phe Thr  Leu Thr Ile Ser Asp  Leu Glu Pro Gly Asp  Ala Ala Thr    1190                 1195                 1200Tyr Tyr  Cys Gln Ser Thr Tyr  Leu Gly Thr Asp Tyr  Val Gly Gly    1205                 1210                 1215Ala Phe  Gly Gly Gly Thr Lys  Val Glu Ile Lys    1220                 1225</s400><s200><s210>66</s210><s211>3690</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 66Gly Ala Ala Ala Thr Cys Gly Thr Thr Ala Thr Gly Ala Cys Gly Cys1               5                   10                  15Ala Gly Ala Gly Thr Cys Cys Cys Thr Cys Cys Ala Cys Gly Cys Thr            20                  25                  30Cys Thr Cys Cys Gly Cys Thr Ala Gly Thr Gly Thr Cys Gly Gly Gly        35                  40                  45Gly Ala Thr Cys Gly Cys Gly Thr Cys Ala Thr Thr Ala Thr Cys Ala    50                  55                  60Cys Ala Thr Gly Cys Cys Ala Gly Gly Cys Cys Thr Cys Cys Gly Ala65                  70                  75                  80Gly Thr Cys Ala Ala Thr Cys Ala Gly Cys Ala Gly Cys Thr Gly Gly                85                  90                  95Cys Thr Thr Gly Cys Ala Thr Gly Gly Thr Ala Thr Cys Ala Ala Cys            100                 105                 110Ala Gly Ala Ala Gly Cys Cys Gly Gly Gly Ala Ala Ala Ala Gly Cys        115                 120                 125Thr Cys Cys Thr Ala Ala Ala Thr Thr Gly Cys Thr Gly Ala Thr Cys    130                 135                 140Thr Ala Thr Gly Ala Ala Gly Cys Gly Thr Cys Ala Ala Ala Ala Thr145                 150                 155                 160Thr Gly Gly Cys Gly Thr Cys Thr Gly Gly Thr Gly Thr Cys Cys Cys                165                 170                 175Ala Thr Cys Thr Ala Gly Gly Thr Thr Cys Thr Cys Cys Gly Gly Cys            180                 185                 190Thr Cys Thr Gly Gly Gly Thr Cys Thr Gly Gly Thr Gly Cys Gly Gly        195                 200                 205Ala Ala Thr Thr Thr Ala Cys Thr Thr Thr Gly Ala Cys Ala Ala Thr    210                 215                 220Cys Thr Cys Cys Ala Gly Thr Cys Thr Thr Cys Ala Ala Cys Cys Ala225                 230                 235                 240Gly Ala Cys Gly Ala Thr Thr Thr Cys Gly Cys Thr Ala Cys Cys Thr                245                 250                 255Ala Cys Thr Ala Cys Thr Gly Cys Cys Ala Ala Gly Gly Gly Thr Ala            260                 265                 270Thr Thr Thr Cys Thr Ala Thr Thr Thr Thr Ala Thr Ala Ala Gly Cys        275                 280                 285Cys Gly Gly Ala Cys Ala Thr Ala Thr Gly Thr Ala Ala Ala Cys Thr    290                 295                 300Cys Cys Thr Thr Cys Gly Gly Cys Cys Ala Ala Gly Gly Ala Ala Cys305                 310                 315                 320Ala Ala Ala Gly Thr Thr Gly Ala Cys Thr Gly Thr Thr Cys Thr Thr                325                 330                 335Gly Gly Thr Gly Gly Cys Gly Gly Ala Gly Gly Cys Ala Gly Thr Gly            340                 345                 350Gly Thr Gly Gly Cys Gly Gly Gly Gly Gly Cys Ala Gly Cys Gly Gly        355                 360                 365Ala Gly Gly Thr Gly Gly Thr Gly Gly Thr Thr Cys Ala Gly Gly Gly    370                 375                 380Gly Gly Thr Gly Gly Thr Gly Gly Gly Ala Gly Cys Gly Ala Ala Gly385                 390                 395                 400Thr Cys Cys Ala Ala Thr Thr Gly Gly Thr Ala Gly Ala Ala Ala Gly                405                 410                 415Thr Gly Gly Cys Gly Gly Thr Gly Gly Thr Cys Thr Gly Gly Thr Gly            420                 425                 430Cys Ala Ala Cys Cys Thr Gly Gly Thr Gly Gly Ala Thr Cys Thr Cys        435                 440                 445Thr Thr Cys Gly Cys Cys Thr Cys Thr Cys Ala Thr Gly Cys Gly Cys    450                 455                 460Cys Gly Cys Thr Ala Gly Thr Gly Gly Cys Thr Thr Thr Ala Cys Thr465                 470                 475                 480Ala Thr Thr Thr Cys Ala Ala Cys Thr Ala Ala Thr Gly Cys Gly Ala                485                 490                 495Thr Gly Ala Gly Cys Thr Gly Gly Gly Thr Thr Cys Gly Cys Cys Ala            500                 505                 510Gly Gly Cys Cys Cys Cys Cys Gly Gly Cys Ala Ala Ala Gly Gly Ala        515                 520                 525Cys Thr Thr Gly Ala Gly Thr Gly Gly Gly Thr Cys Gly Gly Cys Gly    530                 535                 540Thr Cys Ala Thr Cys Ala Cys Cys Gly Gly Cys Ala Gly Gly Gly Ala545                 550                 555                 560Cys Ala Thr Thr Ala Cys Ala Thr Ala Cys Thr Ala Thr Gly Cys Gly                565                 570                 575Ala Gly Thr Thr Gly Gly Gly Cys Ala Ala Ala Gly Gly Gly Cys Ala            580                 585                 590Gly Gly Thr Thr Cys Ala Cys Gly Ala Thr Thr Ala Gly Cys Cys Gly        595                 600                 605Cys Gly Ala Thr Ala Cys Thr Thr Cys Ala Ala Ala Gly Ala Ala Thr    610                 615                 620Ala Cys Cys Gly Thr Thr Thr Ala Cys Cys Thr Thr Cys Ala Ala Ala625                 630                 635                 640Thr Gly Ala Ala Thr Ala Gly Cys Thr Thr Gly Ala Gly Gly Gly Cys                645                 650                 655Gly Gly Ala Ala Gly Ala Cys Ala Cys Ala Gly Cys Thr Gly Thr Gly            660                 665                 670Thr Ala Thr Thr Ala Cys Thr Gly Cys Gly Cys Gly Ala Gly Gly Gly        675                 680                 685Ala Thr Gly Gly Ala Gly Gly Thr Ala Gly Thr Thr Cys Cys Gly Cys    690                 695                 700Cys Ala Thr Ala Ala Cys Thr Thr Cys Cys Ala Ala Cys Ala Ala Cys705                 710                 715                 720Ala Thr Ala Thr Gly Gly Gly Gly Ala Cys Ala Ala Gly Gly Cys Ala                725                 730                 735Cys Gly Cys Thr Gly Gly Thr Thr Ala Cys Thr Gly Thr Cys Thr Cys            740                 745                 750Gly Ala Gly Thr Gly Gly Cys Gly Gly Thr Gly Gly Ala Gly Gly Gly        755                 760                 765Thr Cys Cys Gly Gly Cys Gly Gly Thr Gly Gly Thr Gly Gly Ala Thr    770                 775                 780Cys Ala Cys Ala Gly Gly Thr Gly Cys Ala Gly Cys Thr Gly Ala Ala785                 790                 795                 800Gly Cys Ala Gly Thr Cys Ala Gly Gly Ala Cys Cys Thr Gly Gly Cys                805                 810                 815Cys Thr Ala Gly Thr Gly Cys Ala Gly Cys Cys Cys Thr Cys Ala Cys            820                 825                 830Ala Gly Ala Gly Cys Cys Thr Gly Thr Cys Cys Ala Thr Cys Ala Cys        835                 840                 845Cys Thr Gly Cys Ala Cys Ala Gly Thr Cys Thr Cys Thr Gly Gly Thr    850                 855                 860Thr Thr Cys Thr Cys Ala Thr Thr Ala Ala Cys Thr Ala Ala Cys Thr865                 870                 875                 880Ala Thr Gly Gly Thr Gly Thr Ala Cys Ala Cys Thr Gly Gly Gly Thr                885                 890                 895Thr Cys Gly Cys Cys Ala Gly Thr Cys Thr Cys Cys Ala Gly Gly Ala            900                 905                 910Ala Ala Gly Thr Gly Thr Cys Thr Gly Gly Ala Gly Thr Gly Gly Cys        915                 920                 925Thr Gly Gly Gly Ala Gly Thr Gly Ala Thr Ala Thr Gly Gly Ala Gly    930                 935                 940Thr Gly Gly Thr Gly Gly Ala Ala Ala Cys Ala Cys Ala Gly Ala Cys945                 950                 955                 960Thr Ala Thr Ala Ala Thr Ala Cys Ala Cys Cys Thr Thr Thr Cys Ala                965                 970                 975Cys Ala Thr Cys Cys Ala Gly Ala Cys Thr Gly Ala Gly Cys Ala Thr            980                 985                 990Cys Ala Ala Cys Ala Ala Gly Gly  Ala Cys Ala Ala Thr  Thr Cys Cys        995                 1000                 1005Ala Ala  Gly Ala Gly Cys Cys  Ala Ala Gly Thr Thr  Thr Thr Cys    1010                 1015                 1020Thr Thr  Thr Ala Ala Ala Ala  Thr Gly Ala Ala Cys  Ala Gly Thr    1025                 1030                 1035Cys Thr  Gly Cys Ala Ala Thr  Cys Thr Ala Ala Thr  Gly Ala Cys    1040                 1045                 1050Ala Cys  Ala Gly Cys Cys Ala  Thr Ala Thr Ala Thr  Thr Ala Cys    1055                 1060                 1065Thr Gly  Thr Gly Cys Cys Ala  Gly Ala Gly Cys Cys  Cys Thr Cys    1070                 1075                 1080Ala Cys  Cys Thr Ala Cys Thr  Ala Thr Gly Ala Thr  Thr Ala Cys    1085                 1090                 1095Gly Ala  Gly Thr Thr Thr Gly  Cys Thr Thr Ala Cys  Thr Gly Gly    1100                 1105                 1110Gly Gly  Cys Cys Ala Ala Gly  Gly Gly Ala Cys Thr  Cys Thr Gly    1115                 1120                 1125Gly Thr  Cys Ala Cys Thr Gly  Thr Cys Thr Cys Gly  Ala Gly Thr    1130                 1135                 1140Gly Cys  Thr Ala Gly Cys Ala  Cys Cys Ala Ala Gly  Gly Gly Cys    1145                 1150                 1155Cys Cys  Ala Thr Cys Gly Gly  Thr Cys Thr Thr Cys  Cys Cys Cys    1160                 1165                 1170Cys Thr  Gly Gly Cys Ala Cys  Cys Cys Thr Cys Cys  Thr Cys Cys    1175                 1180                 1185Ala Ala  Gly Ala Gly Cys Ala  Cys Cys Thr Cys Thr  Gly Gly Gly    1190                 1195                 1200Gly Gly  Cys Ala Cys Ala Gly  Cys Gly Gly Cys Cys  Cys Thr Gly    1205                 1210                 1215Gly Gly  Cys Thr Gly Cys Cys  Thr Gly Gly Thr Cys  Ala Ala Gly    1220                 1225                 1230Gly Ala  Cys Thr Ala Cys Thr  Thr Cys Cys Cys Cys  Gly Ala Ala    1235                 1240                 1245Cys Cys  Gly Gly Thr Gly Ala  Cys Gly Gly Thr Gly  Thr Cys Gly    1250                 1255                 1260Thr Gly  Gly Ala Ala Cys Thr  Cys Ala Gly Gly Cys  Gly Cys Cys    1265                 1270                 1275Cys Thr  Gly Ala Cys Cys Ala  Gly Cys Gly Gly Cys  Gly Thr Gly    1280                 1285                 1290Cys Ala  Cys Ala Cys Cys Thr  Thr Cys Cys Cys Gly  Gly Cys Thr    1295                 1300                 1305Gly Thr  Cys Cys Thr Ala Cys  Ala Gly Thr Cys Cys  Thr Cys Ala    1310                 1315                 1320Gly Gly  Ala Cys Thr Cys Thr  Ala Cys Thr Cys Cys  Cys Thr Cys    1325                 1330                 1335Ala Gly  Cys Ala Gly Cys Gly  Thr Gly Gly Thr Gly  Ala Cys Cys    1340                 1345                 1350Gly Thr  Gly Cys Cys Cys Thr  Cys Cys Ala Gly Cys  Ala Gly Cys    1355                 1360                 1365Thr Thr  Gly Gly Gly Cys Ala  Cys Cys Cys Ala Gly  Ala Cys Cys    1370                 1375                 1380Thr Ala  Cys Ala Thr Cys Thr  Gly Cys Ala Ala Cys  Gly Thr Gly    1385                 1390                 1395Ala Ala  Thr Cys Ala Cys Ala  Ala Gly Cys Cys Cys  Ala Gly Cys    1400                 1405                 1410Ala Ala  Cys Ala Cys Cys Ala  Ala Gly Gly Thr Gly  Gly Ala Cys    1415                 1420                 1425Ala Ala  Gly Ala Gly Ala Gly  Thr Thr Gly Ala Gly  Cys Cys Cys    1430                 1435                 1440Ala Ala  Ala Thr Cys Thr Thr  Gly Thr Gly Ala Cys  Ala Ala Ala    1445                 1450                 1455Ala Cys  Thr Cys Ala Cys Ala  Cys Ala Thr Gly Cys  Cys Cys Ala    1460                 1465                 1470Cys Cys  Gly Thr Gly Cys Cys  Cys Ala Gly Cys Ala  Cys Cys Thr    1475                 1480                 1485Gly Ala  Ala Gly Cys Cys Gly  Cys Gly Gly Gly Gly  Gly Cys Ala    1490                 1495                 1500Cys Cys  Gly Thr Cys Ala Gly  Thr Cys Thr Thr Cys  Cys Thr Cys    1505                 1510                 1515Thr Thr  Cys Cys Cys Cys Cys  Cys Ala Ala Ala Ala  Cys Cys Cys    1520                 1525                 1530Ala Ala  Gly Gly Ala Cys Ala  Cys Cys Cys Thr Cys  Ala Thr Gly    1535                 1540                 1545Ala Thr  Cys Thr Cys Cys Cys  Gly Gly Ala Cys Cys  Cys Cys Thr    1550                 1555                 1560Gly Ala  Gly Gly Thr Cys Ala  Cys Ala Thr Gly Cys  Gly Thr Gly    1565                 1570                 1575Gly Thr  Gly Gly Thr Gly Gly  Ala Cys Gly Thr Gly  Ala Gly Cys    1580                 1585                 1590Cys Ala  Cys Gly Ala Ala Gly  Ala Cys Cys Cys Thr  Gly Ala Gly    1595                 1600                 1605Gly Thr  Cys Ala Ala Gly Thr  Thr Cys Ala Ala Cys  Thr Gly Gly    1610                 1615                 1620Thr Ala  Cys Gly Thr Gly Gly  Ala Cys Gly Gly Cys  Gly Thr Gly    1625                 1630                 1635Gly Ala  Gly Gly Thr Gly Cys  Ala Thr Ala Ala Thr  Gly Cys Cys    1640                 1645                 1650Ala Ala  Gly Ala Cys Ala Ala  Ala Gly Cys Cys Gly  Cys Gly Gly    1655                 1660                 1665Gly Ala  Gly Gly Ala Gly Cys  Ala Gly Thr Ala Cys  Ala Ala Cys    1670                 1675                 1680Ala Gly  Cys Ala Cys Gly Thr  Ala Cys Cys Gly Thr  Gly Thr Gly    1685                 1690                 1695Gly Thr  Cys Ala Gly Cys Gly  Thr Cys Cys Thr Cys  Ala Cys Cys    1700                 1705                 1710Gly Thr  Cys Cys Thr Gly Cys  Ala Cys Cys Ala Gly  Gly Ala Cys    1715                 1720                 1725Thr Gly  Gly Cys Thr Gly Ala  Ala Thr Gly Gly Cys  Ala Ala Gly    1730                 1735                 1740Gly Ala  Gly Thr Ala Cys Ala  Ala Gly Thr Gly Cys  Gly Cys Gly    1745                 1750                 1755Gly Thr  Cys Thr Cys Cys Ala  Ala Cys Ala Ala Ala  Gly Cys Cys    1760                 1765                 1770Cys Thr  Cys Cys Cys Ala Gly  Cys Cys Cys Cys Cys  Ala Thr Cys    1775                 1780                 1785Gly Ala  Gly Ala Ala Ala Ala  Cys Cys Ala Thr Cys  Thr Cys Cys    1790                 1795                 1800Ala Ala  Ala Gly Cys Cys Ala  Ala Ala Gly Gly Gly  Cys Ala Gly    1805                 1810                 1815Cys Cys  Cys Cys Gly Ala Gly  Ala Ala Cys Cys Ala  Cys Ala Gly    1820                 1825                 1830Gly Thr  Gly Thr Ala Cys Ala  Cys Cys Cys Thr Gly  Cys Cys Cys    1835                 1840                 1845Cys Cys  Ala Thr Cys Cys Cys  Gly Gly Gly Ala Thr  Gly Ala Gly    1850                 1855                 1860Cys Thr  Gly Ala Cys Cys Ala  Ala Gly Ala Ala Cys  Cys Ala Gly    1865                 1870                 1875Gly Thr  Cys Ala Gly Cys Cys  Thr Gly Ala Cys Cys  Thr Gly Cys    1880                 1885                 1890Cys Thr  Gly Gly Thr Cys Ala  Ala Ala Gly Gly Cys  Thr Thr Cys    1895                 1900                 1905Thr Ala  Thr Cys Cys Cys Ala  Gly Cys Gly Ala Cys  Ala Thr Cys    1910                 1915                 1920Gly Cys  Cys Gly Thr Gly Gly  Ala Gly Thr Gly Gly  Gly Ala Gly    1925                 1930                 1935Ala Gly  Cys Ala Ala Thr Gly  Gly Gly Cys Ala Gly  Cys Cys Gly    1940                 1945                 1950Gly Ala  Gly Ala Ala Cys Ala  Ala Cys Thr Ala Cys  Ala Ala Gly    1955                 1960                 1965Ala Cys  Cys Ala Cys Gly Cys  Cys Thr Cys Cys Cys  Gly Thr Gly    1970                 1975                 1980Cys Thr  Gly Gly Ala Cys Thr  Cys Cys Gly Ala Cys  Gly Gly Cys    1985                 1990                 1995Thr Cys  Cys Thr Thr Cys Thr  Thr Cys Cys Thr Cys  Thr Ala Thr    2000                 2005                 2010Ala Gly  Cys Ala Ala Gly Cys  Thr Cys Ala Cys Cys  Gly Thr Gly    2015                 2020                 2025Gly Ala  Cys Ala Ala Gly Ala  Gly Cys Ala Gly Gly  Thr Gly Gly    2030                 2035                 2040Cys Ala  Gly Cys Ala Gly Gly  Gly Gly Ala Ala Cys  Gly Thr Cys    2045                 2050                 2055Thr Thr  Cys Thr Cys Ala Thr  Gly Cys Thr Cys Cys  Gly Thr Gly    2060                 2065                 2070Ala Thr  Gly Cys Ala Thr Gly  Ala Gly Gly Cys Thr  Cys Thr Gly    2075                 2080                 2085Cys Ala  Cys Ala Ala Cys Cys  Ala Cys Thr Ala Cys  Ala Cys Gly    2090                 2095                 2100Cys Ala  Gly Ala Ala Gly Ala  Gly Cys Cys Thr Cys  Thr Cys Cys    2105                 2110                 2115Cys Thr  Gly Thr Cys Thr Cys  Cys Gly Gly Gly Thr  Gly Gly Cys    2120                 2125                 2130Gly Gly  Thr Gly Gly Ala Gly  Gly Gly Thr Cys Cys  Gly Gly Cys    2135                 2140                 2145Gly Gly  Thr Gly Gly Thr Gly  Gly Ala Thr Cys Cys  Gly Ala Gly    2150                 2155                 2160Gly Thr  Gly Cys Ala Gly Cys  Thr Gly Thr Thr Gly  Gly Ala Gly    2165                 2170                 2175Thr Cys  Thr Gly Gly Gly Gly  Gly Ala Gly Gly Cys  Thr Thr Gly    2180                 2185                 2190Gly Thr  Ala Cys Ala Gly Cys  Cys Thr Gly Gly Gly  Gly Gly Gly    2195                 2200                 2205Thr Cys  Cys Cys Thr Gly Ala  Gly Ala Cys Thr Cys  Thr Cys Cys    2210                 2215                 2220Thr Gly  Thr Gly Cys Ala Gly  Cys Cys Thr Cys Thr  Gly Gly Ala    2225                 2230                 2235Thr Thr  Cys Thr Cys Cys Thr  Thr Cys Ala Gly Thr  Ala Gly Cys    2240                 2245                 2250Gly Gly  Gly Thr Ala Cys Gly  Ala Cys Ala Thr Gly  Thr Gly Cys    2255                 2260                 2265Thr Gly  Gly Gly Thr Cys Cys  Gly Cys Cys Ala Gly  Gly Cys Thr    2270                 2275                 2280Cys Cys  Ala Gly Gly Gly Ala  Ala Gly Gly Gly Gly  Cys Thr Gly    2285                 2290                 2295Gly Ala  Gly Thr Gly Gly Ala  Thr Cys Gly Cys Ala  Thr Gly Cys    2300                 2305                 2310Ala Thr  Thr Gly Cys Thr Gly  Cys Thr Gly Gly Thr  Ala Gly Thr    2315                 2320                 2325Gly Cys  Thr Gly Gly Thr Ala  Thr Cys Ala Cys Thr  Thr Ala Cys    2330                 2335                 2340Gly Ala  Cys Gly Cys Gly Ala  Ala Cys Thr Gly Gly  Gly Cys Gly    2345                 2350                 2355Ala Ala  Ala Gly Gly Cys Cys  Gly Gly Thr Thr Cys  Ala Cys Cys    2360                 2365                 2370Ala Thr  Cys Thr Cys Cys Ala  Gly Ala Gly Ala Cys  Ala Ala Thr    2375                 2380                 2385Thr Cys  Cys Ala Ala Gly Ala  Ala Cys Ala Cys Gly  Cys Thr Gly    2390                 2395                 2400Thr Ala  Thr Cys Thr Gly Cys  Ala Ala Ala Thr Gly  Ala Ala Cys    2405                 2410                 2415Ala Gly  Cys Cys Thr Gly Ala  Gly Ala Gly Cys Cys  Gly Ala Gly    2420                 2425                 2430Gly Ala  Cys Ala Cys Gly Gly  Cys Cys Gly Thr Ala  Thr Ala Thr    2435                 2440                 2445Thr Ala  Cys Thr Gly Thr Gly  Cys Gly Ala Gly Ala  Thr Cys Gly    2450                 2455                 2460Gly Cys  Gly Thr Thr Thr Thr  Cys Gly Thr Thr Cys  Gly Ala Cys    2465                 2470                 2475Thr Ala  Cys Gly Cys Cys Ala  Thr Gly Gly Ala Cys  Cys Thr Cys    2480                 2485                 2490Thr Gly  Gly Gly Gly Cys Cys  Ala Gly Gly Gly Ala  Ala Cys Cys    2495                 2500                 2505Cys Thr  Gly Gly Thr Cys Ala  Cys Cys Gly Thr Gly  Thr Cys Gly    2510                 2515                 2520Ala Gly  Cys Gly Gly Thr Gly  Gly Ala Gly Gly Cys  Gly Gly Ala    2525                 2530                 2535Thr Cys  Thr Gly Gly Cys Gly  Gly Ala Gly Gly Thr  Gly Gly Thr    2540                 2545                 2550Thr Cys  Cys Gly Gly Cys Gly  Gly Thr Gly Gly Cys  Gly Gly Cys    2555                 2560                 2565Thr Cys  Cys Gly Gly Thr Gly  Gly Ala Gly Gly Cys  Gly Gly Cys    2570                 2575                 2580Thr Cys  Thr Gly Ala Cys Ala  Thr Cys Cys Ala Gly  Ala Thr Gly    2585                 2590                 2595Ala Cys  Cys Cys Ala Gly Thr  Cys Thr Cys Cys Thr  Thr Cys Cys    2600                 2605                 2610Ala Cys  Cys Cys Thr Gly Thr  Cys Thr Gly Cys Ala  Thr Cys Thr    2615                 2620                 2625Gly Thr  Ala Gly Gly Ala Gly  Ala Cys Ala Gly Ala  Gly Thr Cys    2630                 2635                 2640Ala Cys  Cys Ala Thr Cys Ala  Cys Thr Thr Gly Cys  Cys Ala Gly    2645                 2650                 2655Gly Cys  Cys Ala Gly Thr Cys  Ala Gly Ala Gly Cys  Ala Thr Thr    2660                 2665                 2670Ala Gly  Thr Thr Cys Cys Cys  Ala Cys Thr Thr Ala  Ala Ala Cys    2675                 2680                 2685Thr Gly  Gly Thr Ala Thr Cys  Ala Gly Cys Ala Gly  Ala Ala Ala    2690                 2695                 2700Cys Cys  Ala Gly Gly Gly Ala  Ala Ala Gly Cys Cys  Cys Cys Thr    2705                 2710                 2715Ala Ala  Gly Cys Thr Cys Cys  Thr Gly Ala Thr Cys  Thr Ala Thr    2720                 2725                 2730Ala Ala  Gly Gly Cys Ala Thr  Cys Cys Ala Cys Thr  Cys Thr Gly    2735                 2740                 2745Gly Cys  Ala Thr Cys Thr Gly  Gly Gly Gly Thr Cys  Cys Cys Ala    2750                 2755                 2760Thr Cys  Ala Ala Gly Gly Thr  Thr Cys Ala Gly Cys  Gly Gly Cys    2765                 2770                 2775Ala Gly  Thr Gly Gly Ala Thr  Cys Thr Gly Gly Gly  Ala Cys Ala    2780                 2785                 2790Gly Ala  Ala Thr Thr Thr Ala  Cys Thr Cys Thr Cys  Ala Cys Cys    2795                 2800                 2805Ala Thr  Cys Ala Gly Cys Ala  Gly Cys Cys Thr Gly  Cys Ala Gly    2810                 2815                 2820Cys Cys  Thr Gly Ala Thr Gly  Ala Thr Thr Thr Thr  Gly Cys Ala    2825                 2830                 2835Ala Cys  Thr Thr Ala Thr Thr  Ala Cys Thr Gly Cys  Cys Ala Ala    2840                 2845                 2850Cys Ala  Gly Gly Gly Thr Thr  Ala Thr Ala Gly Thr  Thr Gly Gly    2855                 2860                 2865Gly Gly  Thr Ala Ala Thr Gly  Thr Thr Gly Ala Thr  Ala Ala Thr    2870                 2875                 2880Gly Thr  Thr Thr Thr Cys Gly  Gly Cys Gly Gly Ala  Gly Gly Gly    2885                 2890                 2895Ala Cys  Cys Ala Ala Gly Gly  Thr Gly Gly Ala Gly  Ala Thr Cys    2900                 2905                 2910Ala Ala  Ala Gly Gly Cys Gly  Gly Thr Gly Gly Ala  Gly Gly Gly    2915                 2920                 2925Thr Cys  Cys Gly Gly Cys Gly  Gly Thr Gly Gly Thr  Gly Gly Cys    2930                 2935                 2940Thr Cys  Cys Gly Gly Ala Cys  Gly Gly Thr Cys Gly  Cys Thr Gly    2945                 2950                 2955Gly Thr  Gly Gly Ala Gly Thr  Cys Thr Gly Gly Gly  Gly Gly Ala    2960                 2965                 2970Gly Gly  Cys Thr Thr Gly Gly  Thr Cys Cys Ala Gly  Cys Cys Thr    2975                 2980                 2985Gly Gly  Gly Gly Gly Gly Thr  Cys Cys Cys Thr Gly  Ala Gly Ala    2990                 2995                 3000Cys Thr  Cys Thr Cys Cys Thr  Gly Thr Ala Cys Thr  Gly Cys Cys    3005                 3010                 3015Thr Cys  Thr Gly Gly Ala Thr  Thr Cys Ala Cys Cys  Ala Thr Cys    3020                 3025                 3030Ala Gly  Thr Ala Gly Cys Thr  Ala Cys Cys Ala Cys  Ala Thr Gly    3035                 3040                 3045Cys Ala  Gly Thr Gly Gly Gly  Thr Cys Cys Gly Cys  Cys Ala Gly    3050                 3055                 3060Gly Cys  Thr Cys Cys Ala Gly  Gly Gly Ala Ala Gly  Gly Gly Gly    3065                 3070                 3075Cys Thr  Gly Gly Ala Gly Thr  Ala Cys Ala Thr Cys  Gly Gly Ala    3080                 3085                 3090Ala Cys  Cys Ala Thr Thr Ala  Gly Thr Ala Gly Thr  Gly Gly Thr    3095                 3100                 3105Gly Gly  Thr Ala Ala Thr Gly  Thr Ala Thr Ala Cys  Thr Ala Cys    3110                 3115                 3120Gly Cys  Ala Ala Gly Cys Thr  Cys Cys Gly Cys Thr  Ala Gly Ala    3125                 3130                 3135Gly Gly  Cys Ala Gly Ala Thr  Thr Cys Ala Cys Cys  Ala Thr Cys    3140                 3145                 3150Thr Cys  Cys Ala Gly Ala Cys  Cys Cys Thr Cys Gly  Thr Cys Cys    3155                 3160                 3165Ala Ala  Gly Ala Ala Cys Ala  Cys Gly Gly Thr Gly  Gly Ala Thr    3170                 3175                 3180Cys Thr  Thr Cys Ala Ala Ala  Thr Gly Ala Ala Cys  Ala Gly Cys    3185                 3190                 3195Cys Thr  Gly Ala Gly Ala Gly  Cys Cys Gly Ala Gly  Gly Ala Cys    3200                 3205                 3210Ala Cys  Gly Gly Cys Thr Gly  Thr Gly Thr Ala Thr  Thr Ala Cys    3215                 3220                 3225Thr Gly  Thr Gly Cys Gly Ala  Gly Ala Gly Ala Cys  Thr Cys Thr    3230                 3235                 3240Gly Gly  Thr Thr Ala Thr Ala  Gly Thr Gly Ala Thr  Cys Cys Thr    3245                 3250                 3255Ala Thr  Gly Thr Gly Gly Gly  Gly Cys Cys Ala Gly  Gly Gly Ala    3260                 3265                 3270Ala Cys  Cys Cys Thr Gly Gly  Thr Cys Ala Cys Cys  Gly Thr Cys    3275                 3280                 3285Thr Cys  Thr Thr Cys Ala Gly  Gly Cys Gly Gly Thr  Gly Gly Cys    3290                 3295                 3300Gly Gly  Thr Ala Gly Thr Gly  Gly Gly Gly Gly Ala  Gly Gly Cys    3305                 3310                 3315Gly Gly  Thr Thr Cys Thr Gly  Gly Cys Gly Gly Cys  Gly Gly Ala    3320                 3325                 3330Gly Gly  Gly Thr Cys Cys Gly  Gly Cys Gly Gly Thr  Gly Gly Ala    3335                 3340                 3345Gly Gly  Ala Thr Cys Ala Gly  Ala Cys Gly Thr Thr  Gly Thr Gly    3350                 3355                 3360Ala Thr  Gly Ala Cys Cys Cys  Ala Gly Thr Cys Thr  Cys Cys Ala    3365                 3370                 3375Thr Cys  Thr Thr Cys Cys Gly  Thr Gly Thr Cys Thr  Gly Cys Ala    3380                 3385                 3390Thr Cys  Thr Gly Thr Ala Gly  Gly Ala Gly Ala Cys  Ala Gly Ala    3395                 3400                 3405Gly Thr  Cys Ala Cys Cys Ala  Thr Cys Ala Cys Cys  Thr Gly Thr    3410                 3415                 3420Cys Ala  Gly Gly Cys Cys Ala  Gly Thr Cys Ala Gly  Ala Ala Cys    3425                 3430                 3435Ala Thr  Thr Ala Gly Gly Ala  Cys Thr Thr Ala Cys  Thr Thr Ala    3440                 3445                 3450Thr Cys  Cys Thr Gly Gly Thr  Ala Thr Cys Ala Gly  Cys Ala Gly    3455                 3460                 3465Ala Ala  Ala Cys Cys Ala Gly  Gly Gly Ala Ala Ala  Gly Cys Cys    3470                 3475                 3480Cys Cys  Thr Ala Ala Gly Cys  Thr Cys Cys Thr Gly  Ala Thr Cys    3485                 3490                 3495Thr Ala  Thr Gly Cys Thr Gly  Cys Ala Gly Cys Cys  Ala Ala Thr    3500                 3505                 3510Cys Thr  Gly Gly Cys Ala Thr  Cys Thr Gly Gly Gly  Gly Thr Cys    3515                 3520                 3525Cys Cys  Ala Thr Cys Ala Ala  Gly Gly Thr Thr Cys  Ala Gly Cys    3530                 3535                 3540Gly Gly  Cys Ala Gly Thr Gly  Gly Ala Thr Cys Thr  Gly Gly Gly    3545                 3550                 3555Ala Cys  Ala Gly Ala Thr Thr  Thr Cys Ala Cys Thr  Cys Thr Cys    3560                 3565                 3570Ala Cys  Cys Ala Thr Cys Ala  Gly Cys Gly Ala Cys  Cys Thr Gly    3575                 3580                 3585Gly Ala  Gly Cys Cys Thr Gly  Gly Cys Gly Ala Thr  Gly Cys Thr    3590                 3595                 3600Gly Cys  Ala Ala Cys Thr Thr  Ala Cys Thr Ala Thr  Thr Gly Thr    3605                 3610                 3615Cys Ala  Gly Thr Cys Thr Ala  Cys Cys Thr Ala Thr  Cys Thr Thr    3620                 3625                 3630Gly Gly  Thr Ala Cys Thr Gly  Ala Thr Thr Ala Thr  Gly Thr Thr    3635                 3640                 3645Gly Gly  Cys Gly Gly Thr Gly  Cys Thr Thr Thr Cys  Gly Gly Cys    3650                 3655                 3660Gly Gly  Ala Gly Gly Gly Ala  Cys Cys Ala Ala Gly  Gly Thr Gly    3665                 3670                 3675Gly Ala  Gly Ala Thr Cys Ala  Ala Ala Thr Gly Ala    3680                 3685                 3690</s400><s200><s210>67</s210><s211>734</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 67Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu    130                 135                 140Ser Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met145                 150                 155                 160Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu                165                 170                 175Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys            180                 185                 190Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu        195                 200                 205Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala    210                 215                 220Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser                245                 250                 255Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly            260                 265                 270Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn        275                 280                 285Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile    290                 295                 300Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly305                 310                 315                 320Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser                325                 330                 335Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr            340                 345                 350Thr Phe Gly Cys Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala        355                 360                 365Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly    370                 375                 380Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala385                 390                 395                 400Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln                405                 410                 415Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser            420                 425                 430Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr        435                 440                 445Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser    450                 455                 460Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser465                 470                 475                 480Gly Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser                485                 490                 495Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser            500                 505                 510Asp Val Gly Gly Tyr Asn Phe Val Ser Trp Tyr Gln Gln His Pro Gly        515                 520                 525Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asp Arg Pro Ser Gly    530                 535                 540Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu545                 550                 555                 560Ile Ile Ser Gly Leu Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys Ser                565                 570                 575Ser Tyr Gly Ser Ser Ser Thr His Val Ile Phe Gly Gly Gly Thr Lys            580                 585                 590Val Thr Val Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly        595                 600                 605Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly    610                 615                 620Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Ser Leu Ser Cys Ala Ala625                 630                 635                 640Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala                645                 650                 655Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Asn Arg Asp Gly Ser            660                 665                 670Ala Ser Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg        675                 680                 685Asp Asp Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala    690                 695                 700Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Val Gly Tyr705                 710                 715                 720Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser                725                 730</s400><s200><s210>68</s210><s211>2205</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 68gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaagtga ccgtcctagg cggtggcggt agtgggggag gcggttctgg cggcggaggg    360tccggcggtg gaggatcaca ggtcacattg aaggaatctg gccccggcct tgttcagcca    420ggacagaccc ttagcctcac ctgtgccttc agtggttttt ctcttagcac tagcggtatg    480ggggtcggct ggattcggca gcctcccggc aaaggtcttg agtggttggc tcacatttgg    540tgggacgacg acaaacggta taatcctgcc ttgaaaagtc ggctgaccat tagtaaggat    600acctcaaaaa atcaagtgta cttgcaaatg aatagccttg acgccgagga tacggctgta    660tattattgcg ctcggatgga actctggtct tactactttg attattgggg gcaggggact    720ctcgtcacgg tctcgagtgg cggtggaggg tccggcggtg gtggatcaga catcttgctg    780actcagtctc cagtcatcct gtctgtgagt ccaggagaaa gagtcagttt ctcctgcagg    840gccagtcaga gtattggcac aaacatacac tggtatcagc aaagaacaaa tggttctcca    900aggcttctca taaagtatgc ttctgagtct atctctggga ttccttccag gtttagtggc    960agtggatcag ggacagattt tactcttagc atcaacagtg tggagtctga agatattgca   1020gattattact gtcaacaaaa taataactgg ccaaccacgt tcggttgtgg gaccaagctg   1080gagctgaaac gtacggtggc tgcaccatct gtcttcatct tcccgccatc tgatgagcag   1140ttgaaatctg gaactgcctc tgttgtgtgc ctgctgaata acttctatcc cagagaggcc   1200aaagtacagt ggaaggtgga taacgccctc caatcgggta actcccagga gagtgtcaca   1260gagcaggaca gcaaggacag cacctacagc ctcagcagca ccctgacgct gagcaaagca   1320gactacgaga aacacaaagt ctacgcctgc gaagtcaccc atcagggcct gagctcgccc   1380gtcacaaaga gcttcaacag gggagagtgt ggcggtggcg gtagcggtgg cggcggaagt   1440ggtggcggag gatcccagtc tgccctgact cagcctgcct ccgtgtctgg gtctcctgga   1500cagtcgatca ccatctcctg cactggaacc agcagtgacg ttggtggtta taactttgtc   1560tcctggtacc aacaacaccc aggcaaagcc cccaaactca tgatctatga tgtcagtgat   1620cggccctcag gggtgtctga tcgcttctcc ggctccaagt ctggcaacac ggcctccctg   1680atcatctctg gcctccaggc tgacgacgag gctgattatt actgcagctc atatgggagc   1740agcagcactc atgtgatttt cggcggaggg accaaggtga ccgtcctagg tggaggcggt   1800tcaggcggag gtggttccgg cggtggcggc tccggtggag gcggctctca ggtgcaattg   1860caggagtcgg ggggaggcct ggtcaagcct ggagggtccc tgagtctctc ctgtgcagcc   1920tctggattca cctttagtag ttattggatg agctgggtcc gccaggctcc agggaagggg   1980ctggagtggg tggccaacat aaaccgcgat ggaagtgcga gttactatgt ggactctgtg   2040aagggccgat tcaccatctc cagagacgac gccaagaact cactgtatct gcaaatgaac   2100agcctgagag ctgaggacac ggctgtgtat tactgtgcga gagatcgtgg ggtgggctac   2160ttcgatctct ggggccgtgg caccctggtc accgtctcta gctga                   2205</s400><s200><s210>69</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 69Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Lys Val Ser Gly Phe Ser Leu Thr Asn Tyr            20                  25                  30Gly Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr    50                  55                  60Ser Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala                85                  90                  95Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>70</s210><s211>357</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 70gaagttcagc tggtggaatc cggcggagga ttggttcaac ctggcggctc tctgagactg     60tcctgtaagg tgtctggctt ctccctgacc aactacggcg tgcactgggt ccgacaggca    120cctggaaaag gactggaatg ggtcggagtg atttggagcg gcggcaacac cgactacaac    180acccctttca ccagccggtt caccatctct cgggacacct ccaagaacac cgtgtacctg    240cagatgaact ccctgagagc cgaggacacc gccgtgtact attgtgctag agccctgacc    300tactatgact acgagttcgc ctattggggc cagggaaccc tggtcacagt ctcctct       357</s400><s200><s210>71</s210><s211>107</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 71Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Ile Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Leu Thr Val Leu            100                 105</s400><s200><s210>72</s210><s211>321</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 72gagatcgtga tgacccagtc tccttccaca ctgtccgcct ctgtgggcga cagagtgatc     60atcacctgta gagccagcca gtccatcggc accaacatcc actggtatca gcagaagcct    120ggcaaggccc ctaagctgct gatctactac gcctccgagt ctatcagcgg catcccctcc    180agattctccg gctctggatc tggcgctgag tttaccctga caatctccag cctgcagcct    240gacgacttcg ccacctacta ctgccagcag aacaacaact ggcccaccac ctttggccag    300ggcaccaaac tgacagttct t                                              321</s400><s200><s210>73</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 73Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1               5                   10                  15Thr Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr            20                  25                  30Gly Val His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu        35                  40                  45Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr    50                  55                  60Ser Arg Phe Thr Ile Thr Lys Asp Asn Ser Lys Asn Gln Val Tyr Phe65                  70                  75                  80Lys Leu Arg Ser Val Arg Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala                85                  90                  95Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>74</s210><s211>357</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 74caagttcagt tgcagcagtc tggccctggc ctggtcaagc cttctgagac actgtccatc     60acctgtaccg tgtccggctt ctccctgacc aattacggcg tgcactggat cagacaggcc    120cctggcaaag gactggaatg gctgggagtg atttggagcg gcggcaacac cgactacaac    180acccctttca ccagccggtt caccatcacc aaggacaact ccaagaacca ggtgtacttc    240aagctgcgga gcgtgcgggc tgatgacacc gccatctact actgtgctcg ggccctgacc    300tactacgact acgagtttgc ttactggggc cagggcaccc tggtcacagt ttcttct       357</s400><s200><s210>75</s210><s211>107</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 75Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Asp Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Val Gln Ser65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Pro Gly Thr Lys Leu Glu Leu Lys            100                 105</s400><s200><s210>76</s210><s211>321</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 76gagatcgtgc tgacccagtc tccttccaca ctgtctgtgt ctcccggcga gagagccacc     60ttcagctgta gagcctctca gtccatcggc accaacatcc actggtatca gcagaagccc    120ggcaagcctc ctcggctgct gattaagtac gcctccgagt ccatcagcgg catccctgac    180agattctccg gctctggctc tggcaccgag tttaccctga ccatctcctc cgtgcagtcc    240gaggatttcg ccgtgtacta ctgccagcag aacaacaact ggcccaccac ctttggaccc    300ggcaccaagc tggaattgaa a                                              321</s400><s200><s210>77</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 77Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1               5                   10                  15Thr Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr            20                  25                  30Gly Val His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu        35                  40                  45Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr    50                  55                  60Ser Arg Phe Thr Ile Thr Lys Asp Asn Ser Lys Asn Gln Val Tyr Phe65                  70                  75                  80Lys Leu Arg Ser Val Arg Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala                85                  90                  95Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>78</s210><s211>357</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 78caagttcagt tgcagcagtc tggccctggc ctggtcaagc cttctgagac actgtccatc     60acctgtaccg tgtccggctt ctccctgacc aattacggcg tgcactggat cagacaggcc    120cctggcaaag gactggaatg gctgggagtg atttggagcg gcggcaacac cgactacaac    180acccctttca ccagccggtt caccatcacc aaggacaact ccaagaacca ggtgtacttc    240aagctgcgga gcgtgcgggc tgatgacacc gccatctact actgtgctcg ggccctgacc    300tactacgact acgagtttgc ttactggggc cagggcaccc tggtcacagt ttcttct       357</s400><s200><s210>79</s210><s211>107</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 79Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Asp Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Val Gln Ser65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Pro Gly Thr Lys Leu Thr Val Leu            100                 105</s400><s200><s210>80</s210><s211>321</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 80gagatcgtgc tgacccagtc tccttccaca ctgtctgtgt ctcccggcga gagagccacc     60ttcagctgta gagcctctca gtccatcggc accaacatcc actggtatca gcagaagccc    120ggcaagcctc ctcggctgct gattaagtac gcctccgagt ccatcagcgg catccctgac    180agattctccg gctctggctc tggcaccgag tttaccctga ccatctcctc cgtgcagtcc    240gaggatttcg ccgtgtacta ctgccagcag aacaacaact ggcccaccac ctttggaccc    300ggcaccaagc tgacagttct t                                              321</s400><s200><s210>81</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 81Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1               5                   10                  15Thr Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr            20                  25                  30Gly Val His Trp Ile Arg Gln Ala Pro Gly Lys Cys Leu Glu Trp Leu        35                  40                  45Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr    50                  55                  60Ser Arg Phe Thr Ile Thr Lys Asp Asn Ser Lys Asn Gln Val Tyr Phe65                  70                  75                  80Lys Leu Arg Ser Val Arg Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala                85                  90                  95Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>82</s210><s211>357</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 82caagtacagt tgcagcaatc cggtcccggt ctcgtcaaac cgagtgagac gcttagtata     60acgtgtactg tttcaggctt tagccttacg aactatggag ttcactggat tcggcaggca    120cccggcaaat gtttggaatg gctgggtgtt atttggtcag gtggaaatac agactataac    180acccccttta caagtcggtt cacaattacg aaagataatt ccaaaaatca agtttatttc    240aagttgagat ccgtccgcgc ggacgacact gcgatctact attgtgcgag ggcactgacc    300tactacgatt acgaatttgc gtattggggg caagggactc ttgtaacagt ctccagt       357</s400><s200><s210>83</s210><s211>107</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 83Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Asp Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Val Gln Ser65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Cys Gly Thr Lys Leu Thr Val Leu            100                 105</s400><s200><s210>84</s210><s211>321</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 84gaaatcgtcc ttacacaatc tcctagcaca ctgagtgtga gccccggcga acgcgcgact     60ttctcttgca gggcaagtca atccataggg actaatatac attggtatca acaaaagcca    120ggtaaaccac ccaggctttt gattaagtat gcaagtgagt ctatttccgg tatccctgac    180cgcttctctg gatcaggcag tggcacagag ttcacactca ccatatctag tgtgcaatca    240gaggacttcg ccgtgtatta ctgccaacag aataataact ggccgactac cttcggatgc    300ggtacaaagc tgaccgtttt a                                              321</s400><s200><s210>85</s210><s211>120</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 85Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln1               5                   10                  15Thr Leu Ser Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser            20                  25                  30Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu        35                  40                  45Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala    50                  55                  60Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val65                  70                  75                  80Tyr Leu Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr                85                  90                  95Cys Ala Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln            100                 105                 110Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>86</s210><s211>360</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 86caggtcacat tgaaggaatc tggccccggc cttgttcagc caggacagac ccttagcctc     60acctgtgcct tcagtggttt ttctcttagc actagcggta tgggggtcgg ctggattcgg    120cagcctcccg gcaaaggtct tgagtggttg gctcacattt ggtgggacga cgacaaacgg    180tataatcctg ccttgaaaag tcggctgacc attagtaagg atacctcaaa aaatcaagtg    240tacttgcaaa tgaatagcct tgacgccgag gatacggctg tatattattg cgctcggatg    300gaactctggt cttactactt tgattattgg gggcagggga ctctcgtcac ggtctcgagt    360</s400><s200><s210>87</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 87Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Thr Val Leu            100                 105</s400><s200><s210>88</s210><s211>318</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 88gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaagtga ccgtccta                                                  318</s400><s200><s210>89</s210><s211>120</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 89Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Ser Thr Asn            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Cys Leu Glu Trp Ile        35                  40                  45Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala Ser Trp Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala                85                  90                  95Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn Ile Trp Gly Gln            100                 105                 110Gly Thr Leu Val Thr Val Ser Thr        115                 120</s400><s200><s210>90</s210><s211>360</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 90gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc     60tcctgtgcag cctctggatt caccatcagt accaatgcaa tgagctgggt ccgccaggct    120ccagggaagt gcctggagtg gatcggagtc attactggtc gtgatatcac atactacgcg    180agctgggcga aaggcagatt caccatctcc agagacaatt ccaagaacac gctgtatctt    240caaatgaaca gcctgagagc cgaggacacg gctgtgtatt actgtgcgag agacggtggt    300tcttctgcta ttactagtaa caacatttgg ggccagggaa ccctggtcac cgtgtcgaca    360</s400><s200><s210>91</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 91Asp Val Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser                85                  90                  95Arg Thr Tyr Val Asn Ser Phe Gly Cys Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>92</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 92gacgtcgtga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc     60atcaattgcc aagccagtga gagcattagc agttggttag cctggtatca gcagaaacca    120gggaaagccc ctaagctcct gatctatgaa gcatccaaac tggcatctgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa tttactctca ccatcagcag cctgcagcct    240gatgattttg caacttatta ctgccaaggc tatttttatt ttattagtcg tacttatgta    300aattctttcg gctgtgggac caaggtggag atcaaa                              336</s400><s200><s210>93</s210><s211>120</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 93Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Ser Thr Asn            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala Ser Trp Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala                85                  90                  95Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn Ile Trp Gly Gln            100                 105                 110Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>94</s210><s211>360</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 94gaagtccaat tggtagaaag tggcggtggt ctggtgcaac ctggtggatc tcttcgcctc     60tcatgcgccg ctagtggctt tactatttca actaatgcga tgagctgggt tcgccaggcc    120cccggcaaag gacttgagtg ggtcggcgtc atcaccggca gggacattac atactatgcg    180agttgggcaa agggcaggtt cacgattagc cgcgatactt caaagaatac cgtttacctt    240caaatgaata gcttgagggc ggaagacaca gctgtgtatt actgcgcgag ggatggaggt    300agttccgcca taacttccaa caacatatgg ggacaaggca cgctggttac tgtctcgagt    360</s400><s200><s210>95</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 95Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Ile Ile Thr Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser                85                  90                  95Arg Thr Tyr Val Asn Ser Phe Gly Gln Gly Thr Lys Leu Thr Val Leu            100                 105                 110</s400><s200><s210>96</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 96gaaatcgtta tgacgcagag tccctccacg ctctccgcta gtgtcgggga tcgcgtcatt     60atcacatgcc aggcctccga gtcaatcagc agctggcttg catggtatca acagaagccg    120ggaaaagctc ctaaattgct gatctatgaa gcgtcaaaat tggcgtctgg tgtcccatct    180aggttctccg gctctgggtc tggtgcggaa tttactttga caatctccag tcttcaacca    240gacgatttcg ctacctacta ctgccaaggg tatttctatt ttataagccg gacatatgta    300aactccttcg gccaaggaac aaagttgact gttctt                              336</s400><s200><s210>97</s210><s211>120</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 97Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Ile Ser Thr Asn            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Cys Leu Glu Trp Val        35                  40                  45Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala Ser Trp Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala                85                  90                  95Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn Ile Trp Gly Gln            100                 105                 110Gly Thr Leu Val Thr Val Ser Thr        115                 120</s400><s200><s210>98</s210><s211>360</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 98gaggtgcagc tggtggagag cggcggcggc ctggtgcagc ccggcggcag cctgaggctg     60agctgcaccg ccagcggctt caccatcagc accaacgcca tgagctgggt gaggcaggcc    120cccggcaagt gcctggagtg ggtgggcgtg atcaccggca gggacatcac ctactacgcc    180agctgggcca agggcaggtt caccatcagc agggacacca gcaagaacac cgtgtacctg    240cagatgaaca gcctgagggc cgaggacacc gccgtgtact actgcgccag ggacggcggc    300agcagcgcca tcaccagcaa caacatctgg ggccagggca ccctggtgac cgtgtcgaca    360</s400><s200><s210>99</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 99Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Ile Ile Thr Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser                85                  90                  95Arg Thr Tyr Val Asn Ser Phe Gly Cys Gly Thr Lys Leu Thr Val Leu            100                 105                 110</s400><s200><s210>100</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 100gagatcgtga tgacccagag ccccagcacc ctgagcgcca gcgtgggcga cagggtgatc     60atcacctgcc aggccagcga gagcatcagc agctggctgg cctggtacca gcagaagccc    120ggcaaggccc ccaagctgct gatctacgag gccagcaagc tggccagcgg cgtgcccagc    180aggttcagcg gcagcggcag cggcgccgag ttcaccctga ccatcagcag cctgcagccc    240gacgacttcg ccacctacta ctgccagggc tacttctact tcatcagcag gacctacgtg    300aacagcttcg gctgcggcac caagctgacc gtgctg                              336</s400><s200><s210>101</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 101Gln Val Gln Leu Gln Glu Ser Gly Gly Arg Leu Val Gln Pro Gly Glu1               5                   10                  15Pro Leu Ser Leu Thr Cys Lys Thr Ser Gly Ile Asp Leu Ser Ser Asn            20                  25                  30Ala Ile Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile        35                  40                  45Gly Val Ile Phe Gly Ser Gly Asn Thr Tyr Tyr Ala Ser Trp Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Ser Thr Ser Thr Val Tyr Leu Lys Met65                  70                  75                  80Asn Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly                85                  90                  95Gly Tyr Ser Ser Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser            100                 105                 110Ser</s400><s200><s210>102</s210><s211>339</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 102caagtgcagt tgcaagaaag tggtggtaga ctggttcagc ctggtgaacc cttgtcactg     60acgtgtaaaa caagcggcat tgatctgtcc tctaacgcca tcggatgggt ccgacaggcc    120ccaggaaaag gtctggagtg gatcggagtt atcttcggga gcggcaatac atactacgca    180agctgggcaa aagggcgatt tacgatatca cggagcacct ctacagttta tttgaaaatg    240aactccctcc ggtccgagga taccgcgata tattactgtg ccagaggggg gtactcctct    300gatatctggg ggcagggtac actggttaca gtttcatcc                           339</s400><s200><s210>103</s210><s211>110</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 103Asp Pro Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Ser Cys Gln Ser Ser Gln Ser Val Ala Lys Asn            20                  25                  30Asn Asn Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ala Gly Val Pro Ser Arg Phe    50                  55                  60Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val65                  70                  75                  80Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ser Ala Arg Asp Ser Gly                85                  90                  95Asn Ile Gln Ser Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>104</s210><s211>330</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 104gatccagttc tgacacaaag tccatccagc ctgtctgcct cagtcggcga cagagtgacc     60atcagttgcc agagctcaca gtctgtggct aagaacaaca acttggcgtg gttccaacag    120aaacctggac aggctccgaa attgctgatc tattctgctt ccacgcttgc tgctggtgtt    180ccttcccgct tttcaggtag tggtagcggg acagacttca ctttgactat aagcagcgtg    240cagcctgaag attttgcgac ctactattgt tctgctagag acagtggaaa tattcagtcc    300tttggggggg gaacgaaggt cgaaataaag                                     330</s400><s200><s210>105</s210><s211>122</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 105Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly            20                  25                  30Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Cys Leu Glu Trp        35                  40                  45Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr Tyr Asp Ala Asn    50                  55                  60Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr65                  70                  75                  80Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala Met Asp Leu Trp            100                 105                 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>106</s210><s211>366</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 106gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc     60tcctgtgcag cctctggatt ctccttcagt agcgggtacg acatgtgctg ggtccgccag    120gctccaggga agtgcctgga gtggatcgca tgcattgctg ctggtagtgc tggtatcact    180tacgacgcga actgggcgaa aggccggttc accatctcca gagacaattc caagaacacg    240ctgtatctgc aaatgaacag cctgagagcc gaggacacgg ccgtatatta ctgtgcgaga    300tcggcgtttt cgttcgacta cgccatggac ctctggggcc agggaaccct ggtcaccgtc    360tcgagc                                                               366</s400><s200><s210>107</s210><s211>110</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 107Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser His            20                  25                  30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp Gly Asn                85                  90                  95Val Asp Asn Val Phe Gly Cys Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>108</s210><s211>330</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 108gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc     60atcacttgcc aggccagtca gagcattagt tcccacttaa actggtatca gcagaaacca    120gggaaagccc ctaagctcct gatctataag gcatccactc tggcatctgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa tttactctca ccatcagcag cctgcagcct    240gatgattttg caacttatta ctgccaacag ggttatagtt ggggtaatgt tgataatgtt    300ttcggctgcg ggaccaaggt ggagatcaaa                                     330</s400><s200><s210>109</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 109Arg Ser Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser1               5                   10                  15Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Ile Ser Ser Tyr His            20                  25                  30Met Gln Trp Val Arg Gln Ala Pro Gly Lys Cys Leu Glu Tyr Ile Gly        35                  40                  45Thr Ile Ser Ser Gly Gly Asn Val Tyr Tyr Ala Ser Ser Ala Arg Gly    50                  55                  60Arg Phe Thr Ile Ser Arg Pro Ser Ser Lys Asn Thr Val Asp Leu Gln65                  70                  75                  80Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg                85                  90                  95Asp Ser Gly Tyr Ser Asp Pro Met Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>110</s210><s211>345</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 110cggtcgctgg tggagtctgg gggaggcttg gtccagcctg gggggtccct gagactctcc     60tgtactgcct ctggattcac catcagtagc taccacatgc agtgggtccg gcaggcacct    120gggaagtgcc tggagtacat cggaaccatt agtagtggtg gtaatgtata ctacgcaagc    180tccgctagag gcagattcac catctccaga ccctcgtcca agaacacggt ggatcttcaa    240atgaacagcc tgagagccga ggacacggct gtgtattact gtgcgagaga ctctggttat    300agtgatccta tgtggggcca gggaaccctg gtcaccgtct cttca                    345</s400><s200><s210>111</s210><s211>111</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 111Asp Val Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asn Ile Arg Thr Tyr            20                  25                  30Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Ala Ala Ala Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asp Leu Glu Pro65                  70                  75                  80Gly Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Thr Tyr Leu Gly Thr Asp                85                  90                  95Tyr Val Gly Gly Ala Phe Gly Cys Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>112</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 112gacgttgtga tgacccagtc tccatcttcc gtgtctgcat ctgtaggaga cagagtcacc     60atcacctgtc aggccagtca gaacattagg acttacttat cctggtatca gcagaaacca    120gggaaagccc ctaagctcct gatctatgct gcagccaatc tggcatctgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcga cttggaacct    240ggcgatgctg caacttacta ttgtcagtct acctatcttg gtactgatta tgttggcggt    300gctttcggct gtgggaccaa ggtggagatc aaatga                              336</s400><s200><s210>113</s210><s211>562</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 113Arg Glu Gly Pro Glu Leu Ser Pro Asp Asp Pro Ala Gly Leu Leu Asp1               5                   10                  15Leu Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu            20                  25                  30Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val        35                  40                  45Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val    50                  55                  60Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg65                  70                  75                  80Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His                85                  90                  95Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu Thr            100                 105                 110Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly        115                 120                 125Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val    130                 135                 140His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln145                 150                 155                 160Gly Ala Thr Val Leu Gly Leu Phe Arg Val Thr Pro Glu Ile Pro Ala                165                 170                 175Gly Leu Gly Ser Thr Gly Ser Gly Ser Lys Pro Gly Ser Gly Glu Gly            180                 185                 190Ser Thr Lys Gly Arg Glu Gly Pro Glu Leu Ser Pro Asp Asp Pro Ala        195                 200                 205Gly Leu Leu Asp Leu Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln    210                 215                 220Asn Val Leu Leu Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly225                 230                 235                 240Leu Ala Gly Val Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr                245                 250                 255Lys Glu Leu Val Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln            260                 265                 270Leu Glu Leu Arg Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser        275                 280                 285Leu Ala Leu His Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala    290                 295                 300Leu Ala Leu Thr Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn305                 310                 315                 320Ser Ala Phe Gly Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln                325                 330                 335Arg Leu Gly Val His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp            340                 345                 350Gln Leu Thr Gln Gly Ala Thr Val Leu Gly Leu Phe Arg Val Thr Pro        355                 360                 365Glu Ile Pro Ala Gly Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser    370                 375                 380Arg Glu Gly Pro Glu Leu Ser Pro Asp Asp Pro Ala Gly Leu Leu Asp385                 390                 395                 400Leu Arg Gln Gly Met Phe Ala Gln Leu Val Ala Gln Asn Val Leu Leu                405                 410                 415Ile Asp Gly Pro Leu Ser Trp Tyr Ser Asp Pro Gly Leu Ala Gly Val            420                 425                 430Ser Leu Thr Gly Gly Leu Ser Tyr Lys Glu Asp Thr Lys Glu Leu Val        435                 440                 445Val Ala Lys Ala Gly Val Tyr Tyr Val Phe Phe Gln Leu Glu Leu Arg    450                 455                 460Arg Val Val Ala Gly Glu Gly Ser Gly Ser Val Ser Leu Ala Leu His465                 470                 475                 480Leu Gln Pro Leu Arg Ser Ala Ala Gly Ala Ala Ala Leu Ala Leu Thr                485                 490                 495Val Asp Leu Pro Pro Ala Ser Ser Glu Ala Arg Asn Ser Ala Phe Gly            500                 505                 510Phe Gln Gly Arg Leu Leu His Leu Ser Ala Gly Gln Arg Leu Gly Val        515                 520                 525His Leu His Thr Glu Ala Arg Ala Arg His Ala Trp Gln Leu Thr Gln    530                 535                 540Gly Ala Thr Val Leu Gly Leu Phe Arg Val Thr Pro Glu Ile Pro Ala545                 550                 555                 560Gly Leu</s400><s200><s210>114</s210><s211>1689</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 114cgagagggcc ccgagctgtc tcctgatgac ccagcaggcc tcttggactt gcggcagggt     60atgttcgctc aacttgtggc tcagaatgtt ctgctcattg atggaccact ctcttggtat    120agtgaccccg gtctggccgg ggtgagtctg accggcgggc tctcttataa agaggatact    180aaggaactgg tcgtagcaaa agcgggcgtt tattacgttt tttttcagct ggagctcagg    240cgcgtggtgg ccggcgaggg cagtggctct gtgtccctgg ccctgcactt acagcccttg    300agaagcgctg caggtgctgc cgcactggct ttaactgttg acctccctcc ggcctcttct    360gaagctagaa acagcgcttt cggcttccaa gggcgcctgc tgcacctgag cgcaggccag    420cgcttaggtg tgcaccttca tacagaggcc agggcccgac acgcttggca gctcacacag    480ggtgccacgg ttctcggact tttccgcgtt actcccgaga tccccgctgg cctcggaagt    540actggttctg ggtctaaacc cggttccggc gaaggtagta ctaaaggacg agaagggcca    600gagttaagtc cagatgaccc tgctgggctt ttggacctgc ggcagggcat gttcgctcaa    660ctggtggctc agaacgtgct gctgatcgat ggccccctga gttggtacag cgatcccggg    720ctggcaggcg tgtcacttac agggggcctc tcttacaagg aagacaccaa ggagttagtg    780gtcgctaagg ctggcgtgta ttacgtgttc ttccaactgg agctgagaag ggttgtggca    840ggagagggta gcggcagcgt gtctttagcc cttcacttgc agcccctgag gtctgctgca    900ggtgcagccg ctctcgcgct caccgtggat ctccccccag cctcatctga agctaggaac    960agtgcatttg gctttcaggg acgcttgctg cacctctccg ctggacagag gctgggcgtg   1020caccttcaca cagaggcccg tgccaggcat gcatggcagc tcactcaggg ggcaacagtg   1080ctgggtctct tccgcgtgac tcctgaaata ccagctggac ttggcggtgg aggcagcggc   1140ggaggaggat ctcgtgaggg gccagaactg tcccccgatg acccagccgg actgctcgat   1200ctcagacagg gcatgttcgc tcagcttgta gcccaaaatg tcctcctgat tgacggccct   1260ttgagctggt atagtgatcc cggcttggcc ggggtatctc tgaccggagg cctctcctac   1320aaggaagaca ccaaagagct ggtggtggca aaagcggggg tgtattatgt gttctttcag   1380ctcgagctgc ggagagttgt ggccggggaa gggtctggga gcgtatctct tgcacttcac   1440ctgcagcccc tgcgcagcgc cgctggagcc gccgcccttg ctcttactgt ggatctgcct   1500cctgcttcct cagaagcacg caacagcgcc ttcggctttc aaggacgtct cctgcacttg   1560tccgcaggac agaggttggg cgtccattta cacactgagg cacgggcacg gcacgcttgg   1620cagcttaccc agggagccac cgtgctggga ctctttagag tgacacccga gatccccgct   1680ggcttgtga                                                           1689</s400><s200><s210>115</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 115Phe Leu Asn Ser Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr Glu1               5                   10                  15Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn Asn            20                  25                  30Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln Ala        35                  40                  45Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys Glu    50                  55                  60Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly Leu65                  70                  75                  80Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser Ile                85                  90                  95Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp Cys            100                 105                 110Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser Thr        115                 120                 125Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Gly Gly Gly Gly Ser    130                 135                 140Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Phe145                 150                 155                 160Leu Asn Ser Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr Glu Ser                165                 170                 175Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn Asn Cys            180                 185                 190Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln Ala Ser        195                 200                 205Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys Glu Asp    210                 215                 220Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly Leu Val225                 230                 235                 240His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser Ile Leu                245                 250                 255Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp Cys Ala            260                 265                 270Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser Thr Pro        275                 280                 285Asn Thr Tyr Ile Cys Met Gln Arg Thr Val    290                 295</s400><s200><s210>116</s210><s211>897</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 116tttcttaatt cccttttcaa ccaagaggtt cagatcccct tgactgaaag ctattgcggc     60ccttgtccga aaaactggat atgttacaag aataattgtt accaattctt cgacgaaagc    120aagaactggt atgagagtca ggcgtcttgt atgagtcaga atgccagcct gcttaaggtt    180tattcaaaag aagaccagga tctgcttaag ttggtaaaga gctaccactg gatggggctg    240gtacatatcc caacgaatgg gtcatggcag tgggaggacg gttctattct gagtccaaat    300ctcctgacga tcatcgaaat gcagaaaggg gactgtgccc tgtatgcatc atccttcaag    360gggtacatcg agaactgcag taccccaaat acctacattt gtatgcaaag aacggttgga    420ggcggtggct caggcggagg cggctcagga ggtggcggtt caggaggcgg cggatctttc    480ctaaactcat tattcaacca agaagttcaa attcccttga ccgaaagtta ctgtggccca    540tgtcctaaaa actggatatg ttacaaaaat aactgctacc aattttttga tgagagtaaa    600aactggtatg agagccaggc ttcttgtatg tctcaaaatg ccagccttct gaaagtatac    660agcaaagagg accaggattt acttaaactg gtgaagtcat atcattggat gggactagta    720cacattccaa caaatggatc ttggcagtgg gaagatggct ccattctctc acccaaccta    780ctaacaataa ttgaaatgca gaagggagac tgtgcactct atgcctcgag ctttaaaggc    840tatatagaaa actgttcaac tccaaatacg tacatctgca tgcaaaggac tgtgtag       897</s400><s200><s210>117</s210><s211>1247</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 117Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Ile Ile Thr Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser                85                  90                  95Arg Thr Tyr Val Asn Ser Phe Gly Cys Gly Thr Lys Leu Thr Val Leu            100                 105                 110Gly Ser Thr Gly Ser Gly Ser Lys Pro Gly Ser Gly Glu Gly Ser Thr        115                 120                 125Lys Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro    130                 135                 140Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Ile Ser145                 150                 155                 160Thr Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Cys Leu Glu                165                 170                 175Trp Val Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala Ser Trp            180                 185                 190Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val        195                 200                 205Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr    210                 215                 220Cys Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn Ile Trp225                 230                 235                 240Gly Gln Gly Thr Leu Val Thr Val Ser Thr Gly Gly Gly Gly Ser Gly                245                 250                 255Gly Gly Gly Ser Phe Leu Asn Ser Leu Phe Asn Gln Glu Val Gln Ile            260                 265                 270Pro Leu Thr Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys        275                 280                 285Tyr Lys Asn Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr    290                 295                 300Glu Ser Gln Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val305                 310                 315                 320Tyr Ser Lys Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His                325                 330                 335Trp Met Gly Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu            340                 345                 350Asp Gly Ser Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln        355                 360                 365Lys Gly Asp Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu    370                 375                 380Asn Cys Ser Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Ala385                 390                 395                 400Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser                405                 410                 415Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe            420                 425                 430Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly        435                 440                 445Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu    450                 455                 460Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr465                 470                 475                 480Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg                485                 490                 495Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro            500                 505                 510Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys        515                 520                 525Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val    530                 535                 540Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr545                 550                 555                 560Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu                565                 570                 575Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His            580                 585                 590Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys        595                 600                 605Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln    610                 615                 620Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu625                 630                 635                 640Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro                645                 650                 655Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn            660                 665                 670Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu        675                 680                 685Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val    690                 695                 700Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln705                 710                 715                 720Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly                725                 730                 735Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro            740                 745                 750Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser        755                 760                 765Ser Gly Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Cys Leu    770                 775                 780Glu Trp Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr Tyr Asp785                 790                 795                 800Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys                805                 810                 815Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala            820                 825                 830Val Tyr Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala Met Asp        835                 840                 845Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly    850                 855                 860Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser865                 870                 875                 880Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly                885                 890                 895Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser His            900                 905                 910Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        915                 920                 925Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    930                 935                 940Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro945                 950                 955                 960Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp Gly Asn                965                 970                 975Val Asp Asn Val Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Gly Gly            980                 985                 990Gly Gly Ser Gly Gly Gly Gly Ser  Gly Arg Ser Leu Val  Glu Ser Gly        995                 1000                 1005Gly Gly  Leu Val Gln Pro Gly  Gly Ser Leu Arg Leu  Ser Cys Thr    1010                 1015                 1020Ala Ser  Gly Phe Thr Ile Ser  Ser Tyr His Met Gln  Trp Val Arg    1025                 1030                 1035Gln Ala  Pro Gly Lys Cys Leu  Glu Tyr Ile Gly Thr  Ile Ser Ser    1040                 1045                 1050Gly Gly  Asn Val Tyr Tyr Ala  Ser Ser Ala Arg Gly  Arg Phe Thr    1055                 1060                 1065Ile Ser  Arg Pro Ser Ser Lys  Asn Thr Val Asp Leu  Gln Met Asn    1070                 1075                 1080Ser Leu  Arg Ala Glu Asp Thr  Ala Val Tyr Tyr Cys  Ala Arg Asp    1085                 1090                 1095Ser Gly  Tyr Ser Asp Pro Met  Trp Gly Gln Gly Thr  Leu Val Thr    1100                 1105                 1110Val Ser  Ser Gly Gly Gly Gly  Ser Gly Gly Gly Gly  Ser Gly Gly    1115                 1120                 1125Gly Gly  Ser Gly Gly Gly Gly  Ser Asp Val Val Met  Thr Gln Ser    1130                 1135                 1140Pro Ser  Ser Val Ser Ala Ser  Val Gly Asp Arg Val  Thr Ile Thr    1145                 1150                 1155Cys Gln  Ala Ser Gln Asn Ile  Arg Thr Tyr Leu Ser  Trp Tyr Gln    1160                 1165                 1170Gln Lys  Pro Gly Lys Ala Pro  Lys Leu Leu Ile Tyr  Ala Ala Ala    1175                 1180                 1185Asn Leu  Ala Ser Gly Val Pro  Ser Arg Phe Ser Gly  Ser Gly Ser    1190                 1195                 1200Gly Thr  Asp Phe Thr Leu Thr  Ile Ser Asp Leu Glu  Pro Gly Asp    1205                 1210                 1215Ala Ala  Thr Tyr Tyr Cys Gln  Ser Thr Tyr Leu Gly  Thr Asp Tyr    1220                 1225                 1230Val Gly  Gly Ala Phe Gly Cys  Gly Thr Lys Val Glu  Ile Lys    1235                 1240                 1245</s400><s200><s210>118</s210><s211>3744</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 118gagatcgtga tgacacaatc tccatctacg ctctccgcct cagtgggcga tagagtaatt     60attacttgtc aagcctcaga gagcatttca tcatggctcg cctggtatca gcaaaagcct    120gggaaggccc ccaaacttct catctatgaa gcatcaaagc tggcctctgg ggttccgtct    180cgcttctccg ggtccggcag tggtgcagag tttacgttga ctatatcttc tttgcaacct    240gacgatttcg caacatatta ttgccaggga tacttttatt ttatttcccg aacatatgtt    300aactcttttg ggtgcgggac caaactcact gtgctggggt ctaccggtag tggttctaag    360cctggttcag gcgaaggcag tacgaaaggg gaagtgcaac tggtcgaaag cggtggaggg    420cttgttcaac ctggaggaag cctccgcttg tcctgcacgg ctagcggctt tacaataagt    480acgaacgcca tgagctgggt ccggcaggct ccaggtaagt gtctcgaatg ggtgggggtc    540ataacaggca gggacattac ctactacgcc agttgggcca agggtcgatt taccatttct    600agagatacat ccaagaacac ggtgtacctc cagatgaatt ctcttagggc ggaagacaca    660gcagtatact actgcgcgcg agatggcggg agcagtgcga tcacatccaa caacatctgg    720ggtcagggca ctcttgtcac ggtgtcgact ggtggtgggg gtagtggcgg cggaggtagc    780tttcttaatt cccttttcaa ccaagaggtt cagatcccct tgactgaaag ctattgcggc    840ccttgtccga aaaactggat atgttacaag aataattgtt accaattctt cgacgaaagc    900aagaactggt atgagagtca ggcgtcttgt atgagtcaga atgccagcct gcttaaggtt    960tattcaaaag aagaccagga tctgcttaag ttggtaaaga gctaccactg gatggggctg   1020gtacatatcc caacgaatgg gtcatggcag tgggaggacg gttctattct gagtccaaat   1080ctcctgacga tcatcgaaat gcagaaaggg gactgtgccc tgtatgcatc atccttcaag   1140gggtacatcg agaactgcag taccccaaat acctacattt gtatgcaaag aacggttgct   1200agcaccaagg gcccatcggt cttccccctg gcaccctcct ccaagagcac ctctgggggc   1260acagcggccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg   1320aactcaggcg ccctgaccag cggcgtgcac accttcccgg ctgtcctaca gtcctcagga   1380ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac ccagacctac   1440atctgcaacg tgaatcacaa gcccagcaac accaaggtgg acaagagagt tgagcccaaa   1500tcttgtgaca aaactcacac atgcccaccg tgcccagcac ctgaagccgc ggggggaccg   1560tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag   1620gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac   1680gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacgccagc   1740acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag   1800tacaagtgcg cggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa   1860gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggatgagctg   1920accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc   1980gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc tcccgtgctg   2040gactccgacg gctccttctt cctctatagc aagctcaccg tggacaagag caggtggcag   2100caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag   2160aagagcctct ccctgtctcc gggtggcggt ggagggtccg gcggtggtgg atccgaggtg   2220cagctgttgg agtctggggg aggcttggta cagcctgggg ggtccctgag actctcctgt   2280gcagcctctg gattctcctt cagtagcggg tacgacatgt gctgggtccg ccaggctcca   2340gggaagtgcc tggagtggat cgcatgcatt gctgctggta gtgctggtat cacttacgac   2400gcgaactggg cgaaaggccg gttcaccatc tccagagaca attccaagaa cacgctgtat   2460ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gagatcggcg   2520ttttcgttcg actacgccat ggacctctgg ggccagggaa ccctggtcac cgtctcgagc   2580ggtggaggcg gttcaggcgg aggtggaagt ggtggtggcg gctctggagg cggcggatct   2640gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc   2700atcacttgcc aggccagtca gagcattagt tcccacttaa actggtatca gcagaaacca   2760gggaaagccc ctaagctcct gatctataag gcatccactc tggcatctgg ggtcccatca   2820aggttcagcg gcagtggatc tgggacagaa tttactctca ccatcagcag cctgcagcct   2880gatgattttg caacttatta ctgccaacag ggttatagtt ggggtaatgt tgataatgtt   2940ttcggctgcg ggaccaaggt ggagatcaaa ggtggtggcg gctctggagg aggagggtcc   3000ggacggtcgc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc   3060tcctgtactg cctctggatt caccatcagt agctaccaca tgcagtgggt ccggcaggca   3120cctgggaagt gcctggagta catcggaacc attagtagtg gtggtaatgt atactacgca   3180agctccgcta gaggcagatt caccatctcc agaccctcgt ccaagaacac ggtggatctt   3240caaatgaaca gcctgagagc cgaggacacg gctgtgtatt actgtgcgag agactctggt   3300tatagtgatc ctatgtgggg ccagggaacc ctggtcaccg tctcttcagg cggtggcggt   3360agtgggggag gcggttctgg cggcggaggg tccggcggtg gaggatcaga cgttgtgatg   3420acccagtctc catcttccgt gtctgcatct gtaggagaca gagtcaccat cacctgtcag   3480gccagtcaga acattaggac ttacttatcc tggtatcagc agaaaccagg gaaagcccct   3540aagctcctga tctatgctgc agccaatctg gcatctgggg tcccatcaag gttcagcggc   3600agtggatctg ggacagattt cactctcacc atcagcgact tggaacctgg cgatgctgca   3660acttactatt gtcagtctac ctatcttggt actgattatg ttggcggtgc tttcggctgt   3720gggaccaagg tggagatcaa atga                                          3744</s400><s200><s210>119</s210><s211>505</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 119Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr            20                  25                  30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Ile Ala Thr Tyr Phe Cys Gln His Phe Asp His Leu Pro Leu                85                  90                  95Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Gly Ser Thr Gly Ser            100                 105                 110Gly Ser Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Gln        115                 120                 125Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser    130                 135                 140Leu Thr Cys Thr Val Ser Gly Gly Ser Val Ser Ser Gly Asp Tyr Tyr145                 150                 155                 160Trp Thr Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Ile Gly                165                 170                 175His Ile Tyr Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser            180                 185                 190Arg Leu Thr Ile Ser Ile Asp Thr Ser Lys Thr Gln Phe Ser Leu Lys        195                 200                 205Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr Cys Val Arg    210                 215                 220Asp Arg Val Thr Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val225                 230                 235                 240Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly                245                 250                 255Gly Gly Ser Phe Leu Asn Ser Leu Phe Asn Gln Glu Val Gln Ile Pro            260                 265                 270Leu Thr Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr        275                 280                 285Lys Asn Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu    290                 295                 300Ser Gln Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr305                 310                 315                 320Ser Lys Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp                325                 330                 335Met Gly Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp            340                 345                 350Gly Ser Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys        355                 360                 365Gly Asp Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn    370                 375                 380Cys Ser Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Arg Thr385                 390                 395                 400Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu                405                 410                 415Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro            420                 425                 430Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly        435                 440                 445Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr    450                 455                 460Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His465                 470                 475                 480Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val                485                 490                 495Thr Lys Ser Phe Asn Arg Gly Glu Cys            500                 505</s400><s200><s210>120</s210><s211>1518</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 120gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc     60atcacttgcc aggcgagtca ggacatcagc aactatttaa attggtatca gcagaaacca    120gggaaagccc ctaaactcct gatctacgat gcatccaatt tggaaacagg ggtcccatca    180aggttcagtg gaagtggatc tgggacagat tttactttca ccatcagcag cctgcagcct    240gaagatattg caacatattt ctgtcaacac tttgatcatc tcccgctcgc tttcggcgga    300gggaccaagg tggaaattaa aggaagtact ggttctgggt ctaaacccgg ttccggcgaa    360ggtagtacta aaggacaggt gcagctgcag gagtcgggcc caggactggt gaagccttcg    420gagaccctgt ccctcacctg cactgtctct ggtggctccg tcagcagtgg tgattactac    480tggacctgga tccggcagtc cccagggaag ggactggagt ggattggaca catctattac    540agtgggaaca ccaattataa cccctccctc aagagccgac tcaccatatc aattgacacg    600tccaagactc agttctccct gaagctgagt tctgtgaccg ctgcggacac ggccatttat    660tactgtgtgc gagatcgagt gactggtgct tttgatatct ggggccaagg gacaatggtc    720accgtctcga gcggtggcgg cggctccggg ggtggcggat caggtggtgg aggctctttc    780ctaaactcat tattcaacca agaagttcaa attcccttga ccgaaagtta ctgtggccca    840tgtcctaaaa actggatatg ttacaaaaat aactgctacc aattttttga tgagagtaaa    900aactggtatg agagccaggc ttcttgtatg tctcaaaatg ccagccttct gaaagtatac    960agcaaagagg accaggattt acttaaactg gtgaagtcat atcattggat gggactagta   1020cacattccaa caaatggatc ttggcagtgg gaagatggct ccattctctc acccaaccta   1080ctaacaataa ttgaaatgca gaagggagac tgtgcactct atgcctcgag ctttaaaggc   1140tatatagaaa actgttcaac tccaaatacg tacatctgca tgcaaaggac tgtgcgtacg   1200gtggctgcac catctgtctt catcttcccg ccatctgatg agcagttgaa atctggaact   1260gcctctgttg tgtgcctgct gaataacttc tatcccagag aggccaaagt acagtggaag   1320gtggataacg ccctccaatc gggtaactcc caggagagtg tcacagagca ggacagcaag   1380gacagcacct acagcctcag cagcaccctg acgctgagca aagcagacta cgagaaacac   1440aaagtctacg cctgcgaagt cacccatcag ggcctgagct cgcccgtcac aaagagcttc   1500aacaggggag agtgttag                                                 1518</s400><s200><s210>121</s210><s211>120</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 121Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln1               5                   10                  15Thr Leu Arg Leu Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser            20                  25                  30Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu        35                  40                  45Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala    50                  55                  60Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val65                  70                  75                  80Tyr Leu Gln Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr                85                  90                  95Cys Ala Arg Met Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln            100                 105                 110Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>122</s210><s211>360</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 122caggtcacat tgaaggaatc tggccccggc cttgttcagc caggacagac ccttaggctc     60acctgtgcct tcagtggttt ttctcttagc actagcggta tgggggtcgg ctggattcgg    120cagcctcccg gcaaaggtct tgagtggttg gctcacattt ggtgggacga cgacaaacgg    180tataatcctg ccttgaaaag tcggctgacc attagtaagg atacctcaaa aaatcaagtg    240tacttgcaaa tgaatagcct tgacgccgag gatacggctg tatattattg cgcgcggatg    300gaactctggt cttactactt tgattattgg gggcagggga ctctcgtcac ggtctcgagc    360</s400><s200><s210>123</s210><s211>1247</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 123Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Ile Ile Thr Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser                85                  90                  95Arg Thr Tyr Val Asn Ser Phe Gly Cys Gly Thr Lys Leu Thr Val Leu            100                 105                 110Gly Ser Thr Gly Ser Gly Ser Lys Pro Gly Ser Gly Glu Gly Ser Thr        115                 120                 125Lys Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro    130                 135                 140Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Ile Ser145                 150                 155                 160Thr Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Cys Leu Glu                165                 170                 175Trp Val Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala Ser Trp            180                 185                 190Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val        195                 200                 205Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr    210                 215                 220Cys Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn Ile Trp225                 230                 235                 240Gly Gln Gly Thr Leu Val Thr Val Ser Thr Gly Gly Gly Gly Ser Gly                245                 250                 255Gly Gly Gly Ser Phe Leu Asn Ser Leu Phe Asn Gln Glu Val Gln Ile            260                 265                 270Pro Leu Thr Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys        275                 280                 285Tyr Lys Asn Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr    290                 295                 300Glu Ser Gln Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val305                 310                 315                 320Tyr Ser Lys Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His                325                 330                 335Trp Met Gly Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu            340                 345                 350Asp Gly Ser Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln        355                 360                 365Lys Gly Asp Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu    370                 375                 380Asn Cys Ser Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Ala385                 390                 395                 400Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser                405                 410                 415Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe            420                 425                 430Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly        435                 440                 445Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu    450                 455                 460Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr465                 470                 475                 480Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg                485                 490                 495Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro            500                 505                 510Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys        515                 520                 525Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val    530                 535                 540Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr545                 550                 555                 560Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu                565                 570                 575Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His            580                 585                 590Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys        595                 600                 605Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln    610                 615                 620Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu625                 630                 635                 640Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro                645                 650                 655Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn            660                 665                 670Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu        675                 680                 685Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val    690                 695                 700Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln705                 710                 715                 720Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly                725                 730                 735Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro            740                 745                 750Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser        755                 760                 765Ser Gly Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Cys Leu    770                 775                 780Glu Trp Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr Tyr Asp785                 790                 795                 800Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys                805                 810                 815Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala            820                 825                 830Val Tyr Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala Met Asp        835                 840                 845Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly    850                 855                 860Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser865                 870                 875                 880Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly                885                 890                 895Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser His            900                 905                 910Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        915                 920                 925Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    930                 935                 940Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro945                 950                 955                 960Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp Gly Asn                965                 970                 975Val Asp Asn Val Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Gly Gly            980                 985                 990Gly Gly Ser Gly Gly Gly Gly Ser  Gly Arg Ser Leu Val  Glu Ser Gly        995                 1000                 1005Gly Gly  Leu Val Gln Pro Gly  Gly Ser Leu Arg Leu  Ser Cys Thr    1010                 1015                 1020Ala Ser  Gly Phe Thr Ile Ser  Ser Tyr His Met Gln  Trp Val Arg    1025                 1030                 1035Gln Ala  Pro Gly Lys Cys Leu  Glu Tyr Ile Gly Thr  Ile Ser Ser    1040                 1045                 1050Gly Gly  Asn Val Tyr Tyr Ala  Ser Ser Ala Arg Gly  Arg Phe Thr    1055                 1060                 1065Ile Ser  Arg Pro Ser Ser Lys  Asn Thr Val Asp Leu  Gln Met Asn    1070                 1075                 1080Ser Leu  Arg Ala Glu Asp Thr  Ala Val Tyr Tyr Cys  Ala Arg Asp    1085                 1090                 1095Ser Gly  Tyr Ser Asp Pro Met  Trp Gly Gln Gly Thr  Leu Val Thr    1100                 1105                 1110Val Ser  Ser Gly Gly Gly Gly  Ser Gly Gly Gly Gly  Ser Gly Gly    1115                 1120                 1125Gly Gly  Ser Gly Gly Gly Gly  Ser Asp Val Val Met  Thr Gln Ser    1130                 1135                 1140Pro Ser  Ser Val Ser Ala Ser  Val Gly Asp Arg Val  Thr Ile Thr    1145                 1150                 1155Cys Gln  Ala Ser Gln Asn Ile  Arg Thr Tyr Leu Ser  Trp Tyr Gln    1160                 1165                 1170Gln Lys  Pro Gly Lys Ala Pro  Lys Leu Leu Ile Tyr  Ala Ala Ala    1175                 1180                 1185Asn Leu  Ala Ser Gly Val Pro  Ser Arg Phe Ser Gly  Ser Gly Ser    1190                 1195                 1200Gly Thr  Asp Phe Thr Leu Thr  Ile Ser Asp Leu Glu  Pro Gly Asp    1205                 1210                 1215Ala Ala  Thr Tyr Tyr Cys Gln  Ser Thr Tyr Leu Gly  Thr Asp Tyr    1220                 1225                 1230Val Gly  Gly Ala Phe Gly Cys  Gly Thr Lys Val Glu  Ile Lys    1235                 1240                 1245</s400><s200><s210>124</s210><s211>3744</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 124gagatcgtga tgacacaatc tccatctacg ctctccgcct cagtgggcga tagagtaatt     60attacttgtc aagcctcaga gagcatttca tcatggctcg cctggtatca gcaaaagcct    120gggaaggccc ccaaacttct catctatgaa gcatcaaagc tggcctctgg ggttccgtct    180cgcttctccg ggtccggcag tggtgcagag tttacgttga ctatatcttc tttgcaacct    240gacgatttcg caacatatta ttgccaggga tacttttatt ttatttcccg aacatatgtt    300aactcttttg ggtgcgggac caaactcact gtgctggggt ctaccggtag tggttctaag    360cctggttcag gcgaaggcag tacgaaaggg gaagtgcaac tggtcgaaag cggtggaggg    420cttgttcaac ctggaggaag cctccgcttg tcctgcacgg ctagcggctt tacaataagt    480acgaacgcca tgagctgggt ccggcaggct ccaggtaagt gtctcgaatg ggtgggggtc    540ataacaggca gggacattac ctactacgcc agttgggcca agggtcgatt taccatttct    600agagatacat ccaagaacac ggtgtacctc cagatgaatt ctcttagggc ggaagacaca    660gcagtatact actgcgcgcg agatggcggg agcagtgcga tcacatccaa caacatctgg    720ggtcagggca ctcttgtcac ggtgtcgact ggtggtgggg gtagtggcgg cggaggtagc    780tttcttaatt cccttttcaa ccaagaggtt cagatcccct tgactgaaag ctattgcggc    840ccttgtccga aaaactggat atgttacaag aataattgtt accaattctt cgacgaaagc    900aagaactggt atgagagtca ggcgtcttgt atgagtcaga atgccagcct gcttaaggtt    960tattcaaaag aagaccagga tctgcttaag ttggtaaaga gctaccactg gatggggctg   1020gtacatatcc caacgaatgg gtcatggcag tgggaggacg gttctattct gagtccaaat   1080ctcctgacga tcatcgaaat gcagaaaggg gactgtgccc tgtatgcatc atccttcaag   1140gggtacatcg agaactgcag taccccaaat acctacattt gtatgcaaag aacggttgct   1200agcaccaagg gcccatcggt cttccccctg gcaccctcct ccaagagcac ctctgggggc   1260acagcggccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg   1320aactcaggcg ccctgaccag cggcgtgcac accttcccgg ctgtcctaca gtcctcagga   1380ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac ccagacctac   1440atctgcaacg tgaatcacaa gcccagcaac accaaggtgg acaagagagt tgagcccaaa   1500tcttgtgaca aaactcacac atgcccaccg tgcccagcac ctgaagccgc ggggggaccg   1560tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag   1620gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac   1680gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacgccagc   1740acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag   1800tacaagtgcg cggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa   1860gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggatgagctg   1920accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc   1980gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc tcccgtgctg   2040gactccgacg gctccttctt cctctatagc aagctcaccg tggacaagag caggtggcag   2100caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag   2160aagagcctct ccctgtctcc gggtggcggt ggagggtccg gcggtggtgg atccgaggtg   2220cagctgttgg agtctggggg aggcttggta cagcctgggg ggtccctgag actctcctgt   2280gcagcctctg gattctcctt cagtagcggg tacgacatgt gctgggtccg ccaggctcca   2340gggaagtgcc tggagtggat cgcatgcatt gctgctggta gtgctggtat cacttacgac   2400gcgaactggg cgaaaggccg gttcaccatc tccagagaca attccaagaa cacgctgtat   2460ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gagatcggcg   2520ttttcgttcg actacgccat ggacctctgg ggccagggaa ccctggtcac cgtctcgagc   2580ggtggaggcg gttcaggcgg aggtggaagt ggtggtggcg gctctggagg cggcggatct   2640gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc   2700atcacttgcc aggccagtca gagcattagt tcccacttaa actggtatca gcagaaacca   2760gggaaagccc ctaagctcct gatctataag gcatccactc tggcatctgg ggtcccatca   2820aggttcagcg gcagtggatc tgggacagaa tttactctca ccatcagcag cctgcagcct   2880gatgattttg caacttatta ctgccaacag ggttatagtt ggggtaatgt tgataatgtt   2940ttcggctgcg ggaccaaggt ggagatcaaa ggtggtggcg gctctggagg aggagggtcc   3000ggacggtcgc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc   3060tcctgtactg cctctggatt caccatcagt agctaccaca tgcagtgggt ccggcaggca   3120cctgggaagt gcctggagta catcggaacc attagtagtg gtggtaatgt atactacgca   3180agctccgcta gaggcagatt caccatctcc agaccctcgt ccaagaacac ggtggatctt   3240caaatgaaca gcctgagagc cgaggacacg gctgtgtatt actgtgcgag agactctggt   3300tatagtgatc ctatgtgggg ccagggaacc ctggtcaccg tctcttcagg cggtggcggt   3360agtgggggag gcggttctgg cggcggaggg tccggcggtg gaggatcaga cgttgtgatg   3420acccagtctc catcttccgt gtctgcatct gtaggagaca gagtcaccat cacctgtcag   3480gccagtcaga acattaggac ttacttatcc tggtatcagc agaaaccagg gaaagcccct   3540aagctcctga tctatgctgc agccaatctg gcatctgggg tcccatcaag gttcagcggc   3600agtggatctg ggacagattt cactctcacc atcagcgact tggaacctgg cgatgctgca   3660acttactatt gtcagtctac ctatcttggt actgattatg ttggcggtgc tttcggctgt   3720gggaccaagg tggagatcaa atga                                          3744</s400><s200><s210>125</s210><s211>505</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 125Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Ser Thr Gly Ser Gly            100                 105                 110Ser Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Thr Leu        115                 120                 125Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu Arg Leu    130                 135                 140Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met Gly Val145                 150                 155                 160Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Ala His                165                 170                 175Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys Ser Arg            180                 185                 190Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu Gln Met        195                 200                 205Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Met    210                 215                 220Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val225                 230                 235                 240Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly                245                 250                 255Gly Gly Ser Phe Leu Asn Ser Leu Phe Asn Gln Glu Val Gln Ile Pro            260                 265                 270Leu Thr Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr        275                 280                 285Lys Asn Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu    290                 295                 300Ser Gln Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr305                 310                 315                 320Ser Lys Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp                325                 330                 335Met Gly Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp            340                 345                 350Gly Ser Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys        355                 360                 365Gly Asp Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn    370                 375                 380Cys Ser Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Arg Thr385                 390                 395                 400Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu                405                 410                 415Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro            420                 425                 430Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly        435                 440                 445Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr    450                 455                 460Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His465                 470                 475                 480Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val                485                 490                 495Thr Lys Ser Phe Asn Arg Gly Glu Cys            500                 505</s400><s200><s210>126</s210><s211>1518</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 126gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaattgg agataaaggg aagtactggt tctgggtcta aacccggttc cggcgaaggt    360agtactaaag gacaggtcac attgaaggaa tctggccccg gccttgttca gccaggacag    420acccttaggc tcacctgtgc cttcagtggt ttttctctta gcactagcgg tatgggggtc    480ggctggattc ggcagcctcc cggcaaaggt cttgagtggt tggctcacat ttggtgggac    540gacgacaaac ggtataatcc tgccttgaaa agtcggctga ccattagtaa ggatacctca    600aaaaatcaag tgtacttgca aatgaatagc cttgacgccg aggatacggc tgtatattat    660tgcgcgcgga tggaactctg gtcttactac tttgattatt gggggcaggg gactctcgtc    720acggtgtcct ctggtggcgg cggctccggg ggtggcggat caggtggtgg aggatccttc    780ctaaactcat tattcaacca agaagttcaa attcccttga ccgaaagtta ctgtggccca    840tgtcctaaaa actggatatg ttacaaaaat aactgctacc aattttttga tgagagtaaa    900aactggtatg agagccaggc ttcttgtatg tctcaaaatg ccagccttct gaaagtatac    960agcaaagagg accaggattt acttaaactg gtgaagtcat atcattggat gggactagta   1020cacattccaa caaatggatc ttggcagtgg gaagatggct ccattctctc acccaaccta   1080ctaacaataa ttgaaatgca gaagggagac tgtgcactct atgcctcgag ctttaaaggc   1140tatatagaaa actgttcaac tccaaatacg tacatctgca tgcaaaggac tgtgcgtacg   1200gtggctgcac catctgtctt catcttcccg ccatctgatg agcagttgaa atctggaact   1260gcctctgttg tgtgcctgct gaataacttc tatcccagag aggccaaagt acagtggaag   1320gtggataacg ccctccaatc gggtaactcc caggagagtg tcacagagca ggacagcaag   1380gacagcacct acagcctcag cagcaccctg acgctgagca aagcagacta cgagaaacac   1440aaagtctacg cctgcgaagt cacccatcag ggcctgagct cgcccgtcac aaagagcttc   1500aacaggggag agtgttag                                                 1518</s400><s200><s210>127</s210><s211>1563</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 127Glu Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Ile Ile Thr Cys Gln Ala Ser Glu Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Ala Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Tyr Phe Tyr Phe Ile Ser                85                  90                  95Arg Thr Tyr Val Asn Ser Phe Gly Cys Gly Thr Lys Leu Thr Val Leu            100                 105                 110Gly Ser Thr Gly Ser Gly Ser Lys Pro Gly Ser Gly Glu Gly Ser Thr        115                 120                 125Lys Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro    130                 135                 140Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Ile Ser145                 150                 155                 160Thr Asn Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Cys Leu Glu                165                 170                 175Trp Val Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala Ser Trp            180                 185                 190Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr Val        195                 200                 205Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr    210                 215                 220Cys Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn Ile Trp225                 230                 235                 240Gly Gln Gly Thr Leu Val Thr Val Ser Thr Gly Gly Gly Gly Ser Gly                245                 250                 255Gly Gly Gly Ser Phe Leu Asn Ser Leu Phe Asn Gln Glu Val Gln Ile            260                 265                 270Pro Leu Thr Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys        275                 280                 285Tyr Lys Asn Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr    290                 295                 300Glu Ser Gln Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val305                 310                 315                 320Tyr Ser Lys Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His                325                 330                 335Trp Met Gly Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu            340                 345                 350Asp Gly Ser Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln        355                 360                 365Lys Gly Asp Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu    370                 375                 380Asn Cys Ser Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Ala385                 390                 395                 400Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser                405                 410                 415Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe            420                 425                 430Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly        435                 440                 445Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu    450                 455                 460Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr465                 470                 475                 480Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg                485                 490                 495Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro            500                 505                 510Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys        515                 520                 525Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val    530                 535                 540Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr545                 550                 555                 560Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu                565                 570                 575Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His            580                 585                 590Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys        595                 600                 605Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln    610                 615                 620Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu625                 630                 635                 640Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro                645                 650                 655Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn            660                 665                 670Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu        675                 680                 685Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val    690                 695                 700Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln705                 710                 715                 720Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly                725                 730                 735Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro            740                 745                 750Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser        755                 760                 765Ser Gly Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Cys Leu    770                 775                 780Glu Trp Ile Ala Cys Ile Ala Ala Gly Ser Ala Gly Ile Thr Tyr Asp785                 790                 795                 800Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys                805                 810                 815Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala            820                 825                 830Val Tyr Tyr Cys Ala Arg Ser Ala Phe Ser Phe Asp Tyr Ala Met Asp        835                 840                 845Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly    850                 855                 860Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser865                 870                 875                 880Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly                885                 890                 895Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser His            900                 905                 910Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        915                 920                 925Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly    930                 935                 940Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro945                 950                 955                 960Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Trp Gly Asn                965                 970                 975Val Asp Asn Val Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Gly Gly            980                 985                 990Gly Gly Ser Gly Gly Gly Gly Ser  Gly Arg Glu Gly Pro  Glu Leu Ser        995                 1000                 1005Pro Asp  Asp Pro Ala Gly Leu  Leu Asp Leu Arg Gln  Gly Met Phe    1010                 1015                 1020Ala Gln  Leu Val Ala Gln Asn  Val Leu Leu Ile Asp  Gly Pro Leu    1025                 1030                 1035Ser Trp  Tyr Ser Asp Pro Gly  Leu Ala Gly Val Ser  Leu Thr Gly    1040                 1045                 1050Gly Leu  Ser Tyr Lys Glu Asp  Thr Lys Glu Leu Val  Val Ala Lys    1055                 1060                 1065Ala Gly  Val Tyr Tyr Val Phe  Phe Gln Leu Glu Leu  Arg Arg Val    1070                 1075                 1080Val Ala  Gly Glu Gly Ser Gly  Ser Val Ser Leu Ala  Leu His Leu    1085                 1090                 1095Gln Pro  Leu Arg Ser Ala Ala  Gly Ala Ala Ala Leu  Ala Leu Thr    1100                 1105                 1110Val Asp  Leu Pro Pro Ala Ser  Ser Glu Ala Arg Asn  Ser Ala Phe    1115                 1120                 1125Gly Phe  Gln Gly Arg Leu Leu  His Leu Ser Ala Gly  Gln Arg Leu    1130                 1135                 1140Gly Val  His Leu His Thr Glu  Ala Arg Ala Arg His  Ala Trp Gln    1145                 1150                 1155Leu Thr  Gln Gly Ala Thr Val  Leu Gly Leu Phe Arg  Val Thr Pro    1160                 1165                 1170Glu Ile  Pro Ala Gly Leu Gly  Ser Thr Gly Ser Gly  Ser Lys Pro    1175                 1180                 1185Gly Ser  Gly Glu Gly Ser Thr  Lys Gly Arg Glu Gly  Pro Glu Leu    1190                 1195                 1200Ser Pro  Asp Asp Pro Ala Gly  Leu Leu Asp Leu Arg  Gln Gly Met    1205                 1210                 1215Phe Ala  Gln Leu Val Ala Gln  Asn Val Leu Leu Ile  Asp Gly Pro    1220                 1225                 1230Leu Ser  Trp Tyr Ser Asp Pro  Gly Leu Ala Gly Val  Ser Leu Thr    1235                 1240                 1245Gly Gly  Leu Ser Tyr Lys Glu  Asp Thr Lys Glu Leu  Val Val Ala    1250                 1255                 1260Lys Ala  Gly Val Tyr Tyr Val  Phe Phe Gln Leu Glu  Leu Arg Arg    1265                 1270                 1275Val Val  Ala Gly Glu Gly Ser  Gly Ser Val Ser Leu  Ala Leu His    1280                 1285                 1290Leu Gln  Pro Leu Arg Ser Ala  Ala Gly Ala Ala Ala  Leu Ala Leu    1295                 1300                 1305Thr Val  Asp Leu Pro Pro Ala  Ser Ser Glu Ala Arg  Asn Ser Ala    1310                 1315                 1320Phe Gly  Phe Gln Gly Arg Leu  Leu His Leu Ser Ala  Gly Gln Arg    1325                 1330                 1335Leu Gly  Val His Leu His Thr  Glu Ala Arg Ala Arg  His Ala Trp    1340                 1345                 1350Gln Leu  Thr Gln Gly Ala Thr  Val Leu Gly Leu Phe  Arg Val Thr    1355                 1360                 1365Pro Glu  Ile Pro Ala Gly Leu  Gly Gly Gly Gly Ser  Gly Gly Gly    1370                 1375                 1380Gly Ser  Arg Glu Gly Pro Glu  Leu Ser Pro Asp Asp  Pro Ala Gly    1385                 1390                 1395Leu Leu  Asp Leu Arg Gln Gly  Met Phe Ala Gln Leu  Val Ala Gln    1400                 1405                 1410Asn Val  Leu Leu Ile Asp Gly  Pro Leu Ser Trp Tyr  Ser Asp Pro    1415                 1420                 1425Gly Leu  Ala Gly Val Ser Leu  Thr Gly Gly Leu Ser  Tyr Lys Glu    1430                 1435                 1440Asp Thr  Lys Glu Leu Val Val  Ala Lys Ala Gly Val  Tyr Tyr Val    1445                 1450                 1455Phe Phe  Gln Leu Glu Leu Arg  Arg Val Val Ala Gly  Glu Gly Ser    1460                 1465                 1470Gly Ser  Val Ser Leu Ala Leu  His Leu Gln Pro Leu  Arg Ser Ala    1475                 1480                 1485Ala Gly  Ala Ala Ala Leu Ala  Leu Thr Val Asp Leu  Pro Pro Ala    1490                 1495                 1500Ser Ser  Glu Ala Arg Asn Ser  Ala Phe Gly Phe Gln  Gly Arg Leu    1505                 1510                 1515Leu His  Leu Ser Ala Gly Gln  Arg Leu Gly Val His  Leu His Thr    1520                 1525                 1530Glu Ala  Arg Ala Arg His Ala  Trp Gln Leu Thr Gln  Gly Ala Thr    1535                 1540                 1545Val Leu  Gly Leu Phe Arg Val  Thr Pro Glu Ile Pro  Ala Gly Leu    1550                 1555                 1560</s400><s200><s210>128</s210><s211>4692</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 128gagatcgtga tgacacaatc tccatctacg ctctccgcct cagtgggcga tagagtaatt     60attacttgtc aagcctcaga gagcatttca tcatggctcg cctggtatca gcaaaagcct    120gggaaggccc ccaaacttct catctatgaa gcatcaaagc tggcctctgg ggttccgtct    180cgcttctccg ggtccggcag tggtgcagag tttacgttga ctatatcttc tttgcaacct    240gacgatttcg caacatatta ttgccaggga tacttttatt ttatttcccg aacatatgtt    300aactcttttg ggtgcgggac caaactcact gtgctggggt ctaccggtag tggttctaag    360cctggttcag gcgaaggcag tacgaaaggg gaagtgcaac tggtcgaaag cggtggaggg    420cttgttcaac ctggaggaag cctccgcttg tcctgcacgg ctagcggctt tacaataagt    480acgaacgcca tgagctgggt ccggcaggct ccaggtaagt gtctcgaatg ggtgggggtc    540ataacaggca gggacattac ctactacgcc agttgggcca agggtcgatt taccatttct    600agagatacat ccaagaacac ggtgtacctc cagatgaatt ctcttagggc ggaagacaca    660gcagtatact actgcgcgcg agatggcggg agcagtgcga tcacatccaa caacatctgg    720ggtcagggca ctcttgtcac ggtgtcgact ggtggtgggg gtagtggcgg cggaggtagc    780tttcttaatt cccttttcaa ccaagaggtt cagatcccct tgactgaaag ctattgcggc    840ccttgtccga aaaactggat atgttacaag aataattgtt accaattctt cgacgaaagc    900aagaactggt atgagagtca ggcgtcttgt atgagtcaga atgccagcct gcttaaggtt    960tattcaaaag aagaccagga tctgcttaag ttggtaaaga gctaccactg gatggggctg   1020gtacatatcc caacgaatgg gtcatggcag tgggaggacg gttctattct gagtccaaat   1080ctcctgacga tcatcgaaat gcagaaaggg gactgtgccc tgtatgcatc atccttcaag   1140gggtacatcg agaactgcag taccccaaat acctacattt gtatgcaaag aacggttgct   1200agcaccaagg gcccatcggt cttccccctg gcaccctcct ccaagagcac ctctgggggc   1260acagcggccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg   1320aactcaggcg ccctgaccag cggcgtgcac accttcccgg ctgtcctaca gtcctcagga   1380ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac ccagacctac   1440atctgcaacg tgaatcacaa gcccagcaac accaaggtgg acaagagagt tgagcccaaa   1500tcttgtgaca aaactcacac atgcccaccg tgcccagcac ctgaagccgc ggggggaccg   1560tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag   1620gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac   1680gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacgccagc   1740acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag   1800tacaagtgcg cggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa   1860gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggatgagctg   1920accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc   1980gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc tcccgtgctg   2040gactccgacg gctccttctt cctctatagc aagctcaccg tggacaagag caggtggcag   2100caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag   2160aagagcctct ccctgtctcc gggtggcggt ggagggtccg gcggtggtgg atccgaggtg   2220cagctgttgg agtctggggg aggcttggta cagcctgggg ggtccctgag actctcctgt   2280gcagcctctg gattctcctt cagtagcggg tacgacatgt gctgggtccg ccaggctcca   2340gggaagtgcc tggagtggat cgcatgcatt gctgctggta gtgctggtat cacttacgac   2400gcgaactggg cgaaaggccg gttcaccatc tccagagaca attccaagaa cacgctgtat   2460ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gagatcggcg   2520ttttcgttcg actacgccat ggacctctgg ggccagggaa ccctggtcac cgtctcgagc   2580ggtggaggcg gttcaggcgg aggtggaagt ggtggtggcg gctctggagg cggcggatct   2640gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc   2700atcacttgcc aggccagtca gagcattagt tcccacttaa actggtatca gcagaaacca   2760gggaaagccc ctaagctcct gatctataag gcatccactc tggcatctgg ggtcccatca   2820aggttcagcg gcagtggatc tgggacagaa tttactctca ccatcagcag cctgcagcct   2880gatgattttg caacttatta ctgccaacag ggttatagtt ggggtaatgt tgataatgtt   2940ttcggctgcg ggaccaaggt ggagatcaaa ggtggtggcg gctctggagg aggagggtcc   3000ggacgagagg gccccgagct gtctcctgat gacccagcag gcctcttgga cttgcggcag   3060ggtatgttcg ctcaacttgt ggctcagaat gttctgctca ttgatggacc actctcttgg   3120tatagtgacc ccggtctggc cggggtgagt ctgaccggcg ggctctctta taaagaggat   3180actaaggaac tggtcgtagc aaaagcgggc gtttattacg ttttttttca gctggagctc   3240aggcgcgtgg tggccggcga gggcagtggc tctgtgtccc tggccctgca cttacagccc   3300ttgagaagcg ctgcaggtgc tgccgcactg gctttaactg ttgacctccc tccggcctct   3360tctgaagcta gaaacagcgc tttcggcttc caagggcgcc tgctgcacct gagcgcaggc   3420cagcgcttag gtgtgcacct tcatacagag gccagggccc gacacgcttg gcagctcaca   3480cagggtgcca cggttctcgg acttttccgc gttactcccg agatccccgc tggcctcgga   3540agtactggtt ctgggtctaa acccggttcc ggcgaaggta gtactaaagg acgagaaggg   3600ccagagttaa gtccagatga ccctgctggg cttttggacc tgcggcaggg catgttcgct   3660caactggtgg ctcagaacgt gctgctgatc gatggccccc tgagttggta cagcgatccc   3720gggctggcag gcgtgtcact tacagggggc ctctcttaca aggaagacac caaggagtta   3780gtggtcgcta aggctggcgt gtattacgtg ttcttccaac tggagctgag aagggttgtg   3840gcaggagagg gtagcggcag cgtgtcttta gcccttcact tgcagcccct gaggtctgct   3900gcaggtgcag ccgctctcgc gctcaccgtg gatctccccc cagcctcatc tgaagctagg   3960aacagtgcat ttggctttca gggacgcttg ctgcacctct ccgctggaca gaggctgggc   4020gtgcaccttc acacagaggc ccgtgccagg catgcatggc agctcactca gggggcaaca   4080gtgctgggtc tcttccgcgt gactcctgaa ataccagctg gacttggcgg tggaggcagc   4140ggcggaggag gatctcgtga ggggccagaa ctgtcccccg atgacccagc cggactgctc   4200gatctcagac agggcatgtt cgctcagctt gtagcccaaa atgtcctcct gattgacggc   4260cctttgagct ggtatagtga tcccggcttg gccggggtat ctctgaccgg aggcctctcc   4320tacaaggaag acaccaaaga gctggtggtg gcaaaagcgg gggtgtatta tgtgttcttt   4380cagctcgagc tgcggagagt tgtggccggg gaagggtctg ggagcgtatc tcttgcactt   4440cacctgcagc ccctgcgcag cgccgctgga gccgccgccc ttgctcttac tgtggatctg   4500cctcctgctt cctcagaagc acgcaacagc gccttcggct ttcaaggacg tctcctgcac   4560ttgtccgcag gacagaggtt gggcgtccat ttacacactg aggcacgggc acggcacgct   4620tggcagctta cccagggagc caccgtgctg ggactcttta gagtgacacc cgagatcccc   4680gctggcttgt ga                                                       4692</s400><s200><s210>129</s210><s211>505</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 129Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Ser Thr Gly Ser Gly            100                 105                 110Ser Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Thr Leu        115                 120                 125Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Gly Gln Thr Leu Arg Leu    130                 135                 140Thr Cys Ala Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met Gly Val145                 150                 155                 160Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Ala His                165                 170                 175Ile Trp Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ala Leu Lys Ser Arg            180                 185                 190Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Tyr Leu Gln Met        195                 200                 205Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Met    210                 215                 220Glu Leu Trp Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val225                 230                 235                 240Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly                245                 250                 255Gly Gly Ser Phe Leu Asn Ser Leu Phe Asn Gln Glu Val Gln Ile Pro            260                 265                 270Leu Thr Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr        275                 280                 285Lys Asn Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu    290                 295                 300Ser Gln Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr305                 310                 315                 320Ser Lys Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp                325                 330                 335Met Gly Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp            340                 345                 350Gly Ser Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys        355                 360                 365Gly Asp Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn    370                 375                 380Cys Ser Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Arg Thr385                 390                 395                 400Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu                405                 410                 415Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro            420                 425                 430Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly        435                 440                 445Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr    450                 455                 460Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His465                 470                 475                 480Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val                485                 490                 495Thr Lys Ser Phe Asn Arg Gly Glu Cys            500                 505</s400><s200><s210>130</s210><s211>1518</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 130gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaattgg agataaaggg aagtactggt tctgggtcta aacccggttc cggcgaaggt    360agtactaaag gacaggtcac attgaaggaa tctggccccg gccttgttca gccaggacag    420acccttaggc tcacctgtgc cttcagtggt ttttctctta gcactagcgg tatgggggtc    480ggctggattc ggcagcctcc cggcaaaggt cttgagtggt tggctcacat ttggtgggac    540gacgacaaac ggtataatcc tgccttgaaa agtcggctga ccattagtaa ggatacctca    600aaaaatcaag tgtacttgca aatgaatagc cttgacgccg aggatacggc tgtatattat    660tgcgcgcgga tggaactctg gtcttactac tttgattatt gggggcaggg gactctcgtc    720acggtgtcct ctggtggcgg cggctccggg ggtggcggat caggtggtgg aggatccttc    780ctaaactcat tattcaacca agaagttcaa attcccttga ccgaaagtta ctgtggccca    840tgtcctaaaa actggatatg ttacaaaaat aactgctacc aattttttga tgagagtaaa    900aactggtatg agagccaggc ttcttgtatg tctcaaaatg ccagccttct gaaagtatac    960agcaaagagg accaggattt acttaaactg gtgaagtcat atcattggat gggactagta   1020cacattccaa caaatggatc ttggcagtgg gaagatggct ccattctctc acccaaccta   1080ctaacaataa ttgaaatgca gaagggagac tgtgcactct atgcctcgag ctttaaaggc   1140tatatagaaa actgttcaac tccaaatacg tacatctgca tgcaaaggac tgtgcgtacg   1200gtggctgcac catctgtctt catcttcccg ccatctgatg agcagttgaa atctggaact   1260gcctctgttg tgtgcctgct gaataacttc tatcccagag aggccaaagt acagtggaag   1320gtggataacg ccctccaatc gggtaactcc caggagagtg tcacagagca ggacagcaag   1380gacagcacct acagcctcag cagcaccctg acgctgagca aagcagacta cgagaaacac   1440aaagtctacg cctgcgaagt cacccatcag ggcctgagct cgcccgtcac aaagagcttc   1500aacaggggag agtgttag                                                 1518</s400><s200><s210>131</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthesized</s223></s220></s200><s400> 131Glu Asn Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly1               5                   10                  15Glu Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Trp Ile Tyr        35                  40                  45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser    50                  55                  60Gly Ser Gly Asn Asp His Thr Leu Thr Ile Ser Ser Met Glu Pro Glu65                  70                  75                  80Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Val Tyr Pro Phe Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys            100                 105</s400><s200><s210>132</s210><s211>318</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthesized</s223></s220></s200><s400> 132gaaaatgtat tgacacagag ccccgcctcc ctcagtgcct cacctgggga aagggtaact     60atcacttgct ctgcatcaag cagcgtctca tacatgcatt ggtatcaaca aaagcctgga    120caggccccca agctctggat atacgatacg agcaagctgg cttccggcgt acctagccgc    180ttcagtggtt ccggctcagg caacgatcac acccttacga tttccagtat ggaacccgaa    240gattttgcaa cttattattg tttccagggg agcgtgtacc cattcacttt cgggcagggg    300acaaaattgg agataaag                                                  318</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002489A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221220" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002489</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17776167</doc-number><date>20201126</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><priority-claims><priority-claim sequence="01" kind="national"><country>CN</country><doc-number>PCT/CN2019/120991</doc-number><date>20191126</date></priority-claim><priority-claim sequence="02" kind="national"><country>CN</country><doc-number>PCT/CN2020/111796</doc-number><date>20200827</date></priority-claim></priority-claims><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>28</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>2809</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>2878</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>2039</main-group><subgroup>505</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e79">ANTIBODIES TO CD3 AND BCMA, AND BISPECIFIC BINDING PROTEINS MADE THEREFROM</invention-title><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>SHANGHAI EPIMAB BIOTHERAPEUTICS CO., LTD.</orgname><address><city>Shanghai</city><country>CN</country></address></addressbook><residence><country>CN</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>WU</last-name><first-name>Chengbin</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>WU</last-name><first-name>Danqing</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>HUANG</last-name><first-name>Lini</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>ZHANG</last-name><first-name>Amin</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>SHUAI</last-name><first-name>Zhengrong</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>ZHANG</last-name><first-name>Rui</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="06" designation="us-only"><addressbook><last-name>GONG</last-name><first-name>Shiyong</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="07" designation="us-only"><addressbook><last-name>WU</last-name><first-name>Xuan</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/CN2020/131767</doc-number><date>20201126</date></document-id><us-371c12-date><date>20220511</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">High-affinity antibodies recognizing CD3 and B Cell Maturation Factor protein (BCMA) are disclosed. Binding sites from humanized anti-CD3 and anti-BCMA antibodies are incorporated into a Fabs-in-Tandem Immunoglobulin format without significant loss of binding affinity, and the resultant bispecific, multivalent binding proteins are able to bind to both CD3 and BCMA simultaneously. Such antibodies, antigen-binding portions thereof, and bispecific FIT-Ig binding proteins are useful for treating cancer.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="67.99mm" wi="119.21mm" file="US20230002489A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="184.91mm" wi="121.24mm" file="US20230002489A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="194.48mm" wi="127.85mm" file="US20230002489A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="198.54mm" wi="138.18mm" file="US20230002489A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="197.95mm" wi="138.18mm" file="US20230002489A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="197.78mm" wi="138.26mm" file="US20230002489A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="199.47mm" wi="138.26mm" file="US20230002489A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="184.83mm" wi="152.65mm" file="US20230002489A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="203.88mm" wi="148.42mm" file="US20230002489A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="192.62mm" wi="147.57mm" file="US20230002489A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="177.63mm" wi="147.07mm" file="US20230002489A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="184.23mm" wi="147.07mm" file="US20230002489A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="214.71mm" wi="133.77mm" file="US20230002489A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="192.28mm" wi="133.77mm" file="US20230002489A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="219.29mm" wi="123.87mm" file="US20230002489A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">FIELD OF THE INVENTION</heading><p id="p-0002" num="0001">The present invention relates to new antibodies recognizing CD3, new antibodies recognizing B Cell Maturation Antigen (BCMA), and bispecific BCMA/CD3 binding proteins such as FIT-Ig binding proteins and MAT-Fab binding proteins made using those antibodies. The antibodies and bispecific binding proteins are useful for treatment of immunological diseases and hematological cancers.</p><heading id="h-0002" level="1">BACKGROUND OF THE INVENTION</heading><p id="p-0003" num="0002">Cluster of Differentiation 3 (CD3)</p><p id="p-0004" num="0003">The T cell receptor (TCR) binds to antigens (Ags) displayed by major histocompatibility complexes (MHCs) and plays critical roles in T cell function. But the TCR does not possess intracellular signaling by itself. Instead, TCR non-covalently associates with the Cluster of Differentiation 3 (CD3) complex and triggers intracellular signaling through immunoreceptor tyrosine-based activation motifs (ITAM) of CD3. The CD3 T cell co-receptor helps to activate both the cytotoxic T cell (CD8+ naive T cells) and also T helper cells (CD4+ naive T cells). It consists of a protein complex and is composed of four distinct chains. In mammals, the complex contains a CD3&#x3b3; chain, a CD3&#x3b4; chain, and two CD3&#x3b5; chains. These chains associate with the T cell receptor (TCR) and the CD3&#x3b6; chain (zeta-chain) to generate an activation signal in T lymphocytes. The TCR, &#x3b6;-chain, and CD3&#x3b3;, &#x3b4;, and &#x3b5; chains together constitute the TCR complex. The CD3 four-chain complex then forms CD3&#x3b5;&#x3b3;, CD3&#x3b5;&#x3b4; and &#x3b6;&#x3b6; dimers in 1:1:1 stoichiometry.</p><p id="p-0005" num="0004">CD3 is initially expressed in the cytoplasm of pro-thymocytes, the stem cells from which T cells arise in the thymus. The pro-thymocytes differentiate into common thymocytes, and then into medullary thymocytes, and it is at this latter stage that CD3 antigen begins to migrate to the cell membrane. The antigen is found bound to the membranes of all mature T cells, and in virtually no other cell type, although it does appear to be present in small amounts in Purkinje cells.</p><p id="p-0006" num="0005">This high specificity, combined with the presence of CD3 at all stages of T cell development, makes it a useful immunohistochemical marker for T cells in tissue sections. The antigen remains present in almost all T cell lymphomas and leukemias, and can therefore be used to distinguish them from superficially similar B cell and myeloid neoplasms. Some antibodies against CD3&#x3b5; chain have been shown to activate TCR-CD3 complex, possibly by clustering CD3 complex on T cells. In addition, bispecific antibodies targeting both CD3 and a tumor specific antigen have been studied for redirected tumor eradication by T cells. Because CD3 is required for T cell activation, drugs (often monoclonal antibodies) that target it are being investigated as immunosuppressant therapies (e.g., otelixizumab) for type 1 diabetes and other autoimmune diseases.</p><p id="p-0007" num="0006">B Cell Maturation Antigen (BCMA)</p><p id="p-0008" num="0007">B cell maturation antigen (BCMA, TNFRSF17, CD269) is a member of the TNF receptor superfamily. BCMA expression is restricted to the B cell lineage, mainly expressed on plasma cells and plasmablasts and is absent on na&#xef;ve B cells. BCMA binds to two ligands, A proliferation-inducing ligand (APRIL, TNFSF13, TALL-2, CD256) and B cell activation factor (BAFF, BLYS, TNFSF13B, TALL-1, CD257). BCMA has higher binding affinity for APRIL than for BAFF. Multiple myeloma (MM) cells express high levels of BCMA. Antibodies targeting BCMA with ligand blocking activity could promote cytotoxicity of MM cells both as naked IgG and as drug-conjugates. The restricted expression of BCMA on late-stage matured B cells also makes it an ideal co-target of chimeric antigen receptor T cells (CAR-T cells), which are T cells genetically engineered to exhibit chimeric antigen receptors to target the modified T cells to specific cellular proteins. CAR-T cells provide a promising immunotherapy for B cell cancers, however their mechanism of action is not well understood, and the side effects of CAR-T cell therapy are often severe and include cytokine release syndrome (cytokine storm) and neurological toxicity.</p><p id="p-0009" num="0008">Understanding of the roles of CD3 and BCMA has also led to a related immunotherapy known as bispecific T cell redirecting antibodies. Bispecific antibodies targeting both CD3 and BCMA would be useful for the treatment of multiple myeloma through redirected T cell cytotoxicity (RTCC).</p><heading id="h-0003" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0010" num="0009">The present invention provides new antibodies that bind to CD3 with high affinity and new antibodies that bind to BCMA with high affinity. The invention also provides BCMA/CD3 bispecific Fabs-in-Tandem immunoglobulins (FIT-Igs) that are reactive with both CD3 and BCMA. The invention also provides BCMA/CD3 bispecific monovalent asymmetric tandem Fab antibodies (MAT-Fabs) that are reactive with both CD3 and BCMA. Antibodies and bispecific binding proteins of the present invention can activate the TCR-CD3 complex. The bispecific, multivalent binding proteins described herein will be useful as BCMA/CD3 bispecific inhibitors to provide a synergistic combination effect for the treatment of multiple myeloma (MM) cells through redirected T cell cytotoxicity.</p><p id="p-0011" num="0010">The invention also provides methods of making and using the anti-CD3 and anti-BCMA antibodies and BCMA/CD3 bispecific binding proteins described herein as well as various compositions that may be used in methods of detecting CD3 and/or BCMA in a sample or in methods of treating or preventing a disorder in an individual that is associated with CD3 and/or BCMA activity.</p><p id="p-0012" num="0011">In a further embodiment, the invention provides a bispecific Fabs-in-Tandem immunoglobulin (FIT-Ig) binding protein comprising first, second, and third polypeptide chains,</p><p id="p-0013" num="0012">wherein said first polypeptide chain comprises, from amino to carboxyl terminus, (i) VL<sub>A</sub>-CL-VH<sub>B</sub>-CH1-Fc wherein CL is directly fused to VH<sub>B</sub>, or (ii) VH<sub>B</sub>-CH1-VL<sub>A</sub>-CL-Fc wherein CH1 is directly fused to VL<sub>A</sub>;</p><p id="p-0014" num="0013">wherein said second polypeptide chain comprises, from amino to carboxyl terminus, VH<sub>A</sub>-CH1; and</p><p id="p-0015" num="0014">wherein said third polypeptide chain comprises, from amino to carboxyl terminus, VL<sub>B</sub>-CL;</p><p id="p-0016" num="0015">wherein VL is a light chain variable domain, CL is a light chain constant domain, VH is a heavy chain variable domain, CH1 is a heavy chain constant domain, Fc is an immunoglobulin Fc region, A is an epitope of CD3 or BCMA and B is an epitope of CD3 or BCMA, with the proviso that A and B are different. In accordance with the present invention, such FIT-Ig binding proteins bind to both CD3 and BCMA.</p><p id="p-0017" num="0016">In one further embodiments, the Fab fragments of such FIT-Ig binding proteins incorporate VL<sub>A </sub>and VH<sub>A </sub>domains from a parental antibody binding to one of the antigen targets CD3 or BCMA and incorporate VL<sub>B </sub>and VH<sub>B </sub>domains from a different parental antibody binding to the other of the antigen targets CD3 and BCMA. Thus, VH<sub>A</sub>-CH1/VL<sub>A</sub>-CL and VH<sub>B</sub>-CH1/VL<sub>B</sub>-CL pairing of the first second and third polypeptide chains will result in tandem Fab moieties recognizing CD3 and BCMA.</p><p id="p-0018" num="0017">In accordance with the present invention, a BCMA/CD3 FIT-Ig binding protein advantageously comprises first, second, and third polypeptide chains, wherein said first polypeptide chain comprises, from amino to carboxyl terminus, VL<sub>CD3</sub>-CL-VH<sub>BCMA</sub>-CH1-Fc wherein CL is directly fused to VH<sub>BCMA</sub>, wherein said second polypeptide chain comprises, from amino to carboxyl terminus, VH<sub>CD3</sub>-CH1; and wherein said third polypeptide chain comprises, from amino to carboxyl terminus, VL<sub>BCMA</sub>-CL; wherein VL<sub>CD3 </sub>is a light chain variable domain of an anti-CD3 antibody, CL is a light chain constant domain, VH<sub>CD3 </sub>is a heavy chain variable domain of an anti-CD3 antibody, CH1 is a heavy chain constant domain, VL<sub>BCMA </sub>is a light chain variable domain of an anti-BCMA antibody, VH<sub>BCMA </sub>is a heavy chain variable domain of an anti-BCMA antibody, and Fc is an immunoglobulin Fc region. Advantageously, in the first polypeptide chain, the domains VL<sub>CD3</sub>-CL are the same as the light chain of an anti-CD3 parental antibody, the domains VH<sub>CD3</sub>-CH1 are the same as the heavy chain variable and heavy chain constant domains of an anti-CD3 parental antibody, the domains VL<sub>BCMA</sub>-CL are the same as the light chain of an anti-BCMA parental antibody, and the domains VH<sub>BCMA</sub>-CH1 are the same as the heavy chain variable and heavy chain constant domains of an anti-BCMA parental antibody.</p><p id="p-0019" num="0018">In alternative embodiments, a BCMA/CD3 FIT-Ig binding protein may advantageously comprise first, second, and third polypeptide chains, wherein said first polypeptide chain comprises, from amino to carboxyl terminus, VL<sub>BCMA</sub>-CL-VH<sub>CD3</sub>-CH1-Fc wherein CL is directly fused to VH<sub>CD3</sub>, wherein said second polypeptide chain comprises, from amino to carboxyl terminus, VH<sub>BCMA</sub>-CH1; and wherein said third polypeptide chain comprises, from amino to carboxyl terminus, VL<sub>CD3</sub>-CL; wherein VL<sub>CD3 </sub>is a light chain variable domain of an anti-CD3 antibody, CL is a light chain constant domain, VH<sub>CD3 </sub>is a heavy chain variable domain of an anti-CD3 antibody, CH1 is a heavy chain constant domain, VL<sub>BCMA </sub>is a light chain variable domain of an anti-BCMA antibody, VH<sub>BCMA </sub>is a heavy chain variable domain of an anti-BCMA antibody, and Fc is an immunoglobulin Fc region. Advantageously, in the first polypeptide chain, the domains VL<sub>BCMA</sub>-CL are the same as the light chain of an anti-BCMA parental antibody, the domains VH<sub>BCMA</sub>-CH1 are the same as the heavy chain variable and heavy chain constant domains of an anti-BCMA parental antibody, the domains VL<sub>CD3</sub>-CL are the same as the light chain of an anti-CD3parental antibody, and the domains VH<sub>CD3</sub>-CH1 are the same as the heavy chain variable and heavy chain constant domains of an anti-CD3 parental antibody.</p><p id="p-0020" num="0019">In alternative embodiments, a BCMA/CD3 FIT-Ig binding protein may advantageously comprise first, second, and third polypeptide chains, wherein said first polypeptide chain comprises, from amino to carboxyl terminus, VH<sub>BCMA</sub>-CH1-VL<sub>CD3</sub>-CL-Fc wherein CH1 is directly fused to VL<sub>CD3</sub>, wherein said second polypeptide chain comprises, from amino to carboxyl terminus, VL<sub>BCMA</sub>-CL; and wherein said third polypeptide chain comprises, from amino to carboxyl terminus, VH<sub>CD3</sub>-CH1; wherein VL<sub>CD3 </sub>is a light chain variable domain of an anti-CD3 antibody, CL is a light chain constant domain, VH<sub>CD3 </sub>is a heavy chain variable domain of an anti-CD3 antibody, CH1 is a heavy chain constant domain, VL<sub>BCMA </sub>is a light chain variable domain of an anti-BCMA antibody, VH<sub>BCMA </sub>is a heavy chain variable domain of an anti-BCMA antibody, and Fc is an immunoglobulin Fc region. Advantageously, in the first polypeptide chain, the domains VL<sub>BCMA</sub>-CL are the same as the light chain of an anti-BCMA parental antibody, the domains VH<sub>BCMA</sub>-CH1 are the same as the heavy chain variable and heavy chain constant domains of an anti-BCMA parental antibody, the domains VL<sub>CD3</sub>-CL are the same as the light chain of an anti-CD3 parental antibody, and the domains VH<sub>CD3</sub>-CH1 are the same as the heavy chain variable and heavy chain constant domains of an anti-CD3 parental antibody.</p><p id="p-0021" num="0020">In alternative embodiments, a BCMA/CD3 FIT-Ig binding protein may advantageously comprise first, second, and third polypeptide chains, wherein said first polypeptide chain comprises, from amino to carboxyl terminus, VH<sub>CD3</sub>-CH1-VL<sub>BCMA</sub>-CL-Fc wherein CH1 is directly fused to VL<sub>BCMA</sub>, wherein said second polypeptide chain comprises, from amino to carboxyl terminus, VL<sub>CD3</sub>-CL; and wherein said third polypeptide chain comprises, from amino to carboxyl terminus, VH<sub>BCMA</sub>-CH1; wherein VL<sub>CD3 </sub>is a light chain variable domain of an anti-CD3 antibody, CL is a light chain constant domain, VH<sub>CD3 </sub>is a heavy chain variable domain of an anti-CD3 antibody, CH1 is a heavy chain constant domain, VL<sub>BCMA </sub>is a light chain variable domain of an anti-BCMA antibody, VH<sub>BCMA </sub>is a heavy chain variable domain of an anti-BCMA antibody, and Fc is an immunoglobulin Fc region. Advantageously, in the first polypeptide chain, the domains VL<sub>BCMA</sub>-CL are the same as the light chain of an anti-BCMA parental antibody, the domains VH<sub>BCMA</sub>-CH1 are the same as the heavy chain variable and heavy chain constant domains of an anti-BCMA parental antibody, the domains VL<sub>CD3</sub>-CL are the same as the light chain of an anti-CD3 parental antibody, and the domains VH<sub>CD3</sub>-CH1 are the same as the heavy chain variable and heavy chain constant domains of an anti-CD3 parental antibody.</p><p id="p-0022" num="0021">In the foregoing formulas for the first polypeptide chain of a FIT-Ig binding protein, an Fc region may be a native or a variant Fc region. In particular embodiments, the Fc region is a human Fc region from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD. In particular embodiments, the Fc is a human Fc from IgG1, such as set forth below:</p><p id="p-0023" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry></row><row><entry>DKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED</entry></row><row><entry> </entry></row><row><entry>PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK</entry></row><row><entry> </entry></row><row><entry>CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK</entry></row><row><entry> </entry></row><row><entry>GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG</entry></row><row><entry> </entry></row><row><entry>NVFSCSVMHEALHNHYTQKSLSLSPGK.</entry></row></tbody></tgroup></table></tables></p><p id="p-0024" num="0022">In an embodiment of the invention, FIT-Ig binding proteins of the present invention retain one or more properties of parental antibodies from which the sequences of their Fab fragments are utilized and incorporated into the FIT-Ig structure. In one further embodiments, the FIT-Ig will retain binding affinity for the target antigens (i.e., CD3 and BCMA) comparable to that of the parental antibodies, meaning that the binding affinity of the FIT-Ig binding protein for the CD3 and BCMA antigen targets does not vary by greater than 10-fold in comparison to the binding affinity of the parental antibodies for their respective target antigens, as measured by surface plasmon resonance or biolayer interferometry.</p><p id="p-0025" num="0023">In one embodiment, a BCMA/CD3 FIT-Ig binding protein of the present invention binds CD3 and BCMA and is comprised of a first polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:50; a second polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:51; and a third polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:52.</p><p id="p-0026" num="0024">In another embodiment, a BCMA/CD3 FIT-Ig binding protein of the present invention binds CD3 and BCMA and is comprised of a first polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:53; a second polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:54; and a third polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:55.</p><p id="p-0027" num="0025">In another embodiment, a BCMA/CD3 FIT-Ig binding protein of the present invention binds CD3 and BCMA and is comprised of a first polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:80; a second polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:81; and a third polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:82.</p><p id="p-0028" num="0026">In another embodiment, a BCMA/CD3 FIT-Ig binding protein of the present invention binds CD3 and BCMA and is comprised of a first polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:83; a second polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:84; and a third polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:85.</p><p id="p-0029" num="0027">In another embodiment, a BCMA/CD3 FIT-Ig binding protein of the present invention binds CD3 and BCMA and is comprised of a first polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:86; a second polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:87; and a third polypeptide chain comprising, consisting essentially of, or consisting of the sequence of amino acids of SEQ ID NO:88.</p><p id="p-0030" num="0028">The invention also provides novel antibodies capable of binding human CD3, wherein the antigen-binding domain of the antibody comprises a set of six CDRs, i.e., CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, selected from the group of CDR sets defined below:</p><p id="p-0031" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="84pt" align="left"/><colspec colname="4" colwidth="56pt" align="left"/><thead><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>CDR&#x2003;Set</entry><entry/><entry>CDR</entry><entry/></row><row><entry>No.</entry><entry>CDR</entry><entry>Amino&#x2003;Acid&#x2003;Sequence</entry><entry>SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>1</entry><entry>CDR-H1</entry><entry>NYYVH</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;56</entry></row><row><entry/><entry>CDR-H2</entry><entry>WISPGSDNTKYNEKFKG</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;57</entry></row><row><entry/><entry>CDR-H3</entry><entry>DDYGNYYFDY</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;58</entry></row><row><entry/><entry>CDR-L1</entry><entry>KSSQSLLNSRTRKNYLA</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;59</entry></row><row><entry/><entry>CDR-L2</entry><entry>WASTRES</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;60</entry></row><row><entry/><entry>CDR-L3</entry><entry>KQSYILRT</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;61</entry></row><row><entry> </entry></row><row><entry>2</entry><entry>CDR-H1</entry><entry>NYYIH</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;62</entry></row><row><entry/><entry>CDR-H2</entry><entry>WINLGDVNTKFNEKFKD</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;63</entry></row><row><entry/><entry>CDR-H3</entry><entry>DGYSFYYFDF</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;64</entry></row><row><entry/><entry>CDR-L1</entry><entry>KASQSLFNSRTRKNYLA</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;65</entry></row><row><entry/><entry>CDR-L2</entry><entry>WASTRES</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;66</entry></row><row><entry/><entry>CDR-L3</entry><entry>IQSHTLRT</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;67</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0032" num="0029">The invention also provides novel antibodies capable of binding human BCMA, wherein the antigen-binding domain of the antibody comprises a set of six CDRs, i.e., CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, selected from the group of CDR sets defined below:</p><p id="p-0033" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="84pt" align="left"/><colspec colname="4" colwidth="56pt" align="left"/><thead><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>CDR&#x2003;Set</entry><entry/><entry>CDR</entry><entry/></row><row><entry>No.</entry><entry>CDR</entry><entry>Amino&#x2003;Acid&#x2003;Sequence</entry><entry>SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>3</entry><entry>CDR-H1</entry><entry>NYGLN</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;68</entry></row><row><entry/><entry>CDR-H2</entry><entry>WINTYSGHPTYVDDFKG</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;69</entry></row><row><entry/><entry>CDR-H3</entry><entry>EKDDGYRLGLDY</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;70</entry></row><row><entry/><entry>CDR-L1</entry><entry>SASSSVSYMY</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;71</entry></row><row><entry/><entry>CDR-L2</entry><entry>DTSNLVS</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;72</entry></row><row><entry/><entry>CDR-L3</entry><entry>LQYSGYPYT</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;73</entry></row><row><entry> </entry></row><row><entry>4</entry><entry>CDR-H1</entry><entry>NFWMH</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;74</entry></row><row><entry/><entry>CDR-H2</entry><entry>AFYPGNDDTYYNQKFK</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;75</entry></row><row><entry/><entry>CDR-H3</entry><entry>SGYYGSSDAMDY</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;76</entry></row><row><entry/><entry>CDR-L1</entry><entry>GASENIYGALN</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;77</entry></row><row><entry/><entry>CDR-L2</entry><entry>GATNLAD</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;78</entry></row><row><entry/><entry>CDR-L3</entry><entry>QSVLTTPWT</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;79</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0034" num="0030">In one embodiment, a binding protein according to the invention is a bispecific, multivalent immunoglobulin binding protein comprising two or more antigen binding sites, wherein at least one antigen binding site comprises a CDR set selected from CDR Sets 1 and 2 above and at least one antigen binding site comprises a CDR set selected from CDR Sets 3 and 4 above.</p><p id="p-0035" num="0031">In an embodiment, an anti-CD3 antibody according to the invention comprises VH and VL domains, wherein the two variable domains comprise amino acid sequences selected from the following VH/VL pairs:</p><p id="p-0036" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="112pt" align="left"/><colspec colname="2" colwidth="105pt" align="left"/><thead><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row><row><entry>VH/VL Pair </entry><entry>VH/VL Pair</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>SEQ ID NO: 6/SEQ ID NO: 7 </entry><entry>SEQ ID NO: 19/SEQ ID NO: 20 </entry></row><row><entry>SEQ ID NO: 8/SEQ ID NO: 9 </entry><entry>SEQ ID NO: 11/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 11/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 12/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 12/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 13/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 13/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 14/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 14/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 15/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 15/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 16/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 16/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 17/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 17/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 18/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 18/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 19/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 11/SEQ ID NO: 25 </entry><entry>SEQ ID NO: 15/SEQ ID NO: 25 </entry></row><row><entry>SEQ ID NO: 18/SEQ ID NO: 25 </entry><entry>SEQ ID NO: 12/SEQ ID NO: 25. </entry></row><row><entry>SEQ ID NO: 17/SEQ ID NO: 25</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0037" num="0032">In a further embodiment, an anti-BCMA antibody according to the invention comprises VH and VL domains, wherein the two variable domains comprise amino acid sequences selected from the following VH/VL pairs:</p><p id="p-0038" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="112pt" align="left"/><colspec colname="2" colwidth="105pt" align="left"/><thead><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row><row><entry>VH/VL Pair </entry><entry>VH/VL Pair</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>SEQ ID NO: 29/SEQ ID NO: 30 </entry><entry>SEQ ID NO: 36/SEQ ID NO: 40 </entry></row><row><entry>SEQ ID NO: 31/SEQ ID NO: 32 </entry><entry>SEQ ID NO: 36/SEQ ID NO: 41 </entry></row><row><entry>SEQ ID NO: 34/SEQ ID NO: 38 </entry><entry>SEQ ID NO: 36/SEQ ID NO: 42 </entry></row><row><entry>SEQ ID NO: 35/SEQ ID NO: 38 </entry><entry>SEQ ID NO: 36/SEQ ID NO: 43 </entry></row><row><entry>SEQ ID NO: 36/SEQ ID NO: 38 </entry><entry>SEQ ID NO: 36/SEQ ID NO: 44 </entry></row><row><entry>SEQ ID NO: 37/SEQ ID NO: 38 </entry><entry>SEQ ID NO: 34/SEQ ID NO: 45 </entry></row><row><entry>SEQ ID NO: 34/SEQ ID NO: 39 </entry><entry>SEQ ID NO: 34/SEQ ID NO: 46 </entry></row><row><entry>SEQ ID NO: 35/SEQ ID NO: 39 </entry><entry>SEQ ID NO: 34/SEQ ID NO: 47 </entry></row><row><entry>SEQ ID NO: 36/SEQ ID NO: 39 </entry><entry>SEQ ID NO: 34/SEQ ID NO: 48 </entry></row><row><entry>SEQ ID NO: 37/SEQ ID NO: 39 </entry><entry>SEQ ID NO: 34/SEQ ID NO: 49</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0039" num="0033">In another embodiment, an anti-CD3 antibody or an anti-BCMA antibody may be used to make derivative binding proteins recognizing the same target antigen by techniques well established in the field. Such a derivative may be, e.g., a single-chain antibody (scFv), a Fab fragment (Fab), an Fab&#x2032; fragment, an F(ab&#x2032;)<sub>2</sub>, an Fv, and a disulfide linked Fv.</p><p id="p-0040" num="0034">A Fab fragment of an immunoglobulin is composed of two components that covalently associate to form an antibody binding site. The two components are each a variable domain-constant domain chain (VH-CH1 or VL-CL), and therefore each V-C chain of a Fab may be described as one &#x201c;half&#x201d; of a Fab binding unit.</p><p id="p-0041" num="0035">In another aspect of the invention, an antibody or bispecific binding protein described herein is capable of modulating a biological function of CD3, BCMA, or both. In another aspect, an anti-CD3 antibody described herein is capable of inhibiting CD3 signaling. In another aspect, an anti-BCMA antibody described herein is capable of inhibiting BCMA interaction with its ligands APRIL and/or BAFF, and optionally an anti-BCMA antibody according to the invention is capable of inhibiting BCMA-mediated cellular signaling pathways.</p><p id="p-0042" num="0036">In an embodiment, an anti-CD3 antibody described herein or an antigen-binding fragment thereof has an on rate constant (k<sub>on</sub>) to human CD3 of at least 1&#xd7;10<sup>5 </sup>M<sup>&#x2212;1</sup>s<sup>&#x2212;1</sup>, for instance, at least 3.3&#xd7;10<sup>5 </sup>M<sup>&#x2212;1</sup>s<sup>&#x2212;1 </sup>or more, as measured by surface plasmon resonance or biolayer interferometry.</p><p id="p-0043" num="0037">In another embodiment, an anti-CD3 antibody described herein or antigen-binding fragment thereof has an off rate constant (k<sub>off</sub>) to human CD3 of less than 5&#xd7;10<sup>&#x2212;3 </sup>as measured by surface plasmon resonance or biolayer interferometry.</p><p id="p-0044" num="0038">In another embodiment, an anti-CD3 antibody described herein or antigen-binding fragment thereof has a dissociation constant (K<sub>D</sub>) to human CD3 of less than 2&#xd7;10<sup>&#x2212;8 </sup>M, for instance, less than 1.5&#xd7;10<sup>&#x2212;8 </sup>M.</p><p id="p-0045" num="0039">In an embodiment, an anti-BCMA antibody described herein or an antigen-binding fragment thereof has an on rate constant (k<sub>on</sub>) to human BCMA of at least 4&#xd7;10<sup>4 </sup>M<sup>&#x2212;1</sup>s<sup>&#x2212;1</sup>, for instance, at least 1&#xd7;10<sup>5 </sup>M<sup>&#x2212;1</sup>s<sup>&#x2212;1</sup>, at least 2&#xd7;10<sup>5 </sup>M<sup>&#x2212;1</sup>s<sup>&#x2212;1 </sup>or more, as measured by surface plasmon resonance or biolayer interferometry.</p><p id="p-0046" num="0040">In another embodiment, an anti-BCMA antibody described herein or antigen-binding fragment thereof has an off rate constant (k<sub>off</sub>) to human BCMA of less than 5&#xd7;10<sup>&#x2212;3 </sup>s<sup>&#x2212;1</sup>, less than 1&#xd7;10<sup>&#x2212;3 </sup>s<sup>&#x2212;1</sup>, less than 5&#xd7;10<sup>&#x2212;4 </sup>s<sup>&#x2212;1</sup>, less than 2&#xd7;10<sup>&#x2212;5 </sup>s<sup>&#x2212;1</sup>, or less than 1&#xd7;10<sup>&#x2212;5 </sup>s<sup>&#x2212;1</sup>, as measured by surface plasmon resonance or biolayer interferometry.</p><p id="p-0047" num="0041">In another embodiment, an anti-BCMA antibody described herein or antigen-binding fragment thereof has a dissociation constant (K<sub>D</sub>) to BCMA of less than 2&#xd7;10<sup>&#x2212;8 </sup>M, less than 1&#xd7;10<sup>&#x2212;9 </sup>M, or less than 5&#xd7;10<sup>&#x2212;10 </sup>M.</p><p id="p-0048" num="0042">In an embodiment, a bispecific BCMA/CD3 FIT-Ig binding protein capable of binding CD3 and BCMA according to this invention has an on rate constant (k<sub>on</sub>) to human CD3 of at least 1&#xd7;10<sup>5 </sup>M<sup>&#x2212;1</sup>s<sup>&#x2212;1</sup>, for instance, at least 2&#xd7;10<sup>5 </sup>M<sup>&#x2212;1</sup>s<sup>&#x2212;1</sup>, or at least 3&#xd7;10<sup>5 </sup>M<sup>&#x2212;1</sup>s<sup>&#x2212;1</sup>, or more, and the same binding protein has an on rate constant (k<sub>on</sub>) to human BCMA of at least 5&#xd7;10<sup>4</sup>M<sup>&#x2212;1</sup>s<sup>&#x2212;1</sup>, for instance, at least 6&#xd7;10<sup>4 </sup>M<sup>&#x2212;1</sup>s<sup>&#x2212;1</sup>, or at least 8&#xd7;10<sup>4 </sup>M<sup>&#x2212;1</sup>s<sup>&#x2212;1</sup>, or more, as measured by surface plasmon resonance or biolayer interferometry. In further embodiments, a bispecific BCMA/CD3 FIT-Ig binding protein capable of binding CD3 and BCMA as described herein will have an on rate constant (k<sub>on</sub>) to human CD3 that is no more than a 10-fold decrease from the k<sub>on </sub>for CD3 of the parental anti-CD3 antibody, and is no more than a 10-fold decrease from the k<sub>on </sub>for BCMA of the parental anti-BCMA antibody from which the anti-CD3 and anti-BCMA specificities, respectively, of the FIT-Ig binding protein were derived. In other words, the FIT-Ig binding protein will retain an on rate constant for each antigen (CD3 or BCMA) that is higher than, the same as, or no more than one order of magnitude less than the on rate constant (k<sub>on</sub>) exhibited by the parental antibodies reactive with the respective CD3 or BCMA antigens. As disclosed herein, a BCMA/CD3 FIT-Ig binding protein for antigen may show improvement in k<sub>on </sub>for one or both antigens in comparison to the k<sub>on </sub>for the respective antigens exhibited by the parental antibodies, or the k<sub>on </sub>for one or both antigens may be essentially the same as exhibited by the parental antibodies, respectively, or, if there is a decrease in k<sub>on </sub>for one or both antigens shown by the FIT-Ig binding protein in comparison to a parental antibody, then that decrease is no more than a 10-fold decrease. For instance, a decrease in k<sub>on </sub>for a particular antigen in the FIT-Ig in comparison to the k<sub>on </sub>for that antigen of a parental antibody is less than 50%, less than a 25% decrease. Such high retained k<sub>on </sub>values in the bispecific FIT-Ig in comparison to the k<sub>on</sub>s of the parental antibodies is a surprising achievement in the field.</p><p id="p-0049" num="0043">In an embodiment, a bispecific FIT-Ig binding protein capable of binding CD3 and BCMA according to this invention has an off rate constant (k<sub>off</sub>) to human CD3 of less than 1&#xd7;10<sup>&#x2212;2 </sup>s<sup>&#x2212;1</sup>, less than 8&#xd7;10<sup>&#x2212;3 </sup>s<sup>&#x2212;1</sup>, less than 7&#xd7;10<sup>&#x2212;3 </sup>s<sup>&#x2212;1</sup>, for instance, less than 6&#xd7;10<sup>&#x2212;3 </sup>s<sup>&#x2212;1</sup>, and the same binding protein has an off rate constant (k<sub>off</sub>) to human BCMA of less than 5&#xd7;10<sup>&#x2212;5 </sup>s<sup>&#x2212;1</sup>, less than 4&#xd7;10<sup>&#x2212;5 </sup>s<sup>&#x2212;1</sup>, less than 3&#xd7;10<sup>&#x2212;5 </sup>s<sup>&#x2212;1</sup>, or less than 5&#xd7;10<sup>&#x2212;6 </sup>s<sup>&#x2212;1</sup>, as measured by surface plasmon resonance or biolayer interferometry.</p><p id="p-0050" num="0044">In another embodiment, a bispecific BCMA/CD3 FIT-Ig binding protein capable of binding CD3 and BCMA according to this invention has a dissociation constant (K<sub>D</sub>) to CD3 of less than 5&#xd7;10<sup>&#x2212;8 </sup>M, less than 3&#xd7;10<sup>&#x2212;8 </sup>M, less than 2&#xd7;10<sup>&#x2212;8 </sup>M, or less than 1.75&#xd7;10<sup>&#x2212;8 </sup>M, and the same binding protein has a dissociation constant (K<sub>D</sub>) for human BCMA of less than 1&#xd7;10<sup>&#x2212;9 </sup>M, less than 6&#xd7;10<sup>&#x2212;10 </sup>M, less than 3&#xd7;10<sup>&#x2212;10 </sup>M, less than 1&#xd7;10<sup>&#x2212;10 </sup>M, less than 8&#xd7;10<sup>&#x2212;11 </sup>M, or less than 6&#xd7;10<sup>&#x2212;11 </sup>M. In further embodiments, a bispecific FIT-Ig binding protein capable of binding CD3 and BCMA as described herein will have a dissociation constant (K<sub>D</sub>) to human CD3 that is no more than 10-fold different from the K<sub>D </sub>for CD3 of the parental anti-CD3 antibody, and is no more than 10-fold different from the K<sub>D </sub>for BCMA of the parental anti-BCMA antibody from which the anti-CD3 and anti-BCMA specificities, respectively, of the FIT-Ig binding protein were derived. In other words, the FIT-Ig binding protein will retain the binding affinity of the parental antibodies for each antigen (CD3 or BCMA) as indicated by a dissociation constant (K<sub>D</sub>) that is within one order of magnitude of the K<sub>D </sub>exhibited by the parental antibodies reactive with the CD3 or BCMA antigens, respectively.</p><p id="p-0051" num="0045">As disclosed herein, a BCMA/CD3 FIT-Ig binding protein may show improvement in K<sub>D</sub>(i.e., has a lower K<sub>D </sub>value; more tightly binds) for one or both antigens in comparison to the K<sub>D </sub>for the respective antigens exhibited by the parental antibodies, or the K<sub>D </sub>for one or both antigens may be essentially the same as exhibited by the parental antibodies, respectively, or the K<sub>D </sub>for one or both antigens shown by the FIT-Ig binding protein may show a decrease (i.e., have a greater K<sub>D </sub>value, binds less tightly) in comparison to the K<sub>D </sub>of a parental antibody, but if there is a difference in K<sub>D </sub>between FIT-Ig binding protein and parental antibody, then that difference is no more than a 10-fold difference. For instance, a BCMA/CD3 FIT-Ig binding protein shows a lower K<sub>D </sub>(binds more tightly) for one or both antigens in comparison to the K<sub>D </sub>for the respective antigens exhibited by the one or both parental antibodies. Retention of the binding affinity of the parental anti-CD3 and anti-BCMA antibodies&#xb1;10-fold change in K<sub>D </sub>is a surprising achievement in the field.</p><p id="p-0052" num="0046">The invention also provides pharmaceutical compositions comprising at least one anti-CD3 antibody or antigen-binding fragment thereof as described herein and a pharmaceutically acceptable carrier. The invention also provides pharmaceutical compositions comprising at least one anti-BCMA antibody or antigen-binding fragments thereof and a pharmaceutically acceptable carrier. The invention also provides pharmaceutical compositions comprising a combination of anti-CD3 and anti-BCMA antibodies as described herein, or antigen-binding fragment(s) thereof, and a pharmaceutically acceptable carrier. The invention also provides bispecific, multivalent immunoglobulin binding proteins reactive with both CD3 and BCMA, which binding proteins incorporate VH/VL binding sites from anti-CD3 and anti-BCMA antibodies described herein. In particular, the invention provides pharmaceutical compositions comprising at least one FIT-Ig binding protein or at least one MAT-Fab binding protein capable of binding CD3 and BCMA and a pharmaceutically acceptable carrier. Pharmaceutical compositions of the invention may further comprise at least one additional active ingredient. In an embodiment, such an additional ingredient includes, but is not limited to, a therapeutic agent, an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule blocker, an antibody of different specificity or functional fragment thereof, a detectable label or reporter; an agonist or antagonist for particular cytokine(s), a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial agent, a corticosteroid, an anabolic steroid, an erythropoietin, an immunogen, an immunosuppressive agent, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant (e.g., an amphetamine, caffeine, etc.), a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine.</p><p id="p-0053" num="0047">In another embodiment, a pharmaceutical composition further comprises at least one additional therapeutic agent for treating a disorder in which CD3-mediated and/or BCMA-mediated signaling activity is detrimental.</p><p id="p-0054" num="0048">In a further embodiment, the invention provides isolated nucleic acids encoding one or more amino acid sequences of an anti-CD3 antibody of the invention or an antigen-binding fragment thereof; isolated nucleic acids encoding one or more amino acid sequences of an anti-BCMA antibody of the invention or an antigen-binding fragment thereof, and isolated nucleic acids encoding one or more amino acid sequences of a bispecific Fabs-in-Tandem immunoglobulin (FIT-Ig) binding protein capable of binding both CD3 and BCMA. Such nucleic acids may be inserted into a vector for carrying out various genetic analyses or for expressing, characterizing, or improving one or more properties of an antibody or binding protein described herein. A vector may comprise a one or more nucleic acid molecules encoding one or more amino acid sequences of an antibody or binding protein described herein in which the one or more nucleic acid molecules is operably linked to appropriate transcriptional and/or translational sequences that permit expression of the antibody or binding protein in a particular host cell carrying the vector. Examples of vectors for cloning or expressing nucleic acids encoding amino acid sequences of binding proteins described herein include, but are not limited to, pcDNA, pTT, pTT3, pEFBOS, pBV, pJV, and pBJ, and derivatives thereof.</p><p id="p-0055" num="0049">The invention also provides a host cell comprising a vector comprising a nucleic acid encoding one or more amino acid sequences of an antibody or binding protein described herein. Host cells useful in the invention may be prokaryotic or eukaryotic. An exemplary prokaryotic host cell is <i>Escherichia coli</i>. Eukaryotic cells useful as host cells in the invention include protist cells, animal cells, plant cells, and fungal cells. An exemplary fungal cell is a yeast cell, including <i>Saccharomyces cerevisiae</i>. An exemplary animal cell useful as a host cell according to the invention includes, but is not limited to, a mammalian cell, an avian cell, and an insect cell. Exemplary mammalian cells include, but are not limited to, CHO cells, HEK cells, and COS cells. An insect cell useful as a host cell according to the invention is an insect Sf9 cell.</p><p id="p-0056" num="0050">In another aspect, the invention provides a method of producing anti-CD3 antibody or a functional fragment thereof comprising culturing a host cell comprising an expression vector encoding the antibody or functional fragment in culture medium under conditions sufficient to cause expression by the host cell of the antibody or fragment capable of binding CD3. In another aspect, the invention provides a method of producing anti-BCMA antibody or a functional fragment thereof comprising culturing a host cell comprising an expression vector encoding the antibody or functional fragment in culture medium under conditions sufficient to cause expression by the host cell of the antibody or fragment capable of binding BCMA. In another aspect, the invention provides a method of producing a bispecific, multivalent binding protein capable of binding CD3 and BCMA, specifically a FIT-Ig binding protein, comprising culturing a host cell comprising an expression vector encoding the FIT-Ig binding protein in culture medium under conditions sufficient to cause expression by the host cell of the binding protein capable of binding CD3 and BCMA. The proteins so produced can be isolated and used in various compositions and methods described herein.</p><p id="p-0057" num="0051">In one embodiment, the present invention provides methods for treating cancer in a subject in need thereof, the method comprising administering to the subject an anti-CD3 antibody or CD3-binding fragment thereof as described herein, wherein the antibody or binding fragment is capable of binding CD3 and inhibiting CD3-mediated signaling in a cell expressing CD3. In another embodiment, the present invention provides methods for treating cancer in a subject in need thereof, the method comprising administering to the subject an anti-BCMA antibody or BCMA binding fragment thereof as described herein, wherein the antibody or binding fragment is capable of binding BCMA and inhibiting BCMA-mediated signaling in a cell expressing BCMA. In another embodiment, the present invention provides methods for treating cancer in a subject in need thereof, the method comprising administering to the subject a bispecific FIT-Ig binding protein capable of binding both CD3 and BCMA as described herein, wherein the binding protein is capable of binding CD3 and BCMA and of inhibiting CD3-mediated signaling in a cell expressing CD3 and of inhibiting BCMA-mediated signaling in a cell expressing BCMA.</p><p id="p-0058" num="0052">In another embodiment, the present invention provides methods for treating an autoimmune disease or a cancer in a subject in need thereof, wherein the binding protein is capable of binding CD3 and BCMA, and wherein the autoimmune disease or cancer is an autoimmune disease or cancer typically responsive to immunotherapy. In another embodiment, the cancer is a cancer that has not been associated with immunotherapy. In another embodiment, the cancer is a cancer that is a refractory or a recurring malignancy. In another embodiment, the binding protein inhibits the growth or survival of tumor cells. In another embodiment, the cancer is selected from the group consisting of melanoma (e.g., metastatic malignant melanoma), renal cancer (e.g. clear cell carcinoma), prostate cancer (e.g. hormone refractory prostate adenocarcinoma), pancreatic adenocarcinoma, breast cancer, colon cancer, lung cancer (e.g. non-small cell lung cancer), esophageal cancer, squamous cell carcinoma of the head and neck, liver cancer, ovarian cancer, cervical cancer, thyroid cancer, glioblastoma, glioma, leukemia, lymphoma, and other neoplastic malignancies.</p><p id="p-0059" num="0053">Methods of treatment described herein may further comprise administering to a subject in need thereof, of an immunostimulatory adjuvant, such as a CpG oligodeoxynucleotide (CpG ODN) comprising a full or partial phosphodiester or phosphorothioate backbone. For example, in a method of treatment of the invention, an immunostimulatory adjuvant may be incorporated into a composition comprising an antibody or FIT-Ig binding protein of the invention, and the composition administered to a subject in need of treatment. In another embodiment, a method of treatment of the invention may comprise a step of administering to a subject in need of treatment an antibody or FIT-Ig binding protein described herein and a separate step of administering an immunostimulatory adjuvant to the subject before, concurrently, or after the step of administering to the subject an antibody or FIT-Ig binding protein of the invention.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0004" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0060" num="0054"><figref idref="DRAWINGS">FIG. <b>1</b></figref> is a collection of plots showing binding of test antibodies against a human CD3&#x3b5;/&#x3b3; heterodimer-Fc fusion protein target immobilized on microplates. The binding activities of newly isolated mAbCD3-001 and mAbCD3-002 are compared against a reference anti-CD3 monoclonal antibody (&#x201c;control &#x3b1;-CD3 mAb&#x201d;) and an irrelevant murine antibody (&#x201c;mIgG&#x201d;) as a negative control.</p><p id="p-0061" num="0055"><figref idref="DRAWINGS">FIG. <b>2</b></figref> is a collection of plots showing binding of test antibodies against a cynomolgus monkey CD3&#x3b5;/&#x3b3; heterodimer-Fc fusion protein target immobilized on microplates. The binding activities of newly isolated mAbCD3-001 and mAbCD3-002 are compared against a reference anti-CD3 monoclonal antibody (&#x201c;control &#x3b1;-CD3 mAb&#x201d;) and an irrelevant murine antibody (&#x201c;mIgG&#x201d;) as a negative control.</p><p id="p-0062" num="0056"><figref idref="DRAWINGS">FIG. <b>3</b></figref> is a bar graph showing that in vitro cultured human T cells were stimulated to proliferation by anti-CD3 antibodies mAbCD3-001 (this invention) and OKT3 (positive control).</p><p id="p-0063" num="0057"><figref idref="DRAWINGS">FIG. <b>4</b></figref> is a bar graph showing that in vitro cultured human T cells were stimulated to secrete interferon gamma (IFN-g) by anti-CD3 antibodies mAbCD3-001 (this invention) and OKT3 (positive control).</p><p id="p-0064" num="0058"><figref idref="DRAWINGS">FIGS. <b>5</b>A-<b>5</b>H</figref> are fluorescence plots comparing the binding activity of humanized anti-CD3 antibody constructs utilizing different humanized VH variants of mAbCD3-001 and one of two VK variants (EM0006-01VK.1 or EM0006-01VK.1A, see Table 2). The plots show that the VH variants were the key to CD3 binding activity, and that varying the VL had little effect on binding to Jurkat cells. Grouping several plots on graph panels <b>5</b>A-<b>5</b>H allowed identification of humanized antibodies of very high affinity, such as HuEM0006-01-8 and HuEM0006-01-17, by contrasting with intermediate and low affinity binders.</p><p id="p-0065" num="0059"><figref idref="DRAWINGS">FIG. <b>6</b></figref> is a graph showing the ability of various anti-BCMA antibodies to inhibit BCMA ligand BAFF-induced NF-&#x3ba;B phosphorylation in the BCMA-expressing tumor cell line, NCI-H929. An anti-BAFF mAb and an irrelevant anti-RAC1 murine IgG were used as positive and negative controls, respectively. The novel anti-BCMA antibodies mAbBCMA-002 and mAbBCMA-003 described herein compared favorably with reference antibodies (labeled TAB1 and TAB2 in <figref idref="DRAWINGS">FIG. <b>6</b></figref>) described in the patent literature. See Example 3.3, infra, for details.</p><p id="p-0066" num="0060"><figref idref="DRAWINGS">FIG. <b>7</b></figref> is a graph showing the ability of various anti-BCMA antibodies to inhibit BCMA ligand BAFF-induced NF-&#x3ba;B phosphorylation in a HEK293 transfected BCMA-expressing cell line, HEK293F-BCMA-NF-&#x3ba;B-luc. Anti-BCMA reference antibodies TAB1 and TAB2 were used as positive controls for comparison. An irrelevant anti-Ro1 murine IgG was used as control.</p><p id="p-0067" num="0061"><figref idref="DRAWINGS">FIG. <b>8</b></figref> is a graph showing the ability of anti-BCMA antibodies to inhibit BCMA ligand APRIL (TNFSF13) induced NF-kB-luciferase signal in BCMA-transfected HEK293 cells.</p><p id="p-0068" num="0062"><figref idref="DRAWINGS">FIG. <b>9</b></figref> is a graph showing the binding of BCMA/CD3 bispecific FIT-Ig Fab fragments to BCMA-expressing NCI-H929 cells. The three FIT-Fabs tested have the same BCMA binding domain. See Examples 4.1, 4.2, and 4.3.</p><p id="p-0069" num="0063"><figref idref="DRAWINGS">FIG. <b>10</b></figref> is a graph showing the binding of BCMA/CD3 FIT-Ig binding proteins to CHO cells (CHOK1/CD3/TCR) transfected to express the human T cell receptor complex (see Example 1.1). The three FIT-Ig binding proteins tested have different CD3 binding sites, from three different humanized parental anti-CD3 antibodies. See Example 4.3.</p><p id="p-0070" num="0064"><figref idref="DRAWINGS">FIG. <b>11</b></figref> is a graph showing the ability of BCMA/CD3 bispecific FIT-Igs and a BCMA/CD3 FIT-Fab to redirect activation of Jurkat-NFAT cells co-cultured with NCI-H929 cells. Monospecific anti-CD3 IgG (HuEM1006-01-24) and its Fab fragment (HuEM1006-01-24-Fab) were tested for comparison, and an irrelevant human IgG was used as a negative control.</p><p id="p-0071" num="0065"><figref idref="DRAWINGS">FIG. <b>12</b></figref> is a graph showing the ability of BCMA/CD3 bispecific FIT-Fab binding proteins to redirect activation of Jurkat-NFAT cells co-cultured with NCI-H929. A combination of anti-BCMA and anti-CD3 monoclonal antibodies and an irrelevant Fab (FIT1002-5a-Fab) were used as controls.</p><p id="p-0072" num="0066"><figref idref="DRAWINGS">FIG. <b>13</b></figref> is a graph showing the ability of various BCMA/CD3 bispecific FIT-Fabs to redirect T cell cytotoxicity to NCI-H929 cells. An irrelevant FIT-Fab (FIT1002-5a-Fab), a combination of an anti-CD3 Fab and an anti-BCMA mAb (combo), a reference anti-BCMA mAb (TAB1) alone, an anti-CD3 Fab alone (HuEM1006-01-24-Fab), and an irrelevant human IgG were used as controls.</p><p id="p-0073" num="0067"><figref idref="DRAWINGS">FIG. <b>14</b></figref> is a graph showing that humanized BCMA/CD3 FIT-Igs and a BCMA/CD3 FIT-Fab demonstrate limited non-target redirected activation of Jurkat-NFAT cells when the assay is performed without BCMA-expressing NCI-H929 target cells. Anti-CD3 IgG (HuEM1006-01-24), its Fab fragment (HuEM1006-01-24-Fab), an irrelevant FIT-Ig (FIT1002-5a), and an irrelevant human IgG (hIgG) were used as controls.</p><p id="p-0074" num="0068"><figref idref="DRAWINGS">FIG. <b>15</b></figref> is a graph showing that the humanized BCMA/CD3 FIT-Igs according to the invention were able to redirect T cell cytotoxicity to NCI-H929 tumor cells. A mouse-human chimeric FIT-Ig (FIT1006-4b) and an irrelevant FIT-Ig (FIT1002-5a) were used as controls.</p><p id="p-0075" num="0069"><figref idref="DRAWINGS">FIG. <b>16</b></figref> is a graph showing binding activity of two BCMA/CD3 humanized bispecific FIT-Ig binding proteins described above to BCMA-expressing NCI-H929 cells. An irrelevant human IgG antibody (hIgG) was used as a control.</p><p id="p-0076" num="0070"><figref idref="DRAWINGS">FIG. <b>17</b></figref> is a graph showing binding activity of two BCMA/CD3 humanized bispecific FIT-Ig binding proteins described above to CD3-expressing Jurkat cells. An irrelevant human IgG antibody (hIgG) was used as a control.</p><p id="p-0077" num="0071"><figref idref="DRAWINGS">FIGS. <b>18</b> and <b>19</b></figref> demonstrate the binding activity to BCMA-expressing (<figref idref="DRAWINGS">FIG. <b>18</b></figref>) and CD3-expressing (<figref idref="DRAWINGS">FIG. <b>19</b></figref>) target cells, confirm that both targets bispecific constructs of two alternative configurations.</p><p id="p-0078" num="0072"><figref idref="DRAWINGS">FIG. <b>20</b></figref> demonstrates inhibition of tumor growth in human PBMC engrafted NPSG mice achieved by treatment with BCMA x CD3 FIT-Ig.</p><p id="p-0079" num="0073"><figref idref="DRAWINGS">FIG. <b>21</b></figref> demonstrates B cell depletion induced by treatment with BCMA x CD3 FIT-Ig.</p><p id="p-0080" num="0074"><figref idref="DRAWINGS">FIG. <b>22</b></figref> demonstrates transient loss of circulating T cells in FIT-Ig treated cynomolgus monkeys.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0005" level="1">DETAILED DESCRIPTION OF THE INVENTION</heading><p id="p-0081" num="0075">This invention pertains to novel anti-CD3 antibodies, novel anti-BCMA antibodies, antigen-binding portions thereof, and multivalent, bispecific binding proteins such as Fabs-in-Tandem immunoglobulins (FIT-Igs) and monovalent asymmetric tandem Fab bispecific antibody&#x201d; or &#x201c;MAT-Fab bispecific antibody&#x201d; or, simply, a &#x201c;MAT-Fab antibody&#x201d;. Various aspects of the invention relate to anti-CD3 and anti-BCMA antibodies and antibody fragments, FIT-Ig binding proteins, and MAT-Fab binding proteins binding to human CD3 and human BCMA, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such antibodies, functional antibody fragments, and binding proteins. Methods of using the antibodies, functional antibody fragments, and bispecific binding proteins of the invention to detect human CD3, human BCMA, or both; to inhibit human CD3 and/or human BCMA activity, either in vitro or in vivo; and to treat diseases, especially cancer, that are mediated by CD3 and/or BCMA binding to their ligands, i.e., T cell receptor and A proliferation-inducing ligand (APRIL), respectively, are also encompassed by the invention.</p><p id="p-0082" num="0076">Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. The meaning and scope of the terms should be clear, however, in the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. In this application, the use of &#x201c;or&#x201d; means &#x201c;and/or&#x201d; unless stated otherwise. Furthermore, the use of the term &#x201c;including&#x201d;, as well as other forms, such as &#x201c;includes&#x201d; and &#x201c;included&#x201d;, is not limiting. Also, terms such as &#x201c;element&#x201d; or &#x201c;component&#x201d; encompass both elements and components comprising one unit and elements and components that comprise more than one subunit unless specifically stated otherwise.</p><p id="p-0083" num="0077">Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.</p><p id="p-0084" num="0078">That the present invention may be more readily understood, select terms are defined below.</p><p id="p-0085" num="0079">The term &#x201c;polypeptide&#x201d; refers to any polymeric chain of amino acids. The terms &#x201c;peptide&#x201d; and &#x201c;protein&#x201d; are used interchangeably with the term polypeptide and also refer to a polymeric chain of amino acids. The term &#x201c;polypeptide&#x201d; encompasses native or artificial proteins, protein fragments and polypeptide analogs of a protein amino acid sequence. The term &#x201c;polypeptide&#x201d; encompasses fragments and variants (including fragments of variants) thereof, unless otherwise contradicted by context. For an antigenic polypeptide, a fragment of polypeptide optionally contains at least one contiguous or nonlinear epitope of polypeptide. The precise boundaries of the at least one epitope fragment can be confirmed using ordinary skill in the art. The fragment comprises at least about 5 contiguous amino acids, such as at least about 10 contiguous amino acids, at least about 15 contiguous amino acids, or at least about 20 contiguous amino acids. A variant of a polypeptide is as described herein.</p><p id="p-0086" num="0080">The term &#x201c;isolated protein&#x201d; or &#x201c;isolated polypeptide&#x201d; is a protein or polypeptide that by virtue of its origin or source of derivation is not associated with naturally associated components that accompany it in its native state, is substantially free of other proteins from the same species, is expressed by a cell from a different species, or does not occur in nature. Thus, a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be &#x201c;isolated&#x201d; from its naturally associated components. A protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well known in the art.</p><p id="p-0087" num="0081">The term &#x201c;recovering&#x201d; refers to the process of rendering a chemical species such as a polypeptide substantially free of naturally associated components by isolation, e.g., using protein purification techniques well known in the art.</p><p id="p-0088" num="0082">The term &#x201c;biological activity&#x201d; refers to all inherent biological properties of the anti-CD3 or anti-BCMA antibodies described herein. Biological properties of CD3 antibodies include, but are not limited to, binding to CD3 protein; biological properties of anti-BCMA antibodies include, but are not limited to, binding to, e.g., A proliferation-inducing ligand (APRIL), and/or B cell activation factor (BAFF) proteins.</p><p id="p-0089" num="0083">The term &#x201c;specific binding&#x201d; or &#x201c;specifically binding&#x201d; in reference to the interaction of an antibody, a binding protein, or a peptide with a second chemical species, means that the interaction is dependent upon the presence of a particular structure (e.g., an antigenic determinant or epitope) on the second chemical species. For example, an antibody recognizes and binds to a specific protein structure rather than to proteins generally. If an antibody is specific for epitope &#x201c;A&#x201d;, the presence of a molecule containing epitope A (or free, unlabeled A), in a reaction containing labeled &#x201c;A&#x201d; and the antibody, will reduce the amount of labeled A bound to the antibody.</p><p id="p-0090" num="0084">The term &#x201c;antibody&#x201d; broadly refers to any immunoglobulin (Ig) molecule comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains, or any functional fragment, mutant, variant, or derivation thereof, which retains the essential epitope binding features of an Ig molecule. Such mutant, variant, or derivative antibody formats are known in the art. Nonlimiting embodiments of which are discussed below.</p><p id="p-0091" num="0085">In a full-length antibody, each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains: CH1, CH2, and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). Each VH and VL is comprised of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. First, second and third CDRs of a VH domain are commonly enumerated as CDR-H1, CDR-H2, and CDR-H3; likewise, first, second and third CDRs of a VL domain are commonly enumerated as CDR-L1, CDR-L2, and CDR-L3. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass.</p><p id="p-0092" num="0086">The term &#x201c;Fc region&#x201d; is used to define the C-terminal region of an immunoglobulin heavy chain, which may be generated by papain digestion of an intact antibody. The Fc region may be a native sequence Fc region or a variant Fc region. The Fc region of an immunoglobulin generally comprises two constant domains, i.e., a CH2 domain and a CH3 domain, and optionally comprises a CH4 domain, for example, as in the case of the Fc regions of IgM and IgE antibodies. The Fc region of IgG, IgA, and IgD antibodies comprises a hinge region, a CH2 domain, and a CH3 domain. In contrast, the Fc region of IgM and IgE antibodies lacks a hinge region but comprises a CH2 domain, a CH3 domain and a CH4 domain. Variant Fc regions having replacements of amino acid residues in the Fc portion to alter antibody effector function are known in the art (see, e.g., Winter et al., U.S. Pat. Nos. 5,648,260 and 5,624,821). The Fc portion of an antibody mediates several important effector functions, for example, cytokine induction, ADCC, phagocytosis, complement dependent cytotoxicity (CDC), and half-life/clearance rate of antibody and antigen-antibody complexes. In some cases these effector functions are desirable for therapeutic antibody but in other cases might be unnecessary or even deleterious, depending on the therapeutic objectives. Certain human IgG isotypes, particularly IgG1 and IgG3, mediate ADCC and CDC via binding to Fc&#x3b3;Rs and complement C1q, respectively. In still another embodiment at least one amino acid residue is replaced in the constant region of the antibody, for example the Fc region of the antibody, such that effector functions of the antibody are altered. The dimerization of two identical heavy chains of an immunoglobulin is mediated by the dimerization of CH3 domains and is stabilized by the disulfide bonds within the hinge region that connects CH1 constant domains to the Fc constant domains (e.g., CH2 and CH3). The anti-inflammatory activity of IgG is completely dependent on sialylation of the N-linked glycan of the IgG Fc fragment. The precise glycan requirements for anti-inflammatory activity have been determined, such that an appropriate IgG1 Fc fragment can be created, thereby generating a fully recombinant, sialylated IgG1 Fc with greatly enhanced potency (see, Anthony et al., Science, 320:373-376 (2008)).</p><p id="p-0093" num="0087">The terms &#x201c;antigen-binding portion&#x201d; and &#x201c;antigen-binding fragment&#x201d; or &#x201c;functional fragment&#x201d; of an antibody are used interchangeably and refer to one or more fragments of an antibody that retain the ability to specifically bind to an antigen, i.e., the same antigen (e.g., CD3, BCMA) as the full-length antibody from which the portion or fragment is derived. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Such antibody embodiments may also be bispecific, dual specific, or multi-specific formats; specifically binding to two or more different antigens (e.g., CD3 and a different antigen, such as BCMA). Examples of binding fragments encompassed within the term &#x201c;antigen-binding portion&#x201d; of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) a F(ab&#x2032;)<sub>2 </sub>fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., Nature, 341: 544-546 (1989); PCT Publication No. WO 90/05144), which comprises a single variable domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see, for example, Bird et al., Science, 242: 423-426 (1988); and Huston et al., <i>Proc. Natl. Acad. Sci. USA, </i>85: 5879-5883 (1988)). Such single chain antibodies are also intended to be encompassed within the term &#x201c;antigen-binding portion&#x201d; of an antibody and equivalent terms given above. Other forms of single chain antibodies, such as diabodies are also encompassed. Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see, for example, Holliger et al., Proc. Natl. Acad. Sci. USA, 90: 6444-6448 (1993). Such antibody binding portions are known in the art (Kontermann and D&#xfc;bel eds., <i>Antibody Engineering </i>(Springer-Verlag, New York, 2001), p. 790 (ISBN 3-540-41354-5)). In addition, single chain antibodies also include &#x201c;linear antibodies&#x201d; comprising a pair of tandem Fv segments (VH-CH1-VH-CH1) which, together with complementary light chain polypeptides, form a pair of antigen binding regions (Zapata et al., <i>Protein Eng., </i>8(10): 1057-1062 (1995); and U.S. Pat. No. 5,641,870)).</p><p id="p-0094" num="0088">An immunoglobulin constant (C) domain refers to a heavy (CH) or light (CL) chain constant domain. Murine and human IgG heavy chain and light chain constant domain amino acid sequences are known in the art.</p><p id="p-0095" num="0089">The term &#x201c;monoclonal antibody&#x201d; or &#x201c;mAb&#x201d; refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic determinant (epitope). Furthermore, in contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each mAb is directed against a single determinant on the antigen. The modifier &#x201c;monoclonal&#x201d; is not to be construed as requiring production of the antibody by any particular method.</p><p id="p-0096" num="0090">The term &#x201c;human antibody&#x201d; includes antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3. However, the term &#x201c;human antibody&#x201d; does not include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.</p><p id="p-0097" num="0091">The term &#x201c;recombinant human antibody&#x201d; includes all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant, combinatorial human antibody library (Hoogenboom, H. R., <i>Trends Biotechnol., </i>15: 62-70 (1997); Azzazy and Highsmith, <i>Clin. Biochem., </i>35: 425-445 (2002); Gavilondo and Larrick, <i>BioTechniques, </i>29: 128-145 (2000); Hoogenboom and Chames, <i>Immunol. Today, </i>21: 371-378 (2000)), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see, e.g., Taylor et al., <i>Nucl. Acids Res., </i>20: 6287-6295 (1992); Kellermann and Green, <i>Curr. Opin. Biotechnol., </i>13: 593-597 (2002); Little et al., <i>Immunol. Today, </i>21: 364-370 (2000)); or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.</p><p id="p-0098" num="0092">The term &#x201c;chimeric antibody&#x201d; refers to antibodies that comprise heavy and light chain variable region sequences from one species and constant region sequences from another species, such as antibodies having murine heavy and light chain variable regions linked to human constant regions.</p><p id="p-0099" num="0093">The term &#x201c;CDR-grafted antibody&#x201d; refers to antibodies that comprise heavy and light chain variable region sequences from one species but in which the sequences of one or more of the CDR regions of VH and/or VL are replaced with CDR sequences of another species, such as antibodies having human heavy and light chain variable regions in which one or more of the human CDRs has been replaced with murine CDR sequences.</p><p id="p-0100" num="0094">The term &#x201c;humanized antibody&#x201d; refers to antibodies that comprise heavy and light chain variable region sequences from a non-human species (e.g., a mouse) but in which at least a portion of the VH and/or VL sequence has been altered to be more &#x201c;human-like&#x201d;, i.e., more similar to human germline variable sequences. One type of humanized antibody is a CDR-grafted antibody, in which CDR sequences from a non-human species (e.g., mouse) are introduced into human VH and VL framework sequences. A humanized antibody is an antibody or a variant, derivative, analog or fragment thereof which immunospecifically binds to an antigen of interest and which comprises framework regions and constant regions having substantially the amino acid sequence of a human antibody but complementarity determining regions (CDRs) having substantially the amino acid sequence of a non-human antibody. As used herein, the term &#x201c;substantially&#x201d; in the context of a CDR refers to a CDR having an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% identical to the amino acid sequence of a non-human antibody CDR. A humanized antibody comprises substantially all of at least one, and typically two, variable domains (Fab, Fab&#x2032;, F(ab&#x2032;)<sub>2</sub>, Fv) in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin (i.e., donor antibody) and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. In an embodiment, a humanized antibody also comprises at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. In some embodiments, a humanized antibody contains both the light chain as well as at least the variable domain of a heavy chain. The antibody also may include the CH1, hinge, CH2, CH3, and CH4 regions of the heavy chain. In some embodiments, a humanized antibody only contains a humanized light chain. In some embodiments, a humanized antibody only contains a humanized heavy chain. In specific embodiments, a humanized antibody only contains a humanized variable domain of a light chain and/or humanized heavy chain.</p><p id="p-0101" num="0095">A humanized antibody may be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA and IgE, and any isotype, including without limitation IgG1, IgG2, IgG3, and IgG4. The humanized antibody may comprise sequences from more than one class or isotype, and particular constant domains may be selected to optimize desired effector functions using techniques well known in the art.</p><p id="p-0102" num="0096">The framework and CDR regions of a humanized antibody need not correspond precisely to the parental sequences, e.g., the donor antibody CDR or the acceptor framework may be mutagenized by substitution, insertion and/or deletion of at least one amino acid residue so that the CDR or framework residue at that site does not correspond to either the donor antibody or the consensus framework. In an exemplary embodiment, such mutations, however, will not be extensive. Usually, at least 80%, for instance, at least 85%, at least 90%, or at least 95% of the humanized antibody residues will correspond to those of the parental FR and CDR sequences. Back mutation at a particular framework position to restore the same amino acid that appears at that position in the donor antibody is often utilized to preserve a particular loop structure or to correctly orient the CDR sequences for contact with target antigen.</p><p id="p-0103" num="0097">The term &#x201c;CDR&#x201d; refers to the complementarity determining regions within antibody variable domain sequences. There are three CDRs in each of the variable regions of the heavy chain and the light chain, which are designated CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3. The term &#x201c;CDR set&#x201d; as used herein refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat et al., <i>Sequences of Proteins of Immunological Interest </i>(National Institutes of Health, Bethesda, Md. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries defining the three CDRs.</p><p id="p-0104" num="0098">The term &#x201c;Kabat numbering&#x201d;, which is recognized in the art, refers to a system of numbering amino acid residues which are more variable (i.e., hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody or an antigen-binding portion thereof. See, Kabat et al., <i>Ann. NY Acad. Sci., </i>190: 382-391 (1971); and Kabat et al., <i>Sequences of Proteins of Immunological Interest, Fifth Edition</i>, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 (1991).</p><p id="p-0105" num="0099">The growth and analysis of extensive public databases of amino acid sequences of variable heavy and light regions over the past twenty years have led to the understanding of the typical boundaries between framework regions (FRs) and CDR sequences within variable region sequences and have enabled persons skilled in the art to accurately determine the CDRs according to Kabat numbering, Chothia numbering, or other systems. See, e.g., Martin, &#x201c;Protein Sequence and Structure Analysis of Antibody Variable Domains,&#x201d; In Kontermann and D&#xfc;bel, eds., <i>Antibody Engineering </i>(Springer-Verlag, Berlin, 2001), chapter 31, pages 432-433.</p><p id="p-0106" num="0100">The term &#x201c;multivalent binding protein&#x201d; denotes a binding protein comprising two or more antigen binding sites. A multivalent binding protein is preferably engineered to have three or more antigen binding sites, and is generally not a naturally occurring antibody. The term &#x201c;bispecific binding protein&#x201d; refers to a binding protein capable of binding two targets of different specificity. &#x201c;Fabs-in-Tandem immunoglobulin&#x201d; (FIT-Ig) binding proteins of the invention comprise two or more antigen binding sites and are typically tetravalent binding proteins. A FIT-Ig may be monospecific, i.e., capable of binding one antigen, or multispecific, i.e., capable of binding two or more antigens. An exemplary FIT-Ig according to this invention binds both CD3 and BCMA and, therefore, is bispecific. A FIT-Ig binding protein comprising two long (heavy) V-C-V-C-Fc chain polypeptides and four short (light) V-C chain polypeptides forms a hexamer exhibiting four Fab antigen binding sites (VH-CH1 paired with VL-CL, sometimes notated VH-CH1::VL-CL). Each half of a FIT-Ig comprises a heavy chain polypeptide and two light chain polypeptides, and complementary immunoglobulin pairing of the VH-CH1 and VL-CL elements of the three chains results in two Fab-structured antigen binding sites, arranged in tandem. In the present invention, it is preferred that the immunoglobulin domains comprising the Fab elements are directly fused in the heavy chain polypeptide, without the use of interdomain linkers. That is, the N-terminal V-C element of the long (heavy) polypeptide chains is directly fused at its C-terminus to the N-terminus of another V-C element, which in turn is linked to a C-terminal Fc region. In bispecific FIT-Ig binding proteins, the tandem Fab elements will be reactive with different antigens. Each Fab antigen binding site comprises a heavy chain variable domain and a light chain variable domain with a total of six CDRs per antigen binding site. In some embodiment, the multivalent binding protein of this invention is a FIT-Ig Fab fragment (i.e., FIT-Fab), which is virtually a FIT-Ig without the C-terminal Fc region. Such FIT-Fab can be obtained by removal of the C-terminal Fc region from an existing FIT-Ig, or produced by any of a number of techniques known in the art, for example, expression from host cells comprising expression vector(s) encoding the corresponding peptide chains.</p><p id="p-0107" num="0101">A description of the design, expression, and characterization of FIT-Ig molecules is provided in PCT Publication WO 2015/103072. An example of such FIT-Ig molecules comprises a heavy chain and two different light chains. The heavy chain comprises the structural formula VL<sub>A</sub>-CL-VH<sub>B</sub>-CH1-Fc where CL is directly fused to VH<sub>B </sub>or VH<sub>B</sub>-CH1-VL<sub>A</sub>-CL-Fc where CH1 is directly fused to VL<sub>A</sub>, wherein VL<sub>A </sub>is a variable light domain from a parental antibody that binds antigen A, VH<sub>B </sub>is a variable heavy domain from a parental antibody that binds antigen B, CL is a light chain constant domain, CH1 is a heavy chain constant domain, and Fe is an immunoglobulin Fc region (e.g., the C-terminal hinge-CH2-CH3 portion of a heavy chain of an IgG1 antibody). The two light polypeptide chains of the FIT-Ig have the formulas VH<sub>A</sub>-CH1 and VL<sub>B</sub>-CL, respectively. In bispecific FIT-Ig embodiments, antigen A and antigen B are different antigens, or different epitopes of the same antigen. In the present invention, one of A and B is CD3 and the other is BCMA.</p><p id="p-0108" num="0102">As used herein, the term &#x201c;fused directly&#x201d; or &#x201c;directly fused&#x201d;, when referring to the linear connection of two domains in a polypeptide structure, means that the domains are joined directly by a peptide bond, without the use of an artificial polypeptide linker or connector.</p><p id="p-0109" num="0103">The term &#x201c;activity&#x201d; includes properties such as the ability to bind a target antigen with specificity, the affinity of an antibody for an antigen, the ability to neutralize the biological activity of a target antigen, the ability to inhibit interaction of a target antigen with its natural receptor(s), and the like. Exemplary antibodies and binding proteins of the present invention have the ability to inhibit CD3 binding to its ligand, the ability to inhibit BCMA binding to its ligand, or both in the case of bispecific binding proteins described herein.</p><p id="p-0110" num="0104">The term &#x201c;k<sub>on</sub>&#x201d; (also &#x201c;Kon&#x201d;, &#x201c;kon&#x201d;), as used herein, is intended to refer to the on rate constant for association of a binding protein (e.g., an antibody) to an antigen to form an association complex, e.g., antibody/antigen complex, as is known in the art. The &#x201c;k<sub>on</sub>&#x201d; also is known by the terms &#x201c;association rate constant&#x201d;, or &#x201c;ka&#x201d;, as used interchangeably herein. This value indicates the binding rate of an antibody to its target antigen or the rate of complex formation between an antibody and antigen as is shown by the equation below:</p><p id="p-0111" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>Antibody (&#x201c;Ab&#x201d;)+Antigen (&#x201c;Ag&#x201d;)&#x2192;Ab-Ag.<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0112" num="0105">The term &#x201c;k<sub>off</sub>&#x201d; (also &#x201c;Koff&#x201d;, &#x201c;koff&#x201d;), as used herein, is intended to refer to the off rate constant for dissociation, or &#x201c;dissociation rate constant&#x201d;, of a binding protein (e.g., an antibody) from an association complex (e.g., an antibody/antigen complex) as is known in the art. This value indicates the dissociation rate of an antibody from its target antigen or separation of Ab-Ag complex over time into free antibody and antigen as shown by the equation below:</p><p id="p-0113" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>Ab+Ag&#x2190;Ab-Ag.<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0114" num="0106">The term &#x201c;K<sub>D</sub>&#x201d; (also &#x201c;K<sub>d</sub>&#x201d;), as used herein, is intended to refer to the &#x201c;equilibrium dissociation constant&#x201d; and refers to the value obtained in a titration measurement at equilibrium, or by dividing the dissociation rate constant (k<sub>off</sub>) by the association rate constant (k<sub>on</sub>). The association rate constant (k<sub>on</sub>), the dissociation rate constant (k<sub>off</sub>), and the equilibrium dissociation constant (K<sub>D</sub>) are used to represent the binding affinity of an antibody to an antigen. Methods for determining association and dissociation rate constants are well known in the art. Using fluorescence-based techniques offers high sensitivity and the ability to examine samples in physiological buffers at equilibrium. Other experimental approaches and instruments such as a BIAcore&#xae; (biomolecular interaction analysis) assay can be used (e.g., instrument available from BIAcore International AB, a GE Healthcare company, Uppsala, Sweden). Biolayer interferometry (BLI) using, e.g., the Octet&#xae; RED96 system (Pall ForteBio LLC), is another affinity assay technique. Additionally, a KinExA&#xae; (Kinetic Exclusion Assay) assay, available from Sapidyne Instruments (Boise, Id.) can also be used.</p><p id="p-0115" num="0107">The term &#x201c;isolated nucleic acid&#x201d; shall mean a polynucleotide (e.g., of genomic, cDNA, or synthetic origin, or some combination thereof) that, by human intervention, is not associated with all or a portion of the polynucleotides with which it is found in nature; is operably linked to a polynucleotide that it is not linked to in nature; or does not occur in nature as part of a larger sequence.</p><p id="p-0116" num="0108">The term &#x201c;vector&#x201d;, as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a &#x201c;plasmid&#x201d;, which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as &#x201c;recombinant expression vectors&#x201d; (or simply, &#x201c;expression vectors&#x201d;). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, &#x201c;plasmid&#x201d; and &#x201c;vector&#x201d; may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.</p><p id="p-0117" num="0109">The term &#x201c;operably linked&#x201d; refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence &#x201c;operably linked&#x201d; to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequence. &#x201c;Operably linked&#x201d; sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. The term &#x201c;expression control sequence&#x201d; as used herein refers to polynucleotide sequences that are necessary to effect the expression and processing of coding sequences to which they are ligated. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences include promoters and transcription termination sequence. The term &#x201c;control sequences&#x201d; is intended to include components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader or signal sequences and fusion partner sequences.</p><p id="p-0118" num="0110">&#x201c;Transformation&#x201d;, as defined herein, refers to any process by which exogenous DNA enters a host cell. Transformation may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed and may include, but is not limited to, transfection, viral infection, electroporation, lipofection, and particle bombardment. Such &#x201c;transformed&#x201d; cells include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome. They also include cells which transiently express the inserted DNA or RNA for limited periods of time.</p><p id="p-0119" num="0111">The term &#x201c;recombinant host cell&#x201d; (or simply &#x201c;host cell&#x201d;), is intended to refer to a cell into which exogenous DNA has been introduced. In an embodiment, the host cell comprises two or more (e.g., multiple) nucleic acids encoding antibodies, such as the host cells described in U.S. Pat. No. 7,262,028, for example. Such terms are intended to refer not only to the particular subject cell, but also to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term &#x201c;host cell&#x201d; as used herein. In an embodiment, host cells include prokaryotic and eukaryotic cells selected from any of the Kingdoms of life. In another embodiment, eukaryotic cells include protist, fungal, plant and animal cells. In another embodiment, host cells include but are not limited to the prokaryotic cell line <i>Escherichia coli</i>; mammalian cell lines CHO, HEK 293, COS, NS0, SP2 and PER.C6; the insect cell line Sf9; and the fungal cell <i>Saccharomyces cerevisiae. </i></p><p id="p-0120" num="0112">Standard techniques may be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques may be performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures may be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook et al., <i>Molecular Cloning: A Laboratory Manual, </i>2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).</p><p id="p-0121" num="0113">The term &#x201c;agonist&#x201d;, as used herein, refers to a modulator that, when contacted with a molecule of interest, causes an increase in the magnitude of a certain activity or function of the molecule compared to the magnitude of the activity or function observed in the absence of the agonist. The terms &#x201c;antagonist&#x201d; and &#x201c;inhibitor&#x201d;, as used herein, refer to a modulator that, when contacted with a molecule of interest causes a decrease in the magnitude of a certain activity or function of the molecule compared to the magnitude of the activity or function observed in the absence of the antagonist. Particular antagonists of interest include those that block or reduce the biological or immunological activity of human CD3 and human BCMA.</p><p id="p-0122" num="0114">As used herein, the term &#x201c;effective amount&#x201d; refers to the amount of a therapy that is sufficient to reduce or ameliorate the severity and/or duration of a disorder or one or more symptoms thereof; prevent the advancement of a disorder; cause regression of a disorder; prevent the recurrence, development, or progression of one or more symptoms associated with a disorder; detect a disorder; or enhance or improve the prophylactic or therapeutic effect(s) of another therapy (e.g., prophylactic or therapeutic agent).</p><heading id="h-0006" level="2">Production of Anti-CD3 and Anti-BCMA Antibodies</heading><p id="p-0123" num="0115">Anti-CD3 and anti-BCMA antibodies of the present invention may be produced by any of a number of techniques known in the art. For example, expression from host cells, wherein expression vector(s) encoding the heavy and light chains is (are) transfected into a host cell by standard techniques. The various forms of the term &#x201c;transfection&#x201d; are intended to encompass a wide variety of techniques commonly used for the introduction of exogenous DNA into a prokaryotic or eukaryotic host cell, e.g., electroporation, calcium-phosphate precipitation, DEAE-dextran transfection, and the like. Although it is possible to express the antibodies of the invention in either prokaryotic or eukaryotic host cells, expression of antibodies in eukaryotic cells is preferable, and for instance, in mammalian host cells, because such eukaryotic cells (and in particular mammalian cells) are more likely than prokaryotic cells to assemble and secrete a properly folded and immunologically active antibody.</p><p id="p-0124" num="0116">Exemplary mammalian host cells for expressing the recombinant antibodies of the invention include Chinese Hamster Ovary (CHO cells) (including dhfr CHO cells, described in Urlaub and Chasin, <i>Proc. Natl. Acad. Sci. USA, </i>77: 4216-4220 (1980), used with a DHFR selectable marker, e.g., as described in Kaufman and Sharp, <i>J. Mol. Biol., </i>159: 601-621 (1982)), NS0 myeloma cells, COS cells, and SP2 cells. When recombinant expression vectors encoding antibody genes are introduced into mammalian host cells, the antibodies are produced by culturing the host cells for a period of time sufficient to allow for expression of the antibody in the host cells or, secretion of the antibody into the culture medium in which the host cells are grown. Antibodies can be recovered from the culture medium using standard protein purification methods.</p><p id="p-0125" num="0117">Host cells can also be used to produce functional antibody fragments, such as Fab fragments or scFv molecules. It will be understood that variations on the above procedure are within the scope of the present invention. For example, it may be desirable to transfect a host cell with DNA encoding functional fragments of either the light chain and/or the heavy chain of an antibody of this invention. Recombinant DNA technology may also be used to remove some, or all, of the DNA encoding either or both of the light and heavy chains that is not necessary for binding to the antigens of interest. The molecules expressed from such truncated DNA molecules are also encompassed by the antibodies of the invention. In addition, bifunctional antibodies may be produced in which one heavy and one light chain are an antibody of the invention and the other heavy and light chain are specific for an antigen other than the antigens of interest by crosslinking an antibody of the invention to a second antibody by standard chemical crosslinking methods.</p><p id="p-0126" num="0118">In an exemplary system for recombinant expression of an antibody, or antigen-binding portion thereof, of the invention, a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain is introduced into dhfr CHO cells by calcium phosphate-mediated transfection. Within the recombinant expression vector, the antibody heavy and light chain genes are each operatively linked to CMV enhancer/AdMLP promoter regulatory elements to drive high levels of transcription of the genes. The recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification. The selected transfected host cells are cultured to allow for expression of the antibody heavy and light chains and intact antibody is recovered from the culture medium. Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transfectants, culture the host cells and recover the antibody from the culture medium. Still further the invention provides a method of making a recombinant anti-CD3 or anti-BCMA antibody of the invention by culturing a transfected host cell of the invention in a suitable culture medium until a recombinant antibody of the invention is produced. The method can further comprise isolating the recombinant antibody from the culture medium.</p><heading id="h-0007" level="2">Production of Bispecific FIT-Igs Binding CD3 and BCMA</heading><p id="p-0127" num="0119">This invention provides Fabs-in-Tandem immunoglobulin binding proteins (FIT-Igs) that bind to both CD3 and BCMA. An exemplary embodiment of such FIT-Ig molecules comprises (1) a heavy polypeptide chain that comprises either the structural formula (i) VL<sub>A</sub>-CL-VH<sub>B</sub>-CH1-Fc wherein CL is directly fused to VH<sub>B</sub>, or the structural formula (ii) VH<sub>B</sub>-CH1-VL<sub>A</sub>-CL-Fc wherein CH1 is directly fused to VL<sub>A</sub>; (2) a light polypeptide chain of the formula VH<sub>A</sub>-CH1; and (3) another light polypeptide chain of the formula VL<sub>B</sub>-CL,</p><p id="p-0128" num="0120">wherein VL is a light chain variable domain, CL is a light chain constant domain, VH is a heavy chain variable domain, CH1 is a heavy chain constant domain, Fc is an immunoglobulin Fc region, A is an epitope of CD3 or BCMA and B is an epitope of CD3 or BCMA, with the proviso that A and B are different. In accordance with the present invention, such FIT-Ig binding proteins bind to both CD3 and BCMA.</p><p id="p-0129" num="0121">When expressed recombinantly in a suitable host cell, the three chains of a FIT-Ig typically associate, in the same manner as a natural immunoglobulin, into a six-chain, multivalent, monomeric protein wherein two of such heavy chains (1), two of such light chains (2), and two of such light chains (3), associate to form a six-chain binding protein monomer exhibiting four functional Fab antigen binding sites. Such a FIT-Ig binding protein comprises two identical subunits, wherein each subunit comprises one heavy chain (1), one light chain (2), and one light chain (3) that together form a pair of Fab binding sites arranged in tandem. Pairing of the Fc regions of two such heavy chain subunits yields a six-chain, bispecific, FIT-Ig binding protein of the invention having a total of four functional Fab binding units.</p><p id="p-0130" num="0122">It is possible to use a peptide linker on the heavy chain to separate the tandemly connected Fab moieties, however for bispecific FIT-Igs according to the invention the omission of such linker sequences is preferred. Whereas in multivalent engineered immunoglobulin formats having tandem binding sites, it was commonly understood in the field that the adjacent binding sites would interfere with each other unless a flexible linker was used to separate the binding sites spatially. It has been discovered for the BCMA/CD3 FIT-Igs of the present invention, however, that the arrangement of the immunoglobulin domains according to the chain formulas given above results in polypeptide chains that are well-expressed in transfected mammalian cells, assemble appropriately, and are secreted as bispecific, multivalent immunoglobulin-like binding proteins that bind the target antigens CD3 and BCMA. Despite the absence of any linker sequences between the Fab binding sites, the BCMA/CD3 FIT-Igs of the invention retain the binding affinities for the target antigens, exhibiting comparable binding affinities to the parental mAbs. Moreover, omission of synthetic linker sequences from the binding proteins can avoid the creation of antigenic sites recognizable by mammalian immune systems, and in this way the elimination of linkers decreases possible immunogenicity of the FIT-Igs and leads to a half-life in circulation that is like a natural antibody, that is, the FIT-Ig is not rapidly cleared through immune opsonization and capture in the liver.</p><p id="p-0131" num="0123">Each variable domain (VH or VL) in a FIT-Ig may be obtained from one or more &#x201c;parental&#x201d; monoclonal antibodies that bind one of the target antigens, i.e., CD3 or BCMA. FIT-Ig binding proteins are advantageously produced using variable domain sequences of anti-CD3 and anti-BCMA monoclonal antibodies as disclosed herein. For instance, the parental antibodies are humanized antibodies. Variable domains may also be prepared or improved using affinity maturation techniques.</p><p id="p-0132" num="0124">An aspect of the present invention pertains to selecting parental antibodies with at least one or more properties desired in the FIT-Ig molecule. In an embodiment, the antibody properties are selected from the group consisting of antigen specificity, affinity to antigen, potency, biological function, epitope recognition, stability, solubility, production efficiency, lack of immunogenicity, pharmacokinetics, bioavailability, tissue cross-reactivity, and orthologous antigen binding. CD3 and BCMA are both cell surface proteins, and interaction with their respective ligands touches off intracellular signaling pathways; accordingly, optimal bispecific BCMA/CD3 FIT-Igs and FIT-Fabs of the invention will be able to inhibit or block CD3-mediated and/or BCMA-mediated signaling.</p><p id="p-0133" num="0125">Antibodies, functional fragments thereof, and binding proteins according to the invention may be purified (for an intended use) by using one or more of a variety of methods and materials available in the art for purifying antibodies and binding proteins. Such methods and materials include, but are not limited to, affinity chromatography (e.g., using resins, particles, or membranes conjugated to Protein A, Protein G, Protein L, or a specific ligand of the antibody, functional fragment thereof, or binding protein), ion exchange chromatography (for example, using ion exchange particles or membranes), hydrophobic interaction chromatography (&#x201c;HIC&#x201d;; for example, using hydrophobic particles or membranes), ultrafiltration, nanofiltration, diafiltration, size exclusion chromatography (&#x201c;SEC&#x201d;), low pH treatment (to inactivate contaminating viruses), and combinations thereof, to obtain an acceptable purity for an intended use. Anon-limiting example of a low pH treatment to inactivate contaminating viruses comprises reducing the pH of a solution or suspension comprising an antibody, functional fragment thereof, or binding protein of the invention to pH 3.5 with 0.5 M phosphoric acid, at 18&#xb0; C.-25&#xb0; C., for 60 to 70 minutes.</p><heading id="h-0008" level="2">Uses of Antibodies and Binding Proteins of the Invention</heading><p id="p-0134" num="0126">Given their ability to bind to human CD3 and/or BCMA, the antibodies described herein, functional fragments thereof, and bispecific multivalent binding proteins described herein can be used to detect CD3 or BCMA, or both, e.g., in a biological sample containing cells that express one or both of those target antigens. The antibodies, functional fragments, and binding proteins of the invention can be used in a conventional immunoassay, such as an enzyme linked immunosorbent assay (ELISA), a radioimmunoassay (RIA), or tissue immunohistochemistry. The invention provides a method for detecting CD3 or BCMA in a biological sample comprising contacting a biological sample with an antibody, antigen-binding portion thereof, or binding protein of the invention and detecting whether binding to a target antigen occurs, thereby detecting the presence or absence of the target in the biological sample. The antibody, functional fragment, or binding protein may be directly or indirectly labeled with a detectable substance to facilitate detection of the bound or unbound antibody/fragment/binding protein. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, p-galactosidase, or acetylcholinesterase. Examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; and examples of suitable radioactive material include <sup>3</sup>H, <sup>14</sup>C, <sup>35</sup>S, <sup>90</sup>Y, <sup>99</sup>Tc, <sup>111</sup>In, <sup>125</sup>I, <sup>131</sup>I, <sup>177</sup>Lu, <sup>166</sup>Ho, or <sup>153</sup>Sm.</p><p id="p-0135" num="0127">The antibodies, functional fragments thereof, and binding proteins of the invention preferably are capable of neutralizing human CD3 and/or human BCMA activity both in vitro and in vivo. Accordingly, the antibodies, functional fragments thereof, and binding proteins of the invention can be used to inhibit human CD3 and/or human BCMA activity, e.g., inhibit cell signaling mediated by CD3/T cell interaction and/or BCMA/B cell interaction in a cell culture containing CD3-expressing and/or BCMA-expressing cells, in human subjects, or in other mammalian subjects having CD3 or BCMA with which an antibody, functional fragment thereof, or binding protein of the invention cross-reacts.</p><p id="p-0136" num="0128">In another embodiment, the invention provides a method for treating a subject suffering from a disease or disorder in which CD3 and/or BCMA activity is detrimental, such method comprising administering to the subject an antibody or binding protein of the invention in an effective amount, such that activity mediated by CD3 binding and/or BCMA binding in the subject is reduced.</p><p id="p-0137" num="0129">As used herein, the term &#x201c;a disorder in which CD3 and/or BCMA activity is detrimental&#x201d; is intended to include diseases and other disorders in which the interaction of CD3 with a CD3 ligand or the interaction of BCMA with a BCMA ligand in a subject suffering from the disorder is either responsible for the pathophysiology of the disorder or is a factor that contributes to a worsening of the disorder. Accordingly, a disorder in which CD3 and/or BCMA activity is detrimental is a disorder in which inhibition of CD3 and/or BCMA activity is expected to alleviate the symptoms and/or progression of the disorder.</p><p id="p-0138" num="0130">In another embodiment, the present invention provides methods for treating an autoimmune disease or a cancer in a subject in need thereof, comprising administering to the subject an antibody, functional fragment thereof, or a binding protein described herein that is capable of binding CD3, BCMA, or both CD3 and BCMA, and wherein the autoimmune disease or cancer is a disease that is responsive to immunotherapy. In another embodiment, a method of the invention is used for treating an autoimmune disease or cancer that has not been associated with immunotherapy. In another embodiment, a method of the invention is used for treating a cancer that is a refractory or a recurring malignancy. In another embodiment, a CD3 or BCMA antibody, functional fragment thereof, or a BCMA/CD3 bispecific binding protein of the invention is used in a method that inhibits the growth or survival of tumor cells.</p><p id="p-0139" num="0131">In another embodiment, the invention provides a method for treating cancer in a subject comprising the step of administering to the subject an antibody to CD3 or BCMA described herein, a functional fragment thereof, or a BCMA/CD3 bispecific binding protein described herein, e.g., such as a Fabs-in-tandem immunoglobulin (FIT-Ig) binding protein, or a MAT-Fab binding protein wherein the cancer is selected from any of a group consisting of: a melanoma (e.g., metastatic malignant melanoma), a renal cancer (e.g., clear cell carcinoma), a prostate cancer (e.g. hormone refractory prostate adenocarcinoma), a pancreatic adenocarcinoma, a breast cancer, a colon cancer, a lung cancer (e.g. non-small cell lung cancer), an esophageal cancer, a squamous cell carcinoma of the head and neck, a liver cancer, an ovarian cancer, a cervical cancer, a thyroid cancer, a glioblastoma, a glioma, a leukemia, a lymphoma, a primary bone cancer (e.g., osteosarcoma, Ewing sarcoma, malignant fibrous histiocytoma, and chondrosarcoma), a metastatic cancer, and other neoplastic malignancies.</p><p id="p-0140" num="0132">The invention also provides pharmaceutical compositions comprising an antibody, or antigen-binding portion thereof, or a bispecific multivalent binding protein of the invention (i.e., the primary active ingredient), or a bispecific monovalent binding protein of the invention and a pharmaceutically acceptable carrier. The pharmaceutical compositions comprising proteins of the invention are for use in, but not limited to, diagnosing, detecting, or monitoring a disorder; treating, managing, or ameliorating a disorder or one or more symptoms thereof; and/or research. In a specific embodiment, a composition comprises one or more antibodies or binding proteins of the invention. In another embodiment, the pharmaceutical composition comprises one or more antibodies or binding proteins of the invention and one or more prophylactic or therapeutic agents other than antibodies or binding proteins of the invention for treating a disorder in which CD3 and/or BCMA activity is detrimental. In an embodiment, the prophylactic or therapeutic agents are known to be useful for or have been or currently are being used in the prevention, treatment, management, or amelioration of a disorder or one or more symptoms thereof. In accordance with these embodiments, the composition may further comprise a carrier, diluent. or excipient. An excipient is generally any compound or combination of compounds that provides a desired feature to a composition other than that of the primary active ingredient (i.e., other than an antibody, functional portion thereof, or binding protein of the invention).</p><p id="p-0141" num="0133">The antibodies (including functional fragments thereof) and binding proteins of the invention can be incorporated into pharmaceutical compositions suitable for administration to a subject. Typically, the pharmaceutical composition comprises an antibody or binding protein of the invention and a pharmaceutically acceptable carrier. As used herein, &#x201c;pharmaceutically acceptable carrier&#x201d; includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Examples of pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols (such as, mannitol or sorbitol), or sodium chloride in the composition. Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives, or buffers, which enhance the shelf life or effectiveness of the antibody or binding protein present in the composition.</p><p id="p-0142" num="0134">A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include, but are not limited to, parenteral (e.g., intravenous, intradermal, subcutaneous, intramuscular), oral, intranasal (e.g., inhalation), transdermal (e.g., topical), intratumoral, transmucosal, and rectal administration. In a specific embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous, subcutaneous, intramuscular, oral, intranasal, or topical administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic, such as lidocaine (xylocaine, lignocaine), to ease pain at the site of the injection.</p><p id="p-0143" num="0135">The method of the invention may comprise administration of a composition formulated for parenteral administration by injection (e.g., by bolus injection or continuous infusion). Formulations for injection may be presented in unit dosage form (e.g., in ampoules or in multi-dose containers) with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the primary active ingredient may be in powder form for constitution with a suitable vehicle (e.g., sterile pyrogen-free water) before use.</p><p id="p-0144" num="0136">The methods of the invention may additionally comprise administration of compositions formulated as depot preparations. Such long acting formulations may be administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compositions may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g., as a sparingly soluble salt).</p><p id="p-0145" num="0137">An antibody, functional fragment thereof, or binding protein of the invention also can be administered with one or more additional therapeutic agents useful in the treatment of various diseases. Antibodies, functional fragments thereof, and binding proteins described herein can be used alone or in combination with an additional agent, e.g., a therapeutic agent, said additional agent being selected by the skilled artisan for its intended purpose. For example, the additional agent can be a therapeutic agent art-recognized as being useful to treat the disease or condition being treated by the antibody or binding protein of the present invention. The additional agent also can be an agent that imparts a beneficial attribute to the therapeutic composition, e.g., an agent that affects the viscosity of the composition.</p><p id="p-0146" num="0138">Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples, which are included for purposes of illustration only and are not intended to be limiting of the invention.</p><heading id="h-0009" level="1">EXAMPLES</heading><heading id="h-0010" level="1">Example 1: Generation of Anti-human CD3 Monoclonal Antibodies</heading><p id="p-0147" num="0139">Anti-human CD3 monoclonal antibodies were generated as follows:</p><heading id="h-0011" level="1">Example 1.1: Immunization with Human CD3 Antigen</heading><p id="p-0148" num="0140">Anti-CD3 antibodies were obtained by immunizing groups of ten Balb/c and SJL/J mice (Shanghai Laboratory Animal Center) with an alternative immunization strategies. Four different CD3 immunogens were used, which included 2 peptides (CD3&#x3b5; fragments: LSLKEFSELEQSGYYVC (SEQ ID NO:2) and QDGNEEMGGITQTPYK (SEQ ID NO:3), a recombinant huCD3&#x3b5;&#x3b3;/Fc fusion protein (a fusion protein heterodimer: first chain, QDGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNIGGDEDDKNIGSDEDH LSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMDGSSGSSDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP QVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:4) and second chain, QSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGKMIGFLTEDKKKWNLGSNAKD PRGMYQCKGSQNKSKPLQVYYRMCQNCIELNAATISGSSGSSDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDE LTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:5)), and a CHO cell line (CHOK1/CD3/TCR) transfected with full-length human CD3&#x3b3; chain, CD3&#x3b5; chain, CD3&#x3b4; chain, CD3&#x3b6; chain (zeta-chain), TCR&#x3b1; chain, and TCR&#x3b2; chain, to express the human T cell receptor complex.</p><heading id="h-0012" level="1">Example 1.2: Generation of Hybridomas</heading><p id="p-0149" num="0141">Mice were immunized at 2-week intervals with one of the immunogens (some groups being boosted with a different immunogen than used in the initial immunization) and monitored for serum titer once a week after the second injection. After 4 to 6 immunizations, splenocytes were harvested and fused with mouse myeloma cells to form hybridoma cell lines. Supernatants of hybridoma cells were then screened against the huCD3/Fc dimer target and counter-selected with an irrelevant protein/Fc dimer to identify cell lines that produce CD3-specific mouse antibodies. Positive hybridomas were tested in a cell binding assay against Jurkat cell and TCR complex-transfected CHO cell targets to confirm cell surface binding of antibodies. Finally, confirmed cell binders were then tested for cynomolgus cross-reactivity by ELISA with a cynoCD3&#x3b5;&#x3b3;/Fc fusion protein as a target, and a Jurkat-NFAT-Luciferase reporter cell line was used to characterize anti-CD3 agonistic activity. Only two of the hybridomas tested in this manner were producing monoclonal antibodies that tested positively in all the assays. These were designated mAbCD3-001 and mAbCD3-002.</p><heading id="h-0013" level="1">Example 1.3: Heavy and Light Chain Variable Region Sequences</heading><p id="p-0150" num="0142">To amplify heavy and light chain variable regions, total RNA of each hybridoma clone was isolated from more than 5&#xd7;10<sup>6 </sup>cells with TRIzol&#x2122; RNA extraction reagent (Invitrogen, Cat. #15596018). cDNA was synthesized using an Invitrogen&#x2122; SuperScript&#x2122; III First-Strand Synthesis SuperMix kit (ThermoFisher Scientific Cat. #18080) following manufacturer's instructions, and the cDNAs encoding the variable regions for light and heavy mouse immunoglobulin chains were amplified using a MilliporeSigma&#x2122; Novagen&#x2122; Mouse Ig-Primer Set (Fisher Scientific Cat. #698313). PCR products were analyzed by electrophoresis on a 1.2% agarose gel with SYBR&#x2122; Safe DNA gel stain (ThermoFisher Cat. #S33102). DNA fragments with correct size were purified using a NucleoSpin&#xae; Gel and PCR Clean-up kit (Macherey-Nagel Cat. #740609) according to manufacturer's instructions and were subcloned into pMD18-T vector individually. Fifteen colonies from each transformation were selected and sequences of insert fragments were analyzed by DNA sequencing. Sequences were confirmed if at least 8 colony fragments matched consensus sequences for VH and VL. The protein sequences of murine monoclonal antibody variable regions were analyzed by sequence homology alignment and listed in Table 1. Complementarity determining regions (CDRs) are underlined based on Kabat numbering.</p><p id="p-0151" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="294pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Variable&#x2003;region&#x2003;sequences&#x2003;of&#x2003;2&#x2003;murine&#x2003;anti-CD3&#x2003;antibodies</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="175pt" align="left"/><tbody valign="top"><row><entry/><entry/><entry>SEQ&#x2003;ID</entry><entry>amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>antibody</entry><entry>domain</entry><entry>NO.</entry><entry>1234567890123456789012345678901234567890</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>mAbCD3-001</entry><entry>VH</entry><entry>6</entry><entry>QVQLQQSGPDLVKPGASVKISCKASGFSFT<u style="single">NYYVH</u>WMKQRP</entry></row><row><entry/><entry/><entry/><entry>GQGLEWIG<u style="single">WISPGSDNTKYNEKFKG</u>KATLTADTSSTTAYMQ</entry></row><row><entry/><entry/><entry/><entry>LSSLTSEDSAVYYCAR<u style="single">DDYGNYYFDY</u>WGRGSTLTVSS</entry></row><row><entry> </entry></row><row><entry/><entry>VL</entry><entry>7</entry><entry>DIVMSQSPSSLAVSAGEKVTMTC<u style="single">KSSQSLLNSRTRKNYLA</u>W</entry></row><row><entry/><entry/><entry/><entry>YQQKPGQSPKLLIY<u style="single">WASTRES</u>GVPDRFTGSGSGTDFTLTIS</entry></row><row><entry/><entry/><entry/><entry>SVQAEDLAVYYC<u style="single">KQSYILRT</u>FGGGTKLEIK</entry></row><row><entry> </entry></row><row><entry>mAbCD3-002</entry><entry>VH</entry><entry>8</entry><entry>QVQLQQSGPELVKPGASVRISCKASGYTFT<u style="single">NYYIH</u>WVKQRP</entry></row><row><entry/><entry/><entry/><entry>GQGLEWIG<u style="single">WINLGDVNTKFNEKFKD</u>KATLTADKSSTTAYMQ</entry></row><row><entry/><entry/><entry/><entry>LSSLTSEDSAVYFCAR<u style="single">DGYSFYYFDF</u>WGQGTTLTVSS</entry></row><row><entry> </entry></row><row><entry/><entry>VL</entry><entry>9</entry><entry>DIVMSQSPSSLAVSVGEKVTMSC<u style="single">KASQSLFNSRTRKNYLA</u>W</entry></row><row><entry/><entry/><entry/><entry>YQQKPGQSPKLLIY<u style="single">WASTRES</u>GVPDRFTGSGSGTDFIFTIS</entry></row><row><entry/><entry/><entry/><entry>SVQAEDLAIYYC<u style="single">IQSHTLRT</u>FGGGTKLEIK</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0014" level="1">Example 1.4: Anti-CD3 Antibodies Bind Both Human and Cynomolgus CD3</heading><p id="p-0152" num="0143">The binding properties of the isolated murine anti-CD3 antibodies were measured with ELISA as follows: Heterodimeric CD3&#x3b5;&#x3b3;/Fc fusion protein was coated at 1 &#x3bc;g/mL on 96-well plates at 4&#xb0; C. overnight. Plates were washed once with washing buffer (PBS containing 0.05% Tween 20) and blocked with ELISA blocking buffer (1% BSA in PBS containing 0.05% Tween 20) at room temperature for 2 hours. Anti-CD3 antibodies were then added and incubated at 37&#xb0; C. for 1 hour. Plates were washed three times with washing buffer. HRP labeled anti-mouse IgG secondary antibody (Sigma, Cat. #A0168) was added and the plates were incubated at 37&#xb0; C. for 30 minutes then washed 5 times in washing buffer. 100 &#x3bc;l of tetramethylbenzidine (TMB) chromogenic solution was added to each well. Following color development, the reaction was stopped with 1 Normal HCl and absorbance at 450 nm was measured on a Varioskan&#x2122; LUX microplate reader (ThermoFisher Scientific). Binding signals were plotted against antibody concentration with GraphPad Prism 5.0 software and EC50s were calculated accordingly. As shown in <figref idref="DRAWINGS">FIG. <b>1</b></figref> and <figref idref="DRAWINGS">FIG. <b>2</b></figref>, mAbCD3-002 showed the highest binding activity, while mAbCD3-001 had similar binding EC50 to a reference anti-CD3&#x3b5; antibody expressed using variable domain sequences reported in U.S. Pat. No. 8,236,308).</p><heading id="h-0015" level="1">Example 1.5: Anti-CD3 Antibodies Activate Human T Cells In Vitro</heading><p id="p-0153" num="0144">Peripheral Blood Mononuclear Cells (PBMCs) were obtained from healthy donors by using Lymphoprep&#x2122; mononuclear cell isolation medium (STEMCELL Technologies, Cat. #07851) and T cells were isolated from PBMCs with a CD3-negative T cell selection kit (EasySep&#x2122; STEMCELL Technologies, Cat. #17951). Proliferation (CTG) and cytokine (IFN-7) production data were acquired using the following protocol: 100 &#x3bc;l of test antibody (mAbCD3-001, OKT3, or negative control IgG) were coated on a high-binding 96-well plate (Nunc&#x2122;, Cat. #3361) at 4&#xb0; C. overnight followed by DPBS washing. Commercially available OKT3 antibody was used as a positive anti-CD3 control and an irrelevant mouse IgG was used as negative control. For each well, 1&#xd7;10<sup>5 </sup>T cells in 200 &#x3bc;l culture medium (RPMI1640+10% FBS+1% Penicillin-Streptomycin solution+1% GlutaMAX&#x2122; supplement) were seeded and incubated at 37&#xb0; C. for 96 hrs. Proliferation was measured by using an ATP catalyzed quantification kit (CellTiter-Glo&#x2122;, Promega). IFN-7 was measured by a LANCE&#xae; (Lanthanide Chelate Excite) TR-FRET assay kit (PerkinElmer, Cat. #TRF1217M). Data were analyzed with GraphPad Prism 5.0 software. The results are shown in <figref idref="DRAWINGS">FIGS. <b>3</b> and <b>4</b></figref>. The cell proliferation and IFN-7 production data indicated that mAbCD3-001 activates human T cells in vitro.</p><heading id="h-0016" level="1">Example 2: Humanization of Anti-CD3 Antibodies</heading><heading id="h-0017" level="1">Example 2.1: Humanization of mAbCD3-001</heading><p id="p-0154" num="0145">The anti-CD3 mAbCD3-001 variable region genes were employed to create a humanized mAb. In the first step of this process, the amino acid sequences of the VH and VK of mAbCD3-001 (see Table 1, supra) were compared against the available database of human Ig V-gene sequences in order to find the overall best-matching human germline Ig V-gene sequences. Additionally, the framework 4 of VH or VL was compared against the J-region database to find the human framework having the highest homology to the murine VH and VL regions, respectively. For the light chain, the closest human V-gene match was the B3 gene (V-base database), and for the heavy chain the closest human match was the VH1-2 gene. Humanized variable domain sequences were then designed where the CDR-L1, CDR-L2 and CDR-L3 of the mAbCD3-001 light chain were grafted onto framework sequences of the B3 gene, with JK4 framework 4 sequence after CDR-L3; and the CDR-H1, CDR-H2, and CDR-H3 sequences of the mAbCD3-001 VH were grafted onto framework sequences of the VH1-2, with JH6 framework 4 sequence after CDR-H3. A3D Fv model of mAbCD3-001 was then generated and analyzed to determine if there were any framework residues that have a less than 4 &#x212b; distance to the CDR residues and that were most likely critical to support loop structures or the VH/VL interface. These residues in humanized sequences should be back-mutated to mouse residues at the same position to retain affinity/activity. Q1E mutation was always included to eliminate N-terminal pyroglutamate formation if applicable. In the case of the heavy chain, potential mutations of Y27F, T28S, V37M, M48I, V67A, M69L and R71A (Kabat numbering) were identified. In the case of the light chain, T5S and N22T were identified for back mutation. Via the importance tier of each back mutation, as determined by its interaction with CDRs, the most important back mutations were introduced in the humanized VH sequence in order of priority, followed by other back mutations in successive designs. Also, the VK CDR-L1 sequence had a NS pattern that was a potential deamidation site. To remove this asparagine deamidation liability, NS was mutated to QS, NT or NA in the humanized kappa chain. The humanized VH and VL constructs are shown in Table 2 (below). (Back mutated framework amino acid residues are indicated with double underscore; murine CDRs from the original parental antibody are underlined.)</p><p id="p-0155" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="301pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Humanized&#x2003;VH/VL&#x2003;design&#x2003;of&#x2003;anti-CD3&#x2003;antibody&#x2003;mAbCD3-001</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="91pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="175pt" align="left"/><tbody valign="top"><row><entry>humanized&#x2003;VH&#x2003;and&#x2003;VL</entry><entry>SEQ&#x2003;ID</entry><entry>amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>domains</entry><entry>NO.</entry><entry>1234567890123456789012345678901234567890</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>EM0006-01VH.1</entry><entry>10</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASGYTFT<u style="single">NYYVH</u>WVRQA</entry></row><row><entry/><entry/><entry>PGQGLEWMG<u style="single">WISPGSDNTKYNEKFKG</u>RVTMTRDTSISTAY</entry></row><row><entry/><entry/><entry>MELSRLRSDDTAVYYCAR<u style="single">DDYGNYYFDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>EM0006-01VH.1A</entry><entry>11</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASGYTFT<u style="single">NYYVH</u>WVRQA</entry></row><row><entry/><entry/><entry>PGQGLEWMG<u style="single">WISPGSDNTKYNEKFKG</u>RVT<u style="double">L</u>T<u style="double">A</u>DTSISTAY</entry></row><row><entry/><entry/><entry>MELSRLRSDDTAVYYCAR<u style="single">DDYGNYYFDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>EM0006-01VH.1B</entry><entry>12</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASGYTFT<u style="single">NYYVH</u>WVRQA</entry></row><row><entry/><entry/><entry>PGQGLEW<u style="double">I</u>G<u style="single">WISPGSDNTKYNEKFKG</u>RVT<u style="double">L</u>T<u style="double">A</u>DTSISTAY</entry></row><row><entry/><entry/><entry>MELSRLRSDDTAVYYCAR<u style="single">DDYGNYYFDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>EM0006-01VH.1C</entry><entry>13</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASGYTFT<u style="single">NYYVH</u>WVRQA</entry></row><row><entry/><entry/><entry>PGQGLEW<u style="double">I</u>G<u style="single">WISPGSDNTKYNEKFKG</u><u style="double">KA</u>T<u style="double">L</u>T<u style="double">A</u>DTSISTAY</entry></row><row><entry/><entry/><entry>MELSRLRSDDTAVYYCAR<u style="single">DDYGNYYFDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>EM0006-01VH.1D</entry><entry>14</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASGYTFT<u style="single">NYYVH</u>W<u style="double">M</u>RQA</entry></row><row><entry/><entry/><entry>PGQGLEW<u style="double">I</u>G<u style="single">WISPGSDNTKYNEKFKG</u><u style="double">KA</u>T<u style="double">L</u>T<u style="double">A</u>DTSISTAY</entry></row><row><entry/><entry/><entry>MELSRLRSDDTAVYYCAR<u style="single">DDYGNYYFDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>EM0006-01VH.1E</entry><entry>15</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASGYTFT<u style="single">NYYVH</u>W<u style="double">M</u>RQA</entry></row><row><entry/><entry/><entry>PGQGLEW<u style="double">I</u>G<u style="single">WISPGSDNTKYNEKFKG</u>RVT<u style="double">L</u>T<u style="double">A</u>DTSISTAY</entry></row><row><entry/><entry/><entry>MELSRLRSDDTAVYYCAR<u style="single">DDYGNYYFDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>EM0006-01VH.1F</entry><entry>16</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASG<u style="double">FS</u>FT<u style="single">NYYVH</u>W<u style="double">M</u>RQA</entry></row><row><entry/><entry/><entry>PGQGLEW<u style="double">I</u>G<u style="single">WISPGSDNTKYNEKFKG</u><u style="double">KA</u>T<u style="double">L</u>T<u style="double">A</u>DTSISTAY</entry></row><row><entry/><entry/><entry>MELSRLRSDDTAVYYCAR<u style="single">DDYGNYYFDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>EM0006-01VH.1G</entry><entry>17</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASG<u style="double">FS</u>FT<u style="single">NYYVH</u>W<u style="double">M</u>RQA</entry></row><row><entry/><entry/><entry>PGQGLEW<u style="double">I</u>G<u style="single">WISPGSDNTKYNEKFKG</u>RVT<u style="double">L</u>T<u style="double">A</u>DTSISTAY</entry></row><row><entry/><entry/><entry>MELSRLRSDDTAVYYCAR<u style="single">DDYGNYYFDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>EM0006-01VH.1H</entry><entry>18</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASG<u style="double">FS</u>FT<u style="single">NYYVH</u>W<u style="double">M</u>RQA</entry></row><row><entry/><entry/><entry>PGQGLEWMG<u style="single">WISPGSDNTKYNEKFKG</u>RVTMTRDTSISTAY</entry></row><row><entry/><entry/><entry>MELSRLRSDDTAVYYCAR<u style="single">DDYGNYYFDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>EM0006-01VH.1I</entry><entry>19</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASG<u style="double">FS</u>FT<u style="single">NYYVH</u>W<u style="double">MK</u>QA</entry></row><row><entry/><entry/><entry>PGQGLEW<u style="double">I</u>G<u style="single">WISPGSDNTKYNEKFKG</u><u style="double">KA</u>T<u style="double">L</u>T<u style="double">A</u>DTSI<u style="double">T</u>TAY</entry></row><row><entry/><entry/><entry>MELSRLRSDDTAVYYCAR<u style="single">DDYGNYYFDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>EM0006-01VK.1</entry><entry>20</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNSRTRKNYLA</u></entry></row><row><entry/><entry/><entry>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGSGTDFTLT</entry></row><row><entry/><entry/><entry>ISSLQAEDVAVYYC<u style="single">KQSYILRT</u>FGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>EM0006-01VK.1A</entry><entry>21</entry><entry>DIVM<u style="double">S</u>QSPDSLAVSLGERATI<u style="double">T</u>C<u style="single">KSSQSLLNSRTRKNYLA</u></entry></row><row><entry/><entry/><entry>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGSGTDFTLT</entry></row><row><entry/><entry/><entry>ISSLQAEDVAVYYC<u style="single">KQSYILRT</u>FGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>EM0006-01VK.1(NS-QS)</entry><entry>22</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLL<b>Q</b>SRTRKNYLA</u></entry></row><row><entry/><entry/><entry>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGSGTDFTLT</entry></row><row><entry/><entry/><entry>ISSLQAEDVAVYYCKQSYILRTFGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>EM0006-01VK.1A(NS-QS)</entry><entry>23</entry><entry>DIVMSQSPDSLAVSLGERATI<u style="double">T</u>C<u style="single">KSSQSLL<b>Q</b>SRTRKNYLA</u></entry></row><row><entry/><entry/><entry>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGSGTDFTLT</entry></row><row><entry/><entry/><entry>ISSLQAEDVAVYYC<u style="single">KQSYILRT</u>FGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>EM0006-01VK.1(NS-NT)</entry><entry>24</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLN<b>T</b>RTRKNYLA</u></entry></row><row><entry/><entry/><entry>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGSGTDFTLT</entry></row><row><entry/><entry/><entry>ISSLQAEDVAVYYC<u style="single">KQSYILRT</u>FGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>EM0006-01VK.1(NS-NA)</entry><entry>25</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLN<b>A</b>RTRKNYLA</u></entry></row><row><entry/><entry/><entry>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGSGTDFTLT</entry></row><row><entry/><entry/><entry>ISSLQAEDVAVYYC<u style="single">KQSYILRT</u>FGGGTKVEIK</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry namest="1" nameend="3" align="left" id="FOO-00001">Note:</entry></row><row><entry namest="1" nameend="3" align="left" id="FOO-00002">EM0006-01VH.1 or EM0006-01VK.1 means CDR-grafted VH/VL without back mutations.</entry></row></tbody></tgroup></table></tables></p><p id="p-0156" num="0146">Humanized VH and VK genes back-translated from corresponding amino acid sequence designs were synthesized de novo and then cloned into vectors containing the human IgG1 and human kappa constant domains (SEQ ID NO:26 and SEQ ID NO:27, respectively).</p><p id="p-0157" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="280pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Human&#x2003;Constant&#x2003;Region&#x2003;Sequences&#x2003;Used&#x2003;in&#x2003;Antibody&#x2003;Humanization</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="175pt" align="left"/><tbody valign="top"><row><entry/><entry>SEQ&#x2003;ID</entry><entry>Amino&#x2003;Acid&#x2003;Sequences</entry></row><row><entry>Constant&#x2003;Region</entry><entry>NO.</entry><entry>1234567890123456789012345678901234567890</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>CH1-hinge-CH2-</entry><entry>26</entry><entry>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS</entry></row><row><entry>CH3</entry><entry/><entry>WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT</entry></row><row><entry>human&#x2003;constant</entry><entry/><entry>YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG</entry></row><row><entry>IgG1&#x2003;mutant</entry><entry/><entry>PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW</entry></row><row><entry/><entry/><entry>YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK</entry></row><row><entry/><entry/><entry>EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE</entry></row><row><entry/><entry/><entry>MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV</entry></row><row><entry/><entry/><entry>LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT</entry></row><row><entry/><entry/><entry>QKSLSLSPGK</entry></row><row><entry> </entry></row><row><entry>CL&#x3ba;</entry><entry>27</entry><entry>RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ</entry></row><row><entry>human&#x2003;constant</entry><entry/><entry>WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE</entry></row><row><entry>kappa</entry><entry/><entry>KHKVYACEVTHQGLSSPVTKSFNRGEC</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0158" num="0147">The pairing of the human VH and the human VK created 27 humanized antibodies, designated HuEM0006-01-1 to HuEM0006-01-27 (Table 3). Chimeric antibody (HuEM0006-01c) with parental mouse VH/VL and human constant sequences was also produced and used as a positive control for humanized antibody ranking. All recombinant humanized mAbs were expressed in 1TEK293 cells transiently and purified by Protein A chromatography.</p><p id="p-0159" num="0000"><tables id="TABLE-US-00009" num="00009"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Production List of Humanized Anti-CD3 Antibodies Derived </entry></row><row><entry>from mAbCD3-001 </entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="63pt" align="left"/><colspec colname="3" colwidth="84pt" align="left"/><tbody valign="top"><row><entry/><entry>VH Region in Heavy </entry><entry/></row><row><entry>Antibody Identifier </entry><entry>Chain </entry><entry>VL Region in Light &#x3ba; Chain</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>HuEM0006-01-1 </entry><entry>EM0006-01VH.1A </entry><entry>EM0006-01VK.1 </entry></row><row><entry>HuEM0006-01-2 </entry><entry>EM0006-01VH.1B </entry><entry>EM0006-01VK.1 </entry></row><row><entry>HuEM0006-01-3 </entry><entry>EM0006-01VH.1C </entry><entry>EM0006-01VK.1 </entry></row><row><entry>HuEM0006-01-4 </entry><entry>EM0006-01VH.1D </entry><entry>EM0006-01VK.1 </entry></row><row><entry>HuEM0006-01-5 </entry><entry>EM0006-01VH.1E </entry><entry>EM0006-01VK.1 </entry></row><row><entry>HuEM0006-01-6 </entry><entry>EM0006-01VH.1F </entry><entry>EM0006-01VK.1 </entry></row><row><entry>HuEM0006-01-7 </entry><entry>EM0006-01VH.1G </entry><entry>EM0006-01VK.1 </entry></row><row><entry>HuEM0006-01-8 </entry><entry>EM0006-01VH.1H </entry><entry>EM0006-01VK.1 </entry></row><row><entry>HuEM0006-01-9 </entry><entry>EM0006-01VH.1I </entry><entry>EM0006-01VK.1 </entry></row><row><entry>HuEM0006-01-10 </entry><entry>EM0006-01VH.1A </entry><entry>EM0006-01VK.1A </entry></row><row><entry>HuEM0006-01-11 </entry><entry>EM0006-01VH.1B </entry><entry>EM0006-01VK.1A </entry></row><row><entry>HuEM0006-01-12 </entry><entry>EM0006-01VH.1C </entry><entry>EM0006-01VK.1A </entry></row><row><entry>HuEM0006-01-13 </entry><entry>EM0006-01VH.1D </entry><entry>EM0006-01VK.1A </entry></row><row><entry>HuEM0006-01-14 </entry><entry>EM0006-01VH.1E </entry><entry>EM0006-01VK.1A </entry></row><row><entry>HuEM0006-01-15 </entry><entry>EM0006-01VH.1F </entry><entry>EM0006-01VK.1A </entry></row><row><entry>HuEM0006-01-16 </entry><entry>EM0006-01VH.1G </entry><entry>EM0006-01VK.1A </entry></row><row><entry>HuEM0006-01-17 </entry><entry>EM0006-01VH.1H </entry><entry>EM0006-01VK.1A </entry></row><row><entry>HuEM0006-01-18 </entry><entry>EM0006-01VH.1I </entry><entry>EM0006-01VK.1A </entry></row><row><entry>HuEM0006-01-19 </entry><entry>EM0006-01VH* </entry><entry>EM0006-01VK.1 (NS-QS) </entry></row><row><entry>HuEM0006-01-20 </entry><entry>EM0006-01VH </entry><entry>EM0006-01VK.1A (NS-QS) </entry></row><row><entry>HuEM0006-01-21 </entry><entry>EM0006-01VH </entry><entry>EM0006-01VK.1 (NS-NT) </entry></row><row><entry>HuEM0006-01-22 </entry><entry>EM0006-01VH </entry><entry>EM0006-01VK.1 (NS-NA) </entry></row><row><entry>HuEM0006-01-23 </entry><entry>EM0006-01VH.1A </entry><entry>EM0006-01VK.1 (NS-NA) </entry></row><row><entry>HuEM0006-01-24 </entry><entry>EM0006-01VH.1H </entry><entry>EM0006-01VK.1 (NS-NA) </entry></row><row><entry>HuEM0006-01-25 </entry><entry>EM0006-01VH.1E </entry><entry>EM0006-01VK.1 (NS-NA) </entry></row><row><entry>HuEM0006-01-26 </entry><entry>EM0006-01VH.1B </entry><entry>EM0006-01VK.1 (NS-NA) </entry></row><row><entry>HuEM0006-01-27 </entry><entry>EM0006-01VH.1G </entry><entry>EM0006-01VK.1 (NS-NA) </entry></row><row><entry>HuEM0006-01c </entry><entry>EM0006-01VH* </entry><entry>EM0006-01VK</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry namest="1" nameend="3" align="left" id="FOO-00003">*EM0006-01VH includes the murine variable heavy region of mAbCD3-001; EM0006-01VK includes the murine variable light region of mAbCD3-001.</entry></row></tbody></tgroup></table></tables></p><heading id="h-0018" level="1">Example 2.2: Humanized Anti-CD3 Antibodies Showed Different CD3 Binding Activity</heading><p id="p-0160" num="0148">Different humanized VH and VK combinations led to humanized anti-CD3 variants with different CD3 binding affinities. The binding activity of the humanized variants of mAbCD3-001 were tested via flow cytometry with the human CD3-expressing Jurkat T cell line. 5&#xd7;10<sup>5 </sup>Jurkat cells in FACS buffer were seeded into each well of a 96-well plate. Cells were centrifuged at 400 g for 5 minutes and supernatants were discarded. For each well, 100 &#x3bc;l of serially diluted antibodies were then added and mixed with the cells. After 40 minutes incubation at 4&#xb0; C., plates were washed several times to remove excess antibodies. Secondary fluorochrome-conjugated antibody (Alexa Fluor&#xae; 647 goat anti-human IgG1 H&#x26;L; Jackson ImmunoResearch, Cat. #109-606-170) was then added and incubated with cells at room temperature for 20 minutes. After another round of centrifugation and a washing step, cells were resuspended in FACS buffer for reading on a CytoFLEX Flow Cytometer (Beckman Coulter). Median Fluorescence Intensity (MFI) readouts were plotted against antibody concentration and analyzed with GraphPad Prism 5.0 software.</p><p id="p-0161" num="0149">As shown in <figref idref="DRAWINGS">FIG. <b>5</b>A-<b>5</b>H</figref>, humanized anti-CD3 antibodies showed a wide range of affinities to the cell surface CD3 target on Jurkat cells. VH variants evidently were the key elements for this CD3 binding modulation, as varying the kappa chain (i.e., between EM0006-01VK.1 and EM0006-01VK.1A) did not appear to have a significant impact on binding. Some humanized antibodies, notably HuEM0006-01-08 and HuEM0006-01-17 having the VH variant EM006-01VH.1H (see Table 4 and SEQ ID NO:18), even showed much higher CD3 binding than chimeric control antibody HuEM0006-01c, having the parental mouse VH region EM0006-01VH (see Table 4).</p><heading id="h-0019" level="1">Example 3: Generation of Anti-BCMA Monoclonal Antibodies</heading><p id="p-0162" num="0150">Anti-BCMA antibodies were obtained by immunizing Balb/c or SJL mice with a recombinant BCMA extracellular domain/Fc dimer formed by homodimerization of human BCMA(ECD) fused to a human Fc region:</p><p id="p-0163" num="0000"><tables id="TABLE-US-00010" num="00010"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;28)</entry></row><row><entry>MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVK</entry></row><row><entry> </entry></row><row><entry>GTNAIEGRMDPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT</entry></row><row><entry> </entry></row><row><entry>PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL</entry></row><row><entry> </entry></row><row><entry>TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRE</entry></row><row><entry> </entry></row><row><entry>EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL</entry></row><row><entry> </entry></row><row><entry>YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</entry></row></tbody></tgroup></table></tables></p><p id="p-0164" num="0151">Mice were immunized at 2-week intervals and monitored for serum titer once a week after the second injection.</p><heading id="h-0020" level="1">Example 3.1: Generation of Hybridomas</heading><p id="p-0165" num="0152">After 4 to 6 immunizations splenocytes were harvested and fused with mouse myeloma cells to form hybridoma cell lines. Fusion products were plated in selection media containing hypoxanthine-aminopterin-thymidine (HAT) in 96-well plates at a density of 1&#xd7;10<sup>5 </sup>spleen cells per well. Seven to ten days post-fusion, macroscopic hybridoma colonies were observed.</p><p id="p-0166" num="0153">Supernatants of hybridoma cells were then screened and selected to identify cell lines producing BCMA-specific mouse antibodies. Five anti-BCMA antibodies were selected and sequenced.</p><heading id="h-0021" level="1">Example 3.2: Heavy and Light Chain Variable Region Sequences</heading><p id="p-0167" num="0154">To amplify heavy and light chain variable region, total RNA of each hybridoma clone was isolated from more than 5&#xd7;10<sup>6 </sup>cells with TRIzol&#x2122; RNA extraction reagent (Invitrogen, Cat. #15596018). cDNA was synthesized using an Invitrogen&#x2122; SuperScript&#x2122; III First-Strand Synthesis SuperMix kit (ThermoFisher Scientific Cat. #18080) following manufacturer's instructions, and the cDNAs encoding the variable regions for light and heavy mouse immunoglobulin chains were amplified using a MilliporeSigma&#x2122; Novagen&#x2122; Mouse Ig-Primer Set (Fisher Scientific Cat. #698313). PCR products were analyzed by electrophoresis on a 1.2% agarose gel with SYBR&#x2122; Safe DNA gel stain (ThermoFisher Cat. #S33102). DNA fragments with correct size were purified using a NucleoSpin&#xae; Gel and PCR Clean-up kit (Macherey-Nagel, Cat. #740609) according to manufacturer's instructions and were subcloned into pMD18-T vector individually. Fifteen colonies from each transformation were selected and sequences of insert fragments were analyzed by DNA sequencing. Sequences were confirmed if at least 8 colony fragments matched consensus sequences for VH and VL. The protein sequences of murine mAb variable regions were analyzed by sequence homology alignment.</p><heading id="h-0022" level="1">Example 3.3: Binding Kinetics of Anti-BCMA Antibodies by Surface Plasmon Resonance (SPR)</heading><p id="p-0168" num="0155">Binding affinities and kinetic constants of anti-BCMA antibodies were determined by surface plasmon resonance at 25&#xb0; C. using a Biacore T200 instrument (GE Healthcare) using standard procedures. Briefly, goat anti-mouse IgG Fc antibody was directly immobilized across a biosensor chip, and antibody samples were injected over reaction matrices at a flow rate of 5 &#x3bc;l/min. Mouse anti-BCMA IgG test antibody was injected over the immobilized surface and captured by the immobilized anti-Fc antibodies. Human and cynomolgus BCMA(ECD)/Fc target polypeptides were then injected over the captured mouse anti-BCMA IgG surface. The association and dissociation rate constants, k<sub>on </sub>(M<sup>&#x2212;1</sup>s<sup>&#x2212;1</sup>) and k<sub>off </sub>(s<sup>&#x2212;1</sup>), respectively, were determined with a continuous flow rate of 30 &#x3bc;l/min. Rate constants were derived by making kinetic binding measurements at five different concentrations of target BCMA(ECD) polypeptide. The equilibrium dissociation constant K<sub>D </sub>(M) of the reaction between antibodies and related target proteins was then calculated from the kinetic rate constants using the formula K<sub>D</sub>=k<sub>off</sub>/k<sub>on</sub>. Kinetic constants were determined by processing and fitting the data to a 1:1 binding model using Biacore analysis software. Results are shown in Table 7.</p><p id="p-0169" num="0000"><tables id="TABLE-US-00011" num="00011"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 7</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Affinity Measurements for Anti-BCMA Monoclonal Antibodies </entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="56pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><colspec colname="5" colwidth="42pt" align="left"/><tbody valign="top"><row><entry>Antigen </entry><entry/><entry/><entry/><entry/></row><row><entry>Capture </entry><entry/><entry/><entry/><entry/></row><row><entry>Target </entry><entry>Antibody </entry><entry>k<sub>on </sub>(1/Ms) </entry><entry>k<sub>off </sub>(1/s) </entry><entry>K<sub>D </sub>(M)</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>Human </entry><entry>TAb1 </entry><entry>6.03 &#xd7; 10<sup>4 </sup></entry><entry>1.98 &#xd7; 10<sup>&#x2212;5</sup></entry><entry>3.28 &#xd7; 10<sup>&#x2212;10</sup></entry></row><row><entry>BCMA </entry><entry>TAb2 </entry><entry>3.03 &#xd7; 10<sup>5 </sup></entry><entry>0.00209 </entry><entry>6.89 &#xd7; 10<sup>&#x2212;9 </sup></entry></row><row><entry>(ECD) </entry><entry>mAbBCMA-001 </entry><entry>2.23 &#xd7; 10<sup>5 </sup></entry><entry>2.00 &#xd7; 10<sup>&#x2212;4 </sup></entry><entry>8.96 &#xd7; 10<sup>&#x2212;10 </sup></entry></row><row><entry/><entry>mAbBCMA-002 </entry><entry>2.12 &#xd7; 10<sup>5 </sup></entry><entry>0.00292 </entry><entry>1.38 &#xd7; 10<sup>&#x2212;8 </sup></entry></row><row><entry/><entry>mAbBCMA-003 </entry><entry>4.54 &#xd7; 10<sup>4 </sup></entry><entry>1.85 &#xd7; 10<sup>&#x2212;5 </sup></entry><entry>4.08 &#xd7; 10<sup>&#x2212;10</sup></entry></row><row><entry/><entry>mAbBCMA-004 </entry><entry>6.63 &#xd7; 10<sup>5 </sup></entry><entry>0.00842 </entry><entry>1.27 &#xd7; 10<sup>&#x2212;8 </sup></entry></row><row><entry/><entry>mAbBCMA-005 </entry><entry>8.36 &#xd7; 10<sup>4 </sup></entry><entry>7.46 &#xd7; 10<sup>&#x2212;5 </sup></entry><entry>8.92 &#xd7; 10<sup>&#x2212;10 </sup></entry></row><row><entry>Cyno </entry><entry>TAb1 </entry><entry>8.64 &#xd7; 10<sup>4 </sup></entry><entry>1.77 &#xd7; 10<sup>&#x2212;5 </sup></entry><entry>2.05 &#xd7; 10<sup>&#x2212;10 </sup></entry></row><row><entry>BCMA </entry><entry>TAb2 </entry><entry>1.03 &#xd7; 10<sup>5 </sup></entry><entry>0.00252 </entry><entry>2.44 &#xd7; 10<sup>&#x2212;8 </sup></entry></row><row><entry>(ECD) </entry><entry>mAbBCMA-001 </entry><entry>N/A </entry><entry>N/A </entry><entry>N/A </entry></row><row><entry/><entry>mAbBCMA-002 </entry><entry>4.03 &#xd7; 10<sup>4 </sup></entry><entry>3.04 &#xd7; 10<sup>&#x2212;4 </sup></entry><entry>7.55 &#xd7; 10<sup>&#x2212;9 </sup></entry></row><row><entry/><entry>mAbBCMA-003 </entry><entry>6.06 &#xd7; 10<sup>4 </sup></entry><entry>2.36 &#xd7; 10<sup>&#x2212;4 </sup></entry><entry>3.90 &#xd7; 10<sup>&#x2212;9 </sup></entry></row><row><entry/><entry>mAbBCMA-004 </entry><entry>N/A </entry><entry>N/A </entry><entry>N/A </entry></row><row><entry/><entry>mAbBCMA-005 </entry><entry>N/A </entry><entry>N/A </entry><entry>N/A</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry namest="1" nameend="5" align="left" id="FOO-00004">N/A = no measurable binding signal detected</entry></row><row><entry namest="1" nameend="5" align="left" id="FOO-00005">TAb1 is a reference anti-BCMA antibody, which is clone CA8 from Int'l Publication No. WO 2012/163805</entry></row><row><entry namest="1" nameend="5" align="left" id="FOO-00006">TAb2 is a reference anti-BCMA antibody, which is clone 83A10 from Int'l Publication No. WO 2014/122143</entry></row></tbody></tgroup></table></tables><br/>The two anti-BCMA antibodies showing high affinity for both human and cynomolgus BCMA targets were further developed and analyzed. The variable domain sequences for these selected anti-BCMA monoclonals, mAbBCMA-002 and mAbBCMA-003, are set out in Table 8, below. Complementarity determining regions (CDRs) are underlined based on Kabat numbering.</p><p id="p-0170" num="0000"><tables id="TABLE-US-00012" num="00012"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="294pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;8</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Variable&#x2003;Region&#x2003;Sequences&#x2003;of&#x2003;anti-BCMA&#x2003;Antibodies</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="175pt" align="left"/><tbody valign="top"><row><entry/><entry/><entry>SEQ&#x2003;ID</entry><entry>amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>Antibody</entry><entry>domain</entry><entry>NO.</entry><entry>1234567890123456789012345678901234567890</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>mAbBCMA-002</entry><entry>VH</entry><entry>29</entry><entry>QIQLVQSGPELKKPGETVKISCKASGYSFT<u style="single">NYGLN</u>WVKQAP</entry></row><row><entry/><entry/><entry/><entry>GKGLKWMG<u style="single">WINTYSGHPTYVDDFKG</u>RFAFSLETSASTAYLQ</entry></row><row><entry/><entry/><entry/><entry>INKLKNEDTSTYFCVR<u style="single">EKDDGYRLGLDY</u>WGQGTSVTVSS</entry></row><row><entry> </entry></row><row><entry/><entry>VL</entry><entry>30</entry><entry>QIVLTQSPAIMSASPGEKVTMTC<u style="single">SASSSVSYMY</u>WYQQRPGS</entry></row><row><entry/><entry/><entry/><entry>SPRLWIY<u style="single">DTSNLVS</u>GVPARFSGSRSGTSYSLTISGMEAEDA</entry></row><row><entry/><entry/><entry/><entry>ATYYC<u style="single">LQYSGYPYT</u>FGGGTKLEIK</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003</entry><entry>VH</entry><entry>31</entry><entry>EVQLQQSGTVLARPGASVRMSCKASGYIFP<u style="single">NFWMH</u>WVKQRP</entry></row><row><entry/><entry/><entry/><entry>GQGLDWIG<u style="single">AFYPGNDDTYYNQKFK</u>GKAKLTAVTSASTAYME</entry></row><row><entry/><entry/><entry/><entry>LSSLTSEDSAVYYCAR<u style="single">SGYYGSSDAMDY</u>WGQGTSVTVSS</entry></row><row><entry> </entry></row><row><entry/><entry>VL</entry><entry>32</entry><entry>DIQMTQSPASLSASVGETVTVTC<u style="single">GASENIYGALN</u>WYQRKQG</entry></row><row><entry/><entry/><entry/><entry>KSPQLLIY<u style="single">GATNLAD</u>GISSRFSGSGSGRQFSLKISSLLPDD</entry></row><row><entry/><entry/><entry/><entry>VATYFC<u style="single">QSVLTTPWT</u>FGGGTKLEIK</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0023" level="1">Example 3.4: Anti-BCMA Antibodies Showed Different BCMA Blocking Activities</heading><p id="p-0171" num="0156">The ability of monoclonal anti-BMCA antibodies to block NF&#x3ba;B phosphorylation stimulated by the BCMA ligand BAFF in the human myeloma cell line NCI-H929 was assessed by using a Phospho-NF&#x3ba;B (Ser536) cellular assay kit (Cisbio; Cat. #64 NFBPEG). NCI-H929 human myeloma cells were starved in assay medium (RPMI1640, 0.1% BSA) at 37&#xb0; C. overnight. Cells were washed, resuspended, and seeded into 384-well microplates (PerkinElmer, Cat. #6008280) at 2&#xd7;10<sup>5 </sup>cells per well. Antibodies were then added into the wells and incubated with cells for about 10 minutes at 37&#xb0; C. Anti-BAFF antibody (R&#x26;D Systems, Cat. #BAF124) was used as a positive control, and an irrelevant anti-RAC1 monoclonal antibody was used as a negative control. Reference anti-BCMA antibodies TAb1 and TAb2 (clone CA8 from Int'l Publication No. WO 2012/163805 and clone 83A10 from Int'l Publication No. WO 2014/122143, respectively) were tested for comparison.</p><p id="p-0172" num="0157">Recombinant BAFF was then added to each well at a concentration of 5 &#x3bc;g/ml and incubated for 30 minutes. Cells were lysed by adding kit lysis buffer and incubated for at least 30 minutes at room temperature with shaking. Cell lysates were then transferred to a 384-well small volume microplate (PerkinElmer, Cat. #6008280). Assay kit reagents were prepared and added into wells following the manufacturer's instructions. After a final incubation at room temperature for 4 hours, plates were read for fluorescence emission at wavelength of 665 nm and 620 nm. Inhibition percentage was calculated and plotted against antibody concentration with GraphPad Prism 5.0 software. As shown in <figref idref="DRAWINGS">FIG. <b>6</b></figref>, the selected anti-BCMA antibodies isolated as described above, mAbBCMA-002 and mAbBCMA-003 showed superior inhibition activity to BAFF-induced NF-&#x3ba;B phosphorylation than the negative control (anti-RAC).</p><p id="p-0173" num="0158">Another reporter gene-based luminescence assay system was also used to characterize antibody blocking of ligand binding activity to BCMA. A stable HEK293F cell line transfected to express BCMA and emitting a luciferase signal when NF-&#x3ba;B phosphorylation is induced (HEK293F-BCMA-NF-kB-luc clone 1H2) was established in-house and used for this luminescence assay. Cells were harvested, washed and re-suspended in assay medium (RPMI1640 with 10% FBS). Cells were then seeded into 96-well microplates (Costar, Cat. #3903) at 5&#xd7;10<sup>4 </sup>cells per well and incubated with test antibodies: mAbBCMA-002, mAbBCMA-003, TAb1 (anti-BCMA), TAb2 (anti-BCMA), or irrelevant murine IgG. A BCMA ligand, either BAFF or APRIL (TNFSF13, CD286), was added and co-incubated with antibody solutions for 10 minutes. One-Glo&#x2122; Luciferase Assay System (Promega, Cat. #E6130) reagents were prepared and added to wells following the manufacturer's instructions. Plates were read for luminescence signals with Varioskan&#x2122; LUX microplate reader (Thermo Scientific). Inhibition percentage was calculated and plotted against antibody concentration with GraphPad Prism 5.0 software. As shown in <figref idref="DRAWINGS">FIG. <b>7</b></figref> (BAFF blocking) and <figref idref="DRAWINGS">FIG. <b>8</b></figref> (APRIL blocking), mAbBCMA-002 showed no activity or weak blocking activity while mAbBCMA-003 showed strong NF-&#x3ba;B signal pathway blocking activity similar to the positive reference antibodies TAb1 and TAb2.</p><p id="p-0174" num="0159">The binding domains of mAbBCMA-002 and mAbBCMA-003 were next used to generate bispecific BCMA/CD3 FIT-Ig binding proteins.</p><heading id="h-0024" level="1">Example 4: Production of BCMA/CD3 Fabs-In-Tandem Immunoglobulins (FIT-Igs)</heading><heading id="h-0025" level="1">Example 4.1: Generation of BCMA/CD3 FIT-Ig Binding Proteins (FIT-Igs)</heading><p id="p-0175" num="0160">Bispecific Fabs-in-Tandem Immunoglobulin (FIT-Ig) binding proteins recognizing both human CD3 and human BCMA were constructed. The FIT-Ig constructs were engineered to omit the use of synthetic linker sequences between immunoglobulin domains, following the general procedures described in international publication WO 2015/103072.</p><p id="p-0176" num="0161">The DNA constructs used to generate FIT-Ig antibodies capable of binding CD3 and BCMA encoded the variable domains of parental anti-CD3 and anti-BCMA monoclonal antibodies (mAbs). Each FIT-Ig binding protein consisted of three polypeptide chains having the following structures:</p><p id="p-0177" num="0162">Chain 1 (long chain): VL<sub>CD3</sub>-CL-VH<sub>BCMA</sub>-CH1-hinge-CH2-CH3;</p><p id="p-0178" num="0163">Chain 2 (first short chain): VH<sub>CD3</sub>-CH1;</p><p id="p-0179" num="0164">Chain 3 (second short chain): VL<sub>BCMA</sub>-CL;</p><p id="p-0180" num="0000">wherein VL<sub>BCMA </sub>is the light chain variable domain of a monoclonal antibody recognizing BCMA, VH<sub>CD3 </sub>is the heavy chain variable domain of a monoclonal antibody recognizing CD3, VL<sub>CD3 </sub>is the light chain variable domain of a monoclonal antibody recognizing CD3, VH<sub>BCMA </sub>is the heavy chain variable domain of a monoclonal antibody recognizing BCMA, each CL is a light chain constant domain, each CH1 is a first heavy chain constant domain, and hinge-CH2-CH3 is an antibody C-terminal Fc region.</p><p id="p-0181" num="0165">To construct the long chain vector, cDNA encoding the VL<sub>CD3</sub>-CL-VH<sub>BCMA </sub>segment was synthesized de novo and inserted into the multiple cloning site (MCS) of a vector including coding sequences for human CH1-hinge-CH2-CH3. In the resulting vector, the MCS sequence was eliminated during homologous recombination to ensure that all the domain fragments were in the correct reading frame. Similarly, to construct the first and second short chains, VH<sub>CD3 </sub>and VL<sub>BCMA </sub>structural genes were de novo synthesized and inserted into the MCS of the appropriate vectors including coding segments for human CH1 and CL domains, respectively.</p><p id="p-0182" num="0166">Three plasmids were mixed at a ratio of 1:2:1.5, then co-transfected into HEK293 cells. After 7 days expression, cell culture supernatants were collected and purified by Protein A chromatography. The concentration of purified FIT-Ig protein was measured by A280, and homogeneity was analyzed by size exclusion chromatography (SEC).</p><p id="p-0183" num="0167">To test the binding characteristics of the new murine anti-BCMA antibodies, mAbBCMA-002 and mAbBCMA-003, in a bispecific FIT-Ig format, the VH<sub>BCMA </sub>and VL<sub>BCMA </sub>domains used in the Chain 1 and Chain 3 polypeptides (supra) were the VH and VL domains set forth in Table 8 (i.e., either SEQ ID NO:29 or SEQ ID NO:31 for VH, and either SEQ ID NO:30 or SEQ ID NO:32 for VL). For the VH<sub>CD3 </sub>and VL<sub>CD3 </sub>domains in Chain 1 and Chain 2 (supra), the parental anti-CD3 antibody was one of three selected humanized anti-CD3 antibodies: HuEM0006-01-24 antibody (VH=SEQ ID NO:18; VL=SEQ ID NO:25), HuEM0006-01-25 antibody (VH=SEQ ID NO:15; VL=SEQ ID NO:25), or HuEM0006-01-26 antibody (VH=SEQ ID NO:12; VL=SEQ ID NO:25). For the constant domains CH1-hinge-CH2-CH3 and CL in the FIT-Ig structure, human sequences were used, i.e., SEQ ID NO:26 and SEQ ID NO:27. Utilizing cDNAs encoding the foregoing polypeptide domains, FIT-Ig expression vectors were constructed and used to transfect HEK293 cells. Cultures of each no-linker FIT-Ig construct were grown and FIT-Igs purified as described above. The six FIT-Ig binding proteins were given the designations shown in Table 9 below:</p><p id="p-0184" num="0000"><tables id="TABLE-US-00013" num="00013"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 9</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Production list for huCD3/chimeric BCMA FIT-Ig binding proteins </entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="70pt" align="center"/><colspec colname="4" colwidth="70pt" align="center"/><tbody valign="top"><row><entry>FIT-Ig </entry><entry>variable </entry><entry>outer Fab binding site </entry><entry>inner Fab binding site </entry></row><row><entry>Antibody ID </entry><entry>domains </entry><entry>(CD3) </entry><entry>(BCMA)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>FIT1006-3a </entry><entry>VH </entry><entry>SEQ ID NO: 18 </entry><entry>SEQ ID NO: 29 </entry></row><row><entry/><entry>VL </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 30 </entry></row><row><entry>FIT1006-5a </entry><entry>VH </entry><entry>SEQ ID NO: 15 </entry><entry>SEQ ID NO: 29 </entry></row><row><entry/><entry>VL </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 30 </entry></row><row><entry>FIT1006-7a </entry><entry>VH </entry><entry>SEQ ID NO: 12 </entry><entry>SEQ ID NO: 29 </entry></row><row><entry/><entry>VL </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 30 </entry></row><row><entry>FIT1006-4a </entry><entry>VH </entry><entry>SEQ ID NO: 18 </entry><entry>SEQ ID NO: 31 </entry></row><row><entry/><entry>VL </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 32 </entry></row><row><entry>FIT1006-6a </entry><entry>VH </entry><entry>SEQ ID NO: 15 </entry><entry>SEQ ID NO: 31 </entry></row><row><entry/><entry>VL </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 32 </entry></row><row><entry>FIT1006-8a </entry><entry>VH </entry><entry>SEQ ID NO: 12 </entry><entry>SEQ ID NO: 31 </entry></row><row><entry/><entry>VL </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 32</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0026" level="1">Example 4.2: Generation of BCMA/CD3 FIT-Ig Fab Fragment Binding Proteins (FIT-Fabs)</heading><p id="p-0185" num="0168">Full-length FIT-Ig protein was digested and purified with a Pierce&#x2122; Fab Preparation Kit (ThermoFisher Scientific, Cat. #44985). In this process, the Fe domain of the FIT-Ig protein was removed by enzymatic cleavage using immobilized papain on agarose beads. The FIT-Ig Fab fragment (FIT-Fab) was then purified from the flow-through from Protein A chromatography. The concentration of purified FIT-Fab protein was measured by A280, and homogeneity was analyzed by size exclusion chromatography (SEC).</p><heading id="h-0027" level="1">Example 4.3: FIT-Ig Bispecific Antibodies Showed Binding to Both CD3 and BCMA Targets</heading><p id="p-0186" num="0169">Binding activity of the chimeric bispecific BCMA/CD3 FIT-Ig antibodies was tested via flow cytometry with a human CD3/TCR complex transfected CHO cell line (CHOK1/CD3/TCR cells) and BCMA-expressing NCI-H929 cells. Briefly, 5&#xd7;10<sup>5 </sup>cells in FACS buffer were seeded into 96 well plates. Cells were centrifuged at 400&#xd7;g for 5 minutes and supernatants were discarded. For each well, 100 &#x3bc;l serially diluted FIT-Ig or FIT-Fab antibodies were then added and mixed with the cells. Following incubation for 40 minutes at 4&#xb0; C., plates were washed several times to remove excess antibodies. Secondary antibody (goat anti-huIgG kappa chain specific) was then added and incubated with cells at room temperature for 20 minutes. After another round of centrifugation and washing, cells were resuspended with FACS buffer for reading on a CytoFLEX Flow Cytometer. Results were analyzed and plotted with GraphPad Prism 5.0 software. The results are shown in <figref idref="DRAWINGS">FIGS. <b>9</b> and <b>10</b></figref>.</p><p id="p-0187" num="0170">As shown in <figref idref="DRAWINGS">FIG. <b>9</b></figref>, binding activity to BCMA with Fab fragments of bispecific chimeric BCMA/CD3 FIT-Fab antibodies showed exactly the same binding curve when they consist of the same BCMA binding domains. As shown in <figref idref="DRAWINGS">FIG. <b>10</b></figref>, chimeric BCMA/CD3 FIT-Ig binding proteins maintained similar binding activity curves to the parental monoclonal humanized CD3 antibodies (Cf. <figref idref="DRAWINGS">FIG. <b>5</b>B, <b>5</b>C</figref>).</p><heading id="h-0028" level="1">Example 4.4: Chimeric FIT-Fab and FIT-Ig Showed Redirected CD3 Activation</heading><p id="p-0188" num="0171">To measure redirected CD3 activation by BCMA/CD3 bispecific FIT-Ig and FIT-Fab antibodies, a co-cultured reporter gene assay was used. Jurkat-NFAT-luc cells will trigger downstream luciferase signal once cell surface CD3 is activated. NCI-H929 cells were used as the BCMA-expressing target cell, which can crosslink CD3/TCR complex on T cells via bispecific BCMA/CD3 antibodies upon BCMA binding. Jurkat-NFAT-luc and NCI-H929 cells were washed and resuspended in assay medium (RPMI1640 with 10% FBS) separately. Both cell types were seeded into 96 well plates (Costar #3903) at 1&#xd7;10<sup>5 </sup>cells per well in a ratio of 1:1. FIT-Ig or FIT-Fab antibodies were added and mixed with the cells and incubated for 4 hours at 37&#xb0; C. At the end of incubation, ONE-Glo&#x2122; luminescence assay kit (Promega, Cat. #E6130) reagents were prepared and added into wells according the manufacturer's instructions. Plates were read for luminescence signals with Varioskan&#x2122; LUX microplate reader (ThermoFisher Scientific). The results are shown in <figref idref="DRAWINGS">FIGS. <b>11</b> and <b>12</b></figref>.</p><p id="p-0189" num="0172">Referring to <figref idref="DRAWINGS">FIG. <b>11</b></figref>, FIT-Ig concentration causing T cell activation is plotted for the FIT-Ig binding proteins prepared as described in Example 4.1, utilizing two of the highest affinity anti-BCMA and anti-CD3 antibodies, namely, mAbBCMA-003 and HuEM0006-01-24. In the figure, FIT1006-4a is a FIT-Ig having an outer CD3-binding Fab binding site and an inner BCMA-binding Fab binding site (supra; see Table 9); FIT1006-4b is a FIT-Ig constructed using the same amino acid sequences but having the position of the binding domains reversed, that is, having an outer BCMA-binding Fab binding site and an inner CD3-binding Fab binding site; and FIT1006-4a-Fab which was made from FIT1006-4a by papain digestion (see Example 4.2). The performance of these binding proteins is compared against two negative controls: (i) a FIT-Ig having binding sites reactive with two irrelevant antigen targets (&#x201c;FIT1002-5a&#x201d;), and (ii) a humanized IgG monoclonal antibody reactive with an irrelevant antigen (&#x201c;hIgG&#x201d;). Also, two anti-CD3 binding proteins, namely, a humanized anti-CD3 monoclonal antibody (HuEM0006-01-24) and a Fab fragment made therefrom (HuEM0006-01-24-Fab), were also tested. It can be seen that all of the bispecific BCMA/CD3 binding proteins led to increased T cell activation in the presence of BCMA-expressing target cells in comparison to monospecific anti-CD3 binding proteins having no BCMA binding activity.</p><p id="p-0190" num="0173">Referring to <figref idref="DRAWINGS">FIG. <b>12</b></figref>, the concentration of various bispecific BCMA/CD3 FIT-Fab binding proteins causing T cell activation in the presence of BCMA-expressing target cells is plotted for FIT-Fabs prepared from FIT-Ig binding proteins described in Table 9, above (designated FIT1006-3a-Fab, FIT1006-4a-Fab, FIT1006-5a-Fab, FIT1006-6a-Fab, FIT1006-7a-Fab, FIT1006-8a-Fab). The performance of these FIT-Fabs was compared against a combination of a reference anti-CD3 Fab and mAbBCMA-002, a reference FIT-Fab antibody designated FIT1006-la-Fab utilizing anti-CD3 and anti-BCMA binding regions disclosed in WO 2016/020332, and a negative control FIT-Fab designated FIT1002-5a-Fab prepared using parental antibody binding sites directed at two irrelevant antigen targets.</p><p id="p-0191" num="0174">These results demonstrated that the BCMA/CD3 bispecific antibodies can activate CD3 by crosslinking upon binding to BCMA on the surface of tumor cells. Not only FIT-Ig binding proteins (<figref idref="DRAWINGS">FIG. <b>11</b></figref>) but also FIT-Fab binding proteins (<figref idref="DRAWINGS">FIG. <b>12</b></figref>) showed redirected activation in this assay. Additionally, FIT1006-4a-Fab showed a surprisingly steep activation curve at low concentration.</p><heading id="h-0029" level="1">Example 4.5: Chimeric BCMA/CD3 FIT-Fabs Showed Redirected T Cell Cytotoxicity</heading><p id="p-0192" num="0175">The tumor cell killing potency of the BCMA/CD3 bispecific binding proteins was measured in a redirected T cell cytotoxicity assay using the human myeloma cell line NCI-H929 as target cells and human T cells as effector cells. Briefly, cells were harvested, washed, and resuspended with assay medium (RPMI1640 with 10% FBS). NCI-H929 cells were seeded into flat-bottom 96 well plates (Corning, Cat. #3599) at 5&#xd7;10<sup>4 </sup>cells per well. T cells were purified from human PBMC with a commercial PBMC isolation kit (EasySep&#x2122;, Stemcell Technologies, Cat. #17951) and were added to the wells at 2&#xd7;10<sup>5 </sup>cells per well. Test antibodies were added and incubated with the cells mixture for 48 hours at 37&#xb0; C. Lactate dehydrogenase (LDH) release was measured with a CytoTox 96&#xae; cytotoxicity assay kit (Promega, Cat. #G1780). OD490 readouts were obtained following the manufacturer's instructions. Target cells NCI-H929 max lysis (100%) minus minimal lysis (0%) was presented as the normalization denominator. The percentage of LDH release was plotted against the concentrations of bispecific antibodies. As shown in <figref idref="DRAWINGS">FIG. <b>13</b></figref>, bispecific FIT-Fabs having anti-BCMA and anti-CD3 specificity demonstrated redirected T cell cytotoxicity to NCI-H929 tumor cells, while monospecific humanized anti-CD3 Fab and a combination of anti-CD3 Fab (Fab fragment of HuEM0006-01-24) and anti-BCMA mAb (TAB1) showed no cytotoxic activity.</p><heading id="h-0030" level="1">Example 4.5: Chimeric FIT-Ig Showed Limited Non-Target Redirected CD3 Activation In Vitro</heading><p id="p-0193" num="0176">Non-target redirected CD3 activation was tested using a Jurkat-NFAT-luc based reporter gene assay in the absence of target cells. Jurkat-NFAT-luc cells were harvested, washed and resuspended in assay medium (RPMI1640 with 10% FBS) and seeded into 96 well plates (Costar #3903) at 1&#xd7;10<sup>5 </sup>cells per well. Test antibodies were added and mixed with the cells and incubated for 4 hours at 37&#xb0; C. Following incubation, ONE-Glo&#x2122; luminescence assay kit (Promega, Cat. #E6130) reagents were prepared and added into wells following the manufacturer's instructions. Plates were read for luminescence signals with Varioskan&#x2122; Lux plate reader. The results are shown in <figref idref="DRAWINGS">FIG. <b>14</b></figref>.</p><p id="p-0194" num="0177">This assay was similar to the test conducted in Example 4.4, above, except in the absence of cells expressing a co-target for the bispecific binding proteins, in this case BCMA. The results show that bispecific BCMA/CD3 FIT-Ig antibodies (FIT1006-4a and FIT1006-4b) and the BCMA/CD3 FIT-Fab designated FIT1006-4a-Fab, all having the same CD3 binding domain as the humanized anti-CD3 monoclonal antibody HuEM0006-01-24, showed much less non-target redirected activation than the anti-CD3 antibody alone, in the absence of BCMA-expressing target cells (Cf. <figref idref="DRAWINGS">FIG. <b>11</b></figref>).</p><heading id="h-0031" level="1">Example 5: Production of Humanized Bispecific BCMA/CD3 FIT-Ig Binding Proteins</heading><p id="p-0195" num="0178">The anti-BCMA monoclonal mAbBCMA-003 showed higher BCMA binding affinity and better redirected cell killing when used in a BCMA/CD3 FIT-Ig and FIT-Fab format. Accordingly mAbBCMA-003 was selected for humanization and subsequent use in constructing humanized bispecific binding proteins.</p><heading id="h-0032" level="1">Example 5.1: Humanization of Anti-BCMA Antibody mAbBCMA-003</heading><p id="p-0196" num="0179">The mAbBCMA-003 variable region genes were employed to create humanized mAbs. In the first step of this process, the amino acid sequences of the VH and VK of mAbBCMA-003 (see Table 8, supra) were compared against the available database of human Ig V-gene sequences in order to find the overall best-matching human germline Ig V-gene sequences. Additionally, the framework 4 of VH or VL was compared against the J-region database to find the human framework having the highest homology to the murine VH and VL regions, respectively. For the light chain, the closest human V-gene match was the VK1-39(02) gene, and for the heavy chain the closest human match was the VH1-03 gene. Humanized variable domain sequences were then designed where the CDR-L1, CDR-L2 and CDR-L3 of the mAbBCMA-003 light chain were grafted onto framework sequences of the VK1-39(02) gene, with JK2 framework 4 sequence after CDR-L3; and the CDR-H1, CDR-H2, and CDR-H3 sequences of the mAbBCMA-003 VH were grafted onto framework sequences of the VH1-03 gene, with JH6 framework 4 sequence after CDR-H3. A 3D Fv model of mAbBCMA-003 was then generated and analyzed to determine if there were any framework residues that have a less than 4A distance to the CDR residues and that were most likely critical to support loop structures or the VH/VL interface. These residues in humanized sequences should be back-mutated to mouse residues at the same position to retain affinity/activity. Q1E mutation was always included to eliminate N-terminal pyroglutamate formation if applicable. In the case of the heavy chain, potential mutations of P30T, I48M, K66R, A67V, L69I, and A71R (Kabat numbering) were identified as desirable back mutations. In the case of the light chain, V58I and R69T were identified as desirable back mutations. Via the importance tier of each back mutation, as determined by its interaction with CDRs, the most important back mutations were introduced in the humanized VH sequence in order of priority, followed by other back mutations in successive designs. In addition, a DG dipeptide occurring at the C-terminal end of CDR-L2 presented a potential aspartic acid isomerization site, and this was eliminated in light chain variants by the following alternative substitutions: D56A, D56E, D56S, D56T, or G57A. The humanized VH and VL design constructs are shown in Table 10 (below). (Back mutated framework amino acid residues are indicated with double underscore; murine CDRs from the original parental antibody are underlined.)</p><p id="p-0197" num="0000"><tables id="TABLE-US-00014" num="00014"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="294pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;10</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Humanized&#x2003;VH/VL&#x2003;design&#x2003;of&#x2003;anti-BCMA&#x2003;mAbBCMA-003</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="182pt" align="left"/><tbody valign="top"><row><entry/><entry>SEQ&#x2003;ID</entry><entry>Amino&#x2003;acid&#x2003;sequences</entry></row><row><entry>Humanized&#x2003;VH/VL</entry><entry>NO.</entry><entry>1234567890123456789012345678901234567890</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>mAbBCMA-003&#x2003;VH.1</entry><entry>33</entry><entry><u style="double">E</u>VQLVQSGAEVKKPGASVKVSCKASGYTFT<u style="single">NFWMH</u>WVRQAP</entry></row><row><entry/><entry/><entry>GQRLEWMG<u style="single">AFYPGNDDTYYNQKFKG</u>RVTITRDTSASTAYME</entry></row><row><entry/><entry/><entry>LSSLRSEDMAVYYCAR<u style="single">SGYYGSSDAMDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VH.1A</entry><entry>34</entry><entry><u style="double">E</u>VQLVQSGAEVKKPGASVKVSCKASGYTFT<u style="single">NFWMH</u>WVRQAP</entry></row><row><entry/><entry/><entry>GQRLEWMG<u style="single">AFYPGNDDTYYNQKFKG</u>RVTIT<u style="double">A</u>DTSASTAYME</entry></row><row><entry/><entry/><entry>LSSLRSEDMAVYYCAR<u style="single">SGYYGSSDAMDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VH.1B</entry><entry>35</entry><entry><u style="double">E</u>VQLVQSGAEVKKPGASVKVSCKASGYTFT<u style="single">NFWMH</u>WVRQAP</entry></row><row><entry/><entry/><entry>GQRLEW<u style="double">I</u>G<u style="single">AFYPGNDDTYYNQKFKG</u><u style="double">KA</u>T<u style="double">L</u>T<u style="double">A</u>DTSASTAYME</entry></row><row><entry/><entry/><entry>LSSLRSEDMAVYYCAR<u style="single">SGYYGSSDAMDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VH.1C</entry><entry>36</entry><entry><u style="double">E</u>VQLVQSGAEVKKPGASVKVSCKASGYTF<u style="double">P</u><u style="single">NFWMH</u>WVRQAP</entry></row><row><entry/><entry/><entry>GQRLEW<u style="double">I</u>G<u style="single">AFYPGNDDTYYNQKFKG</u><u style="double">KA</u>T<u style="double">L</u>T<u style="double">A</u>DTSASTAYME</entry></row><row><entry/><entry/><entry>LSSLRSEDMAVYYCAR<u style="single">SGYYGSSDAMDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VH.1D</entry><entry>37</entry><entry><u style="double">E</u>VQLVQSGAEVKKPGASVKVSCKASGYTF<u style="double">P</u><u style="single">NFWMH</u>WVRQAP</entry></row><row><entry/><entry/><entry>GQRLEWMG<u style="single">AFYPGNDDTYYNQKFKG</u>RVTITRDTSASTAYME</entry></row><row><entry/><entry/><entry>LSSLRSEDMAVYYCAR<u style="single">SGYYGSSDAMDY</u>WGQGTTVTVSS</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VK.1</entry><entry>38</entry><entry>DIQMTQSPSSLSASVGDRVTITC<u style="single">GASENIYGALN</u>WYQQKPG</entry></row><row><entry/><entry/><entry>KAPKLLIY<u style="single">GATNLAD</u>GVPSRFSGSGSGTDFTLTISSLQPED</entry></row><row><entry/><entry/><entry>FATYYC<u style="single">QSVLTTPWT</u>FGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VK.1A</entry><entry>39</entry><entry>DIQMTQSPSSLSASVGDRVTITC<u style="single">GASENIYGALN</u>WYQQKPG</entry></row><row><entry/><entry/><entry>KAPKLLIY<u style="single">GATNLAD</u>G<u style="double">I</u>PSRFSGSGSG<u style="double">R</u>DFTLTISSLQPED</entry></row><row><entry/><entry/><entry>FATYYC<u style="single">QSVLTTPWT</u>FGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VK.1</entry><entry>40</entry><entry>DIQMTQSPSSLSASVGDRVTITC<u style="single">GASENIYGALN</u>WYQQKPG</entry></row><row><entry>(D-A)</entry><entry/><entry>KAPKLLIY<u style="single">GATNLA</u><u style="double">A</u>GVPSRFSGSGSGTDFTLTISSLQPED</entry></row><row><entry/><entry/><entry>FATYYC<u style="single">QSVLTTPWT</u>FGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VK.1</entry><entry>41</entry><entry>DIQMTQSPSSLSASVGDRVTITC<u style="single">GASENIYGALN</u>WYQQKPG</entry></row><row><entry>(D-E)</entry><entry/><entry>KAPKLLIY<u style="single">GATNLA</u><u style="double">E</u>GVPSRFSGSGSGTDFTLTISSLQPED</entry></row><row><entry/><entry/><entry>FATYYC<u style="single">QSVLTTPWT</u>FGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VK.1</entry><entry>42</entry><entry>DIQMTQSPSSLSASVGDRVTITC<u style="single">GASENIYGALN</u>WYQQKPG</entry></row><row><entry>(D-S)</entry><entry/><entry>KAPKLLIY<u style="single">GATNLA</u><u style="double">S</u>GVPSRFSGSGSGTDFTLTISSLQPED</entry></row><row><entry/><entry/><entry>FATYYC<u style="single">QSVLTTPWT</u>FGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VK.1</entry><entry>43</entry><entry>DIQMTQSPSSLSASVGDRVTITC<u style="single">GASENIYGALN</u>WYQQKPG</entry></row><row><entry>(D-T)</entry><entry/><entry>KAPKLLIY<u style="single">GATNLA</u><u style="double">T</u>GVPSRFSGSGSGTDFTLTISSLQPED</entry></row><row><entry/><entry/><entry>FATYYC<u style="single">QSVLTTPWT</u>FGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VK.1</entry><entry>44</entry><entry>DIQMTQSPSSLSASVGDRVTITC<u style="single">GASENIYGALN</u>WYQQKPG</entry></row><row><entry>(G-A)</entry><entry/><entry>KAPKLLIY<u style="single">GATNLAD</u><u style="double">A</u>VPSRFSGSGSGTDFTLTISSLQPED</entry></row><row><entry/><entry/><entry>FATYYC<u style="single">QSVLTTPWT</u>FGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VK.1A</entry><entry>45</entry><entry>DIQMTQSPSSLSASVGDRVTITC<u style="single">GASENIYGALN</u>WYQQKPG</entry></row><row><entry>(D-A)</entry><entry/><entry>KAPKLLIY<u style="single">GATNLA</u><u style="double">A</u>G<u style="double">I</u>PSRFSGSGSG<u style="double">R</u>DFTLTISSLQPED</entry></row><row><entry/><entry/><entry>FATYYC<u style="single">QSVLTTPWT</u>FGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VK.1A</entry><entry>46</entry><entry>DIQMTQSPSSLSASVGDRVTITC<u style="single">GASENIYGALN</u>WYQQKPG</entry></row><row><entry>(D-E)</entry><entry/><entry>KAPKLLIY<u style="single">GATNLA</u><u style="double">E</u>G<u style="double">I</u>PSRFSGSGSG<u style="double">R</u>DFTLTISSLQPED</entry></row><row><entry/><entry/><entry>FATYYC<u style="single">QSVLTTPWT</u>FGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VK.1A</entry><entry>47</entry><entry>DIQMTQSPSSLSASVGDRVTITC<u style="single">GASENIYGALN</u>WYQQKPG</entry></row><row><entry>(D-S)</entry><entry/><entry>KAPKLLIY<u style="single">GATNLA</u><u style="double">S</u>G<u style="double">I</u>PSRFSGSGSG<u style="double">R</u>DFTLTISSLQPED</entry></row><row><entry/><entry/><entry>FATYYC<u style="single">QSVLTTPWT</u>FGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VK.1A</entry><entry>48</entry><entry>DIQMTQSPSSLSASVGDRVTITC<u style="single">GASENIYGALN</u>WYQQKPG</entry></row><row><entry>(D-T)</entry><entry/><entry>KAPKLLIY<u style="single">GATNLA</u><u style="double">T</u>G<u style="double">I</u>PSRFSGSGSG<u style="double">R</u>DFTLTISSLQPED</entry></row><row><entry/><entry/><entry>FATYYC<u style="single">QSVLTTPWT</u>FGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>mAbBCMA-003&#x2003;VK.1A</entry><entry>49</entry><entry>DIQMTQSPSSLSASVGDRVTITC<u style="single">GASENIYGALN</u>WYQQKPG</entry></row><row><entry>(G-A)</entry><entry/><entry>KAPKLLIY<u style="single">GATNLAD</u><u style="double">AI</u>PSRFSGSGSG<u style="double">R</u>DFTLTISSLQPED</entry></row><row><entry/><entry/><entry>FATYYC<u style="single">QSVLTTPWT</u>FGQGTKLEIK</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0198" num="0180">The humanized anti-BCMA VH and VL genes were produced synthetically and then respectively cloned into FIT-Ig vectors as described in Example 4.1, which also contained the VH and VL genes from anti-CD3 monoclonal HuEM0006-01-24. The pairing of the humanized VH and the humanized VL created the humanized BCMA/CD3 FIT-Ig binding proteins listed in Table 11 below. A chimeric antibody with parental mouse VH/VL of mAbBCMA-003 and human constant sequences was also produced as a positive control for humanized binding protein ranking. All recombinant FIT-Igs were expressed and purified as described in Example 4.1.</p><p id="p-0199" num="0000"><tables id="TABLE-US-00015" num="00015"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="259pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 11</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Production List of Humanized BCMA/CD3 FIT-Igs </entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="63pt" align="center"/><colspec colname="2" colwidth="98pt" align="center"/><colspec colname="3" colwidth="98pt" align="center"/><tbody valign="top"><row><entry>FIT-Ig </entry><entry>Outer Fab Binding Site </entry><entry>Inner Fab Binding Site </entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="63pt" align="center"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><colspec colname="5" colwidth="49pt" align="center"/><tbody valign="top"><row><entry>Identifier </entry><entry>VL<sub>BCMA </sub></entry><entry>VH<sub>BCMA </sub></entry><entry>VL<sub>CD3 </sub></entry><entry>VH<sub>CD3</sub></entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>FIT1006-27b </entry><entry>SEQ ID NO: 38 </entry><entry>SEQ ID NO: 34 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-28b </entry><entry>SEQ ID NO: 38 </entry><entry>SEQ ID NO: 35 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-29b </entry><entry>SEQ ID NO: 38 </entry><entry>SEQ ID NO: 36 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-30b </entry><entry>SEQ ID NO: 38 </entry><entry>SEQ ID NO: 37 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-31b </entry><entry>SEQ ID NO: 39 </entry><entry>SEQ ID NO: 34 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-32b </entry><entry>SEQ ID NO: 39 </entry><entry>SEQ ID NO: 35 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-33b </entry><entry>SEQ ID NO: 39 </entry><entry>SEQ ID NO: 36 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-34b </entry><entry>SEQ ID NO: 39 </entry><entry>SEQ ID NO: 37 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-29b (D-A) </entry><entry>SEQ ID NO: 45 </entry><entry>SEQ ID NO: 36 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-29b (D-E) </entry><entry>SEQ ID NO: 46 </entry><entry>SEQ ID NO: 36 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-29b (D-S) </entry><entry>SEQ ID NO: 47 </entry><entry>SEQ ID NO: 36 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-29b (D-T) </entry><entry>SEQ ID NO: 48 </entry><entry>SEQ ID NO: 36 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-29b (G-A) </entry><entry>SEQ ID NO: 49 </entry><entry>SEQ ID NO: 36 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-31b (D-A) </entry><entry>SEQ ID NO: 45 </entry><entry>SEQ ID NO: 34 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-31b (D-E) </entry><entry>SEQ ID NO: 46 </entry><entry>SEQ ID NO: 34 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-31b (D-S) </entry><entry>SEQ ID NO: 47 </entry><entry>SEQ ID NO: 34 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-31b (D-T) </entry><entry>SEQ ID NO: 48 </entry><entry>SEQ ID NO: 34 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-31b (G-A) </entry><entry>SEQ ID NO: 49 </entry><entry>SEQ ID NO: 34 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 18 </entry></row><row><entry>FIT1006-35b (D-T) </entry><entry>SEQ ID NO: 48 </entry><entry>SEQ ID NO: 34 </entry><entry>SEQ ID NO: 25 </entry><entry>SEQ ID NO: 17</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0200" num="0181">Bispecific FIT-Ig and FIT-Fab binding proteins having the ability to bind both BCMA and CD3 antigens were constructed in the same manner as in Examples 4.1 and 4.2, supra, using cDNAs encoding the humanized variable domains listed in Table 11 above and human constant region sequences as shown in Table 3 (SEQ ID NO:26 and SEQ ID NO:27). No linkers between immunoglobulin domains were used, therefore the complete sequences for the FIT-Ig binding proteins can be derived from the sequence information in Tables 11 and 3. For example, the amino acid sequences for the three polypeptide chains of three exemplary FIT-Ig binding proteins disclosed in Table 11 are set forth in Tables 12, 13, and 14 below, for FIT-Igs FIT1006-29b(D-A), FIT1006-31b(D-T), and FIT1006-35b(D-T). These FIT-Igs have the BCMA binding site at the N-terminal position of the assembled chains, and the CD3 binding site is situated internally in the FIT-Ig structure adjacent (N-terminal) to the Fc region but C-terminal to the BCMA binding site. In other words, the domain configuration of the component polypeptide chains is:</p><p id="p-0201" num="0182">Chain 1 (long chain): VL<sub>BCMA</sub>-CL-VH<sub>CD3</sub>-CH1-hinge-CH2-CH3;</p><p id="p-0202" num="0183">Chain 2 (first short chain): VH<sub>BCMA</sub>-CH1;</p><p id="p-0203" num="0184">Chain 3 (second short chain): VL<sub>CD3</sub>-CL;</p><p id="p-0204" num="0000">wherein VL<sub>BCMA </sub>is the light chain variable domain of a humanized monoclonal antibody recognizing BCMA, VH<sub>CD3 </sub>is the heavy chain variable domain of a humanized monoclonal antibody recognizing CD3, VL<sub>CD3 </sub>is the light chain variable domain of a humanized monoclonal antibody recognizing CD3, VH<sub>BCMA </sub>is the heavy chain variable domain of a humanized monoclonal antibody recognizing BCMA, each CL is a light chain constant domain (SEQ ID NO:27), each CH1 is a first heavy chain constant domain, and CH1-hinge-CH2-CH3 the C-terminal heavy chain constant region from CH1 through the terminus of the Fc region (see SEQ ID NO:26).</p><p id="p-0205" num="0000"><tables id="TABLE-US-00016" num="00016"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="280pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;12</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Amino&#x2003;Acid&#x2003;Sequences&#x2003;of&#x2003;FIT-Ig&#x2003;FIT1006-29b(D-A)&#x2003;Component&#x2003;Chains</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="175pt" align="left"/><tbody valign="top"><row><entry/><entry>SEQ&#x2003;ID</entry><entry>Amino&#x2003;Acid&#x2003;Sequence</entry></row><row><entry>Polypeptide</entry><entry>NO:</entry><entry>1234567890123456789012345678901234567890</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>FIT1006-29b(D-A)</entry><entry>50</entry><entry>DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKP</entry></row><row><entry>Chain&#x2003;#1</entry><entry/><entry>GKAPKLLIYGATNLAAGVPSRFSGSGSGTDFTLTISSLQP</entry></row><row><entry/><entry/><entry>EDFATYYCQSVLTTPWTFGQGTKLEIKRTVAAPSVFIFPP</entry></row><row><entry/><entry/><entry>SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ</entry></row><row><entry/><entry/><entry>ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG</entry></row><row><entry/><entry/><entry>LSSPVTKSFNRGECEVQLVQSGAEVKKPGASVKVSCKASG</entry></row><row><entry/><entry/><entry>FSFTNYYVHWMRQAPGQGLEWMGWISPGSDNTKYNEKFKG</entry></row><row><entry/><entry/><entry>RVTMTRDTSISTAYMELSRLRSDDTAVYYCARDDYGNYYF</entry></row><row><entry/><entry/><entry>DYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC</entry></row><row><entry/><entry/><entry>LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS</entry></row><row><entry/><entry/><entry>VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH</entry></row><row><entry/><entry/><entry>TCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV</entry></row><row><entry/><entry/><entry>DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS</entry></row><row><entry/><entry/><entry>VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR</entry></row><row><entry/><entry/><entry>EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN</entry></row><row><entry/><entry/><entry>GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS</entry></row><row><entry/><entry/><entry>CSVMHEALHNHYTQKSLSLSPGK</entry></row><row><entry> </entry></row><row><entry>FIT1006-29b(D-A)</entry><entry>51</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASGYTFPNFWMHWVRQA</entry></row><row><entry>Chain&#x2003;#2</entry><entry/><entry>PGQRLEWIGAFYPGNDDTYYNQKFKGKATLTADTSASTAY</entry></row><row><entry/><entry/><entry>MELSSLRSEDMAVYYCARSGYYGSSDAMDYWGQGTTVTVS</entry></row><row><entry/><entry/><entry>SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV</entry></row><row><entry/><entry/><entry>SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ</entry></row><row><entry/><entry/><entry>TYICNVNHKPSNTKVDKKVEPKSC</entry></row><row><entry> </entry></row><row><entry>FIT1006-29b(D-A)</entry><entry>52</entry><entry>DIVMTQSPDSLAVSLGERATINCKSSQSLLNARTRKNYLA</entry></row><row><entry>Chain&#x2003;#3</entry><entry/><entry>WYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLT</entry></row><row><entry/><entry/><entry>ISSLQAEDVAVYYCKQSYILRTFGGGTKVEIKRTVAAPSV</entry></row><row><entry/><entry/><entry>FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ</entry></row><row><entry/><entry/><entry>SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE</entry></row><row><entry/><entry/><entry>VTHQGLSSPVTKSFNRGEC</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0206" num="0000"><tables id="TABLE-US-00017" num="00017"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="287pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;13</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Amino&#x2003;Acid&#x2003;Sequences&#x2003;of&#x2003;FIT-Ig&#x2003;FIT1006-31b(D-T)&#x2003;Component&#x2003;Chains</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="175pt" align="left"/><tbody valign="top"><row><entry/><entry>SEQ&#x2003;ID</entry><entry/></row><row><entry>Polypeptide</entry><entry>NO:</entry><entry>1234567890123456789012345678901234567890</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>FIT1006-31b(D-T)</entry><entry>53</entry><entry>DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKP</entry></row><row><entry>Chain&#x2003;#1</entry><entry/><entry>GKAPKLLIYGATNLATGIPSRFSGSGSGRDFTLTISSLQP</entry></row><row><entry/><entry/><entry>EDFATYYCQSVLTTPWTFGQGTKLEIKRTVAAPSVFIFPP</entry></row><row><entry/><entry/><entry>SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ</entry></row><row><entry/><entry/><entry>ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG</entry></row><row><entry/><entry/><entry>LSSPVTKSFNRGECEVQLVQSGAEVKKPGASVKVSCKASG</entry></row><row><entry/><entry/><entry>FSFTNYYVHWMRQAPGQGLEWMGWISPGSDNTKYNEKFKG</entry></row><row><entry/><entry/><entry>RVTMTRDTSISTAYMELSRLRSDDTAVYYCARDDYGNYYF</entry></row><row><entry/><entry/><entry>DYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC</entry></row><row><entry/><entry/><entry>LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS</entry></row><row><entry/><entry/><entry>VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH</entry></row><row><entry/><entry/><entry>TCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV</entry></row><row><entry/><entry/><entry>DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS</entry></row><row><entry/><entry/><entry>VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR</entry></row><row><entry/><entry/><entry>EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN</entry></row><row><entry/><entry/><entry>GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS</entry></row><row><entry/><entry/><entry>CSVMHEALHNHYTQKSLSLSPGK</entry></row><row><entry> </entry></row><row><entry>FIT1006-31b(D-T)</entry><entry>54</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASGYTFTNFWMHWVRQA</entry></row><row><entry>Chain&#x2003;#2</entry><entry/><entry>PGQRLEWMGAFYPGNDDTYYNQKFKGRVTITADTSASTAY</entry></row><row><entry/><entry/><entry>MELSSLRSEDMAVYYCARSGYYGSSDAMDYWGQGTTVTVS</entry></row><row><entry/><entry/><entry>SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV</entry></row><row><entry/><entry/><entry>SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ</entry></row><row><entry/><entry/><entry>TYICNVNHKPSNTKVDKKVEPKSC</entry></row><row><entry> </entry></row><row><entry>FIT1006-31b(D-T)</entry><entry>55</entry><entry>DIVMTQSPDSLAVSLGERATINCKSSQSLLNARTRKNYLA</entry></row><row><entry>Chain&#x2003;#3</entry><entry/><entry>WYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLT</entry></row><row><entry/><entry/><entry>ISSLQAEDVAVYYCKQSYILRTFGGGTKVEIKRTVAAPSV</entry></row><row><entry/><entry/><entry>FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ</entry></row><row><entry/><entry/><entry>SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE</entry></row><row><entry/><entry/><entry>VTHQGLSSPVTKSFNRGEC</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0207" num="0000"><tables id="TABLE-US-00018" num="00018"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="287pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;14</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Amino&#x2003;Acid&#x2003;Sequences&#x2003;of&#x2003;FIT-Ig&#x2003;FIT1006-35b(D-T)&#x2003;Component&#x2003;Chains</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="175pt" align="left"/><tbody valign="top"><row><entry/><entry>SEQ&#x2003;ID</entry><entry>Amino&#x2003;Acid&#x2003;Sequence</entry></row><row><entry>Polypeptide</entry><entry>NO:</entry><entry>1234567890123456789012345678901234567890</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>FIT1006-35b(D-T)</entry><entry>80</entry><entry>DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKP</entry></row><row><entry>Chain&#x2003;#1</entry><entry/><entry>GKAPKLLIYGATNLATGIPSRFSGSGSGRDFTLTISSLQP</entry></row><row><entry/><entry/><entry>EDFATYYCQSVLTTPWTFGQGTKLEIKRTVAAPSVFIFPP</entry></row><row><entry/><entry/><entry>SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ</entry></row><row><entry/><entry/><entry>ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG</entry></row><row><entry/><entry/><entry>LSSPVTKSFNRGECEVQLVQSGAEVKKPGASVKVSCKASG</entry></row><row><entry/><entry/><entry>FSFTNYYVHWMRQAPGQGLEWIGWISPGSDNTKYNEKFKG</entry></row><row><entry/><entry/><entry>RVTLTADTSISTAYMELSRLRSDDTAVYYCARDDYGNYYF</entry></row><row><entry/><entry/><entry>DYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC</entry></row><row><entry/><entry/><entry>LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS</entry></row><row><entry/><entry/><entry>VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH</entry></row><row><entry/><entry/><entry>TCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVV</entry></row><row><entry/><entry/><entry>DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS</entry></row><row><entry/><entry/><entry>VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR</entry></row><row><entry/><entry/><entry>EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN</entry></row><row><entry/><entry/><entry>GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS</entry></row><row><entry/><entry/><entry>CSVMHEALHNHYTQKSLSLSPGK</entry></row><row><entry> </entry></row><row><entry>FIT1006-35b(D-T)</entry><entry>81</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASGYTFTNFWMHWVRQA</entry></row><row><entry>Chain&#x2003;#2</entry><entry/><entry>PGQRLEWMGAFYPGNDDTYYNQKFKGRVTITADTSASTAY</entry></row><row><entry/><entry/><entry>MELSSLRSEDMAVYYCARSGYYGSSDAMDYWGQGTTVTVS</entry></row><row><entry/><entry/><entry>SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV</entry></row><row><entry/><entry/><entry>SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ</entry></row><row><entry/><entry/><entry>TYICNVNHKPSNTKVDKKVEPKSC</entry></row><row><entry> </entry></row><row><entry>FIT1006-35b(D-T)</entry><entry>82</entry><entry>DIVMTQSPDSLAVSLGERATINCKSSQSLLN<b>A</b>RTRKNYLA</entry></row><row><entry>Chain&#x2003;#3</entry><entry/><entry>WYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLT</entry></row><row><entry/><entry/><entry>ISSLQAEDVAVYYCKQSYILRTFGGGTKVEIKRTVAAPSV</entry></row><row><entry/><entry/><entry>FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ</entry></row><row><entry/><entry/><entry>SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE</entry></row><row><entry/><entry/><entry>VTHQGLSSPVTKSFNRGEC</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0033" level="1">Example 5.3: Binding Kinetics of Humanized BCMA/CD3 FIT-Igs</heading><p id="p-0208" num="0185">Binding affinities and kinetic constants of BCMA/CD3 bispecific FIT-Ig antibodies was measured by Surface Plasmon Resonance (SPR) at 25&#xb0; C. using a Biacore&#x2122; T200 instrument (GE Healthcare) using standard procedures. Results are shown in Table 15.</p><p id="p-0209" num="0186">Briefly, heterodimeric CD3/Fc antigen or BCMA/Fc antigen following a typical amine coupling method was directly immobilized across a biosensor chip, then test antibodies were injected over reaction matrices at a flow rate of 5 &#x3bc;l/minute and the binding response recorded. The association and dissociation rate constants, k<sub>on </sub>(M<sup>&#x2212;1</sup>s<sup>&#x2212;1</sup>) and k<sub>off </sub>(s<sup>&#x2212;1</sup>) respectively, were determined with a continuous flow rate of 30 l/minute. Rate constants were derived by making kinetic binding measurements at five different concentrations of human CD3/Fc protein or human BCMA/Fc protein. The equilibrium dissociation constant K<sub>D </sub>(M) of the reaction between antibodies and related target proteins was then calculated from the kinetic rate constants using the formula K<sub>D</sub>=k<sub>off</sub>/k<sub>on</sub>. Affinities for humanized anti-CD3/humanized anti-BCMA FIT-Ig antibodies were measured, as set forth in Table 15, below.</p><p id="p-0210" num="0000"><tables id="TABLE-US-00019" num="00019"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="266pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 15</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Binding Affinities for Humanized BCMA/CD3 FIT-Ig Binding Proteins </entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><colspec colname="5" colwidth="56pt" align="center"/><tbody valign="top"><row><entry>Antigen Target </entry><entry>FIT-Ig </entry><entry>k<sub>on </sub>(1/Ms) </entry><entry>k<sub>off </sub>(1/s) </entry><entry>K<sub>D </sub>(M)</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="21pt" align="right"/><colspec colname="4" colwidth="28pt" align="left"/><colspec colname="5" colwidth="21pt" align="right"/><colspec colname="6" colwidth="28pt" align="left"/><colspec colname="7" colwidth="28pt" align="right"/><colspec colname="8" colwidth="28pt" align="left"/><tbody valign="top"><row><entry>huCD3&#x3b5;/&#x3b3;-Fc </entry><entry>FIT1006-29b (D-A) </entry><entry>3.494 </entry><entry>&#xd7; 10<sup>5 </sup></entry><entry>5.849 </entry><entry>&#xd7; 10<sup>&#x2212;3 </sup></entry><entry>1.674 </entry><entry>&#xd7; 10<sup>&#x2212;8 </sup></entry></row><row><entry/><entry>FIT1006-29b (D-E) </entry><entry>2.870 </entry><entry>&#xd7; 10<sup>5 </sup></entry><entry>5.711 </entry><entry>&#xd7; 10<sup>&#x2212;3</sup></entry><entry>1.990 </entry><entry>&#xd7; 10<sup>&#x2212;8 </sup></entry></row><row><entry/><entry>FIT1006-31b (D-E) </entry><entry>3.369 </entry><entry>&#xd7; 10<sup>5</sup></entry><entry>5.743 </entry><entry>&#xd7; 10<sup>&#x2212;3 </sup></entry><entry>1.705 </entry><entry>&#xd7; 10<sup>&#x2212;8 </sup></entry></row><row><entry/><entry>FIT1006-31b (D-T) </entry><entry>3.670 </entry><entry>&#xd7; 10<sup>5</sup></entry><entry>5.722 </entry><entry>&#xd7; 10<sup>&#x2212;3 </sup></entry><entry>1.559 </entry><entry>&#xd7; 10<sup>&#x2212;8 </sup></entry></row><row><entry>cynoBCMA/Fc </entry><entry>FIT1006-29b (D-A) </entry><entry>1.919 </entry><entry>&#xd7; 10<sup>5</sup></entry><entry>2.101 </entry><entry>&#xd7; 10<sup>&#x2212;4 </sup></entry><entry>1.095 </entry><entry>&#xd7; 10<sup>&#x2212;9 </sup></entry></row><row><entry/><entry>FIT1006-29b (D-E) </entry><entry>1.178 </entry><entry>&#xd7; 10<sup>5</sup></entry><entry>2.765 </entry><entry>&#xd7; 10<sup>&#x2212;4 </sup></entry><entry>2.346 </entry><entry>&#xd7; 10<sup>&#x2212;9 </sup></entry></row><row><entry/><entry>FIT1006-31b (D-E) </entry><entry>1.036 </entry><entry>&#xd7; 10<sup>5</sup></entry><entry>1.665 </entry><entry>&#xd7; 10<sup>&#x2212;4 </sup></entry><entry>1.607 </entry><entry>&#xd7; 10<sup>&#x2212;9 </sup></entry></row><row><entry/><entry>FIT1006-31b (D-T) </entry><entry>1.881 </entry><entry>&#xd7; 10<sup>5</sup></entry><entry>1.913 </entry><entry>&#xd7; 10<sup>&#x2212;4 </sup></entry><entry>1.017 </entry><entry>&#xd7; 10<sup>&#x2212;9 </sup></entry></row><row><entry>huBCMA/Fc </entry><entry>FIT1006-29b (D-A) </entry><entry>8.777 </entry><entry>&#xd7; 10<sup>4</sup></entry><entry>&#x3c;5.0 </entry><entry>&#xd7; 10<sup>&#x2212;6 </sup></entry><entry>&#x3c;5.697 </entry><entry>&#xd7; 10<sup>&#x2212;11</sup></entry></row><row><entry/><entry>FIT1006-29b (D-E) </entry><entry>6.424 </entry><entry>&#xd7; 10<sup>4 </sup></entry><entry>3.673 </entry><entry>&#xd7; 10<sup>&#x2212;5 </sup></entry><entry>5.717 </entry><entry>&#xd7; 10<sup>&#x2212;10 </sup></entry></row><row><entry/><entry>FIT1006-31b (D-E) </entry><entry>6.221 </entry><entry>&#xd7; 10<sup>4</sup></entry><entry>2.434 </entry><entry>&#xd7; 10<sup>&#x2212;5 </sup></entry><entry>3.913 </entry><entry>&#xd7; 10<sup>&#x2212;10 </sup></entry></row><row><entry/><entry>FIT1006-31b (D-T) </entry><entry>8.585 </entry><entry>&#xd7; 10<sup>4</sup></entry><entry>1.688 </entry><entry>&#xd7; 10<sup>&#x2212;5 </sup></entry><entry>1.966 </entry><entry>&#xd7; 10<sup>&#x2212;10 </sup></entry></row><row><entry>cynoCD3&#x3b5;/&#x3b3;-Fc </entry><entry>FIT1006-29b (D-A) </entry><entry>5.407 </entry><entry>&#xd7; 10<sup>5</sup></entry><entry>6.066 </entry><entry>&#xd7; 10<sup>&#x2212;3 </sup></entry><entry>1.122 </entry><entry>&#xd7; 10<sup>&#x2212;8 </sup></entry></row><row><entry/><entry>FIT1006-29b (D-E) </entry><entry>5.472 </entry><entry>&#xd7; 10<sup>5</sup></entry><entry>5.765 </entry><entry>&#xd7; 10<sup>&#x2212;3 </sup></entry><entry>1.054 </entry><entry>&#xd7; 10<sup>&#x2212;8 </sup></entry></row><row><entry/><entry>FIT1006-31b (D-E) </entry><entry>5.827 </entry><entry>&#xd7; 10<sup>5</sup></entry><entry>6.321 </entry><entry>&#xd7; 10<sup>&#x2212;3 </sup></entry><entry>1.085 </entry><entry>&#xd7; 10<sup>&#x2212;8 </sup></entry></row><row><entry/><entry>FIT1006-31b (D-T) </entry><entry>5.459 </entry><entry>&#xd7; 10<sup>5</sup></entry><entry>6.210 </entry><entry>&#xd7; 10<sup>&#x2212;3 </sup></entry><entry>1.137 </entry><entry>&#xd7; 10<sup>&#x2212;8</sup></entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0034" level="1">Example 5.4: Humanized Bispecific FIT-Igs Showed Redirected CD3 Activation and Cytotoxicity</heading><p id="p-0211" num="0187">The tumor cell killing potency of BCMA/CD3 humanized bispecific FIT-Ig antibodies was measured in a redirected T cell cytotoxicity assay using human myeloma cell line NCI-H929 as target cells and human T cells as effector cells. Briefly, cells were harvested, washed and resuspended with assay medium (RPMI1640 with 10% FBS). NCI-H929 cells were seeded into flat-bottom 96 wells plate (Corning #3599) at 5&#xd7;10<sup>4 </sup>cells per well. T cells were purified from human PBMC with a commercial kit (Stemcell #17951) and were added into the same plates at 2&#xd7;10<sup>5 </sup>cells per well. FIT-Ig binding proteins were then added and incubated with the cell mixture. After 48 hours of incubation at 37&#xb0; C., LDH release was measured with an assay kit (Promega #G1780). Following the manufacturer's instructions, OD490 readouts were obtained. Target cells NCI-H929 max lysis (100%) minus minimal lysis (0%) was presented as normalization denominator. The percentage of LDH release was plotted against the concentrations of bispecific Abs. In this example, the humanized FIT-Ig showed similar redirected T cell cytotoxicity as the parental chimeric FIT-Ig. The results are shown in <figref idref="DRAWINGS">FIG. <b>15</b></figref>. The results show that humanized BCMA/CD3 FIT-Igs according to the invention were able to redirect T cell cytotoxicity to NCI-H929 tumor cells in co-culture. Referring to <figref idref="DRAWINGS">FIGS. <b>16</b> and <b>17</b></figref>, the binding of two BCMA/CD3 bispecific FIT-Ig binding proteins according to the invention to BCMA-expressing and CD3-expressing target cells is confirmed.</p><p id="p-0212" num="0188">Alternative configurations of two of the exemplary BCMA/CD3 FIT-Ig binding proteins, wherein the outer binding site is the CD3 Fab binding site and the inner binding site is the BCMA Fab binding site of the tandemly arranged Fab regions were prepared, designated FIT1006-31a(D-T) and FIT1006-35a(D-T). The polypeptide chain formulas for these two FIT-Igs were:</p><p id="p-0213" num="0189">Chain 1 (long chain): VL<sub>CD3</sub>-CL-VH<sub>BCMA</sub>-CH1-hinge-CH2-CH3;</p><p id="p-0214" num="0190">Chain 2 (first short chain): VH<sub>CD3</sub>-CH1;</p><p id="p-0215" num="0191">Chain 3 (second short chain): VL<sub>BCMA</sub>-CL;</p><p id="p-0216" num="0192">The amino acid sequences of the polypeptide chains for FIT1006-31a(D-T) and FIT1006-35a(D-T) are given below:</p><p id="p-0217" num="0000"><tables id="TABLE-US-00020" num="00020"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="287pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;16</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Amino&#x2003;Acid&#x2003;Sequences&#x2003;of&#x2003;FIT-Ig&#x2003;FIT1006-31a(D-T)&#x2003;Component&#x2003;Chains</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="175pt" align="left"/><tbody valign="top"><row><entry/><entry>SEQ&#x2003;ID</entry><entry>Amino&#x2003;Acid&#x2003;Sequence</entry></row><row><entry>Polypeptide</entry><entry>NO:</entry><entry>1234567890123456789012345678901234567890</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>FIT1006-31a(D-T)</entry><entry>83</entry><entry>DIVMTQSPDSLAVSLGERATINCKSSQSLLN<b>A</b>RTRKNYLA</entry></row><row><entry>Chain&#x2003;#1</entry><entry/><entry>WYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLT</entry></row><row><entry/><entry/><entry>ISSLQAEDVAVYYCKQSYILRTFGGGTKVEIKRTVAAPSV</entry></row><row><entry/><entry/><entry>FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ</entry></row><row><entry/><entry/><entry>SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE</entry></row><row><entry/><entry/><entry>VTHQGLSSPVTKSFNRGECEVQLVQSGAEVKKPGASVKVS</entry></row><row><entry/><entry/><entry>CKASGYTFTNFWMHWVRQAPGQRLEWMGAFYPGNDDTYYN</entry></row><row><entry/><entry/><entry>QKFKGRVTITADTSASTAYMELSSLRSEDMAVYYCARSGY</entry></row><row><entry/><entry/><entry>YGSSDAMDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSG</entry></row><row><entry/><entry/><entry>GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS</entry></row><row><entry/><entry/><entry>GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP</entry></row><row><entry/><entry/><entry>KSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTP</entry></row><row><entry/><entry/><entry>EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN</entry></row><row><entry/><entry/><entry>STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS</entry></row><row><entry/><entry/><entry>KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI</entry></row><row><entry/><entry/><entry>AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW</entry></row><row><entry/><entry/><entry>QQGNVFSCSVMHEALHNHYTQKSLSLSPGK</entry></row><row><entry> </entry></row><row><entry>FIT1006-31a(D-T)</entry><entry>84</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASGFSFTNYYVHWMRQA</entry></row><row><entry>Chain&#x2003;#2</entry><entry/><entry>PGQGLEWMGWISPGSDNTKYNEKFKGRVTMTRDTSISTAY</entry></row><row><entry/><entry/><entry>MELSRLRSDDTAVYYCARDDYGNYYFDYWGQGTTVTVSSA</entry></row><row><entry/><entry/><entry>STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW</entry></row><row><entry/><entry/><entry>NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY</entry></row><row><entry/><entry/><entry>ICNVNHKPSNTKVDKKVEPKSC</entry></row><row><entry> </entry></row><row><entry>FIT1006-31a(D-T)</entry><entry>85</entry><entry>DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKP</entry></row><row><entry>Chain&#x2003;#3</entry><entry/><entry>GKAPKLLIYGATNLATGIPSRFSGSGSGRDFTLTISSLQP</entry></row><row><entry/><entry/><entry>EDFATYYCQSVLTTPWTFGQGTKLEIKRTVAAPSVFIFPP</entry></row><row><entry/><entry/><entry>SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ</entry></row><row><entry/><entry/><entry>ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG</entry></row><row><entry/><entry/><entry>LSSPVTKSFNRGEC</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0218" num="0000"><tables id="TABLE-US-00021" num="00021"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="287pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;17</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Amino&#x2003;Acid&#x2003;Sequences&#x2003;of&#x2003;FIT-Ig&#x2003;FIT1006-35a(D-T)&#x2003;Component&#x2003;Chains</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="175pt" align="left"/><tbody valign="top"><row><entry/><entry>SEQ&#x2003;ID</entry><entry>Amino&#x2003;Acid&#x2003;Sequence</entry></row><row><entry>Polypeptide</entry><entry>NO:</entry><entry>1234567890123456789012345678901234567890</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>FIT1006-35a(D-T)</entry><entry>86</entry><entry>DIVMTQSPDSLAVSLGERATINCKSSQSLLN<b>A</b>RTRKNYLA</entry></row><row><entry>Chain&#x2003;#1</entry><entry/><entry>WYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLT</entry></row><row><entry/><entry/><entry>ISSLQAEDVAVYYCKQSYILRTFGGGTKVEIKRTVAAPSV</entry></row><row><entry/><entry/><entry>FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ</entry></row><row><entry/><entry/><entry>SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE</entry></row><row><entry/><entry/><entry>VTHQGLSSPVTKSFNRGECEVQLVQSGAEVKKPGASVKVS</entry></row><row><entry/><entry/><entry>CKASGYTFTNFWMHWVRQAPGQRLEWMGAFYPGNDDTYYN</entry></row><row><entry/><entry/><entry>QKFKGRVTITADTSASTAYMELSSLRSEDMAVYYCARSGY</entry></row><row><entry/><entry/><entry>YGSSDAMDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSG</entry></row><row><entry/><entry/><entry>GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS</entry></row><row><entry/><entry/><entry>GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP</entry></row><row><entry/><entry/><entry>KSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTP</entry></row><row><entry/><entry/><entry>EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN</entry></row><row><entry/><entry/><entry>STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS</entry></row><row><entry/><entry/><entry>KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI</entry></row><row><entry/><entry/><entry>AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW</entry></row><row><entry/><entry/><entry>QQGNVFSCSVMHEALHNHYTQKSLSLSPGK</entry></row><row><entry> </entry></row><row><entry>FIT1006-35a(D-T)</entry><entry>87</entry><entry>EVQLVQSGAEVKKPGASVKVSCKASGFSFTNYYVHWMRQA</entry></row><row><entry>Chain&#x2003;#2</entry><entry/><entry>PGQGLEWIGWISPGSDNTKYNEKFKGRVTLTADTSISTAY</entry></row><row><entry/><entry/><entry>MELSRLRSDDTAVYYCARDDYGNYYFDYWGQGTTVTVSSA</entry></row><row><entry/><entry/><entry>STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW</entry></row><row><entry/><entry/><entry>NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY</entry></row><row><entry/><entry/><entry>ICNVNHKPSNTKVDKKVEPKSC</entry></row><row><entry> </entry></row><row><entry>FIT1006-35a(D-T)</entry><entry>88</entry><entry>DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKP</entry></row><row><entry>Chain&#x2003;#3</entry><entry/><entry>GKAPKLLIYGATNLATGIPSRFSGSGSGRDFTLTISSLQP</entry></row><row><entry/><entry/><entry>EDFATYYCQSVLTTPWTFGQGTKLEIKRTVAAPSVFIFPP</entry></row><row><entry/><entry/><entry>SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ</entry></row><row><entry/><entry/><entry>ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG</entry></row><row><entry/><entry/><entry>LSSPVTKSFNRGEC</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables><br/>The binding activity to BCMA-expressing and CD33-expressing target cells of the two alternative configurations are shown in <figref idref="DRAWINGS">FIG. <b>18</b></figref> and <figref idref="DRAWINGS">FIG. <b>19</b></figref> respectively. Comparing the two configurations for each target, the corresponding binding domain placed distal to Fc exhibited relatively higher binding activity than the same binding domain placed proximal to Fc, indicating certain impact of configuration on binding activity. Nonetheless, the results confirm both configurations possess the desired target binding activity towards both BCMA and CD3.</p><heading id="h-0035" level="1">Example 6 Treatment with BCMA x CD3 FIT-Ig Decreases NCI-H929 Tumor Volume in Human PBMC Engrafted NPSG Mice</heading><p id="p-0219" num="0193">The antitumor efficacy was evaluated in NPSG mice, which is an immunodeficient strain lacking T cells, B cells and natural killer cells. The NCI-H929 cells (5&#xd7;10<sup>6</sup>) were injected subcutaneously into the right dorsal flank NPSG mice. In the same day, the mice received a single intravenous dose of 5&#xd7;10<sup>6 </sup>human PBMC. The animals were randomized based on tumor size (70-140 mm<sup>3</sup>) on day 11 and treatment was initiated in the same day. Tumor growth was monitored by caliper measurements. The study was terminated on day 25, mice were euthanized when tumors size exceeded 3000 mm<sup>3</sup>. Mice were treated once a week for 3 weeks (QW&#xd7;3) with 6 mg/kg of FIT1006-31b(D-T) or FIT1006-35b(D-T) or vehicle by intraperitoneal (i.p.) injection. As shown in <figref idref="DRAWINGS">FIG. <b>20</b></figref>, FIT-Ig treatment group mice showed significant tumor growth inhibition by comparing with vehicle group. Especially for the FIT1006-35b(D-T) treatment group, tumors were completely eradicated.</p><heading id="h-0036" level="1">Example 7 BCMA x CD3 FIT-Ig Depletes B Cell Populations in Cynomolgus Monkeys and Shows Limited Cytokine Release Profile</heading><p id="p-0220" num="0194">Cynomolgus monkeys B cells were reported to have higher BCMA expression than human (Seckinger, A. et al., (2017). Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. Cancer Cell, 31(3), 396-410). A pilot non-GLP toxicology and pharmacology study was performed in cynomolgus monkeys to evaluate the ability of BCMA x CD3 FIT-Ig to deplete B cell populations in these animals. The study has three groups each consists of 1 male and 1 female monkey with comparable body weight across these groups, Group 1 received vehicle, Group 2 received a single injection of 0.5 mg/kg FIT1006-31b(D-T), and Group 3 received a single injection of 0.5 mg/kg FIT1006-35b(D-T), all dosed by i.v. injection on Day 1. Blood samples were collected via forelimb or hindlimb subcutaneous vein 2 days before dosing (Day &#x2212;1, baseline), 2, 4, 6 and 24 hours after dosing on Day 1, and on Day 8 and Day 15. Blood samples were analyzed by FACS for B and T cell markers and relative percentage change of each population was determined by comparing with the baseline level on Day &#x2212;1. Serum samples were also analyzed for cytokine levels (INF&#x3b3;, IL-2, IL-6 and TNF&#x3b1;) using a commercial Cytometric Bead Array (CBA) kit.</p><p id="p-0221" num="0195"><figref idref="DRAWINGS">FIG. <b>21</b></figref> demonstrates over 50% depletion of circulating B cells resulted from administration of the BCMA x CD3 FIT-Ig from the first post-dosing point (2 hours postdosing) till the last time point (day 15). A transient B cell depletion was also seen in the vehicle group by the second and third time point (2 hours and 4 hours of day 1), which may relate to the blood sampling schedule. But the B cell population of vehicle group exhibited quick recovery reaching plateau by 6 hours post dosing.</p><p id="p-0222" num="0196">As shown in <figref idref="DRAWINGS">FIG. <b>22</b></figref>, circulating T cell levels in FIT-Ig treatment groups exhibited a transient loss, which was recovered to the level of vehicle group on day 8 and maintained until the end of the experiment. The transient T cell loss was considered due to T cell activation and re-distribution upon treatment.</p><p id="p-0223" num="0197">The invention may be embodied in other specific forms without departing from the essential characteristics of the invention described above. The foregoing embodiments are therefore to be considered illustrative rather than limiting of the invention described herein. The scope of the invention is indicated by the appended claims.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230002489A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><us-claim-statement>What is claimed is:</us-claim-statement><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. An anti-CD3 antibody or antigen-binding portion thereof, comprising a set of six CDRs, of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, selected from the group of CDR sets as follows:</claim-text><claim-text><tables id="TABLE-US-00022" num="00022"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="84pt" align="left"/><colspec colname="4" colwidth="63pt" align="left"/><thead><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>CDR&#x2003;Set</entry><entry/><entry>CDR</entry><entry/></row><row><entry>No.</entry><entry>CDR</entry><entry>Amino&#x2003;Acid&#x2003;Sequence</entry><entry>SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>1</entry><entry>CDR-H1</entry><entry>NYYVH</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;56</entry></row><row><entry/><entry>CDR-H2</entry><entry>WISPGSDNTKYNEKFKG</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;57</entry></row><row><entry/><entry>CDR-H3</entry><entry>DDYGNYYFDY</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;58</entry></row><row><entry/><entry>CDR-L1</entry><entry>KSSQSLLNSRTRKNYLA</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;59</entry></row><row><entry/><entry>CDR-L2</entry><entry>WASTRES</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;60</entry></row><row><entry/><entry>CDR-L3</entry><entry>KQSYILRT</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;61</entry></row><row><entry> </entry></row><row><entry>2</entry><entry>CDR-H1</entry><entry>NYYIH</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;62</entry></row><row><entry/><entry>CDR-H2</entry><entry>WINLGDVNTKFNEKFKD</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;63</entry></row><row><entry/><entry>CDR-H3</entry><entry>DGYSFYYFDF</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;64</entry></row><row><entry/><entry>CDR-L1</entry><entry>KASQSLFNSRTRKNYLA</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;65</entry></row><row><entry/><entry>CDR-L2</entry><entry>WASTRES</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;66</entry></row><row><entry/><entry>CDR-L3</entry><entry>IQSHTLRT</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;67</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The anti-CD3 antibody or antigen-binding portion thereof according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, comprising VH and VL domains having amino acid sequences selected from the following VH/VL pairs:</claim-text><claim-text><tables id="TABLE-US-00023" num="00023"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="112pt" align="left"/><colspec colname="2" colwidth="105pt" align="left"/><thead><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row><row><entry>VH/VL Pair </entry><entry>VH/VL Pair</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>SEQ ID NO: 6/SEQ ID NO: 7 </entry><entry>SEQ ID NO: 19/SEQ ID NO: 20 </entry></row><row><entry>SEQ ID NO: 8/SEQ ID NO: 9 </entry><entry>SEQ ID NO: 11/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 11/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 12/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 12/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 13/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 13/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 14/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 14/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 15/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 15/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 16/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 16/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 17/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 17/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 18/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 18/SEQ ID NO: 20 </entry><entry>SEQ ID NO: 19/SEQ ID NO: 21 </entry></row><row><entry>SEQ ID NO: 11/SEQ ID NO: 25 </entry><entry>SEQ ID NO: 12/SEQ ID NO: 25 </entry></row><row><entry>SEQ ID NO: 15/SEQ ID NO: 25 </entry><entry>SEQ ID NO: 17/SEQ ID NO: 25. </entry></row><row><entry>SEQ ID NO: 18/SEQ ID NO: 25</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. A pharmaceutical composition comprising at least one anti-CD3 antibody or antigen-binding fragment thereof according to <claim-ref idref="CLM-00001">claim 1</claim-ref> or <claim-ref idref="CLM-00002">2</claim-ref>, and a pharmaceutically acceptable carrier.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. Use of the anti-CD3 antibody or antigen-binding portion thereof according to <claim-ref idref="CLM-00001">claim 1</claim-ref> or <claim-ref idref="CLM-00002">2</claim-ref> for preparation of a medicament for treating a disease or disorder in which CD3-mediated activity and/or BCMA-mediated activity is detrimental.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The use according to <claim-ref idref="CLM-00004">claim 4</claim-ref>, wherein said disease is a cancer and optionally selected from: a multiple myeloma, a melanoma (e.g., metastatic malignant melanoma), a renal cancer (e.g., clear cell carcinoma), a prostate cancer (e.g., hormone refractory prostate adenocarcinoma), a pancreatic adenocarcinoma, a breast cancer, a colon cancer, a lung cancer (e.g., non-small cell lung cancer), an esophageal cancer, a squamous cell carcinoma of the head and neck, a liver cancer, an ovarian cancer, a cervical cancer, a thyroid cancer, a glioblastoma, a glioma, a leukemia, a lymphoma, and a primary bone cancer (e.g., osteosarcoma, Ewing sarcoma, malignant fibrous histiocytoma, or chondrosarcoma).</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. A binding protein comprising first, second and third polypeptide chains, or a FIT-Fab fragment thereof, wherein<claim-text>said first polypeptide chain comprises, from amino to carboxyl terminus, (i) VL<sub>A</sub>-CL-VH<sub>B</sub>-CH1-Fc wherein CL is directly fused to VH<sub>B</sub>, or (ii) VH<sub>B</sub>-CH1-VL<sub>A</sub>-CL-Fc wherein CH1 is directly fused to VL<sub>A</sub>;</claim-text><claim-text>said second polypeptide chain comprises, from amino to carboxyl terminus, VH<sub>A</sub>-CH1; and</claim-text><claim-text>said third polypeptide chain comprises, from amino to carboxyl terminus, VL<sub>B</sub>-CL;</claim-text><claim-text>wherein VL is a light chain variable domain, CL is a light chain constant domain, VH is a heavy chain variable domain, CH1 is a heavy chain constant domain, Fc is an immunoglobulin Fc region, A is an epitope of CD3 or BCMA and B is an epitope of CD3 or BCMA, with the proviso that A and B are different, said binding protein being capable of binding to both CD3 and BCMA.</claim-text></claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The binding protein or FIT-Fab fragment according to <claim-ref idref="CLM-00006">claim 6</claim-ref>, wherein the VL<sub>A </sub>and VH<sub>A </sub>are variable domains from a parental antibody binding to one of the antigen targets CD3 or BCMA, and the VL<sub>B </sub>and VH<sub>B </sub>are variable domains from a different parental antibody binding to the other of the antigen targets CD3 or BCMA.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The binding protein or FIT-Fab fragment of <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein<claim-text>said first polypeptide chain comprises, from amino to carboxyl terminus, VL<sub>CD3</sub>-CL-VH<sub>BCMA</sub>-CH1-Fc wherein CL is directly fused to VH<sub>BCMA</sub>, said second polypeptide chain comprises, from amino to carboxyl terminus, VH<sub>CD3</sub>-CH1, and said third polypeptide chain comprises, from amino to carboxyl terminus, VL<sub>BCMA</sub>-CL;</claim-text><claim-text>said first polypeptide chain comprises, from amino to carboxyl terminus, VL<sub>BCMA</sub>-CL-VH<sub>CD3</sub>-CH1-Fc wherein CL is directly fused to VH<sub>CD3</sub>, said second polypeptide chain comprises, from amino to carboxyl terminus, VH<sub>BCMA</sub>-CH1, and said third polypeptide chain comprises, from amino to carboxyl terminus, VL<sub>CD3</sub>-CL;</claim-text><claim-text>said first polypeptide chain comprises, from amino to carboxyl terminus, VH<sub>BCMA</sub>-CH1-VL<sub>CD3</sub>-CL-Fc wherein CH1 is directly fused to VL<sub>CD3</sub>, said second polypeptide chain comprises, from amino to carboxyl terminus, VL<sub>BCMA</sub>-CL, and said third polypeptide chain comprises, from amino to carboxyl terminus, VH<sub>CD3</sub>-CH1; or</claim-text><claim-text>said first polypeptide chain comprises, from amino to carboxyl terminus, VH<sub>CD3</sub>-CH1-VL<sub>BCMA</sub>-CL-Fc wherein CH1 is directly fused to VL<sub>BCMA</sub>, said second polypeptide chain comprises, from amino to carboxyl terminus, VL<sub>CD3</sub>-CL, and said third polypeptide chain comprises, from amino to carboxyl terminus, VH<sub>BCMA</sub>-CH1;</claim-text><claim-text>wherein VL<sub>CD3 </sub>is a light chain variable domain of an anti-CD3 antibody, CL is an antibody light chain constant domain, VH<sub>CD3 </sub>is a heavy chain variable domain of an anti-CD3 antibody, CH1 is an antibody first heavy chain constant domain, VL<sub>BCMA </sub>is a light chain variable domain of an anti-BCMA antibody, VH<sub>BCMA </sub>is a heavy chain variable domain of an anti-BCMA antibody, and Fc is an antibody Fc region.</claim-text></claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The binding protein or FIT-Fab fragment of <claim-ref idref="CLM-00008">claim 8</claim-ref>, wherein, the domains VL<sub>CD3</sub>-CL are the same as the light chain of an anti-CD3 parental antibody, the domains VH<sub>CD3</sub>-CH1 are the same as the heavy chain variable and heavy chain first constant domains of an anti-CD3 parental antibody, the domains VL<sub>BCMA</sub>-CL are the same as the light chain of an anti-BCMA parental antibody, and the domains VH<sub>BCMA</sub>-CH1 are the same as the heavy chain variable and heavy chain first constant domains of an anti-BCMA parental antibody.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The binding protein or FIT-Fab fragment of <claim-ref idref="CLM-00006">claim 6</claim-ref>, wherein<claim-text>said first polypeptide chain comprises a sequence of amino acids of SEQ ID NO:50, said second polypeptide chain comprises a sequence of amino acids of SEQ ID NO:51, and said third polypeptide chain comprises a sequence of amino acids of SEQ ID NO:52;</claim-text><claim-text>said first polypeptide chain comprises a sequence of amino acids of SEQ ID NO: 53, said second polypeptide chain comprises a sequence of amino acids of SEQ ID NO:54, and said third polypeptide chain comprises a sequence of amino acids of SEQ ID NO:55;</claim-text><claim-text>said first polypeptide chain comprises a sequence of amino acids of SEQ ID NO:80, said second polypeptide chain comprises a sequence of amino acids of SEQ ID NO: 81, and said third polypeptide chain comprises a sequence of amino acids of SEQ ID NO: 82;</claim-text><claim-text>said first polypeptide chain comprises a sequence of amino acids of SEQ ID NO:83, said second polypeptide chain comprises a sequence of amino acids of SEQ ID NO:84, and said third polypeptide chain comprises a sequence of amino acids of SEQ ID NO:85; or</claim-text><claim-text>said first polypeptide chain comprises a sequence of amino acids of SEQ ID NO:86, said second polypeptide chain comprises a sequence of amino acids of SEQ ID NO:87, and said third polypeptide chain comprises a sequence of amino acids of SEQ ID NO:88.</claim-text></claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. A pharmaceutical composition comprising at least one binding protein or FIT-Fab fragment according to any one of <claim-ref idref="CLM-00006">claims 6</claim-ref>-<claim-ref idref="CLM-00010">10</claim-ref> and a pharmaceutically acceptable carrier.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. Use of a binding protein or FIT-Fab fragment according to any one of <claim-ref idref="CLM-00006">claims 6</claim-ref>-<claim-ref idref="CLM-00010">10</claim-ref> for preparation of a medicament for treating a disease or disorder in which CD3-mediated activity and/or BCMA-mediated activity is detrimental.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The use according to <claim-ref idref="CLM-00012">claim 12</claim-ref> wherein said disease is a cancer and optionally selected from: a multiple myeloma, a melanoma (e.g., metastatic malignant melanoma), a renal cancer (e.g., clear cell carcinoma), a prostate cancer (e.g., hormone refractory prostate adenocarcinoma), a pancreatic adenocarcinoma, a breast cancer, a colon cancer, a lung cancer (e.g., non-small cell lung cancer), an esophageal cancer, a squamous cell carcinoma of the head and neck, a liver cancer, an ovarian cancer, a cervical cancer, a thyroid cancer, a glioblastoma, a glioma, a leukemia, a lymphoma, and a primary bone cancer (e.g., osteosarcoma, Ewing sarcoma, malignant fibrous histiocytoma, or chondrosarcoma).</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. A method of treating a disorder wherein CD3-mediated and/or BCMA-mediated activity is detrimental, comprising administering to a subject in need thereof an effective amount of a binding protein or FIT-Fab fragment according to any one of <claim-ref idref="CLM-00006">claims 6</claim-ref>-<claim-ref idref="CLM-00010">10</claim-ref>, or a combination thereof.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. The method according to <claim-ref idref="CLM-00014">claim 14</claim-ref> wherein said disease is a cancer and optionally selected from: a multiple myeloma, a melanoma (e.g., metastatic malignant melanoma), a renal cancer (e.g., clear cell carcinoma), a prostate cancer (e.g., hormone refractory prostate adenocarcinoma), a pancreatic adenocarcinoma, a breast cancer, a colon cancer, a lung cancer (e.g., non-small cell lung cancer), an esophageal cancer, a squamous cell carcinoma of the head and neck, a liver cancer, an ovarian cancer, a cervical cancer, a thyroid cancer, a glioblastoma, a glioma, a leukemia, a lymphoma, and a primary bone cancer (e.g., osteosarcoma, Ewing sarcoma, malignant fibrous histiocytoma, or chondrosarcoma).</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. The method according to <claim-ref idref="CLM-00014">claim 14</claim-ref> or <claim-ref idref="CLM-00015">15</claim-ref>, wherein said subject is a human.</claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. An anti-BCMA antibody or an antigen-binding portion thereof, comprising a set of six CDRs, of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, selected from the group of CDR sets as follows:</claim-text><claim-text><tables id="TABLE-US-00024" num="00024"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="84pt" align="left"/><colspec colname="4" colwidth="56pt" align="left"/><thead><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>CDR&#x2003;Set</entry><entry/><entry>CDR</entry><entry/></row><row><entry>No.</entry><entry>CDR</entry><entry>Amino&#x2003;Acid&#x2003;Sequence</entry><entry>SEQ&#x2003;ID&#x2003;NO:</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>3</entry><entry>CDR-H1</entry><entry>NFWMH</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;74</entry></row><row><entry/><entry>CDR-H2</entry><entry>AFYPGNDDTYYNQKFK</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;75</entry></row><row><entry/><entry>CDR-H3</entry><entry>SGYYGSSDANDY</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;76</entry></row><row><entry/><entry>CDR-L1</entry><entry>GASENIYGALN</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;77</entry></row><row><entry/><entry>CDR-L2</entry><entry>GATNLAD</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;78</entry></row><row><entry/><entry>CDR-L3</entry><entry>QSVLTTPWT</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;79</entry></row><row><entry> </entry></row><row><entry>4</entry><entry>CDR-H1</entry><entry>NYGLN</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;68</entry></row><row><entry/><entry>CDR-H2</entry><entry>WINTYSGHPTYVDDFKG</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;69</entry></row><row><entry/><entry>CDR-H3</entry><entry>EKDDGYRLGLDY</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;70</entry></row><row><entry/><entry>CDR-L1</entry><entry>SASSSVSYMY</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;71</entry></row><row><entry/><entry>CDR-L2</entry><entry>DTSNLVS</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;72</entry></row><row><entry/><entry>CDR-L3</entry><entry>LQYSGYPYT</entry><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;73</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The anti-BCMA antibody or antigen-binding portion thereof according to <claim-ref idref="CLM-00017">claim 17</claim-ref>, comprising VH and VL domains having amino acid sequences selected from the following VH/VL pairs:</claim-text><claim-text><tables id="TABLE-US-00025" num="00025"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="112pt" align="left"/><colspec colname="2" colwidth="105pt" align="left"/><thead><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row><row><entry>VH/VL Pair </entry><entry>VH/VL Pair</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>SEQ ID NO: 29/SEQ ID NO: 30 </entry><entry>SEQ ID NO: 36/SEQ ID NO: 40 </entry></row><row><entry>SEQ ID NO: 31/SEQ ID NO: 32 </entry><entry>SEQ ID NO: 36/SEQ ID NO: 41 </entry></row><row><entry>SEQ ID NO: 34/SEQ ID NO: 38 </entry><entry>SEQ ID NO: 36/SEQ ID NO: 42 </entry></row><row><entry>SEQ ID NO: 35/SEQ ID NO: 38 </entry><entry>SEQ ID NO: 36/SEQ ID NO: 43 </entry></row><row><entry>SEQ ID NO: 36/SEQ ID NO: 38 </entry><entry>SEQ ID NO: 36/SEQ ID NO: 44 </entry></row><row><entry>SEQ ID NO: 37/SEQ ID NO: 38 </entry><entry>SEQ ID NO: 34/SEQ ID NO: 45 </entry></row><row><entry>SEQ ID NO: 34/SEQ ID NO: 39 </entry><entry>SEQ ID NO: 34/SEQ ID NO: 46 </entry></row><row><entry>SEQ ID NO: 35/SEQ ID NO: 39 </entry><entry>SEQ ID NO: 34/SEQ ID NO: 47 </entry></row><row><entry>SEQ ID NO: 36/SEQ ID NO: 39 </entry><entry>SEQ ID NO: 34/SEQ ID NO: 48 </entry></row><row><entry>SEQ ID NO: 37/SEQ ID NO: 39 </entry><entry>SEQ ID NO: 34/SEQ ID NO: 49</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. A pharmaceutical composition comprising at least one anti-BCMA antibody or antigen-binding fragment thereof according to <claim-ref idref="CLM-00017">claim 17</claim-ref> or <claim-ref idref="CLM-00018">18</claim-ref>, and a pharmaceutically acceptable carrier.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. Use of the anti-CD3 antibody or antigen-binding portion thereof according to <claim-ref idref="CLM-00017">claim 17</claim-ref> or <claim-ref idref="CLM-00018">18</claim-ref> for preparation of a medicament for treating a disease or disorder in which CD3-mediated activity and/or BCMA-mediated activity is detrimental.</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. The use according to <claim-ref idref="CLM-00020">claim 20</claim-ref> wherein said disease is a cancer and optionally selected from: a multiple myeloma, a melanoma (e.g., metastatic malignant melanoma), a renal cancer (e.g., clear cell carcinoma), a prostate cancer (e.g., hormone refractory prostate adenocarcinoma), a pancreatic adenocarcinoma, a breast cancer, a colon cancer, a lung cancer (e.g., non-small cell lung cancer), an esophageal cancer, a squamous cell carcinoma of the head and neck, a liver cancer, an ovarian cancer, a cervical cancer, a thyroid cancer, a glioblastoma, a glioma, a leukemia, a lymphoma, and a primary bone cancer (e.g., osteosarcoma, Ewing sarcoma, malignant fibrous histiocytoma, or chondrosarcoma).</claim-text></claim></claims></us-patent-application>